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Preface to ”Chemical and Molecular Approach to
Tumor Metastases”
The study of cancer metastasis is gaining particular attention, given the impact that this
disseminated disease has on the success of tumour therapy. This special issue draws attention to
the biochemical and molecular aspects of metastatic diseases, but also to potential targets and some
specific emerging treatment opportunities.
The work of Huijnun Xie et al. presents the role of phosphoglycerate kinase 1, an important enzyme
involved in glycolysis, in the progression of the hepatocellular carcinoma. An interesting warning is
presented by Kangyun Lan et al. regarding the excess of antioxidants, such as sulphoredoxin, which
can promote cancer growth and metastases. Kosuke Toda el al. demonstrate that KRAS mutated
colorectal cancer is maintained by the overexpression of the ASCT2 (SLC1A5) aminoacid transporter,
suggesting its potential role as a specific target for the pharmacological control of this tumour. Alysha K.
Croker et al. point out that aldehyde deydrogenase activity and CD44 expression are responsible for the
metastatic progression of therapy-resistant human breast cancer, and Hsiang-Cheng Chi et al. review
the literature on the roles of noncoding RNAs in relation to the resistance to radiotherapy of cancer
stem cells in metastatic foci. Laura Mercatali et al. stress the role of the relationships between tumour
cells and the extracellular matrix, showing how EGFR is crucial to the osteoclastogenic effect in breast
cancer. The work of Ana Cavaco et al. focuses on a similar aspect, indicating that stroma-producing
fibroblasts and the tumour vasculature can be promising targets for cancer therapy. In this context,
Sung-Ying Huang et al. and Bo-Gyoung Kim et al. report on the Epithelial to Mesenchymal Transition
and demonstrate the role of inhibition of this process with an extract of a traditionally used herbal
Chinese medicine and with 3,3’-diindolylmethane. Metformine also plays an important role in this
process, report Keyang Cheng and Min Hao, throughout the TGF-beta1 influence on the mTOR
signalling activity. From another point of view, Coralie Genevois presents an imaging model based on
the use of non-specific nanoparticles to visualize prostate cancer tumours and their metastases in vivo.
Yan Lu et al. point out on the importance of inactivating SMAD2, with inhibition of CLDN6
methylation, leading to the control of the processes of migration and invasion of breast cancer, and
Thaiz F. Borin et al. suggest the targeting of 20-hydroxyeicosanotetraenoic acid as a novel therapy
approach to breast cancer metastases. Ronald F.S. Lee et al. present data on the cell distribution
of an innovative inorganic compound for the treatment of metastatic tumours. Stefano Guadagni
et al. conclude the series of presentations of this special issue, discussing whether the locoregional
chemotherapy for the treatment of advanced melanomas is still a valid therapeutic option.
Gianni Sava and Alberta Bergamo
Special Issue Editors
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Tumours are not merely masses of abnormally proliferating cancer cells. Today, we have a clearer
view of cancer complexity in which the participation of cancer and host cells leads to a tremendous
heterogeneity of neoplastic diseases concerning the genetics, epigenetics, proteomics and biochemistry
of the tumour [1]. Such intra-tumour heterogeneity provides the basis for inter-metastatic heterogeneity
among different metastatic lesions of the same patient, each originating from a founder cell, or small
group of cells, with a very different mutation kit, and likely originating from different and distinct
primary tumour areas [1]. This situation has important implications regarding chemotherapeutic
sensitivity and responses. In addition, the offspring of the founder cell(s) can generate heterogeneity
among the cells of an individual metastasis, affecting the response to systemic therapies and providing
the seeds for drug resistance.
Correspondingly, drug treatment is progressively shifting from the use of chemicals producing
toxics effects in general processes of cell division, with the goal of killing the tumour cell, to compounds
targeting specific cell behaviours with the goal of disarming the malignancy of the tumour cell
(Figure 1) [2,3]. This new strategy implies the use of novel systems of drug design, particularly those
concerning biological drugs leading to compounds capable of targeting specific molecules expressed
only by selected tumour cells [4–6]. The main aim of this novel era of drug development is the
response to the need of overcoming the heavy toxicity of the “conventional” chemotherapy that poorly
distinguishes between cancer and healthy cells, therefore, causing severe side effects that often hamper
the compliance of the patient.
Figure 1. Graphical representation of the tumour/metastasis heterogeneity and of the main targets and
therapeutic approaches (CAR-T = Chimeric Antigen Receptor T cell; TME = Tumour Micro Environment).
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Metastasis is the primary target for cancer chemotherapy, independently of the kind of drug being
used. The main reason is that the primary tumour can often, if not always, be aggressed by surgery
and/or radiotherapy whereas metastases, spread in several tissues and organs, are believed to be
better reached with drugs that follow the pharmacological rules of distribution in the body.
The generation of these novel drugs, whether selective and specific monoclonal antibodies or
small organic molecules, requires a deep knowledge of the nature of the tumour cell and particularly
of tumour metastasis. Similarly, to the primary lesions, tumour metastases are characterised by the
interactions with healthy cells and extracellular matrix leading to a complex microenvironment in
dynamic evolution but extremely important for the metastatic growth [7,8].
The twin research that joins the biochemistry and molecular biology of cancer metastasis with
the study of novel targets and novel approaches to combat their growth is even more mandatory in
a scientific era in which the improvements of human health are transforming cancers into chronic
diseases and therefore significantly prolonging the life-time expectancy.
Conflicts of Interest: The authors declare no conflict of interest.
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Abstract: During the proliferation and metastasis, the tumor cells prefer glycolysis (Warburg effect), but
its exact mechanism remains largely unknown. In this study, we demonstrated that phosphoglycerate
kinase 1 (PGK1) is an important enzyme in the pathway of metabolic glycolysis. We observed a significant
overexpression of PGK1 in hepatocellular carcinoma tissues, and a correlation between PGK1 expression
and poor survival of hepatocellular carcinoma patients. Also, the depletion of PGK1 dramatically
reduced cancer cell proliferation and metastasis, indicating an oncogenic role of PGK1 in liver cancer
progression. Further experiments showed that PGK1 played an important role in MYC-induced
metabolic reprogramming, which led to an enhanced Warburg effect. Our results revealed a new
effect of PGK1, which can provide a new treatment strategy for hepatocellular carcinoma, as PGK1 is
used to indicate the prognosis of hepatocellular carcinoma (HCC).
Keywords: PGK1; MYC; hepatocellular carcinoma; metastasis; Warburg effect
1. Introduction
Tumor cells mainly obtain energy in a special metabolic condition, which is called the Warburg
effect. This is effective in reducing incidence and mortality [1]. The key enzymes in this process can
regulate the metabolism, and metabolites produced by tumor cells significantly affect tumor migration
and invasion [2]. In solid tumors, possible metabolic exchange is an important dimension of metabolic
heterogeneity [3]. However, the metabolic biology of hepatocellular carcinoma (HCC) is yet to be
well characterized.
Phosphoglycerate k inase 1 (PGK1) is an important ATP-generating enzyme in the glycolytic
pathway [4]. It catalyzes the reversible transfer of a phosphate group from 1,3-bisphosphoglycerate
(1,3-BPG) to ADP that produced 3-phosphoglycerate (3-PG) and ATP [4]. PGK1 is very important in
tumorigenesis and progression. PGK1 regulates autophagy to promote tumorigenesis [5]. PGK1 is
a predictor of poor survival and a novel prognostic biomarker of chemoresistance to paclitaxel
treatment in breast cancer [6]. PGK1 appeared to be a predictor of CXCR4 expression, bone marrow
metastases, and survival in neuroblastoma [7]. PGK1 is a promoter of metastasis in colon cancer [8],
which might be a potential protein biomarker of intracellular oxidative status in human colon
carcinoma cells [9]. PGK1 secreted by prostate cancer regulates bone formation at the metastatic
site [10]. PGK1 is a potential marker [11] and a promoting enzyme for peritoneal dissemination in
gastric cancer [12].
Int. J. Mol. Sci. 2017, 18, 1630 3 www.mdpi.com/journal/ijms
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Involved in the glycolytic pathway, PGK1 promotes invasion and metastasis in HCC [13].
Several proteins associates with PGK1 signaling have already been identified, including ornithine
transaminase (OTA) [14] and hypoxia inducible factor 1 (HIF-1) [15]. A recent article shows that
acetylation at the K323 site of PGK1, as an important regulatory mechanism, promotes its enzymatic
activity and cancer cell metabolism [16]. All of these findings indicate that PGK1 is a potential marker
for progression in HCC. However, its role in HCC metastasis remains to be further explored.
On the other side, the structure of human PGK1 (hPGK1) has been well understood. hPGK1, as
long as 417 amino acids, is a typical hinge-bending enzyme with two similar sized Rossmann fold
domains [17]. When the two substrates are bonded, the hinge flexion moves the enzyme into a closed
form to allow the substrate to contact [17]. PGK1 inhibits susceptibility to chemotherapeutic drugs in
gastric cancer cells and tumor stem cells [18]. PGK1 might be an advisable target molecule for specific
immunotherapy of HLA-A2+ colon cancer patients [19]. All these findings indicate the possibility that
PGK1 can be a biomarker in the treatment of hepatocellular carcinoma.
MYC promotes multiple processes, such as uncontrolled cell proliferation, cell growth, and
genomic instability for promoting malignant transformation [20]. Importantly, in order to adapt to the
tumor microenvironment, MYC also joins the metabolic reprogramming, which is essential for cancer
cells [20]. MYC as a regulator of PGK1 is essential for proliferation of clear cell renal cell carcinoma
cells when its pathway is activated [21]. Proto-oncogene c-MYC as an upstream regulator links to the
tumor-secreted protein PGK1 in the process of breast cancer development [22]. As for hepatocellular
carcinoma, there is a hypothesis that c-MYC mainly regulates controlling PGK1 expression [16].
Therefore, the role of MYC regulates the metabolic function of PGK1 in HCC which needs to be
further studied.
Here we utilized a public database and HCC cell lines to assess the expression and to evaluate the
significance of PGK1. The results showed that PGK1 not only promoted HCC cell lines proliferation, but
also boosted metastasis via MYC-dependent PGK1 expression to modulate the HCC cells metabolism.
Moreover, PGK1 was overexpressed in HCC, and it was associated with poor prognosis and worse
malignancy. These results recommend a new view of PGK1 in HCC development.
2. Results
2.1. Phosphoglycerate Kinase 1 (PGK1) Promotes Proliferation in Hepatocellular Carcinoma (HCC) In Vitro
Concerned with the function of PGK1 protein, Western blotting assays were used to detect
endogenous expression of PGK1 in a panel of HCC cell lines and a normal liver cell line, HL7702.
The result indicated that SNU449 and HCCLM3 expressed higher levels of PGK1 protein compared to
HL7702 cells. While among the HCC cell lines examined, SNU182 and JHH5 expressed the lowest,
which was similar to HL7702 (Figure 1A). According to the results of endogenous expression of PGK1
in HCC cell lines, SNU182 and JHH5 were selected for the overexpression of PGK1, SNU182/Vector
and JHH5/Vector were used as the normal control; SNU449 and HCCLM3 were selected for knocking
down PGK1, then we examined the transfection efficiency by Western blotting with SNU449/NC and
HCCLM3/NC as normal controls (Figure 1B).
Cell counting kit-8 (CCK8) assay displayed that the forced PGK1 expression significantly increased
the ability of SNU182 and JHH5 cells to proliferate (p < 0.01, Figure 1C). As PGK1 was knocked
down in SNU449 and HCCLM3 cells, the proliferation rate evidently decreased (p < 0.01, Figure 1D).
These results were validated by the plate colony formation assay (p < 0.01, Figure 1E,F). Thus, PGK1 is
adequate to promote the proliferation of HCC cells.
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Figure 1. Effect of Phosphoglycerate Kinase 1 (PGK1) on the proliferation of Hepatocellular Carcinoma
(HCC) cells. (A) Endogenous expression of PGK1 in nomal and five HCC cell lines by Western blotting.
Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used as internal control. (B) Transfection
efficiency of PGK1 overexpress and knockdown in HCC. GAPDH was used as internal control.
(C) Effect of PGK1 on proliferation of SNU182 and JHH5 cells by cell counting kit-8 (CCK8) assay.
(D) Effect of PGK1 knockdown on proliferation of SNU449 and HCCLM3 cells by CCK8 assay. (E) Effect
of PGK1 on proliferation of SNU182 and JHH5 cells by plate colony formation assay. (F) Effect of PGK1
knockdown on proliferation of SNU449 and HCCLM3 cells by plate colony formation assay. ** p < 0.01.
NC, negative control; sh-PGK1, short hairpin RNA inhibiting PGK1 gene.
2.2. PGK1 Is Effective in Promoting Tumor Metastasis In Vivo
To investigate the function of PGK1 in tumor growth in vivo, SNU449/sh-PGK1 cells or
SNU449/negative control (NC) cells were subcutaneously implanted into nude mice (n = 6) and
monitored tumor growth. Notably, knocking down PGK1 obviously inhibited tumor growth in vivo
(p < 0.01, Figure 2A). Additionally, compared to control groups, sh-PGK1 decreased tumor proliferation
indices by Ki-67 expression (p < 0.01, Figure 2B).
Furthermore, we performed tail vein injecting assay (n = 6) in nude mice to evaluate the effect of
PGK1 in tumor metastasis in vivo. We injected SNU449/sh-PGK1 cells or SNU449/NC cells into node
mice’s tail veins. As shown in Figure 2C, the metastatic lung nodules of sh-PGK1 group was larger
than the control group (p < 0.01). These results declared that PGK1 is sufficient to promote tumor
metastasis in vivo.
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Figure 2. Effect of PGK1 on proliferation and metastasis in vivo. (A) Effect of PGK1 knockdown in
HCC cell proliferation in vivo. PGK1 knockdowning SNU449 cells and control cells were implanted
subcutaneously into nude mice to perform xenograft assay (n = 6). Tumor volumes were measured on
the indicated days. Data points are presented as the mean tumor volume ± SD. (B) Histopathological
analysis of xenograft tumors. The tumor sections were stained with H&E or subjected to IHC
staining using an antibody against Ki-67. (C) Effect of PGK1 knockdown on CRC metastasis in vivo.
1 × 106 cells knockdowning PGK1 or control vector were injected into each nude mouse through tail
vein. The number of lung metastasis nodules was counted under the microscope. Error bars represent
mean ± SD. The tumor sections were stained with H&E. ** p < 0.01.
2.3. MYC-Dependent PGK1 Modulates Metabolic Reprogramming of HCC Cells
PGK1 is a major metabolic enzyme in the glycolysis pathway, and c-MYC is the main regulator in
controlling PGK1 expression [16]. Therefore, we explored the rescue experiment to detect the metabolic
process in HCC. Western blotting analysis was performed to assess the expression of solute carrier
family 2 facilitated glucose transporter member 4, SLC2A4 gene (GLUT4), hexokinase 2 (HK2), and
lactate dehydrogenase A (LDHA) in the rescue experiment. Results revealed that PGK1 significantly
increased the expression of GLUT4, HK2, and LDHA in SNU182 cells, while si-MYC could not rescue
this effect (Figure 3A). Knockdown of PGK1 decreased the expression of GLUT4, HK2 and LDHA
in SNU449 cells, while MYC could not rescue this effect (Figure 3A). However, knockdown of MYC
decreased the expression of GLUT4, HK2, and LDHA in SNU182 cells; while PGK1 could rescue this
effect (Figure 3A). These results support that the knockdown of MYC decreases the expression of
GLUT4, HK2, and LDHA by PGK1 inhibition.
Extracellular acidification measurement was used to determine the metabolic condition of HCC.
Knockdown of PGK1 decreased cellular glucose uptake in SNU449 cells, while MYC could not
rescue this effect (p < 0.01, Figure 3B). PGK1 significantly increased glucose uptake in SNU182
cells, while si-MYC could not rescue this effect (p < 0.01, Figure 3B). However, MYC significantly
increased glucose uptake in SNU449 cells, while sh-PGK1 could rescue this effect (p < 0.01, Figure 3B).
The knockdown of MYC decreased cellular glucose uptake in SNU182 cells, while PGK1 could rescue
6
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this effect (p < 0.01, Figure 3B). Analogous results were observed in lactate production and ATP levels
(Figure 3C,D). MYC induces PGK1 to improve metabolic efficiency in HCC. We hypothesize that this
improved metabolic efficiency is one of the mechanisms by which PGK1 promotes the proliferation
and metastasis of HCC.
Figure 3. PGK1 modulated Warburg effects of HCC cells. (A) Western blot analysis of the expression
of GLUT4, hexokinase 2 (HK2), and lactate dehydrogenase A (LDHA of PGK1, sh-PGK1, si-MYC, or
MYC cells. GAPDH was used as internal control. (B) Glucose uptake levels of SNU449 and SNU182 cells
with PGK1 overpression, sh-PGK1, si-MYC, or MYC overpression. (C) Lactate production of SNU449
and SNU182 cells with PGK1 overpression, sh-PGK1, si-MYC, or MYC overpression. (D) ATP levels of
SNU449 and SNU182 cells with PGK1 overpression, sh-PGK1, si-MYC, or MYC overpression. ** p < 0.01.
2.4. PGK1 Is Overexpressed in Human Hepatocellular Carcinoma Specimens
The clinical relevance of PGK1 expression was determined by three online databases. First, we
analyzed the PGK1 protein expression in clinical specimens from the human protein atlas
(www.proteinatlas.org). We found that PGK1 had the positive strong expression in HCC, and
negative weak expression in normal liver (Figure 4A). Secondly, in the Roesser liver database
(Compendia Biosciences, www.oncomine.org), PGK1 mRNA level was superior in HCC tissues
to normal liver tissues (p < 0.001, n = 22, Figure 4B). At last, we exploited the TCGA Research
Network: http://cancergenome.nih.gov/ to evaluate the results of survival data. The results showed
that patients with high PGK1 expression may have a significantly shorter 10-year survival time
(p = 0.0401, Figure 4C). These results suggest that PGK1 upregulation in HCC tissue is closely related
to the prognosis of HCC patients.
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Figure 4. PGK1 is upregulated in human hepatocellular carcinoma specimens. (A) PGK1 expression
in normal liver tissue and hepatocellular carcinoma specimens. Images were taken from the Human
Protein Atlas online database. (B) Oncomine data showing PGK1 expression in normal vs. tumor
of liver (n = 22). (C) Kaplan Meier survival analysis of HCC patients with high and lowPGK1
expression based upon data generated by the TCGA Research Network (p = 0.0401). ** p < 0.01.
LIHC, Liver hepatocellular carcinoma.
3. Discussion
Metabolic reprogramming was thought to be a sign of cancer [23], and had been a popular
research field for the past decade. The Warburg effect was not only beneficial to the growth of cancer
cells, but also conducive to tumor migration and invasion.
The carcinogenic signaling pathway directly promoted the acquisition of nutrients and promoted
the decomposition of carbon into macromolecules (lipids, proteins, and nucleic acids) when
nutrient-enriched for the proliferation of cancer cells. These net effects of conducts were expected
to strengthen growth and cell proliferation [3]. In the hierarchical structure of the tumor alteration
pathway, the mutations of MYC, TP53, Ras-related oncogene, LKB1-AMP kinase (AMPK) and PI3K
kinase (PI3K) signaling pathway were always invoved in glucose and glutamine metabolism [3].
The increase in MYC caused a number of metabolic effects by reprogramming gene expression,
including promoted glycolysis, partial activation by LDHA transcription [24], improved mitochondrial
biogenesis [25], and increased glutamine catabolism [26,27], eventually achieving biomass assimilation.
The intersection of glucose and glutamine in many aspects reflected their richness and they both could
enter the central metabolic multiple nodes. Glutamine was necessary for growth, as it provided two
nitrogen atoms to synthesize hexosamine, nucleotides, and amino acids [28].
However, for resisting the physical environment of solid tumors, cancer cells must optimize nutritional
use due to the scarce resources. Some works highlighted the importance of culturing cells and metabolic
flexibility in vivo. For instance, in colon cancer cells, the deprivation of glucose or subcutaneous space
in mice grown in a harsh environment caused selective stress on KRAS mutations [29].
Here, KRAS mutation allowed the cells to tolerate low glucose conditions. Cancer cells usually
employ a nutrient to pack another nutrient normally provided into the metabolite pool, which can
recombine their metabolism to remunerate the loss of glucose or glutamine in the culture [30–32].
As a means of sustaining growth, high-throughput screening showed that long-term exposure
to low glucose cells required oxidative phosphorylation [33]. Similarly, a subset of lymphomas
was preferentially used and it perfered to depend on oxidative metabolism in a classic glycolytic
phenotype [34]. Thus, hypoxia-inducible factor (HIF1) activation, lactate released and redox production,
these metabolic transitions caused by cancer cells, changed by associating with the development of
invasive cancers [2]. A mathematical model provided an acid-mediated hypothesis of invasion of
tumor [35]. Through this model, due to the additional glucose production and glucose metabolism
changes, the H+ flow concentration gradient generated adjacent to the normal organization. The release
of cathepsin B and other proteolytic enzymes to normal cells caused cellular death and extracellular
matrix degradation, resulting in chronic exposure to the acidic microenvironment of the surrounding
normal tissue. All of these allow cancer cells to invade adjacent normal tissues [2]. In addition,
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glycolytic enzymes are very important to the migration of tumor cells. GLUT4 is a member of the
solute carrier family 2 (promotes glucose transporter) family and transmits glucose through the cell
membrane. HK2 is the key enzyme for the first step in most glucose metabolic pathways. As a key
metabolic enzyme, lactate dehydrogenase (LDH) catalyzes pyruvate conversely to lactate. LDHA is
a subunit of LDH. LDHA was essential for maintaining glycolysis and improving the cancer cells’
invasive activity [2].
Here we showed that PGK1 was overexpressed in human HCC tissues, and MYC induced PGK1
to improve the metabolic efficiency in HCC. We demonstrated that, in HCC cells, more and more
glucoses were transported into cells by improved GLUT4, which induced by MYC-dependent PGK1.
Then with the over expressed of HK2 and LDHA (they are both the key enzymes in glycolysis) induced
by MYC-dependent PGK1, the rate of glycolysis was accelerated. After that, more and more ATP and
lactate were produced. Finally, a large amount of ATP provided energy required for HCC proliferation,
and lactate promoted metastasis and had a interrelation with poor hepatic carcinoma overall survival
and patient prognosis (Figure 5). Our results demonstrated that oncogenic PGK1 enhanced expression
of GLUT4 to stimulate glucose uptaken; on the other hand, PGK1 utilizated the glucose by anabolic
pathways. MYC upregulated PGK1, resulting in more metabolic product and ultimately cell survival
and growth. Moreover, the structure of Human PGK1 was well understood. Our findings strongly
suggest that targeting PGK1 is a therapeutic strategy for HCC.
 
Figure 5. A model for the role of PGK1 in human hepatocellular carcinoma. PGK1 had an important
role in metabolic reprogramming induced by MYC, leading to an enhanced Warburg effect.
4. Materials and Methods
4.1. Cell Culture
Human HCC cell lines (SNU182, SNU449, JHH5, HepG2, and HCCLM3) and normal liver cell
line HL7702 were acquired from Cell Bank of Type Culture Collection (Shanghai City, China). The cells
were cultured in DMEM (Hyclone, Los Angeles, CA, USA) with 10% FBS under 5% CO2 at 37 ◦C.
4.2. Cell Transfection with siRNAs and Plasmids
All the primers for PGK1 and MYC detection assays were purchased from Ribobio. Transfection of
MYC siRNA and negative control (NC) were conducted via siRNA kit (RIBOBIO, Guangzhou, China)
according to the manufacturer’s protocol.
The steps of PGK1 and MYC overexpression are as follows: the CDS full length of human PGK1
and MYC genes was synthesized and cloned into Pez-Lv105 vector by GeneCopoeia (Guangzhou,
China). The vectors were transfected into lentiviral packaged 293T cell lines. Then 1 mL of viral
supernatant (containing 4 Attograms (Ag) of polybrene) was added into HCC cell lines for 14 days.
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To eliminate PGK1, a lentivirus with shRNA vector targeting PGK1 was transfected into HEK293T
cells, and 1 mL of virus supernatant (containing 4 Ag of polybrene) was added to the HCC cell line.
Western blotting detected PGK1 expression after 72 h.
4.3. Western Blotting
First, cells were lyzed on ice in a radioimmunoprecipitation (RIPA) buffer with a protease inhibitor
then quantified by quinolinic acid (BCA) assay. Second, SDS-PAGE isolated a total of 50 μg of protein
lysate, which was then transferred to a PVDF membrane (Millipore Corp, Billerica, MA, USA). Third,
the membrane was blocked with 5% fat-free milk, then incubated with PGK1 (ABclonal Biotech Co.,
Woburn, MA, USA, 1:100), MYC (ABclonal Biotech Co., Woburn, MA, USA, 1:100), LDHA (ABclonal
Biotech Co., Woburn, MA, USA, 1:100), HK2 (ABclonal Biotech Co., Woburn, MA, USA, 1:100), GLUT4
(ABclonal Biotech Co., Woburn, MA, USA, 1:100), or glyceraldehyde 3-phosphate dehydrogenase
(GAPDH) (ABclonal Biotech Co., Woburn, MA, USA, 1:1000) at 4 ◦C overnight. After that, the
membranes were incubated with secondary antibodies. Then, ECL test reagent (Fudebio, China) was
used to show the bands.
4.4. Cell Proliferation Assay
8 × 102 cells were suspended in 100 μL medium, then seeded in 96-well plates and incubated
for seven days. 10 μL of CCK8 (Dojindo Molecular Technologies, Inc., Kumamoto, Japan) added in
the new 100 μL medium was added to every well and the cells were incubated with 5% CO2 at 37 ◦C
for 2 h. Then the absorbance values were measured with a microplate reader set at 570 nm. Each
experiment was conducted for three times.
4.5. Plate Colony Formation Assay
2 × 102 cells were suspended in 2 mL medium, then seeded in 6-well plates and incubated at
37 ◦C with 5% CO2 for 14 days, then stained with hematoxylin. After that, counting colonies containing
more than 50 cells. Last, a calculated with the formula—plate clone formation efficiency = (number of
colonies/number of cells inoculated) × 100% was applied.
4.6. Proliferation and Metastasis in Mouse Model
For assessing tumor growth in vivo, 2 × 106 cells were subcutaneously injected into the
left abdomen or right abdomen of the six-week-old non-obese diabetic (NOD)/severe combined
immunodeficiency (SCID) mice, each group had six mice. After 28 days, the tumor was measured with
a caliper to assess the tumor volume.
For assessing tumor transfer in vivo, 2 × 106 cells were injected into the tail vein of six-week-old
NOD/SCID mice, each group had six mice. After eight weeks, the animals were euthanized; the
thoracic, peritoneum, and peritoneal cavity of the various organs removed, washed, fixed, and then
underwent pathological examination. The number of metastatic lung nodules was determined.
4.7. Glucose Uptake, Lactate Production, ATP Level Detection
In glucose uptake assay, first, cells were cultured in 6-well plates. Then according to the
manufacturer’s protocol, glucose uptake was determined using a glucose assay kit (Biovision Inc.,
Milpitas, CA, USA).
In lactate production measurement, according to the manufacturer’s protocol, first cells were
seeded into 96-well plates with phenol red-free medium, then determined using a lactate assay kit
(Biovision Inc., Milpitas, CA, USA).
In ATP levels assay, an ATP assay kit (Biovision Inc., Milpitas, CA, USA) was used according to
the manufacturer’s protocol.
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4.8. Analysis of PGK1 Expression in Human HCC
In HCC tissues and normal tissues, PGK1 protein expression was determined from the human
protein atlas (www.proteinatlas.org). HCC PGK1 gene expression was determined through analysis
of Roessler and TCGA databases, which are available through Oncomine (Compendia Biosciences,
www.oncomine.org) and UCSC (http://xena.ucsc.edu/getting-started/). Survival analysis for the
gene expression data were performed using OncoLnc [36].
4.9. Statistical Analysis
Statistical analysis was carried out by SPSS 13.0 software. Utilizated Student’s t-test to compare the
groups in the cell experiments. The data were expressed as the mean ± SEM of the three independent
experiments. p < 0.05 was considered statistically significant.
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Abstract: The abnormal elevation of sulfiredoxin (Srx/SRXN1)—an antioxidant enzyme whose main
function is to protect against oxidative stress—has been shown to be closely correlated with the
progression of several types of cancer, including human cervical cancer. However, the molecular
mechanism by which Srx promotes tumor progression, especially cancer metastasis in cervical
cancer, has not been elucidated. Here, we show that Srx expression gradually increases during the
progression of human cervical cancer and its expression level is closely correlated with lymph node
metastasis. Our study also reveals a significant positive correlation between the expression of Srx and
β-catenin in cervical cancer tissues. Loss-of-function studies demonstrate that Srx knockdown using
a lentiviral vector-mediated specific shRNA decreases the migration and invasion capacity in HeLa
(human papilloma virus 18 type cervical cancer cell line) and SiHa SiHa (cervical squamous cancer cell
line). Notably, the exact opposite effects were observed in gain-of-function experiments in C-33A cells.
Mechanistically, downregulation or upregulation of Srx leads to an altered expression of proteins
associated with the Wnt/β-catenin signaling pathway. Furthermore, blockage of the Wnt/β-catenin
signaling pathway contributed to attenuated Srx expression and resulted in significant inhibition
of cell migration and invasion in cervical cancer cell lines. Combined, Srx might be an oncoprotein
in cervical cancer, playing critical roles in activating the Wnt/β-catenin signaling pathway; it may
therefore be a therapeutic target for cervical cancer.
Keywords: sulfiredoxin; cervical cancer; metastasis; Wnt/β-catenin signaling
1. Introduction
Cervical cancer is the second leading cause of death among young women aged 19–39 years [1],
and the fourth leading cause of mortality in females worldwide [2]. Many patients with cervical
carcinoma metastasis previously treated with surgery or chemotherapy will develop recurrent disease
which seriously affects the quality of life of patients [3]. Thus, it is critical to elucidate the molecular and
biologic mechanisms in the development of cervical tumor and develop better therapeutic strategies in
cervical cancer.
Sulfiredoxin (Srx) is a novel discovered antioxidant enzyme [4,5], which was initially identified in
yeast. The main role of Srx is to reduce its downstream target gene hyperoxidized peroxiredoxin (Prx;
a member of antioxidant protein) back to active peroxidases in the presence of ATP [6–8], and then
counteract the excessive reactive oxygen species (ROS) to protect the host organism from oxidative
damages [9]. However, this property of Srx becomes a damaging effect to host cells when it starts
protecting the survival of cancer cells [10,11]. As per published literature and the data from the
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microarray database, Srx is altered in multiple types of cancer and plays critical roles in carcinogenesis
by modulating cell signal transduction involved in cell proliferation, migration and metastasis [10].
It has been reported that Srx was upregulated in several human cancers, including colorectal cancer [12],
skin malignancies [13], lung cancer [14] and human cervical cancer [15], suggesting the potential role
of Srx in tumor. As we mentioned above, Srx is associated with cancer metastasis. For example, Srx
can modulate cancer cell motility via redox sensitive interaction with non-muscle myosin IIA (NMIIA)
and S100A4 [16], and promotes colorectal cancer cell adhesion and migration through a mechanism of
enhancing EGFR (epidermal growth factor receptor) signaling [12]. These studies indicate that Srx
plays a critical role in cancer progression and metastasis. However, the complicated function and
molecular mechanism of Srx in cervical cancer metastasis has remained largely undiscovered.
Wnt/β-catenin signaling, which activates β-catenin to initiate the transcription of its downstream
target genes, has been reported to be associated with carcinogenesis and progression in cervical
cancer [17–19]. A study showed that Prx, a target gene of Srx [20], has been implicated in the regulation
of the Wnt/β-catenin signaling pathway. For example, knockdown of Prx inhibits the growth of
colorectal cells by downregulating the Wnt/β-catenin signaling [21]. Our previously study revealed a
significant positive correlation between the expression of Srx and E-catenin (an upstream molecule of
the Wnt/β-catenin signaling pathway) in cervical cancer tissues [15].
In light of these observation, we hypothesize that Srx may be an important molecule in human
cervical cancer development and progression. We assessed Srx expression in human cervical tissue
specimens, including normal cervical squamous cell epithelium tissues (NC), cervical intraepithelial
neoplasia tissues (CIN) and human cervical cancer tissues; investigated the biological function of
Srx in cervical cancer; and examined whether these effects are mediated by the Wnt/β-catenin
signaling pathway.
2. Results
Srx and β-catenin are overexpressed and correlated with metastasis in cervical cancer, and the
expression of the two proteins is positively correlated.
We evaluated the expression of Srx and β-catenin in 20 normal cervical samples (NC), 30 cervical
intraepithelial neoplasia (CIN) and 90 human cervical cancer tissues by immunohistochemistry. The
results showed that Srx was predominantly localized in the cytoplasm of cervical cancer tissues
(Figure 1(Ac)), and was rarely found in NC tissues (Figure 1(Aa)). Based on the expression scores,
the percentage of Srx positive expression samples increased gradually from 15% in NC, to 46.7%
in CIN to 73.3% in cervical cancer (Table 1). β-catenin was located in the membrane of the cell in
NC (Figure 1(Ad)). However, its location transfers to the cytoplasm and nucleus in cervical cancer
(Figure 1(Af)). The positive rate of β-catenin in cervical cancer (78.9%) and CIN (53.3%) was higher than
in NC (20%) (Table 1). The differences in the positive expression rate of Srx or β-catenin in NC, CIN,
and cervical cancer groups were statistically significant (p < 0.05). Then, we evaluated the expression
of Srx and β-catenin in five NC, five CIN and five cervical cancer tissues by Western blotting, and the
results showed that the two proteins significantly upregulated in both NC and CIN tissues, compared
to the NC group (p < 0.05; Figure 1B). These findings indicated that Srx and β-catenin are highly
expressed in human cervical cancer tissues (Figure 1 and Table 1). Next, we assessed the correlation
between the expression of the two proteins and the clinicopathological features of cervical cancer,
respectively. In these 90 patients with cervical cancer, there were significant associations between Srx
expression and lymph node metastasis (p < 0.05) or infiltration of the haemal tube (p < 0.05), but we did
not find a correlation between Srx expression and age, tumor size, degree of histologic differentiation,
clinical stage or depth of cancer invasion (p > 0.05) (Table 2). The data also revealed that expression
of β-catenin was closely associated with lymph node metastasis (p < 0.05) (Table 2). Furthermore,
Spearman’s rank correlation analysis showed a significant positive correlation between Srx expression
and β-catenin expression in human cervical cancer tissues (r = 0.365, p = 0.000) (Table 3).
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Figure 1. Sulfiredoxin (Srx) and β-catenin are highly expressed in human cervical cancer tissues.
(A) Immunohistochemical staining to detect Srx and β-catenin. (a) Normal cervical (NC) tissues without
Srx expression; (b) Cervical intraepithelial neoplasia (CIN) with mild expression of Srx; (c) Strong
positive staining for Srx was observed in cervical cancer tissues; (d) Cytomembrane expression of
β-catenin in NC tissues; (e) Partial defect of β-catenin in cytomembrane from CIN; (f) Cytoplasmic and
nuclear strong positive staining of β-catenin in cervical cancer tissues; (g–i) No measurable staining of
PBS (phosphate belanced solution )was used as a negative control; (a–i) Original magnification 200×.
All the images in the Figure 2B have the same scale bar; (B) The protein expression of Srx and β-catenin
in NC, CIN and cervical cancer tissues was assayed by Western blotting. (a) Western blotting showing
the expression of Srx in NC, CIN and cervical cancer tissues; (b) Dot plot of individual patients and
their corresponding Srx protein relative level; (c) Box plot shows median, lower and upper quartiles,
and minimum and maximum values of Srx protein relative level for NC cases, CIN cases and cervical
cancer cases; (d) Dot plot of individual patients and their corresponding β-catenin protein relative
level; (e) Box plot shows median, lower and upper quartiles, and minimum and maximum of β-catenin
protein relative level for NC cases, CIN cases and cervical cancer cases. Srx and β-catenin expression
was significantly increased in cervical cancer tissues. (p < 0.05, NC vs. CIN; p < 0.01, NC vs. Cancer).
The expression of β-actin was used as a loading control.
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Table 1. Expression of Srx and β-catenin in different cervical tissues.
Sample Case
Expression of Srx Expression of β-Catenin
+ (%) − (%) χ2 p + (%) − (%) χ2 p
NC 20 3(15.0) 17(85.0) 4(20) 16(80.0)
CIN 30 14(46.7) 16(53.3) 16(53.3) 14(46.7)
CINI 5 1(20.0) 4(80.0) 1(20.0) 3(80.0)
CINII 12 5(41.7) 7(58.3) 6(50.0) 6(50.0)
CINIII 13 8(61.5) 5(38.5) 9(69.2) 4(30.8)
CSCC 90 66(73.3) 22(26.7) 71(78.9) 19(21.1)
NC vs. CIN 3.980 0.021 4.253 0.018
CINvs. Cancer 7.200 0.013 7.370 0.010
NC vs. Cancer 21.386 0.000 23.514 0.000
NC vs. CIN vs. Cancer 26.476 0.000 27.037 0.000
CINI (Cervical intra-epithelial-neoplasia1); CINII (Cervical intra-epithelial-neoplasia2); CINIII (Cervical
intra-epithelial-neoplasia3). CIN = CINI + CINII + CINIII.
Table 2. Correlation between the expression of the two proteins and clinical pathological features of
cervical cancer.
Variable N
Expression of Srx Expression of β-Catenin
+ (%) − (%) p + (%) − (%) p
Age (year)
≥45 42 33(78.6) 9(21.4)
0.209
36(85.7) 6(14.3)
0.110<45 48 33(68.7) 15(31.3) 35(72.9) 13(27.1)
FIGO stage
I 70 49(70.0) 21(30.0)
0.146
52(74.3) 18(25.7)
0.037II 20 17(85.0) 3(15.0) 19(95.0) 1(5.0)
Tumor size (cm)
≥4 10 6(60.0) 4(40.0)
0.255
6(60.0) 4(40.0)
0.129<4 80 60(75.0) 20(25.0) 65(81.2) 15(18.8)
Histologic differentiation
Well and moderate 63 44(69.8) 19(30.2)
0.190
46(73.0) 17(27.0)
0.030Poor 27 22(81.5) 5(18.5) 25(92.6) 2(7.4)
Lymph node metastasis
+ 27 24(88.9) 3(11.1)
0.023
25(92.6) 2(7.4)
0.030− 63 42(66.7) 21(33.3) 46(73.0) 17(27.0)
Infiltration of haemal tube
+ 21 19(90.5) 2(9.5)
0.034
15(71.4) 6(28.6)
0.252− 69 47(68.1) 22(31.9) 56(81.2) 13(18.8)
Depth of cancer invasion
Light layer 54 36(66.7) 18(33.3)
0.064
41(75.9) 13(24.1)
0.284Deep layer 36 30(83.3) 6(6.7) 30(83.3) 16(16.7)
FIGO (International Federation of Gynecology and Obstetrics); “+” means positive expression; “−” means negative
expression. Bold values are statistically significant.
Table 3. Correlation of Srx and β-catenin expression in cervical cancer tissues.
Expression of β-Catenin
Expression of Srx
Positive (n = 66) Negative (n = 24)
Positive (n = 71) 58 13
Negative (n = 19) 8 11
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2.1. Srx Promotes the Migration and Invasion of Cervical Cancer Cells
The correlation between Srx and human cervical cancer metastasis suggested that Srx may play a
role in the process of cervical cancer migration and invasion. To test this hypothesis, we subsequently
established an effective cell model and performed the transwell assay to measure it. First, we examined
the expression of Srx in HeLa, SiHa and C33A cervical cancer cells by Western blotting and qRT-PCR,
and results showed that Srx was highly expressed in the HeLa and SiHa cells (Figure 2A). Then,
we knocked down Srx in HeLa and SiHa cells by transfecting lentiviruses containing Srx shRNA
(Srx-shRNA) (Figure 2B–D), and explored loss-of-function of Srx in human cervical cancer cell lines.
The transwell assay showed that cell migration (Figure 3A) (p < 0.05) and invasion (Figure 3B) (p < 0.05)
were significantly reduced with Srx knockdown in HeLa cell lines. The role of Srx knockdown in SiHa
cells was similar to that in HeLa cells. Knockdown of Srx inhibited migration (Figure 3A) (p < 0.05) and
invasion (Figure 3B) (p < 0.05) in SiHa cells. Gain-of-function of Srx in C33A cell lines by transfecting
lentiviruses containing Srx (Srx-LV) (Figure 2B–D) revealed that overexpression of Srx promoted C33A
cell migration (Figure 3A) (p < 0.05) and invasion (Figure 3B) (p < 0.05).
Figure 2. Srx was knocked down by Srx-shRNA and overexpressed by Srx-LV efficiently in cervical
cancer cell lines. (A) Western blotting (left panel) and qRT-PCR (right panel) were used to detect the
expression of Srx in HeLa (human papilloma virus 18 type cervical cancer cell line), SiHa (cervical
squamous cancer cell line).and C33A cervical cancer cell lines; (B) HeLa and SiHa cells were transduced
with lentivirus containing Srx-shRNA, and C33A cells were transduced with lentivirus containing
Srx-LV for 72 h, respectively. GFP signals were measured by fluorescence microscopy (100×) and
showed that lentiviruses were successfully transduced into cervical cancer cell lines. All the images
in the Figure 2B have the same scale bar; (C,D) Overexpressed and knockdown efficiency of Srx
were confirmed by Western blotting (C and the left panel of D) and qRT-PCR (the right panel of D).
The NC-LV-transduced cells (NC-LV) and NC-shRNA-transduced cells (NC-shRNA) were used as
negative control (NC). Non-transduced cells were used as blank control (BC). The results are expressed
as mean ± S.D. * p < 0.05.
18
Int. J. Mol. Sci. 2017, 18, 917
 
Figure 3. Srx promoted the migration and invasion of cervical cancer cells by the transwell assay.
(A) The migration of HeLa (upper panels) and SiHa cells (middle panels) was significantly inhibited
with Srx knockdown in comparison to the blank control (BC) and NC-shRNA-transduced negative
control (NC) group cells. C33A cell (lower panels) migration was markedly increased with Srx
overexpression in comparison to the BC and NC-LV-transduced negative control (NC) group cells, as
determined by the transwell assay without Matrigel; (B) The invasion of HeLa (upper panels) and SiHa
cells (middle panels) was significantly inhibited with Srx knockdown in comparison to BC and NC
group cells. C33A cell (lower panels) invasion was markedly increased with Srx overexpression in
comparison to the BC and NC group cells, as determined by the transwell assay coated with Matrigel.
The cells on transwell chambers were fixed, dyed and photographed after culture for 24 h (invasion) or
22 h (migration). All the images in the Figure 2A,B have the same scale bar. The values are expressed
as the mean ± SD. (* p < 0.05 vs. control).
2.2. Silencing or Overexpression of Srx Resulted in Alteration of Proteins Levels Associated with
Wnt/β-Catenin Signaling Pathway
To explore whether Srx promotes the migration and invasion of cervical cancer cells via
Wnt/β-catenin signaling, Srx was silenced in HeLa and SiHa cell lines by lentiviruses containing Srx
shRNA, and overexpressed in C33A cell lines by lentiviruses containing Srx-LV. In the present study,
with the alteration of Srx expression, we focused on the changing of β-catenin and GSK-3β activity,
and the transcriptional activity of target genes. Following over-expression of Srx, total expression
of intracellular β-catenin was significantly increased in C33A cells (p < 0.05; Figure 4A). In addition,
the phosphorylated β-catenin (P-β-catenin), which was generated to break down the Wnt signal,
was appreciably decreased with Srx over-expression (p < 0.05; Figure 4A). Furthermore, GSK/3β,
a critical factor of the Wnt signal, was decreased when Srx was overexpressed in C33A cells, whereas
the level of phosphorylated GSK/3b (p-GSK/3b) was notably increased with Srx upregulated in
C33A cells (p < 0.05; Figure 4A). CD44, a target gene of the Wnt signal, was remarkably increased
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with Srx over-expression in C33A cells (p < 0.05; Figure 4A). Notably, the exact opposite effects were
observed in loss-of-function experiments in HeLa and SiHa cells. β-Catenin, p-GSK/3b and CD44
were significantly reduced by knocking down the expression of Srx in HeLa and SiHa cells. We also
found that treatment of HeLa and SiHa cells with Srx shRNA significantly increased the expression of
GSK-3β and P-β-catenin (p < 0.05; Figure 4). These findings indicated that Srx may be involved in the
regulation of the Wnt/β-catenin signal pathway in human cervical cancer cells.
Figure 4. Knockdown of Srx expression inhibits the activation of Wnt/β-catenin signal pathways
and upregulation of Srx level promotes the activation of Wnt/β-catenin signal pathways.
(A) The expression of β-catenin, P-β-catenin, GSK-3β and p-GSK-3β in Srx-depleted HeLa and SiHa
cells and Srx-upregulated C33A cells were determined by Western blotting; (B) The expression of
CD44 (Wnt/β-catenin pathway target genes) in Srx-depleted HeLa and SiHa cells and Srx-upregulated
C33A cells were measured by Western blotting. β-Actin was used as the loading controls (* p < 0.05
vs. controls).
2.3. The Suppression of Wnt/β-Catenin Signaling Pathway by XAV-939 Inhibits Migration, Invasion and Srx
Expression in Cervical Cancer Cell Lines
To further confirm that the canonical Wnt signaling is the pathway where Srx promotes the
migration and invasion of human cervical cancer, XAV-939 (an inhibitor of the canonical Wnt signaling
pathway) was used to block Wnt/β-catenin signaling in HeLa, SiHa and Srx-over-expressing C33A
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(LV-C33A) cell lines. When HeLa, SiHa and LV-C33A cell lines were treated with XAV-939, β-catenin
was obviously reduced compared to those in the two cell lines treated with DMSO by Western blotting
(p < 0.05, Figure 5C). In addition, the inhibition of this pathway caused remarkable suppression of Srx
expression (p < 0.05, Figure 5C) and highly degreased the migration (p < 0.05, Figure 5A) and invasion
(p < 0.05, Figure 5B) in HeLa, SiHa and LV-C33A cell lines. Taken together, these results suggest that
Srx promotes the migration and invasion of cervical cancer cells and may be involved in the activation
of the Wnt/β-catenin signaling pathway.
Figure 5. Inhibition of the Wnt/β-catenin signal decreases migration, invasion and Srx expression in
cervical cancer cell lines. (A) The migration of HeLa, SiHa and LV-C33A cells was markedly inhibited
after treatment with XAV-939, an inhibitor of β-catenin, in comparison to the DMSO negative control
and blank control (BC), as determined by the transwell assay (* p < 0.05 vs. control); (B) The effects
of XAV-939 on the invasion of HeLa, SiHa and LV-C33A cells were evaluated by the transwell assay,
in comparison to the DMSO and BC control (* p < 0.05 vs. control); (C) Western blotting showed that
treatment with XAV-939 in HeLa, SiHa and LV-C33A cells resulted in significant inhibition of β-catenin
and Srx expression, in comparison to DMSO and BC control (* p < 0.05 vs. control).
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3. Discussion
The abnormally elevated expression of Srx was shown to be associated with carcinogenesis in
colorectal cancer [22], skin malignancies [23], lung cancer [24], etc. Subsequently, the overexpression of
Srx has already been demonstrated to promote cancer metastasis in multiple cancers [10], including
those cancers we just mentioned. It is well documented that cancer cells are known to bring about
numerous ROS. Thus, it is not difficult to understand that the elevated expression of antioxidant protein
such as Srx could be of benefit to cancer cell survival. Furthermore, it is not difficult to understand that
cancer treatment may via controlling Srx expression in cancer cells. Based on these observations, our
purposes were to elucidate the molecular mechanism by which Srx regulates the metastasis of cervical
cancer and establishes the associated signaling mechanisms.
In our present study, the expression of Srx was found to be gradually enhanced from NC tissues
to CIN tissues and then to cervical cancer tissues, in agreement with the results of previous studies
of cervical cancer [15]. Then, to further explore the function of Srx in cervical carcinogenesis, the
correlation between the expression of Srx and clinical pathological features in cervical cancer tissues
was analyzed. Furthermore, the results showed that there were significant associations between Srx
expression and lymph node metastasis and the infiltration of the haemal tube in cervical cancer tissues.
Srx is highly expressed in colorectal cancer cells and is required for colorectal cancer adhesion and
migration [12,16], which provides us with evidence that Srx is associated with cancer metastasis.
Subsequently, we knocked down Srx in HeLa and SiHa cells by transfecting lentiviruses containing Srx
shRNA and upregulated Srx in C33A cell lines by transfecting lentiviruses containing Srx to further
confirm that Srx expression might be associated with metastasis in cervical cancer. The results showed
that Srx significantly promoted the migration and invasion of cervical cancer cells.
The Wnt/β-catenin signaling pathway, which activates β-catenin to initiate the transcription
of its specific downstream target genes [25], has been reported to be associated with numerous
cancers [26–29]. Aberrant activation of the canonical Wnt pathway plays a significant role in human
cervical cancer. However, limited data show the correlation between the cancer clinical pathological
characteristics and the key molecules such as β-catenin. In our study, we confirmed that β-catenin,
indeed, is highly expressed in cervical carcinoma tissues and its expression level was closely associated
with lymph node metastasis, which was similar to the findings of other investigators [30]. Based
on the published literature, in order to take part in the regulation of serious cancer development,
the Wnt/β-catenin signaling pathway does not always stay in the same situation, and is regulated
by lots of factors. Here, we suppose that Srx is involved in the regulation of the Wnt/β-catenin
signaling pathway. Srx is an antioxidant enzyme that exclusively reduces over-oxidized typical 2-Cys
Prx [31], and the reduction of hyperoxidized Prx by Srx can be considered as a rate limiting step in the
reduction of hyperoxidized Prx [32]. Individual components of the Srx–Prx axis play critical roles in
carcinogenesis by modulating the cell signaling pathway involved in cell migration and metastasis [10].
For example, knockdown of Prx inhibits the growth of colorectal cancer cells via downregulating
Wnt/β-catenin signaling [21]. In our study, Spearman’s rank correlation analysis showed a significant
positive correlation between Srx expression and β-catenin expression in human cervical cancer tissues.
Then, we confirmed that the Wnt/β-catenin pathway was stimulated by Srx in HeLa, SiHa and C33A
cells, with activation of CD44—its target genes—resulting in the promotion of invasion and migration
in cervical cancer cell lines. All of these studies and evidence offer proof that Srx really is involved in
the regulation of the Wnt/β-catenin signaling pathway in human cancer.
4. Methods and Materials
4.1. Clinical Patient Specimens
A total of 140 cervical specimens, including 20 normal cervical epithelia (NC), 30 cervical
intraepithelial neoplasia (CIN) and 90 human cervical cancer tissues, were obtained from the
First Affiliated Hospital of Chongqing Medical University (Chongqing, China) from 2010 to 2016.
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The histological classifications and clinical stages were based on the International Federation of
Gynecology and Obstetrics (FIGO) criteria. None of the patients had received chemotherapy,
radiotherapy or immunotherapy before specimen collection. All patients voluntarily signed the
informed consent before operation. This study protocol was approved by the ethics committee of
Chongqing Medical University in 2 March 2015. No. 2015-0302. This study protocol was approved by
the ethics committee of Chongqing Medical University.
4.2. Cell Lines and Reagents
Human cervical cancer cell lines (HeLa (human papilloma virus 18 type cervical cancer cell
line) C33A) were purchased from the Shanghai Cell Bank, Chinese Academy of Sciences (Shanghai,
China). Human cervical cancer cell line (SiHa (cervical squamous cancer cell line)) was obtained from
Proteintech Group (Wuhan, China). These cell lines were cultured in Dulbecco’s Modified Eagle’s
Medium (DMEM; Gibco, Grand Island, NY, USA), respectively supplemented with 10% fetal bovine
serum (FBS; Hyclone, Shanghai, China). All cell lines were maintained at 37 ◦C with 5% CO2. XAV-939
was purchased from Sigma-Aldrich (St. Louis, MO, USA), and was added to the cells for 12 h treatment
at a final concentration of 5 μM. Culture media were changed after 12 h.
4.3. Immunohistochemistry (IHC)
IHC staining was performed using the Immunohistochemical SABC kit (Boster, Wuhan, China)
according to the manufacturer’s instructions. The paraffin sections of tissues were deparaffinized
as routine. Endogenous peroxidase was removed by 3% H2O2 for 10 min at 37 ◦C and antigen was
retrieved by citrate buffer (pH 6.0) at 95 ◦C for 15 min. To prevent non-specific binding, tissues were
blocked with 5% bovine serum albumin (BSA) for 20 min at room temperature. Next, tissues were
incubated with anti-Srx (1:100; Proteintech; Cat No: 14273-1-AP) and anti-β-catenin (1:100; Proteintech;
Cat No: 51067-2-AP) primary rabbit monoclonal antibodies overnight at 4 ◦C, then goat anti-rabbit
secondary antibody for 1 h at 37 ◦C. Then, the tissues were stained with DAB (diaminobenzidine)
dehydrated, fixed and photographed.
Srx and β-catenin expression levels were evaluated based on the staining intensity (0, no staining;
1, light yellow; 2, brown; and 3 dark brown) and the percentage of positive cells (0, <10%; 1, 10–25%; 2,
25–50%; 3, 50–75%; and 4, >75%). Protein staining positivity was calculated by using the following
formula: immunoreactivity score (IRS) = intensity score × quantity score. The final score was defined
as follows: negative, final score ≤3; weak positive, final score >3; strong positive, final score <6.
4.4. Lentiviral Transduction and Establishment of Stable Cell Lines
All lentiviruses, including those containing Srx (Srx-LV) and Srx shRNA (Srx-shRNA) for
overexpressing and knocking down Srx, respectively, and control (ctrl-LV) were purchased from





cacaccagacttgcagtag-3′) and Srx-shRNA (5′-TCGATGTCCTCTGGATCAA-3′). All the transfection
experiments were performed according to the manufacturer’s instructions. Srx-LV was transduced
into C33A cells at a multiplicity of infection (MOI) of 60 and Srx-shRNA was transduced into HeLa
and SiHa cells at a MOI of 30. Polybrene (GenePharma, Shanghai, China) was added in each well at a
final concentration of 5 μg/mL to enhance infection solution. The effects of gene interference on Srx
overexpression or silencing were validated using real-time quantitative polymerase chain reaction
(RT-qPCR) and Western blotting.
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4.5. RT-qPCR
Total RNA was extracted using the TRIzol reagent (TaKaRa, Dalian, China) and then
reversely transcribed into cDNA using the Prime Script RT Reagent Kit (TakaRa), according to the
manufacturer’s instructions. RT-qPCR was performed with the CFX96™ Real-Time System (Bio-Rad,
Hercules, California, USA) using SYBR Green (SYBR Premix Ex Taq™ II; TaKaRa) for fluorescent
quantification. The following cycling conditions were used for RT-qPCR: pre-denaturation (95 ◦C,
30 s), denaturation (95 ◦C, 5 s, 35 cycles), annealing (55–60 ◦C, 30 s), extension (72 ◦C, 1 min) and
final extension (72 ◦C, 10 min). The relative mRNA expression was calculated using the 2−ΔΔCt
method. The primers were used as follows: Srx (Forward 5′-AAGGTGCAGAGCCTCGTGG-3′ and
Reverse 5′-GCTACTGCAAGTCTGGTGTGGA-3′); and β-actin (Forward 5′-CCACGAAACTACCTTCA
ACTCC-3′ and Reverse 5′-GTGATCTCCTTCTGCATCCTGT-3′).
4.6. Western Blot Analysis (WB)
Total Proteins were extracted from tissues and cells by the Protein Extraction Kit (Beyotime,
Haimen, China) and the protein concentrations were determined with a BCA (Bicinchoninic acid)
protein assay kit (Pierce Biotechnology, Shanghai, China), according to the manufacturer’s instructions.
Equal amounts of protein (50 μg) were separated by 10% sodium dodecyl sulfatepolyacrylamide
gel electrophoresis (SDS-PAGE) and transferred onto poplvinylidene fluoride (PVDF) membrane.
Next, the PVDF membrane was blocked with 5% w/v non-fat milk for 2 h at room temperature,
then incubated with primary antibodies to Srx (1:300; Proteintech), β-catenin (1:500; Cell Signaling
Technology, Shanghai, China), GSK/3β (1:500; Cell Signaling Technology), P-β-catenin (1:1000; Cell
Signaling Technology), p-GSK/3β (1:1000; Cell Signaling Technology), CD44 (1:1000; Proteintech) and
β-actin (1:1000; Abcam, Shanghai, China) at 4 ◦C with gentle shaking, overnight. After washing with
PBS (phosphate belanced solution; PBS) containing 0.05% Tween 20, membranes were incubated with
HRP-labeled secondary antibodies (1:2000) for 1.5 h at 37 ◦C. To calculate protein expression levels,
chemiluminescent signals were captured by a chemiluminescence detection system (ChemiDoc™ XRS
imager, (Bio-Rad, Hercules, California, USA) and the signal intensity of each PVDF membrane was
detected by Fusion software (Vilber Lourmat, Marne-laVallée CEDEX, Shanghai, China).
4.7. Cell Migration and Invasion Assay
For cell migration assay, HeLa, SiHa and C33A cells were re-suspended in serum-free DMEM
medium and then seeded into the upper chamber of transwell chambers (Corning Costar, Corning,
NY, USA). DMEM medium with 10% FBS was added into the lower chamber as a chemoattractant.
After 20 h, the chamber was washed three times with PBS and non-invading cells were removed using
a soft cotton swab. Migrated cells on the lower membrane surface were fixed in 4% paraformaldehyde,
stained with crystal violet, and photographed at 100× selected in a random manner from five different
fields of each sample. Cell invasion assay is basically similar to cell migration assay. The difference is
that the transwell chambers used in the cell invasion assay are coated with Matrigel (BD Biosciences,
Hercules, CA, USA) and the time of incubation is 24 h. The values for cell migration and invasion were
obtained through the mean counting of cells in five fields per membrane. The results are presented as
the average of three independent experiments.
4.8. Statistical Analyses
All data from these experiments were assessed with statistical software SPSS 20.0 (SPSS, Chicago,
IL, USA). The results, not including correlation analysis, from immunohistochemistry were analysis by
Pearson’s Chi-Square or Fisher’s exact tests. The correlation between Srx and β-catenin expression
was examined by Spearman’s rank correlation. The analysis of variance (ANOVA) was applied to
evaluate the significant differences. The data are presented as the mean ± standard deviation. p < 0.05
was considered statistically significant. Each experiment was repeated in triplicate.
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5. Conclusions
In conclusion, our findings indicated that Srx promotes cell invasion and migration in cervical
cancer via activating the Wnt/β-catenin signaling pathway. More in-depth mechanistic studies in
the future will help to unravel inter weaved behavior of Srx and lead to the development of better
therapeutic strategies for cancer prevention and treatment.
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Abstract: Mutation in the KRAS gene induces prominent metabolic changes. We have recently
reported that KRAS mutations in colorectal cancer (CRC) cause alterations in amino acid metabolism.
However, it remains to be investigated which amino acid transporter can be regulated by mutated
KRAS in CRC. Here, we performed a screening of amino acid transporters using quantitative
reverse-transcription polymerase chain reaction (RT-PCR) and then identified that ASCT2 (SLC1A5)
was up-regulated through KRAS signaling. Next, immunohistochemical analysis of 93 primary CRC
specimens revealed that there was a significant correlation between KRAS mutational status and
ASCT2 expression. In addition, the expression level of ASCT2 was significantly associated with
tumor depth and vascular invasion in KRAS-mutant CRC. Notably, significant growth suppression
and elevated apoptosis were observed in KRAS-mutant CRC cells upon SLC1A5-knockdown. ASCT2
is generally known to be a glutamine transporter. Interestingly, SLC1A5-knockdown exhibited a more
suppressive effect on cell growth than glutamine depletion. Furthermore, SLC1A5-knockdown also
resulted in the suppression of cell migration. These results indicated that ASCT2 (SLC1A5) could be a
novel therapeutic target against KRAS-mutant CRC.
Keywords: colorectal cancer; KRAS; ASCT2; SLC1A5
1. Introduction
Colorectal cancer (CRC) is one of the most common cancers worldwide; therefore, development
of novel diagnostic measures and treatment is very important [1]. KRAS mutations are found in
approximately 40% of CRC cases [2–4]. A number of clinical trials have shown that KRAS mutations
in CRC can predict a lack of responses towards anti-epidermal growth factor receptor (EGFR)-based
therapy [2–4]. Therefore, development of new therapy for CRC with mutated KRAS has been desired
clinically. Some studies have investigated the correlation between KRAS mutations and metabolic
alterations in pancreatic and lung cancers [5–9] as well as in CRC [10–15]. We have recently reported
that, using metabolome analysis, concentration of amino acids is elevated in CRC cells with mutated
KRAS compared to CRC cells with wild-type KRAS [12]. The increase in glucose transporter 1 (GLUT1)
expression and glucose uptake was critically dependent on mutated KRAS [16–18]. However, it
remains to be investigated which amino acid transporter is specifically regulated by mutated KRAS in
CRC. In the present study, we performed a screening of amino acid transporters in KRAS-mutant CRC
cells transfected by siKRAS and found that ASCT2 (SLC1A5) was particularly up-regulated through
KRAS signaling.
The SLC1A5 gene encodes alanine-serine-cysteine amino acid transporter (ASCT2), which is an
essential glutamine transporter. ASCT2 over-expression has been reported in several cancers [19–31].
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However, the role of ASCT2 in CRC has not yet been reported. In addition to glucose, glutamine is an
essential source of cellular building blocks to fuel cell proliferation. Recent studies have established a
better understanding about the importance of glutamine as a critical nutrient in fast growing cancer
cells [32–34]. In the present study, we investigated the significance of ASCT2 expression in CRC using
in vitro cultures and clinical samples.
2. Results
2.1. SLC1A5 (ASCT2) Is Regulated through KRAS Signaling in KRAS-Mutant CRC Cells
We have recently reported that mutated KRAS induces metabolic alterations in many amino
acids [12]. Therefore, we hypothesized that the expression of amino acid transporters might be
regulated by mutated KRAS. Several amino acid transporters (SLC1A5, SLC7A5, SLC7A11, SLC3A2,
and SLC43A1) have been reported to be up-regulated in different cancers [32]. To determine the
specific transporter that could be regulated by mutated KRAS, we introduced two different small
interfering RNAs (siRNAs) targeting KRAS in KRAS-mutant CRC cell lines (HCT116 and DLD-1).
We confirmed that siKRAS significantly reduced the mRNA levels of KRAS in both cell lines (Figure
S1a). Interestingly, KRAS-knockdown significantly reduced SLC1A5 expression in both KRAS-mutant
cell lines (Figure 1a). SLC1A5 (ASCT2) is a known glutamine transporter. Next, we investigated
whether glutamine transporters other than SLC1A5 (i.e., SLC1A4, SLC38A1, SLC38A2, SLC38A3, and
SLC38A5) could be regulated by KRAS signaling [33]. Expression levels of SLC1A4 and SLC38A1
were decreased after KRAS-knockdown in HCT116; however, their expression was not decreased in
DLD-1 (Figure 1b). We also found that KRAS-knockdown significantly reduced protein expression of
ASCT2 in both KRAS-mutant cell lines (Figure 1c). The mutated KRAS continuously activates both
Raf/MEK/ERK and PI3K/Akt/mTOR pathways. To investigate which pathway regulates ASCT2
expression, we used specific inhibitors of each pathway. Western blot analysis revealed that ASCT2
expression was dramatically reduced in KRAS-mutant CRC cell lines by addition of LY 294002 (PI3K
inhibitor) or rapamycin (mTOR inhibitor), which suggested that KRAS signaling may regulate ASCT2
expression in CRC mainly via the PI3–Akt–mTOR pathway (Figure 1d).
2.2. Relationship between ASCT2 Expression and KRAS Mutational Status in CRC Clinical Samples
We next performed immunohistochemistry (IHC) to evaluate the relationship between ASCT2
expression and KRAS mutational status in clinical specimens of human primary CRC. Regarding the
expression levels of ASCT2, we classified the clinical specimens into four groups; score 0 (0–10%), score
1+ (10–40%), score 2+ (40–70%), and score 3+ (≥70%). Score 0 was found in 12 patients (12.9%), score
1+ in 22 patients (23.6%), score 2+ in 29 patients (31.2%), and score 3+ in 30 patients (32.3%) (Figure 2a).
We defined score 3+ as the high expression group, while score 0, 1+, and 2+ were categorized as the
low expression group. Regarding KRAS mutational status, mutated KRAS and wild-type KRAS were
found in 39 and 54 patients, respectively. ASCT2 expression was high in 43.6% (17 of 39) of CRC
patients with mutated KRAS, whereas in 24.1% (13 of 54) of CRC patients with wild-type KRAS, which
indicated that there was a significant correlation between high ASCT2 expression and KRAS mutation
(risk ratio: 1.62, 95%; confidence interval (CI): 1.02–2.57, p = 0.047, Figure 2b).
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Figure 1. Identification of the amino acid transporter regulated by mutated KRAS. (a) Relative mRNA
levels of amino acid transporters that are reported to be associated with cancer; (b) relative mRNA levels
of amino acid transporters that are involved in glutamine transport. HCT116 cells (left) and DLD-1 cells
(right) were treated separately with two independent siRNA constructs (#1 and #2) targeting KRAS and
negative control (NC) siRNA. Mean; bars, ± SD, n = 3 (Student’s t-test; * p < 0.05); (c) Western blotting
for KRAS, ASCT2, and β-actin (Actin). The relative ASCT2 expression levels for three independent
experiments are shown by quantitative analysis normalized to β-actin (Actin); (d) CRC cells (HCT116
and DLD-1) were treated with 0.1% dimethyl sulfoxide (DMSO), 20 μM U0126 (MEK inhibitor), and
50 μM LY294002 (PI3K inhibitor) or 20 nM rapamycin (mTOR inhibitor) for 48 h. Protein levels
of ASCT2 were normalized to β-actin (Actin). Densitometry values were expressed as fold change
compared with DMSO-treated cells.
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Figure 2. Immunohistochemical staining for ASCT2 of primary colorectal cancer (CRC) specimens.
(a) Representative picture. Scale bar, 200 μm (200× magnification); (b) Relationship between KRAS
mutational status and ASCT2 expression.
2.3. Knockdown of SLC1A5 (ASCT2) Results in Suppression of Cell Growth
To investigate the role of SLC1A5 (ASCT2) in CRC cell lines with mutated KRAS, we introduced
non-silencing siRNA and two different siRNAs targeting SLC1A5 (referred as siSLC1A5#1 and
siSLC1A5#2) into CRC cell lines (Figure S2). Knockdown of SLC1A5 (ASCT2) significantly suppressed
the cell growth in all the 3 cell lines with mutated KRAS (HCT116, DLD-1, and SW480), whereas in 1 out
of 3 cell lines with wild-type KRAS (RKO) (Figure 3a). Furthermore, we investigated the knockdown
effect of SLC1A5 on cell apoptosis. Knockdown of SLC1A5 induced a significant increase in caspase
3/7 activities in all the 3 cell lines with mutated KRAS (HCT116, DLD-1, and SW480), whereas in 2
out of 3 cell lines with wild-type KRAS (HT29 and RKO) (Figure 3b). Oncogenic PIK3CA mutations
were reported to reprogram glutamine metabolism in CRC [35]. PIK3CA mutations are observed in
HCT116 (a H1047R mutation), DLD-1 (E545K; D549N mutations), HT29 (a P449T mutation), WiDR (a
P449T mutation), and RKO (a H1047R mutation), whereas the PIK3CA status is wild-type in SW480.
The PIK3CA status might be related to the differences in the knockdown effect of SLC1A5 between
cell lines.
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Figure 3. SLC1A5 knockdown inhibits cell proliferation and induces cell apoptosis of CRC cells. (a) Cell
proliferation measured by CCK-8 assay. CRC cells were transfected with negative control (NC) or two
independent siSLC1A5 and cultured for 72 h. Viability in each siSLC1A5 was normalized to that in
NC. Student’s t-test; * p < 0.05; (b) caspase 3/7 activities measured by Caspase-Glo assay. CRC cells
transfected with negative control (NC) or two independent siSLC1A5 were cultured for 72 h. Caspase
3/7 activity was normalized to the cell viability measured by CCK-8 assay under the same density and
conditions. Mean; bars, ± SD, n = 3 (Student’s t-test; * p < 0.05).
2.4. Role of SLC1A5 (ASCT2) in KRAS-Mutant CRC Cells
SLC1A5 (ASCT2) is generally regarded as a glutamine transporter. In a KRAS-mutant CRC cell
line (HCT116), glutamine depletion resulted in decreased cell proliferation and enhanced caspase
3/7 activities. Importantly, even in the presence of glutamine, siSLC1A5 dramatically suppressed cell
proliferation and up-regulated caspase 3/7 activities (Figure 4a,b), which indicated that the effect of
SLC1A5-knockdown was more prominent on cell growth and apoptosis than glutamine depletion.
To further investigate the functional role of SLC1A5, we established stable HCT116 transfectant
cell lines in which SLC1A5 was knocked down by shRNA constructs targeting SLC1A5 (referred as
shSLC1A5#1 and shSLC1A5#2) (Figure S3). In the clonogenic assay, SLC1A5-knockdown significantly
31
Int. J. Mol. Sci. 2017, 18, 1632
suppressed colony number as compared to the control (Figure 4c). Moreover, in the wound healing
assay, SLC1A5-knockdown significantly inhibited wound closure as compared to the control (Figure 4d).
Taken together, these results indicate that the inhibition of SLC1A5 (ASCT2) could be a therapeutic
target in KRAS-mutant CRC.
Figure 4. The role of SLC1A5 (ASCT2) in KRAS-mutant CRC cells. SLC1A5 knockdown exhibited more
effective on suppressing cell growth (a) and inducing apoptosis (b) than under glutamine deprivation.
Mean; bars, ± SD, n = 3 (Student’s t-test; * p < 0.05); (c) clonogenic assay with HCT116 transfected
with control or two independent shSLC1A5 vectors. Cells were maintained under 4 mM glutamine
condition containing 10% fetal bovine serum (FBS) for 10 days. Mean; bars, ± SD, n = 3 (Student’s
t-test; * p < 0.05); (d) wound healing assay with HCT116 transfected with control or shSLC1A5 vector.
Cells were photographed at 50× magnification at 0, 24, and 48 h. Wound closure (%) was evaluated.
Mean; bars, ± SD, n = 3 (Student’s t-test; * p < 0.05).
2.5. Tumor Characteristics and ASCT2 Expression in CRC Clinical Samples
Table 1 shows the relationship between ASCT2 expression and clinicopathologic variables. ASCT2
expression was significantly correlated with tumor location, but not with age, sex, tumor size, stage,
T-/N-/M-category, lymphatic invasion, or vascular invasion. We further investigated the clinical
significance of ASCT2, based on the KRAS mutational status. Interestingly, we found that high ASCT2
expression was significantly associated with tumor depth and vascular invasion in KRAS-mutant CRC,
which was not observed in wild-type KRAS CRC.
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2.6. Patients’ Prognosis
To evaluate the relationship between ASCT2 expression and patients’ prognosis, we performed
the log-rank test analysis with CRC patients who underwent curative resection of primary CRC (n = 90).
Kaplan–Meier survival curves indicated that ASCT2 expression was not significantly correlated with
recurrence-free survival (RFS) in all cases (Figure 5a). However, in KRAS-mutant CRC cases (n = 38),
the estimated RFS rate at 5-year tended to be lower in the high ASCT2 group than in the low ASCT2
group (52.9% vs. 70.2%; p = 0.251) (Figure 5b, right). On the other hand, in wild-type KRAS CRC cases
(n = 52), the estimated RFS rate at 5-year was almost similar between the high and low ASCT2 groups
(84.6% vs. 75.8%; p = 0.513) (Figure 5b, left). Taken together, high ASCT2 expression can be one of the
crucial prognostic factors in KRAS-mutant CRC.
Figure 5. Kaplan–Meier analysis of relapse-free survival (RFS) according to ASCT2 expression and
KRAS status. (a) RFS according to ASCT2 expression in total patients; (b) RFS according to ASCT2
expression in KRAS-mutant cases (right) and wild-type KRAS cases (left).
3. Discussion
KRAS mutations are found in a variety of human cancers, including pancreatic cancer, non-small
cell lung cancer, and CRC. Recent studies have shown that mutated KRAS promotes metabolic
reprogramming through nutrients uptake, glycolysis, glutaminolysis, and synthesis of nucleotides
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and fatty acids. The mechanism by which mutated KRAS coordinates the metabolic reprogramming
to promote tumor growth remains to be investigated. The International CRC Subtyping Consortium
has suggested that CRC can be divided into four subtypes with distinguished features: CMS1, CMS2,
CMS3, and CMS4 [15]. Notably, CMS3 is characterized by metabolic dysregulation and is strongly
associated with KRAS mutations. Using a comprehensive metabolomics analysis with isogenic CRC
cell lines harboring mutated or wild-type KRAS, we have recently reported that mutated KRAS induces
some metabolic alterations in glycolysis, the pentose phosphate pathway (PPP), the tricarboxylic
acid (TCA) cycle, and most significantly in the amino acid pathway [12]. We identified that mutated
KRAS regulated asparagine synthetase (ASNS), an enzyme that is involved in de novo synthesis of
asparagine from aspartate, and that KRAS-mutant CRC cells could become adaptive to glutamine
depletion through ASNS-dependent asparagine biosynthesis. There is also some evidence from
other groups that KRAS mutations in CRC are associated with glutamine metabolism. Wong et al.
reported that SLC25A22 (a mitochondrial glutamine transporter) was a synthetic lethal metabolic
gene in KRAS-mutant CRC cells and that expression of SLC25A22 was correlated with poor prognosis
in patients harboring KRAS mutations [11]. Miyo et al. reported that glutamine dehydrogenase 1
(GLUD1) and SLC25A13 (a mitochondrial aspartate-glutamate carrier) played an essential role in cell
survival of CRC cells under glucose-deprived conditions, and that combined expression of GLUD1
and SLC25A13 was significantly associated with tumor aggressiveness and poorer prognosis in CRC
patients [13]. These results indicate that the amino acid metabolism including glutaminolysis is more
essential for cell survival in KRAS-mutant CRC than in wild-type KRAS CRC.
In this study, we focused on the amino acid transporter which was exclusively regulated by
mutated KRAS, although several amino acid transporters have been reported to be up-regulated in
cancer [32]. Herein, we identified SLC1A5 as a novel target gene regulated by mutated KRAS in CRC.
Expressions of SLC25A22 and SLC25A13 were not affected by KRAS-knockdown in our experiments
(Figure S1b). Up-regulation of SLC1A5 (ASCT2) and its clinical significance has been reported in
a variety of human cancers [19–31]. In the present study, we demonstrated that SLC1A5 (ASCT2)
expression was regulated through KRAS signaling, and that SLC1A5-knockdown resulted in reduced
cell growth and increased cell apoptosis in KRAS-mutant CRC cells (Figures 1 and 3). Importantly, the
effect of SLC1A5-knockdown was more prominent on cell growth and apoptosis than that of glutamine
depletion (Figure 4a,b), which indicates that SLC1A5 (ASCT2) plays a critical role in the malignant
progression of KRAS-mutant CRC. Furthermore, SLC1A5-knockdown resulted in the suppression of
cell migration (Figure 4d). In primary CRC clinical specimens, we found that ASCT2 expression was
significantly associated with tumor depth and vascular invasion in KRAS-mutant CRC, but not in
wild-type KRAS CRC (Table 1). In conclusion, our data indicates that SLC1A5 (ASCT2) could be a
novel biomarker as well as a potential therapeutic target in KRAS-mutant CRC.
4. Materials and Methods
4.1. Cell Lines and Reagents
HCT116, DLD-1, SW480, SW620, HT29, RKO, and WiDR cells were obtained from American
Type Culture Collection. All cell lines were cultured in Dulbecco’s Modified Eagle Medium (DMEM)
(glucose 25 mM, glutamine 4 mM) (043-30085, Wako, Tokyo, Japan) supplemented with 10% FBS and
penicillin–streptomycin. Media without glutamine were prepared by using glutamine-free DMEM
(glucose 25 mM, glutamine 0 mM) (045-32245, Wako) supplemented with 10% FBS. The identity of
each cell line was confirmed by STR analysis (Takara Bio, Shiga, Japan). U0126 was purchased from
Calbiochem, LY294002 and rapamycin were from Wako.
4.2. Quantitative Reverse Transcription Polymerase Chain Reaction (RT-PCR) Analysis
Total RNAs were extracted from cells with High Pure RNA Isolation Kit (Roche, Mannheim,
Germany) according to the manufacturer’s instructions. RNA was reverse transcribed to cDNA with
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Transcriptor First Strand cDNA Synthesis Kit (Roche) according to the manufacturer’s instructions.
The relative levels of respective genes were quantified using StepOnePlusTM Real-Time PCR System
(Applied Biosystems, Foster City, CA, USA). The respective mRNA levels were normalized to that for
ACTB. Primer sequences were found in Table S1.
4.3. Western Blot Analysis
Cells were washed with ice-cold phosphate-buffered saline and lysed in sodium dodecyl sulfate
lysis buffer supplemented with inhibitor cocktails of protease and phosphatase. Primary antibodies
can be found in Table S2.
4.4. Small Interfering RNA and Short Hairpin RNA
FlexiTube GeneSolutions for siSLC1A5 (#1: SI05141017, #2: SI00079730) and non-silencing control
siRNA (AllStars negative control siRNA, SI03650318) were purchased from Qiagen (Hilden, Germany).
The siRNA (10 nM) was transfected with Lipofectamine RNAiMAX (Invitrogen, Carlsbad, CA, USA)
according to the manufacturer’s reverse-transfection protocol. SLC1A5 shRNA vectors were made
from the same sequence of siSLC1A5 (#1, #2), and cloned into pLKO.1 vectors. pLKO.1-scramble vector
(Addgene) was used as control.
4.5. Cell Proliferation Assay
A cell proliferation assay was measured by Cell Counting Kit-8 (Dojindo, Kumamoto, Japan)
according to the manufacturer’s instruction. Cells transfected with siRNA were cultured in 96-well
plates at a density of 5000 cells/well for 72 h.
4.6. Clonogenic Assay
Cells were seeded in 6-well plates at a density of 100 cells per well in complete media. At the end
point, colonies were fixed in 1% glutaraldehyde and stained with 0.2% crystal violet for 30 min, and
number of colonies was counted. A colony was defined as a cluster of at least 50 cells.
4.7. Apoptosis Assay
The activity of Caspase-3 and -7 was measured by using Caspase-Glo 3/7 assay (Promega,
Madison, WI, USA) according to the manufacturer’s protocol. Caspase activity was normalized to the
cell number counted by CCK-8 cell proliferation assay under the same density and conditions.
4.8. Wound Healing Assay
Cell lines were seeded into 12-well plates and grew until 80–90% confluence. Confluent cultures
were scratched with sterile tips, washed with PBS, and cultured in DMEM containing 5% FBS. Cells
were photographed by a 50× magnification at 0, 24, and 48 h. Wound closure (%) was evaluated using
the ImageJ software.
4.9. Immunohistochemistry
Formalin-fixed, paraffin-embedded sections were stained with anti-rabbit ASCT2 (Sigma-Aldrich,
St. Louis, MO, USA) antibody. Antigen retrieval was achieved with microwave in citrate buffer (pH:
6.0). For primary CRC tissue, ASCT2 immunoreactivity score was determined by the proportion, as
previously described [30]. The proportion was scored based on the positively rate as “0” (0–10%), “1”
(10–40%), “2” (40–70%), “3” (>70%). Scores of 0, 1, and 2 were defined as low expression, whereas 3
was high expression.
Two researchers (Kosuke Toda and Gen Nishikawa) independently evaluated all
immunohistochemistry samples without prior knowledge of other data. The slides with different
evaluations among them were reinterpreted at a conference to reach the consensus.
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4.10. Patients, Clinicopathological Data
93 patients were collected from patients who underwent primary colorectal cancer resection at
Kyoto University Hospital between April 2009 and September 2013.
No patients received chemotherapy and/or radiation therapy. KRAS mutational status in all
patients was analyzed by using an ABI 3130 Genetic Analyzer (Applied Biosystems, foster City, CA,
USA), as described previously. Pathologic staging was categorized in accordance with the 7th edition
of Union for International Cancer Control (UICC) classification of malignant tumors.
4.11. Statistical Analysis
All values were expressed as mean ± standard deviation (SD). Statistical analyses were conducted
with the JMP Pro 12 (SAS Institute, Inc., Cary, NC, USA). Student’s t-test was used for comparing
means between two groups. In clinical data, the statistical significance of differences between variables
of two groups was determined by student’s t-test, chi-squared test, or Fisher’s exact test. Relapse-free
survival (RFS) rates were evaluated by the Kaplan–Meier survival curve and log-rank test. All analyses
were two-sided, and differences with a p value of less than 0.05 were considered statistically significant
in all analyses.
Supplementary Materials: Supplementary materials can be found at www.mdpi.com/1422-0067/18/8/1632/s1.
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Abstract: Previous studies indicate that breast cancer cells with high aldehyde dehydrogenase
(ALDH) activity and CD44 expression (ALDHhiCD44+) contribute to metastasis and therapy
resistance, and that ALDH1 correlates with poor outcome in breast cancer patients. The current
study hypothesized that ALDH1 functionally contributes to breast cancer metastatic behavior and
therapy resistance. Expression of ALDH1A1 or ALDH1A3 was knocked down in MDA-MB-468 and
SUM159 human breast cancer cells using siRNA. Resulting impacts on ALDH activity (Aldefluor®
assay); metastatic behavior and therapy response in vitro (proliferation/adhesion/migration/colony
formation/chemotherapy and radiation) and extravasation/metastasis in vivo (chick choroiallantoic
membrane assay) was assessed. Knockdown of ALDH1A3 but not ALDH1A1 in breast cancer
cells decreased ALDH activity, and knockdown of ALDH1A1 reduced breast cancer cell metastatic
behavior and therapy resistance relative to control (p < 0.05). In contrast, knockdown of ALDH1A3
did not alter proliferation, extravasation, or therapy resistance, but increased adhesion/migration
and decreased colony formation/metastasis relative to control (p < 0.05). This is the first study to
systematically examine the function of ALDH1 isozymes in individual breast cancer cell behaviors that
contribute to metastasis. Our novel results indicate that ALDH1 mediates breast cancer metastatic
behavior and therapy resistance, and that different enzyme isoforms within the ALDH1 family
differentially impact these cell behaviors.
Keywords: breast cancer; metastasis; therapy resistance; ALDH1A1; ALDH1A3
1. Introduction
Breast cancer is a leading cause of death in women, due primarily to ineffective treatment of
metastatic disease. In order to reduce mortality from breast cancer, it is therefore essential to learn more
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about the metastatic process, and in particular, mechanisms that may contribute to therapy resistance
and disease progression [1,2].
Metastasis is a complex process that involves tumor dissemination from the primary tumor to
distant sites throughout the body, arrest and extravasation at secondary organ sites, and initiation
and maintenance of growth of metastatic lesions [1,3,4]. Given the multi-step nature of this
process, it is not surprising that metastasis is highly inefficient, with the main rate-limiting steps
being initiation of growth at the secondary site from single tumor cells to micrometastases, and
maintenance of that growth into clinically detectable macrometastases [1,3–5]. Given the heterogeneous
nature of breast cancer, this metastatic inefficiency suggests that only a small subpopulation of
tumor cells can successfully navigate the entire metastatic process to successfully form metastases.
We have previously identified such a subset of breast cancer cells with high aldehyde dehydrogenase
(ALDH) activity and expression of CD44, and demonstrated that these ALDHhiCD44+ cells have
enhanced tumor-initiating and metastatic abilities both in vitro and in vivo [6]. Subsequent studies by
Charafe-Jauffret et al. (2009, 2010) supported our findings, indicating that ALDHhiCD44+ cells may
have a role as metastasis-initiating cells [7,8]. We have also demonstrated that these ALDHhiCD44+
cells are significantly more resistant to chemotherapy and radiation therapy, and that the observed
therapy resistance may occur, at least in part, via ALDH-dependent mechanisms [9].
The ALDH superfamily of enzymes is involved in detoxification and/or bioactivation of various
intracellular aldehydes in a NAD(P)+-dependent manner [10,11]. Of particular biological importance,
the ALDH1 family of enzymes (namely ALDH1A1 and ALDH1A3) plays an important role in oxidizing
vitamin A (retinal) to retinoic acid (RA) through an alcohol intermediary. RA functions as a ligand for
nuclear retinoid receptors and leads to transactivation and transrepression of target genes, and is finally
degraded by CYP26 enzymes [12]. ALDH activity has been shown to be involved in self-protection
of normal stem cells and in resistance to the chemotherapeutic drug cyclophosphamide [13]. In the
treatment of acute promyelocytic leukemia (APL), the differentiation agent all-trans retinoic acid
(ATRA) is used clinically in combination with chemotherapy [14,15]. Increased levels of RA signaling
from ATRA treatment have been shown to indirectly suppress ALDH1 promoter activity in liver
cells [16], as well as driving the differentiation of promyelocytes into neutrophils, causing enhanced
cell-cycle arrest and apoptosis [17]. Additionally, ATRA has been shown to modulate cell growth,
apoptosis, and differentiation of breast cancer cells [18]. In terms of therapy resistance, Tanei et al.
(2009) conducted a clinical study looking at 108 breast cancer patients who received neoadjuvant
paclitaxel and epirubicin-based chemotherapy [19]. When ALDH1A1+ and CD24−CD44+ expression
was compared between core needle biopsies (pre-treatment) and subsequent excision (post-treatment),
there was a significant increase in ALDH1A1 positive cells, but no change in CD24−CD44+ cells,
indicating that ALDH1A1+ cells may play a significant role in resistance to chemotherapy.
High ALDH1 expression has been shown to correlate with poor prognosis in breast cancer
patients [20], and has been associated with early relapse, metastasis development, therapy resistance
and poor clinical outcome [7,8,21–23]. The ALDH1A1 isozyme has been shown to have increased
expression in breast cancer patients who present with positive lymph nodes and in patients who
succumb to their disease [24]. In a meta-analysis that looked at almost 900 breast cancer cases
compared to over 1800 control samples, Zhou et al. (2010) found that ALDH1A1 expression was
significantly associated with a high histological grade, ER/PR negativity, HER2 positivity, and worse
overall survival [25]. Furthermore, when ALDHbright cells in various tumors, including breast, are
treated with ALDH1A1-specific CD8+ T cells which target and eliminate ALDH1A1-positive cells,
inhibition of tumorigenic and metastatic growth is observed [26]. In contrast, Marcato et al. (2011)
demonstrated that ALDH1A3 (but not ALDH1A1) expression in patient breast tumors correlates
significantly with tumor grade, metastasis, and cancer stage, indicating that even within the ALDH1
family, alternate isozymes may function differently [27]. Thus, in addition to the classical role of ALDH
as a detoxification enzyme, growing evidence suggests that it may also be playing an additional role in
disease progression.
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The goal of the current study was to test the hypothesis that ALDH1 is not simply a marker of
highly aggressive breast cancer cells and poor patient prognosis, but that it also contributes functionally
to metastatic behavior and therapy resistance. Importantly, we wanted to begin to elucidate the
differential roles of ALDH1 isozymes, namely ALDH1A1 and ALDH1A3. The novel findings presented
here indicate that ALDH1 is functionally involved in breast cancer metastasis and therapy resistance,
and that different isozymes within the ALDH1 family differentially impact these cell behaviors.
2. Results
2.1. Treatment with DEAB (Diethylaminobenzaldehyde) Reduces Breast Cancer Cell Proliferation, Adhesion,
Migration, and Colony Formation In Vitro
We first investigated whether treating cells with previously established chemical inhibitors of
ALDH would have a functional effect on malignant breast cancer cell behavior in vitro, including
proliferation, adhesion, migration, and colony formation. This included treatment with a direct
competitive substrate of ALDH (diethylaminobenzaldehyde (DEAB)) [28]), as well as the differentiation
agent ATRA which has been shown to reduce ALDH promoter activity [9,16]. We observed that cells
treated with either ATRA or DEAB demonstrated decreased growth in normal culture relative to
respective vehicle control (EtOH) treated cells (p < 0.05) (Figure 1A). MDA-MB-468 cells treated with
DEAB were significantly less adherent (Figure 1A) and migratory (Figure 1C) than vehicle control
cells, and DEAB-treated SUM159 cells also demonstrated a significant decrease in migration (p < 0.05)
(Figure 1C). In contrast, MDA-MB-468 and SUM159 cells treated with ATRA were observed to be
significantly more adherent (p < 0.01) (Figure 1B) and migratory (Figure 1C) than respective control
cells (p < 0.05). Finally, in keeping with the proliferation results, cells treated with either ATRA or
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Figure 1. Treatment with diethylaminobenzaldehyde (DEAB) reduces breast cancer cell (A) proliferation,
(B) adhesion, (C) migration, and (D) colony formation in vitro. MDA-MB-468 (left panels) and SUM159
(right panels) human breast cancer cells were treated with 5 μM all-trans retinoic acid (ATRA), 100 μM
DEAB or ethanol (EtOH) as a vehicle control (CON). In all cases, data represents the mean ± standard
error of the mean (SEM) normalized to vehicle control. * = significantly different than respective vehicle
control treatment (p < 0.05).
2.2. Decreased Expression of ALDH1A3 but Not ALDH1A1 Reduces ALDH Activity as Measured by the
ALDEFLUOR® Assay
Rather than being direct inhibitors of ALDH isozyme expression, DEAB is a competitive substrate
of ALDH [28] and ATRA inhibits ALDH promoter activity indirectly through the retinoic acid pathway.
In support of this, we did not observe any significant effect of these inhibitors on directly reducing
ALDH1A1 or ALDH1A3 protein expression (Figure S1). However, given that previous studies have
demonstrated that expression of ALDH1A1 versus ALDH1A3 isozymes have differential correlation
with tumor grade, metastasis, and cancer stage in breast cancer patients [27], we wanted to test the
hypothesis that directly inhibiting ALDH using the alternative approach of targeted knockdown of
ALDH1A1 or ALDH1A3 would also reduce proliferation, adhesion, migration, and colony formation
of breast cancer cells.
siRNA was used to knockdown expression of two ALDH1 isozymes (ALDH1A1 and ALDH1A3)
in MDA-MB-468 and SUM159 breast cancer cells and generate the following cell populations: 468CON,
468ALDH1A1low, 468ALDH1A3low, 159CON, 159ALDH1A1low, and 159ALDH1A3low. Knockdown
of RNA and protein expression was confirmed by quantitative real-time polymerase chain reaction
(RT-PCR) and immunoblotting respectively (Figure 2A–C).
There has been some debate over which ALDH1 isozyme is responsible for the ALDH enzymatic
activity measured in the ALDEFLUOR® assay. (StemCell Technologies, Vancouver, BC, Canada), with
some groups suggesting that ALDH1A1 is responsible, while others believe that it is ALDH1A3 [27,29].
Compared to respective siRNA scrambled controls, we observed that 468ALDH1A3low and
159ALDH1A3low cell populations did demonstrate a significant decrease in ALDH activity (p < 0.001),
while 468ALDH1A1low and 159ALDH1A1low cell populations did not exhibit a change in ALDH
activity (p > 0.05) (Figure 2D). This data is further supported by the observation that ALDH1A3
mRNA expression is higher than ALDH1A1 mRNA expression in sorted ALDHhi versus unsorted cell
populations (Figure S2). Our data also supports previous observations by Marcato et al. (2011), and
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indicates that the ALDH1A3 isozyme is the major contributor to ALDH activity in breast cancer cells
as measured by the ALDEFLUOR® assay [27].
Figure 2. Decreased expression of ALDH1A3 but not ALDH1A1 reduces ALDH activity as measured
by the Aldefluor® assay. MDA-MB-468 (left panels) or SUM159 (right panels) human breast cancer
cells were transfected with 100 pmol siRNA pool targeted towards ALDH1A1, ALDH1A3, or a
scrambled control using Lipofectamine to generate the following cell lines: 468CON, 468ALDH1A1low,
468ALDH1A3low, 159CON, 159ALDH1A1low, and 159ALDH1A3low. After 4 days, RNA, cell lysates, or
cells were collected and (A,B) qRT-PCR, (C) immunoblotting, or (D) Aldefluor® assays were performed
to assess ALDH1 gene expression, ALDH1 protein expression, and ALDH enzyme activity (respectively).
Data represents the mean ± SEM. * = significantly different than respective siCON, 468CON, or 159CON
scrambled control cells (p < 0.05).
2.3. Decreased Expression of ALDH1A1 Reduces Breast Cancer Cell Proliferation, but Adhesion and Migration
of Human Breast Cancer Cells Is Differentially Influenced by ALDH1A1 versus ALDH1A3 In Vitro
Malignant breast cancer cell behavior in vitro was assessed in response to direct knockdown of
ALDH1A1 or ALDH1A3 by siRNA (Figure 3). 468ALDH1A1low and 159ALDH1A1low cells demonstrated
significantly decreased growth in normal culture relative to respective control cells (p < 0.05), whereas
468ALDH1A3low and 159ALDH1A3low cells showed no difference in proliferation compared to control
cells. Lag times (time to reach exponential growth phase) were also observed to be longer for
468ALDH1A1low and 159ALDH1A1low cells versus respective control cells (9 days vs. 5 days for
MDA-MB-468 cells; 5 days vs. 3 days for SUM159 cells) (Figure 3A). We next assessed the influence
of ALDH1A1 and ALDH1A3 knockdown on breast cancer cell adhesion and migration in vitro
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(Figure 3B,C). 468ALDH1A1low and 159ALDH1A1low cells were observed to be significantly less
adherent (Figure 3B), and less migratory (Figure 3C) than respective control cells (p < 0.05). In contrast,
468ALDH1A3low and 159ALDH1A3low cells were observed to be significantly more adherent and more
migratory (Figure 3B,C) than respective control cells (p < 0.05), suggesting that adhesion and migration
of human breast cancer cells is differentially influenced by ALDH1A1 versus ALDH1A3. Knockdown
of either ALDH1A1 or ALDH1A3 resulted in reduced colony formation in soft agar relative to control
cells (p < 0.05) (Figure 3D). It should be noted that the adhesion and migration assays (Figure 3B,C)
are performed over time periods of 24 h or less when siRNA knockdown is strong. However, in
the proliferation and colony-forming assays (Figure 3A,D), the studies extend well past when the
knockdown would be expected to persist. This suggests that the influence of ALDH1 on proliferation
and colony formation is an early but important effect that then has a “feed-forward” or downstream
effect on the ability of breast cancer cells to proliferate or form established/persistent colonies.
Figure 3. Decreased expression of ALDH1A1 reduces breast cancer cell proliferation, but adhesion and
migration of human breast cancer cells is differentially influenced by ALDH1A1 versus ALDH1A3
in vitro. MDA-MB-468 (left panels) and SUM159 (right panels) human breast cancer cells were treated
with control siRNA (siCON) or ALDH-specific siRNA (siALDH1A1 or siALDH1A3) for 96 h to generate
the following cell lines: 468CON, 468ALDH1A1low, 468ALDH1A3low, 159CON, 159ALDH1A1low,
159ALDH1A3low. (A) Proliferation; (B) adhesion assays; (C) migration; and (D) colony formation. In all
cases, data represents the mean ± SEM normalized to respective scrambled control. * = significantly
different than respective scrambled control (p < 0.05).
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2.4. Decreased Expression of ALDH1A1 and ALDH1A3 Reduces In Vivo Metastatic Ability of Breast Cancer
Cells in the Chick Chorioallantoic Membrane (CAM) Assay
In order to assess the metastatic ability of ALDH-deficient cell populations in vivo, GFP-labeled
MDA-MB-468 cell populations (468CON, 468ALDH1A1low, 468ALDH1A3low cells) or CMFDA-labeled
SUM159 cell populations (159CON, 159ALDH1A1low, 159ALDH1A3low cells) were inoculated on the
CAM of 9- or 12-day-old chicken embryos, and the percentage of breast cancer cell extravasation
into the CAM and formation of micrometastases in the chicken embryo were analyzed (Figure 4).
468ALDH1A1low and 159ALDH1A1low cells demonstrated a significant decrease in extravasation
compared to respective control cells (p < 0.05), whereas there was no significant difference observed
in the extravasation of 468ALDH1A3low or 159ALDH1A3low cells compared to control (Figure 4A).
In contrast, Both ALDH1A1low and ALDH1A3low cell populations from both MDA-MB-468 and
SUM159 cell lines demonstrated a significant decrease in the number of micrometastatic tumors that
were able to form compared to control (p < 0.05) (Figure 4B).
Figure 4. Decreased expression of ALDH1A1 and ALDH1A3 reduces in vivo metastatic ability of
breast cancer cells in the chick CAM assay. GFP-labeled MDA-MB-468 or CMFDA-labeled SUM159 cell
populations were transfected with 100 pmol (MDA-MB-468) or 400 pmol (SUM159) siRNA targeted
towards ALDH1A1, ALDH1A3, or scrambled control using Lipofectamine to generate the following
cell lines: 468CON, 468ALDH1A1low, 468ALDH1A3low, 159CON, 159ALDH1A1low, 159ALDH1A3low.
After 4 days, 1 × 105 (extravasation assay) or 2 × 105 (micrometastasis assay) cells were injected into
chicken embryos and (A) cell extravasation was observed after 24 h, or (B) micrometastatic formation
was observed after 7days. Data represents the mean ± SEM normalized to control cells. * = significantly
different than respective 468CON and 159CON cells (p < 0.05).
2.5. Decreased Expression of ALDH1A1 but Not ALDH1A3 Sensitizes Breast Cancer Cells to Chemotherapy
and Radiation In Vitro
Finally, we have previously observed that breast cancer cells with high ALDH activity and
CD44 expression (ALDHhiCD44+ phenotype) are significantly more resistant to chemotherapy and
radiation therapy, and that this therapy resistance may occur, at least in part, via ALDH1-dependent
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mechanisms [9]. Taken together with the known role of ALDH activity in cellular self-protection
and detoxification [30], we hypothesized that a siRNA-mediated reduction in ALDH1 expression
would sensitize MDA-MB-468 and SUM159 cells to chemotherapy and radiation. We observed that
knockdown of ALDH1A1 caused a significant sensitization of both MDA-MB-468 and SUM159 cells to
paclitaxel (Figure 5A), doxorubicin (Figure 5B), and radiation therapy (Figure 5C) (p < 0.05). In contrast,
ALDH1A3 knockdown did not reduce therapy resistance compared to control cells (Figure 5A–C).
Figure 5. Decreased expression of ALDH1A1 but not ALDH1A3 sensitizes breast cancer cells to
chemotherapy and radiation. MDA-MB-468 cells (left panels) and SUM159 cells (right panels)
were treated with control siRNA (siCON) or ALDH-specific siRNA (ALDH1A1 or ALDH1A3) for
96 h to generate the following cell lines: 468CON, 468ALDH1A1low, 468ALDH1A3low, 159CON,
159ALDH1A1low, 159ALDH1A3low. Cell populations were treated with (A) paclitaxel (0.2 μg/mL),
(B) doxorubicin (0.2 μg/mL), or (C) radiation (2 × 5Gy; MDA-MB-468 or 2 × 15Gy; SUM159).
Data represents the mean ± SEM normalized to respective control cells. * = significantly different than
respective 468CON or 159CON cells treated with paclitaxel, doxorubicin, or radiation (p < 0.01).
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3. Discussion
Breast cancer is a leading cause of death in women, primarily due to ineffective treatment of
metastatic disease [1,2]. Our group has previously demonstrated that stem-like ALDHhiCD44+ cells play
a key role in breast cancer metastasis [6] and are highly resistant to chemotherapy and radiation compared
to their ALDHlowCD44− counterparts, potentially as a result of ALDH-dependent mechanisms [9].
Additionally, it has been shown that ALDH1 expression is correlated with early recurrence, worse
prognosis, and a higher incidence of metastasis in breast cancer patients [7,20,21,27]. While this suggests
that ALDH is an important player in breast cancer metastasis; the actual functional contribution of
ALDH1 (in particular its isozymes ALDH1A1 and ALDH1A3) in breast cancer metastasis requires
further elucidation, and this was the goal of the current study.
Although the Aldefluor® assay is often used to isolate ALDHhi cancer cells [6–9,20,31,32], the
specific ALDH isozymes that contribute to this activity remain a subject of debate. In this assay, cells
are incubated in a buffer containing a fluorescent aldehyde substrate (bodipy-aminoacetylaldehyde).
The aminoacetylaldehyde is taken up into the cells via passive diffusion. Once inside the cell,
intracellular ALDH oxidizes the aminoacetylaldehyde into aminoacetate, which is negatively charged,
and therefore retained inside the cell, causing the cells to fluoresce [32]. When ALDH1A1 was
knocked down in both MDA-MB-468 and SUM159 cell lines, there was no observable change in ALDH
activity as measured by the Aldefluor® assay; however, when ALDH1A3 was knocked down, there
was an approximate 50% reduction in ALDH activity measured by the Aldefluor® assay. This is
consistent with breast cancer studies done by Marcato et al. (2011), who observed that ALDH1A3
knockdown was better correlated with a decrease in Aldefluor® activity compared to ALDH1A1 and
ALDH2 [27]. Additional studies have reported that ALDH1A1, ALDH7A1, ALDH2 and/or ALDH1A2
are responsible for driving Aldefluor® activity in other tumor types [32–34], indicating that the ALDH
isoform(s) responsible for Aldefluor® activity may be tumor-specific. Furthermore, in the present
study, even after ALDH1A3 knockdown, there was still approximately 50% normal ALDH activity,
indicating that other ALDH isozymes might be involved in the context of breast cancer. Taken together,
these results suggest that many ALDH isozymes may contribute to the ALDH activity measured by the
Aldefluor® assay, and potentially that different isozymes may contribute to ALDH activity in different
tumor types.
We previously reported that ALDHhiCD44+ cells demonstrated enhanced proliferation, adhesion,
and migration [6]. Additional work in lung and liver cancer cells has suggested that a decrease in
ALDH expression can result in a decrease in proliferation [35–37]. In the current study, we treated
breast cancer cells with DEAB (a direct competitive substrate of ALDH [28]) and observed a decrease
in cell proliferation, as well as in adhesion and migration in vitro compared to control cells, suggesting
that ALDH may potentially contribute to these processes. In order to determine whether ALDH1
isozymes were also involved in these processes, we used siRNA to specifically knockdown ALDH1A1
or ALDH1A3 and observed that ALDH1A1low cells demonstrated decreased proliferation, adhesion,
and migration in vitro. In contrast, cells in which ALDH1A3 had been knocked down showed no
change in proliferation and in fact demonstrated increased levels of adhesion and migration in vitro.
ALDH1 expression has been clinically correlated with an increased incidence of metastasis [7,20,27].
We used the chick CAM assay to elucidate whether ALDH1A1 and/or ALDH1A3 functionally
contributed to metastasis. Cells with decreased ALDH1A1 expression demonstrated decreased abilities
to invade/extravasate; whereas cells with decreased ALDH1A3 expression demonstrated no change
in invasive capabilities compared to control cells in vivo. However, in terms of the actual formation of
metastases in vivo; both ALDH1A1low and ALDH1A3low cells demonstrated a decrease in metastatic
potential, with an approximate 50% reduction in the number of micrometastases that were able to form
in the chick CAM compared to control cells.
Finally, we have previously observed that that ALDHhiCD44+ cells demonstrate high levels of
therapy resistance, and that pre-treatment targeting of ALDH activity using DEAB or ATRA can
sensitize these resistant cells to both anthracycline and taxane chemotherapy, as well as radiation [9].
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In the current study, we directly targeted specific ALDH1 isozymes using siRNA and tested the effect
on therapy response. Notably, when ALDH1A1 expression was decreased, there was a significant
sensitization of the cancer cells to both chemotherapy and radiation. Cells with decreased ALDH1A3
expression, however, showed no change in therapy resistance to either chemotherapy or radiation.
These results suggest that the ALDH1A1 isozyme is an important contributor to therapy resistance in
breast cancer cells, not only to cyclophosphamide chemotherapy (as previously reported [13,38]), but
also to other classes of chemotherapy and radiotherapy.
Our study is the first in the literature to systematically examine the functional roles of ALDH1
isozymes on individual breast cancer cell behaviors that collectively contribute to the metastatic process.
The combined in vitro and in vivo data presented in this study suggests that ALDH1A1 and ALDH1A3
both contribute functionally to various steps in the breast cancer metastatic cascade; however, they
may do so in different ways (summarized in Table 1). For example, it appears that ALDH1A1 may
mediate the adhesion, migration, extravasation, and initial colonization steps; whereas ALDH1A3 may
only participate in colonization and sustainment of metastatic growth. This data both supports and
contradicts previous work by Marcato et al. (2011), who reported that ALDH1A3 and not ALDH1A1
correlated with metastatic disease in breast cancer patients [27]. More recent work by this group led to
the observation that overexpression of ALDH1A3 in MDA-MB-231 human breast cancer cells increases
in vitro invasion and in vivo primary tumor growth and lung metastasis in mice, likely due to changes
in RA signaling [39]. Although they observed that knockdown of either ALDH1A1 or ALDH1A3 in
MDA-MB-231 cells did not have an effect on malignant behavior, this was not surprising given that
this cell line has very low levels of these isozymes to begin with [27]. In contrast, it was somewhat
surprising that their knockdown of ALDH1A1 in MDA-MB-468 cells (one of the cell lines used in the
present study) actually increased primary tumor growth in mice, which is somewhat in contrast with
our observed reduction in proliferation, colony-formation, and in vivo metastasis data presented in
the current study. Overall, Marcato et al. [39] observed cell line-specific differences with regards to
ALDH1A3 function in malignancy and metastasis. In contrast, our data shows that knockdown of
ALDH1A1 consistently reduces most steps in the metastatic cascade except for basic proliferation in
two different human breast cancer cell lines with different genetic backgrounds and differing metastatic
ability. These experimental findings are supported by clinical data, which demonstrates that ALDH1A1
expression is often associated with worse prognosis in breast and other cancers [7,20,24,40–43].
Overall, the results of this study support the concept that ALDH1 plays a functional role in both
breast cancer metastasis and therapy resistance; although the ALDH1A1 and ALDH1A3 isozymes
seemed to contribute to these behaviors in different ways. In order to determine the underlying reasons
for the differential influence of ALDH1 on different malignant behaviors, in-depth mechanistic studies
will need to be carried out in the future. In addition, the observation that ALDH1A3 knockdown only
caused a 50% reduction in ALDH activity suggests that other ALDH isozymes must be involved in
Aldefluor® activity in breast cancer cells. It would therefore be interesting in the future to determine
the functional role of other ALDH isozymes in breast cancer metastasis (i.e., ALDH7A1, ALDH1A2,
and/or ALDH2) [33], as well as to assess corresponding changes in genes, transcription factors,
and epigenetic modifiers that may ultimately be driving the process of metastasis. Elucidation of
the mechanisms by which ALDH1A1, ALDH1A3 and other ALDH isozymes contribute to disease
progression could have potentially important implications for the management and treatment of breast
cancer in the future. Furthermore, additional investigation of ALDH1A1-specific therapy resistance
mechanisms is required, and translating this knowledge into the clinic through development of either
a direct, specific ALDH1A1 inhibitor or an ALDH1A1-related inhibitor that is safe for human use
could have important implications for the management of both primary and metastatic breast cancer.
Finally, it is well known that treating breast cancer before metastasis is observed (i.e., in the adjuvant
setting) is significantly correlated with better patient survival [6,9,44]. Given that ALDH1 has been
both correlated with metastatic disease and shown to functionally contribute to metastasis, it may be
beneficial to use assessment of ALDH1 expression in the primary tumor as a clinical tool for identifying
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breast cancer patients with a high risk of metastasis and stratifying them for aggressive therapy to
prevent disease recurrence or progression.
Table 1. Summary of functional consequences of ALDH1A1 and ALDH1A3 knockdown in
MDA-MB-468 and SUM159 human breast cancer cells.
Functional Behavior/Activity ALDH1A1 Knockdown ALDH1A3 Knockdown
ALDH Activity (Aldeflour) No effect ↓
Proliferation ↓ No effect
Adhesion ↓ ↑
Migration ↓ ↑
Colony Formation ↓ ↓
Extravasation ↓ No effect
Metastasis ↓ ↓
Therapy Resistance ↓ No effect
↑ = increase in respective functional behavior/activity; ↓ = decrease in respective functional behavior/activity.
4. Materials and Methods
4.1. Cell Culture, Reagents, and Therapy Conditions
MDA-MB-468 cells were a kind gift from Dr. Janet Price, M.D. Anderson Cancer Center,
(Houston, TX, USA) [45], and were maintained in αMEM +10% fetal bovine serum (FBS).
The 468 subline expressing green fluorescent protein (GFP) was generated previously as described [46].
SUM159 cells [47] were obtained from Asterand (Detriot, MI, USA) and maintained in Hams: F12 + 5%
FBS. CellTracker™ 5-chloromethylfluorescein diacetate (CMFDA; Invitrogen, Carlsbad, CA, USA)
was used to label SUM159 cells for the CAM assay. All cell lines were authenticated via third party
testing of 9 short tandem repeat (STR) loci on 11 April 2103. (CellCheck, RADIL, Columbia, MO,
USA). All media was obtained from Invitrogen. FBS was obtained from Sigma (St. Louis, MO, USA).
Tissue culture plastic was obtained from NUNC (Roskilde, Denmark).
All-trans retinoic acid (ATRA) and diethylamino-benzaldehyde DEAB (Sigma) were constituted in
100% ethanol and diluted in either Hams:F12 (SUM159 cells) or α-MEM (MDA-MB-468 cells) at 5 μM
(ATRA) or 100 μM (DEAB). Doxorubicin (Novopharm Limited, Toronto, ON, Canada) and paclitaxel
(Biolyse Pharma Corporation, St. Catherines, ON, Canada) were diluted in either Hams: F12 or α-MEM
to the concentrations noted below. Radiation was administered at the doses noted below using a
Cobalt-60 irradiator (Theratron 60, Atomic Energy of Canada Limited, Chalk River, ON, Canada).
All treatment doses were selected based on LC50 values determined in previous experiments [9].
4.2. Cell Proliferation Assays
Breast cancer cells were counted and plated at a density of 5.0 × 104 cells/60 mm plate (n = 3
per time point) and maintained in regular growth media. Every 48 h for 14 days, cultures (n = 3) were
trypsinized and counted using a hemocytometer. Doubling time of each cell population was estimated
during the exponential growth phase according to Td = 0.693t/ln (Nt/N0), where t is time (in hours),
Nt is the cell number at time t, and N0 is the cell number at initial time.
4.3. Cell Adhesion Assays
Breast cancer cells were plated onto sterile 96-well non-tissue culture plates (Titertek, Flow
Laboratories Inc.; McLean, VA, USA) that had been treated with one of: 20 μg/mL of human laminin
(Sigma; SUM159 cells), 5 μg/mL of human vitronectin (Sigma; MDA-MB-468 cells), or PBS (negative
control), using 1 × 104 cells/well (n = 3) for each cell population. Laminin and vitronectin were chosen
based on previous experiments in our laboratory that have demonstrated that SUM159 and MDA-MB-468
cells differentially express integrin receptors for vitronectin and laminin respectively [48,49]. Cells were
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allowed to adhere for 5 h, after which non-adhered cells were rinsed away. Adhered cells were fixed
with 2% gluteraldehyde and stained using Harris’ hematoxylin. Five high powered fields (HPF) (200×)
were counted for each well, and mean numbers of adhered cells/field were calculated and normalized
to control cell populations.
4.4. Cell Migration Assays
Transwell plates (8 μm pore size, 6.5 mm; Becton Dickinson; Franklin Lakes, NJ, USA) were coated
with 6 μg/well of gelatin (Sigma) [50,51]. Chemoattractant (5% FBS) or control (0.01% BSA) media was
placed in the bottom portion of each well. For each cell population, 5 × 104 cells were plated on top of
the transwells. After 24 h, the upper transwell was removed, inverted, fixed with 1% gluteraldehyde,
and stained with Harris’ hematoxylin. A cotton swab was used to carefully remove non-migrated cells
on the inner surface of the transwell. For each well, five HPF were counted and mean numbers of
migrated cells/field were calculated and normalized to control cell populations.
4.5. Colony Forming Assays
Dishes (60 mm) were coated with 1% agarose (Bioshop; Burlington, ON, Canada) in normal
growth media and allowed to solidify for 1 hr. Breast cancer cell suspensions (1.0 × 104 cells/60 mm
plate) were prepared using 0.6% agarose in normal growth media and plated on top of the base agarose
base layer (n = 4 for each time point). Normal growth media was added on top of the cell layer and
changed every 3–4 days for 4 weeks, after which the media was removed and plates were fixed in 10%
neutral-buffered formalin (EM Sciences, Gladstone, NJ, USA). For each dish, 5 HPF were counted and
mean number of colonies per field were calculated and normalized to control cell populations.
4.6. siRNA Knockdown of ALDH1A1 and ALDH1A3
ON-TARGET plus SMART pool small interfering RNAs (siRNA) (Dharmacon Thermo Scientific,
Lafayette, CO, USA) were used to transiently transfect human ALDH1A1 and ALDH1A3 into
MDA-MB-468 and SUM149 cells. All siRNAs were suspended in sterile RNAse-free water at a
concentration of 25 μM. Scrambled control (20–50 μL/mL), ALDH1A1 (20 μL/mL), ALDH1A3
(50 μL/mL) siRNAs and Lipofectamine RNAiMax reagent (20 μL/mL; Invitrogen) were diluted into
serum-free Opti-MEM (Invitrogen). Lipofectamine and siRNA concentrations were determined based
on preliminary experiments which indicated the greatest knockdown of the proteins of interest [49].
The transfections yielded the following cell populations used in further experiments: 468CON,
468ALDH1A1low, 468ALDH1A3low, 159CON, 159ALDH1A1low, and 159ALDH1A3low.
4.7. RNA Isolation and Quantitative RT-PCR
Total RNA was extracted using TRIzol (Invitrogen) according to the manufacturer’s protocol.
Total RNA was reverse transcribed using Superscript III (Invitrogen) and the Eppendorf Mastercycler
Gradient (Eppendorf, Hamburg, Germany). Primers and cycling conditions used for ALDH1A1,
ALDH1A3, and GAPDH are provided in Table 2. Relative quantification of ALDH1A1 and ALDH1A3
gene expression in MDA-MB-468 and SUM159 breast cancer cells was determined by quantitative PCR
using Brilliant® II SYBR® Green qPCR Low ROX Master Mix (Agilent Technologies, Eugene, OR, USA)
and the delta Ct method. GAPDH was used for normalization.
51
Int. J. Mol. Sci. 2017, 18, 2039




Number of Cycles Product Size (bp)
ALDH1A1 Fwd: 5
′-CGT TGG TTA TGC TCA TTT GGA A-3′
Rev: 5′-TGA TCA ACT TGC CAA CCT CTG T-3′
60 s 55 ◦C
60 s 72 ◦C
60 s 95 ◦C
45 22 bp
ALDH1A3 Fwd: 5
′-ATG TGG GAA AAC CCC CTG TG-3′
Rev: 5′-GAA TGG TCC CAC CTT CAC CT-3′
60 s 57 ◦C
60 s 72 ◦C
60 s 95 ◦C
45 20 bp
GAPDH Fwd: 5
′-CAT GTT CGT CAT GGG TGT GAA CCA-3′
Rev: 5′-ATG GCA TGG ACT GTG GTC ATG AGT -3′
45 s 60 ◦C
45 s 72 ◦C
60 s 95 ◦C
40 24 bp
4.8. Immunoblotting
Cell lysates were extracted and protein (10 μg) was subjected to sodium dodecyl sulfate
polyacrylamide gel electrophoresis (SDS-PAGE, 12%) and transferred onto polyvinylidene difluoride
membranes (PVDF; Immobilon™, Millipore; Bedford, MA, USA). Blocking and antibody dilution was
done using 5% skim milk in Tris-buffered saline with 0.1% Tween-20 (TBST). Anti-human primary
antibodies included mouse monoclonal ALDH1A1 (clone IG6; 1:1000) and rabbit polyclonal ALDH1A3
(1:500) (Abcam, Cambridge, MA, USA). Secondary antibodies included goat anti-mouse and mouse
anti-rabbit antibodies conjugated to horseradish peroxidase (Calbiochem, Gibbstown, NJ, USA)
(1:2000). Protein expression was visualized using Amersham ECL Plus (GE Healthcare, Baie d’Urfe,
QC, Canada) using β-actin (Sigma, 1:5000) as a loading control.
4.9. ALDEFLUOR® Assay
The ALDEFLUOR® assay (StemCell Technologies, Vancouver, BC, Canada) was used to assess
ALDH activity as described previously [52–54]. Briefly, cells were harvested, placed in ALDEFLUOR®
assay buffer (2 × 106/mL), and incubated with ALDEFLUOR® substrate for 45 min at 37 ◦C to allow
substrate conversion. As a negative control for all experiments, an aliquot of ALDEFLUOR®-stained
cells was immediately quenched with 1.5-mM diethylaminobenzaldehyde (DEAB), a specific ALDH
inhibitor. Cells were analyzed using the green fluorescence channel (FL1) on a Beckman Coulter EPICS
XL-MCL flow cytometer.
4.10. Chick Embryo Chorioallantoic Membrane (CAM) Assay
For assessment of in vivo extravasation and metastasis, chick embryo chorioallantoic membrane
(CAM) assays were used as described previously [55,56]. Briefly, fertilized chicken eggs (McKinley
Hatchery, St. Mary’s, ON, Canada) were removed from their shell, placed in covered dishes, and
maintained ex ovo at 37 ◦C with 90% humidity. Embryos were used at day 9 (micrometastasis assay) and
day 12 (extravasation assay). Green-fluorescent protein (GFP) labeled MDA-MB-468 or CellTracker™
CMFDA-labeled SUM159 cell populations were injected intravenously (i.v.) into the CAM as described
previously [55,56] using 1 × 105 (extravasation assay) or 2 × 105 (micrometastasis assay) cells/egg
(n = 8–17 eggs per treatment group). For the extravasation assay, a portion of the CAM was sectioned off
using aluminum foil and the number of cells arrested in the sectioned-off area was manually counted
using a fluorescence microscope at 20× magnification. Embryos were then returned to the incubator
for 24 h, after which time the number of extravasated cells in the sectioned off area were manually
counted using a fluorescence microscope. Percent extravasation was calculated by dividing the number
of initial cells by the number of successfully extravasated cells in the CAM. For the micrometastasis
assay, embryos were returned to the incubator for 7 days after cell injection to allow the formation
of metastases. After 7 days, the number of micrometastatic tumors that developed following the i.v.
injection were manually counted using a fluorescence microscope at 4× magnification.
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4.11. Chemotherapy and Radiation Treatment
Cell populations were plated at a density of 5 × 105 cells in 6-well plates (n = 3/treatment group)
and maintained in normal growth medium for 24 h. Cells were then treated with either normal
media alone (control), chemotherapy (paclitaxel (0.2 μM); doxorubicin (0.4 μM)), or radiation (2 × 5Gy,
MDA-MB-468; or 2 × 15Gy, SUM159) and cultured for a further 72 h. Cells were then harvested and
viable cells were quantified using trypan blue exclusion and manual counting on a hemocytometer
using light microscopy.
4.12. Statistical Analysis
All experiments were performed following at least three separate siRNA transfections with
at least 3 biological replicates included within each experiment. In all cases, quantitative data was
compiled from all experiments. Statistical analysis was performed using GraphPad Prism 4.0 software©
(San Diego, CA, USA) using either t-test (for comparison between 2 groups) or analysis of variance
(ANOVA) with Tukey post-test (for comparison between more than 2 groups) when groups passed
both a normality test and an equal variance test. When this was not the case, the Mann-Whitney
Rank-Sum test was used. Unless otherwise noted, data is presented as the mean ± SEM. In all cases,
p values of ≤0.05 were regarded as being statistically significant.
Supplementary Materials: Supplementary materials can be found at www.mdpi.com/1422-0067/18/10/2039/s1.
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ALDH Aldehyde dehydrogenase
ANOVA Analysis of variance
APL Acute promyelocytic leukemia
ATRA All-trans retinoic acid
BSA Bovine serum albumin
CAM Choroiallantoic membrane assay







FBS Fetal bovine serum
GAPDH Glyceraldehyde 3-phosphate dehydrogenase
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GFP Green fluorescent protein
Gy Gray
HPF High-powered field
LC50 Lethal concentration (50%)
NAD(P) Nicotinamide adenine dinucleotide phosphate
PBS Phosphate buffered saline





SDS-PAGE Sodium dodecyl sulfate polyacrylamide gel electrophoresis
SEM Standard error of the mean
siRNA Small interfering RNA
STR Short tandem repeat
TBST Tris-buffered saline + Tween-20
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Abstract: Radiotherapy is a well-established therapeutic regimen applied to treat at least half of all
cancer patients worldwide. Radioresistance of cancers or failure to treat certain tumor types with
radiation is associated with enhanced local invasion, metastasis and poor prognosis. Elucidation of the
biological characteristics underlying radioresistance is therefore critical to ensure the development of
effective strategies to resolve this issue, which remains an urgent medical problem. Cancer stem cells
(CSCs) comprise a small population of tumor cells that constitute the origin of most cancer cell types.
CSCs are virtually resistant to radiotherapy, and consequently contribute to recurrence and disease
progression. Metastasis is an increasing problem in resistance to cancer radiotherapy and closely
associated with the morbidity and mortality rates of several cancer types. Accumulating evidence
has demonstrated that radiation induces epithelial–mesenchymal transition (EMT) accompanied
by increased cancer recurrence, metastasis and CSC generation. CSCs are believed to serve as the
basis of metastasis. Previous studies indicate that CSCs contribute to the generation of metastasis,
either in a direct or indirect manner. Moreover, the heterogeneity of CSCs may be responsible for
organ specificity and considerable complexity of metastases. Long noncoding RNAs (lncRNAs)
are a class of noncoding molecules over 200 nucleotides in length involved in the initiation and
progression of several cancer types. Recently, lncRNAs have attracted considerable attention as novel
critical regulators of cancer progression and metastasis. In the current review, we have discussed
lncRNA-mediated regulation of CSCs following radiotherapy, their association with tumor metastasis
and significance in radioresistance of cancer.
Keywords: radiotherapy; radioresistance; CSCs; EMT; metastasis; LncRNAs
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1. Introduction
Radiotherapy has remained one of the mainstay treatments for cancer in the clinic for over
100 years. The principle of the treatment is based on the theory that cancerous regions are more
sensitive than normal tissues to radiation because cancer cells have a limited ability to repair damaged
DNA and tend to divide more quickly, while the normal tissue parts surrounding tumor lesions can
withstand radiotherapy and recover [1]. However, the biological complexity and heterogeneity of
cancers lead to certain tumor types being more resistant to radiotherapy. Importantly, resistance to
treatment often leads to subsequent recurrence and metastasis of cancer in numerous patients [2,3].
Previous studies have reported that intrinsic cancer stem cells (CSC) representing a small subpopulation
of cancer cells existing within heterogeneous tumors are responsible for radioresistance and metastasis
in various cancer types [4–6]. In contrast, rather than CSCs, the progeny that differentiates from CSCs
accounting for substantial tumor regions is hypothesized to be sensitive to radiotherapy, leading to
short-term regression of cancer. Failure to treat and prevent cancer is therefore attributable to the fact
that radiotherapy is aimed at the tumor bulk but not CSCs [7]. Findings to date have implied that
radiation can paradoxically enhance tumor recurrence and metastasis [3,8,9].
The process of cancer metastasis is thought to consist of several steps. The initial escape from
the primary region requires the epithelial tumor cells to become motile and degrade the underlying
basement membrane and extracellular matrix (ECM). Activation of epithelial–mesenchymal transition
(EMT) is considered necessary to allow epithelial cancer cells local invasion and dissemination at
distant organs [10,11]. Moreover, radiation induces EMT in several cancer cell types [12,13]. EMT
is closely linked to CSC generation and radioresistance [2,14,15]. As mentioned above, several CSC
characteristics are relevant to metastasis, such as motility, invasiveness, and resistance to radiotherapy.
Therefore, regulation of CSCs and therapies that specifically target stem cells are required for
prevention of radiation-induced metastasis and developing improved radiotherapeutic strategies.
A small fraction of the human genome (~1.5%) codes for proteins [16]. The majority of the remaining
noncoding regulatory regions transcribed are defined as noncoding RNAs (ncRNA). ncRNAs have
been shown to influence a variety of human diseases, including cancers. Long noncoding RNAs
(lncRNAs) are a subclass of ncRNAs implicated in the development and progression of cancers [17].
Several investigations on large clinical cancer samples have demonstrated that specific lncRNAs,
such as HOX transcript antisense RNA (HOTAIR) and Growth arrest specific 5 (GAS5), can influence
the outcomes of radiotherapy and act as valuable prognostic biomarkers [18]. Increasing studies
have focused on the biological functions and mechanisms of lncRNAs in recurrence or progression
following radiotherapy.
While the relationship between lncRNAs and CSCs has gradually become an important topic in
cancer research, the specific cellular mechanisms by which these RNAs regulated in the cancer stem
cells and subsequently affect recurrence and metastasis of radioresistant cancers remain unclear at
present. In the current review, we have summarized recent studies focusing on: (1) the relationship
between CSCs and radiotherapy; (2) underlying mechanisms implicated in radiation-induced
metastasis, radioresistance and CSC generation; (3) roles of lncRNAs participating in radioresistance
and radiotherapy-induced cancer metastasis; and (4) roles of lncRNAs in the progression and metastasis
of CSCs. It is speculated that the long noncoding RNAs potentially contribute to radioresistant tumor
occurrence and metastasis by affecting the population or behavior of cancer stem cells. Elucidation of
the molecular cues underlying the effects of noncoding RNAs on CSCs may thus facilitate the design
of effective strategies to improve radiotherapy and prevent cancer metastasis.
2. Cancer Stem Cells and Radiotherapy
Several reports to date have demonstrated that CSCs serve as the crucial contributor to
radioresistance and recurrence after radiotherapy in the majority of cancers, including lung cancer,
breast cancer and hepatocellular carcinoma (HCC) [4–6,19]. CSCs are defined as a small population of
cancer cells within tumors that exhibit self-renewal capacity. These cells can effectively differentiate
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into the heterogeneous lineages of tumor cells constituting a specific cancer type [20]. At present, it is
hypothesized that tumor development is triggered by the capacity of self-renewal and multi-lineage
differentiation of CSCs, whereas differentiated offspring of CSCs do not display the ability to self-renew
and extensively proliferate, therefore losing tumorigenesis potential [21].
CSCs were initially identified in human acute myeloid leukemia (AML) with the capacity to
reconstruct the original disease entirely over several transplantations into immunocompromised mice.
In this study, self-renewal and differentiation properties were only detected within the immature
CD34+/CD38− population of cells [22]. CSCs from solid tumors were identified initially in breast
tumors [23] and subsequently in a broad spectrum of solid tumors, including colorectal, brain,
melanoma, pancreatic, ovarian, lung, prostate and gastric cancers [24]. As CSCs display similar
characteristics as normal stem cells with self-renewal and differentiation capacities, they have high
clonogenic ability and can generate a serially transplantable phenocopy of the primary tumor in
immunocompromised or syngenic animals [20]. At present, however, no reliable markers that allow
precise measurement of CSCs in different tumors are available in the clinic. The most widely used
strategy for isolation of CSCs is based on specific sets of surface markers [20]. Several specific
surface markers of CSCs have been identified in diverse human tumors, including CD133, CD44,
CD44+/CD24− and CD34+/CD38− [2,24]. Furthermore, specific membrane transporters and activities
or expression patterns of enzymes in CSCs are different from those in non-CSCs. For instance, levels of
adenosine triphosphate-binding cassette (ABC) transporters on the cell membrane are increased and
consequently facilitate efflux of Hoechst dye in CSCs of several cancer types, including ovarian, lung,
glioma and nasopharyngeal carcinoma [25–27]. ALDH1 (aldehyde dehydrogenase 1) activity in CSCs
is additionally enhanced in several tumor types, such as lung, breast and pancreatic cancers [28–30].
Transcription factors, such as NANOG (Nanog homeobox), OCT4 (POU class 5 homeobox 1, POU5F1),
SOX2 (SRY-box 2), c-MYC (MYC proto-oncogene, bHLH transcription factor) and KLF4 (Kruppel like
factor 4), and signaling pathways, including WNT (Wingless-type MMTV integration site family), Hh
(Hedgehog), Notch, TGF-β (Transforming growth factor beta), PDGF (Platelet derived growth factor)
and JAK (Janus kinase 1)/STAT (signal transducer and activator of transcription), play crucial roles in
maintaining self-renewal capacity in CSCs and therefore present potential targets in the development
of therapeutic strategies [2,31]. In addition to surface markers and functional regulators, CSCs display
unique characteristics, including increased levels of anti-apoptotic regulators, enhanced DNA repair
efficiency and cellular quiescence [2,31].
The radioresistant ability of CSC markers/regulator-positive cells has been established [2,4,32–34].
Functional markers/regulators, together with the stem cell characteristics, influence the outcomes of
radiotherapy [31,35,36]. Moreover, markers of CSCs may serve as predictors of clinical outcomes in
patients receiving radiotherapy. In view of the crucial effects of CSCs on radiotherapy, clarification
of the underlying mechanisms that mediate radioresistance is an urgent consideration. Generally,
radioresistance of CSCs is associated with increased self-renewal capacity, activation of anti-apoptosis
genes, enhanced capacity of DNA repair and reduced DNA damage via inhibition of reactive oxygen
species (ROS) [36]. Additionally, radiotherapy has been shown to trigger EMT, and, consequently,
metastasis and radioresistance of cancer cells [12,13]. The relationship between radiation and EMT is
discussed below.
3. Mechanisms Implicated in Radiation-Induced Metastasis, Radioresistance and
CSC Generation
3.1. Radiation Promotes Cancer Metastasis and Radioresistance via Induction of EMT
Metastasis is one of the major obstacles to successful cancer therapy [10,37,38] and closely
associated with EMT, a biological process critical in embryogenesis, organ fibrosis and wound healing.
Moreover, the EMT process confers mesenchymal phenotypes to epithelial cells, characterized by
loss of epithelial phenotypes and markers, such as E-Cadherin, ZO-1 (tight junction protein 1, TJP1),
and Desmoplakin, and simultaneous gain of mesenchymal markers, including N-cadherin, Vimentin,
60
Int. J. Mol. Sci. 2017, 18, 1903
Fibronectin, and α-smooth muscle actin (α-SMA). Thus, cancer cells undergoing EMT gain invasive
and metastatic abilities [10,11].
Notably, radiation is reported to trigger EMT and promote metastasis of several cancer types.
For example, radiation treatment enhances the stability of β-catenin (catenin β 1) via the activation of
PI3K (phosphatidylinositol-4,5-bisphosphate 3-kinase)/AKT (AKT Serine/threonine kinase), thereby
inducing the expression and secretion of granulocyte colony-stimulating factor (G-CSF). Recent report
also indicates that radiation promotes the expressions of Nrf2 and Notch1 to activate EMT process in
non-small cell lung cancer (NSCLC) cells. Inhibition of Nrf2-Notch axis reduces EMT but enhanced
radiosensitivity of NSCLC, and consequently decreases radiation-induced NSCLC invasion [39].
Another report also suggests that radiation treatment can activate TGF-β1 signaling to induce EMT
process in Lewis lung carcinoma [40]. Additionally, irradiation induces EMT of human alveolar type
II epithelial carcinoma A549 cells, characterized by elimination of E-cadherin and enhancement of
Vimentin expression is mediated via TBK-GSK-3β axis [41].
In esophageal cancer cells, irradiation induces the EMT phenotype accompanied by increased
migration, invasion, and radioresistance through the induction of SNAIL (Snail family transcriptional
repressor 1), TWIST (Twist family bHLH transcription factor 1), IL-6 (interleukin-6) and STAT3
(signal transducer and activator of transcription 3) signals [42,43]. In glioma cells, sub-lethal doses
of radiation have been shown to promote the metastatic ability through inducing the expression
of αvβ3 integrin, enhancing matrix metalloproteinase (MMP) activity, and altering the ratio of
BCL-2 (B cell leukemia/lymphoma 2)/BAX (BCL2 associated X) toward the apoptosis-resistant
phenotype [8,44]. Further, radiation treatment induces the expression and activity of MET though ATM
(ATM serine/threonine kinase)-NF-κB (nuclear factor kappa-light-chain-enhancer of activated B cells)
signaling pathway, and consequently promotes invasion and apoptosis-resistance of breast cancer
cells [12]. Similar phenomena have been observed in nasopharyngeal carcinoma, colorectal, lung, and
liver cancer subjected to radiation therapy [3,8,13,45,46]. Furthermore, preclinical and clinical evidence
suggests that radiation enhances metastatic potential, in both the primary tumor region and normal
tissues, under specific circumstances [3,47].
In addition to radiation-induced metastasis, cancer cells that have gained mesenchymal
characteristics via EMT are more resistant to radiotherapy, indicating that radiation-induced EMT
confers radioresistance, which contributes to relapse [48]. For example, prostate cancer cells have been
shown to exhibit EMT phenotypes and become more resistant to radiation after radiotherapy [49].
Similar results have been reported with other cancer types, including nasopharyngeal carcinoma,
colorectal cancer (CRC), lung cancer, HCC cells, breast cancer and gastric cancer [45,50–54].
The process of EMT contributes to radioresistance of cancer cells via induction of EMT-related
genes/signals, such as PI3K/AKT, PTEN (phosphatase and tensin homolog), mTOR (mechanistic
target of rapamycin kinase) and TGF-β, which inhibit cell death signals. Accordingly, silencing the
expression of SNAIL and SLUG (Snail family transcriptional repressor 2), crucial EMT inducers,
could sensitize cancer cells to genotoxic stress induced by chemo or radiotherapy [55]. In addition,
activation of the Notch signaling pathway induces SNAIL and SLUG expression in tumor cells and
the phenomenon of EMT, leading to the suppression of p53-mediated apoptosis induced by cancer
therapy [14,56]. Therefore, initiation of EMT is accompanied by the activation of crucial gene sets or
signals that influence sensitivity to radiotherapy.
As mentioned above, radiotherapy-induced EMT in cancer cells promotes the development of
cancer cell radioresistance. Additionally, previous studies have demonstrated that EMT leads to
the generation of CSCs generally resistant to therapy with elevated expression of genes involved in
free-radical scavenging, DNA repair pathways and drug transporting capacity [57,58]. Interestingly,
non-stem cancer cells can spontaneously dedifferentiate into CSCs via EMT. Thus, generation of CSCs
after radiation via EMT may be an important factor in the development of resistance of cancer cells to
radiotherapy. In conclusion, radiation treatment is prone to damage cancer cells and shrink tumors.
However, irradiation triggers a small percentage of cancer cells to adopt the malignant phenotypes
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including stemness, metastasis and anti-apoptosis through EMT (Figure 1A). The inhibition of the
signals associated with EMT represents a potentially efficient strategy for the treatment patients with
radioresistant tumors, although further investigation is required.
Figure 1. Molecular mechanisms of radiotherapy induced cancer recurrence and metastasis: (A) Cancer
stem cells (CSCs) representing a small subpopulation of cancer cells existing within heterogeneous
tumors are responsible for radioresistance and metastasis. After the radiation treatment, the
majority of cancer cells are killed via the induction of apoptosis or mitotic death. However, a
small number of non-CSCs exhibit the radioresistant property and dedifferentiate and transform
into CSCs through radiation induced epithelial–mesenchymal transition (EMT). The newly generated
CSCs from non-CSCs, together with the intrinsic CSCs, consequently contribute to recurrence and
metastasis of cancer; (B) radioresistant CSC associated long noncoding RNAs (lncRNAs); and (C) CSC
associated lncRNA.
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3.2. Radiation Promotes CSC Generation
Radiation treatment causes enrichment of CSCs both in vitro and in vivo, implying that CSC
generation is triggered by radiation. For instance, radiotherapy has been shown to enhance the
population of CD44+ cells that display CSC properties in patients with prostate cancer [59]. Another
study reported an increase in expression of CSC surface markers in the MDA-MB-231-xenograft
model after stimulation with fractionated radiation [60]. Enrichment of breast CSCs via radiation
is considered the result of different sensitivities of CSC and non-CSC cancer cells to radiotherapy.
Notably, earlier studies have demonstrated that radiation promotes reprogramming of differentiated
cancer cells into CSCs. Enrichment of breast CSCs after radiation stimulation is implicated in the
induction of stem cell-like characteristics in non-stem cancer cells [61,62]. In these studies, ALDH1−
breast cancer cells in a single cell suspension were isolated from either human breast specimens or
established cell lines and subsequently subjected to various doses of radiation. The number of ALDH1+
cells was dramatically increased in a dose-dependent manner after five days of radiation treatment.
The results clearly indicate that radiotherapy can induce the CSC phenotype in non-stem breast cancer
cells. Moreover, radiation-induced CSCs display better capacity of mammosphere formation and
tumorigenicity, and express stem cell-related genes similar to breast CSCs isolated from samples
without radiation treatment. In addition to breast cancers, radiotherapy could induce a stem cell-like
phenotype in non-stem HCC cells [63]. Non-CSCs isolated from HepG2 and Huh7 cells display better
sphere formation ability and express stem cell-related genes after exposure to radiation [63].
Non-stem cancer cells can generate cells with CSC properties via the EMT process [15,64,65].
Additionally, radiation treatment induces cancer cells to undergo EMT, leading to radioresistance [49].
For example, after radiotherapy, resistant cells display a complex phenotype involving a combination of
the properties of CSCs and EMT with higher expression of Snail, CD44, CD24, and PDGFR-β (platelet
derived growth factor receptor β) in non-small cell lung cancer (NSCLC) cells [6]. Additionally, the
subpopulation of CD133+ colorectal or CD24+ ovarian cancer cells exhibits both properties of CSC
and EMT, characterized as increased SNAIL, TWIST, and Vimentin along with decreased E-cadherin
expression [66,67]. EMT is reported to induce transcriptional regulators or signaling pathways, such
as SNAIL, STAT3, NF-κB, Notch and PI3K/AKT and the MAPK (mitogen-activated protein kinase)
cascade, indicative of a critical role in radiation-induced CSC properties [2]. The collective findings
suggest that radiation promotes the generation of CSCs from non-stem cancer cells and shed light on
the novel interactions between cancer cells and radiotherapy, which pave the way for clarifying the
precise mechanisms leading to cancer radioresistance.
4. Cellular Functions of LncRNAs in Radioresistance
With the advent of genome sequencing efforts [68,69], numerous RNA transcripts with similar
properties to mRNAs that are not translated into proteins have been identified. These transcripts,
collectively defined as long noncoding RNAs (lncRNAs), are generally primary non-protein coding
sequences greater than 200 nucleotides in length [70]. Although the cellular function of the majority of
lncRNAs is still unknown [70], a number of reports are suggested to be functional RNA molecules
involved in the regulation of diverse biological processes [70]. LncRNAs can interact with DNA, RNA
or proteins. Recent large-scale sequencing analyses have revealed that many transcripts of lncRNAs
may, in fact, be translated into functional peptides [71]. Accumulating studies indicate that lncRNAs
regulate the transcription of genes related to the DNA damage response via different regulatory modes,
including signal, decoy, guide, and scaffold [72]. DNA damage response and repair capacity are
closely related to sensitivity to radiotherapy. In addition, numerous lncRNAs are aberrantly expressed
in cancer cells and have been implicated in development of the radioresistant phenotype of cancer
cells. Thus, lncRNAs may present effective target molecules in combination with radiation treatment
for cancer. Here, we have systematically reviewed documented literature focusing on the lncRNAs
participating in resistance to radiotherapy.
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4.1. LncRNAs Associated with Apoptosis
4.1.1. LincRNA-p21
LincRNA-p21 is an intergenic long noncoding RNA (3100 nucleotides) located on chromosome 17,
~15 kb upstream from the Cdkn1a (p21) gene [73]. LincRNA-p21 has been identified as the downstream
target of p53 modulating the expression of numerous genes involved in cell cycle control, DNA damage
and repair pathways [73]. The RNA acts as a suppressor of p53-dependent transcriptional responses
and its inhibition influences the expression patterns of genes that are generally repressed by p53. In the
presence of DNA damage, lincRNA-p21 is required to induce p53-dependent apoptosis via physical
association with ribonucleoprotein K (hnRNP-K). This step leads to proper genomic localization of
lincRNA-p21/hnRNP-K at the gene promoter region and consequently suppresses their expression
in a p53-dependent manner [74]. Additionally, lincRNA-p21 is implicated in cell cycle regulation.
Specifically, lincRNA-p21 is proposed to enforce the G1/S checkpoint and regulate cell proliferation via
activating p21 expression in cis to promote Polycomb target genes expression [75]. Notably, expression
of lincRNA-p21 is downregulated in several cancer types, and recent reports have also demonstrated
a role in radiation-mediated cell death [76,77]. LincRNA-p21 is frequently reduced in colorectal
cancer (CRC) cancer cell lines and human tissues and leads to elevation of the WNT/β-catenin signal
pathway [77,78]. Furthermore, expression of lincRNA-p21 is increased upon X-ray treatment. Higher
levels of lincRNA enhance the sensitivity of CRC to radiotherapy via repression of β-catenin signals
and induction of the proapoptotic gene, NOXA, consequently promoting apoptosis [77]. Silencing of
lincRNA-p21 causes β-catenin overexpression and leads to increased stemness and radioresistance
of glioma stem cells [79]. Another study showed that lincRNA-p21 is transcriptionally induced by
ultraviolet B in a p53-dependent manner in keratinocytes in vitro or skin from mice in vivo. Ultraviolet
B-mediated lincRNA-p21 triggered cell cycle arrest and apoptosis in keratinocytes, and conversely, its
inhibition resulted in evasion of apoptosis caused by ultraviolet B [74].
4.1.2. LOC285194
The lncRNA LOC285194, also termed LSAMP antisense RNA, was first identified as a
p53-regulated tumor suppressor that influences the cell cycle and apoptosis by regulating VEGF
receptor 1 and miR-211 in osteosarcoma [80,81]. Recent evidence has shown decreased expression of
LOC285194 in esophageal squamous cell carcinoma in relation to larger tumor size, high-grade TNM
stage, lymph node and distant metastasis. Additionally, low expression of LOC285194 serves as an
independent prognosis factor closely associated with preoperative chemoradiotherapy response and
poorer disease-free and overall survival rates [82]. Thus, LOC285194 may be considered a potential
therapeutic marker for screening of patients to determine their suitability for chemoradiotherapy and
estimate outcomes.
4.1.3. ANRIL
The lncRNA ANRIL, also designated CDKN2B-AS (CDKN2B antisense RNA 1), was initially
identified from familial melanoma patients [83]. LncRNA ANRIL produces a 3834 nt RNA transcript
in the antisense orientation of the INK4B-ARF-INK4A gene cluster. Previous studies have documented
upregulation of ANRIL in various cancer types and its utility as a prognosis marker [84–86].
Upregulation of ANRIL in cancer cells has been shown to enhance resistance to radiotherapy
via inhibition of apoptosis and induction of cell proliferation. Conversely, inhibition of ANRIL
expression causes repression of cellular proliferation and radioresistance via induction of apoptosis.
Further experiments revealed that oncogenic effects of ANRIL are mediated through negative
regulation of miR-125a, a tumor suppressor implicated in apoptosis and metastasis [87]. Moreover,
Silencing of ANRIL upregulates the expression of the pro-apoptotic genes, BAX and SMAC (second
mitochondria-derived activator of caspases), but suppresses the anti-apoptotic gene, BCL-2 [88].
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Thus, lncRNA ANRIL is considered an important suppressor of apoptosis that influences cancer cell
sensitivity to radiotherapy.
4.1.4. AK294004
Recent microarray analyses by Wang et al. [89] investigated changes in the lncRNA profiles
in nasopharyngeal carcinoma in response to radiation in combination with curcumin treatment,
following reports that curcumin (Cur) could sensitize cancer cells to radiotherapy. Among the
116 radiation-induced and Cur-reversed differentially expressed lncRNAs, six (AF086415, AK095147,
RP1-179N16.3, MUDENG, AK056098, and AK294004) were identified. Further functional studies
indicated that lncRNA AK294004 directly targets Cyclin D1 and exerts a negative effect. In view of the
finding that Cyclin D1 is an important mediator of the cellular DNA damage response and apoptosis
after radiation treatment [90], AK294004 may be a potential lncRNA participating in radioresistance of
cancer [89].
4.1.5. LncRNA-ROR
LncRNA-ROR was initially identified in induced pluripotent stem cells and shown to play a
key role in maintaining the properties of these cells by suppressing stress pathways such as the p53
response [91,92]. Further studies provided evidence that lncRNA-ROR serves as a suppressor of p53 in
response to DNA damage [93] and contributes to cancer progression, recurrence and chemoresistance,
in part, by negatively regulating p53 and miR-145 in various cancer types [92,94]. Expression
of lncRNA-ROR is increased in several cancer types and serves as a prognosis marker including
colorectal cancer [95–97], and silencing its expression in CRC cells enhances sensitivity to radiotherapy
via negative regulation of the p53/miR-145 axis. Importantly, combination of radiotherapy with
specific knockdown of lncRNA-ROR was shown to induce significant tumor reduction in a xenograft
model [95]. Thus, lncRNA-ROR may present an effective potential therapeutic target in combination
with radiotherapy.
4.1.6. MALAT1
Metastasis-associated lung adenocarcinoma transcript 1 (MALAT1) (also termed NEAT2 or
nuclear-enriched abundant transcript 2) was one of the first lncRNAs identified in relation to tumorigenesis
and used as a prognostic marker for development of metastatic disease and poorer survival rate in
early-stage lung adenocarcinoma [98]. MALAT1 is overexpressed in various cancers and linked to
promotion of radioresistance through triggering EMT, CSC activity, and anti-apoptosis ability [99–101].
For instance, MALAT1 is significantly upregulated in nasopharyngeal carcinoma (NPC) specimens
or cell lines. Silencing the expression of MALAT1 sensitizes NPC cells to radiotherapy, both in vitro
and in vivo. Further investigation revealed a negative regulation loop of MALAT1 and miR-1. SLUG,
a crucial regulator of EMT, was determined as a direct target of miR-1. The function of MALAT1 in
activating EMT and CSCs via modulating the miR-1/SLUG axis supports its utility as a therapeutic
target for NPC patients [101]. MALAT1 was upregulated in esophageal squamous cell carcinoma
(ESCC) and cervical cancer tissues [99,102,103]. Following radiation treatment, expression of MALAT1
was decreased in radiosensitive but increased in both radioresistant cancer cells and clinical cases.
Ectopic expression of MALAT1 induced an increase in CKS1 in ESCC cells and decrease in miR-145
in cervical cancer cells, and which is leading to inhibition of cancer cell apoptosis after radiation
treatment [99,103]. These reports collectively support a critical role of MALAT1 in radioresistance
of cancers.
4.1.7. NEAT1
Nuclear paraspeckle assembly transcript 1 (NEAT1) has been identified as a transcriptional target
of p53 involved in the cellular response to stress or DNA damage [104,105]. Upon activation of p53,
formation of paraspeckles is stimulated in mouse and human cells. Silencing of NEAT1 expression
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prevents paraspeckle formation and sensitizes preneoplastic cells to DNA damage-induced cell death,
preventing chemical-induced skin tumorigenesis in mice and enhancing chemotherapy-induced
cytotoxicity [105], consistent with the theory that increased DNA damage sensitizes cells to p53
reactivation therapy [106]. NEAT1 overexpression has been reported in different types of solid tumors,
such as lung cancer, esophageal cancer, CRC and HCC, whereby higher levels are associated with
poor prognosis [107]. NEAT1 targeting may therefore present a potential strategy to enhance the
effectiveness of DNA-damaging chemotherapeutics and p53-reactivating molecules. Recent evidence
suggested that the lncRNA NEAT1 regulates EMT and radioresistance in NPC cells [108]. Specifically,
NEAT1 was significantly upregulated in NPC cell lines and tissues and its knockdown sensitized NPC
cells to radiation in vitro. Further experiments revealed reciprocal suppression effects of NEAT1 and
miR-204. Upregulated NEAT1 in NPC cells inhibited the targeting of miR-204 to ZEB1, an important
modulator of EMT in cancer cells [10], resulting in radioresistance and EMT activation [108]. Thus,
NEAT1 is considered a potential target to enhance the effectiveness of radiotherapy.
4.2. LncRNAs Associated with DNA Repair
4.2.1. LINP1
DNA repair is a complex process in cells that occurs to identify and correct damaged DNA. This
process is vital for maintaining genomic integrity and crucially involved in tumorigenesis and cancer
radiotherapy. Non-homologous end joining (NHEJ) is one of the major mechanisms responsible for
repairing damaged DNA in cancer cells [109]. Human triple-negative breast cancer (TNBC) is an
aggressive subtype that presents poor prognosis and resistance to radiotherapy [110]. Recently, an
lncRNA in the non-homologous end joining (NHEJ) pathway 1 (LINP1) was shown to be overexpressed
in TNBC [111]. Upon EGFR (epidermal growth factor receptor) activation, LINP1 is transcriptionally
upregulated via RAS-MEK-ERK signaling and AP1 (activator protein 1) transcription factors. The
increased level of LINP1 acts as a scaffold to stabilize Ku80 and DNA-PKcs interactions and coordinates
the NHEJ pathway to enhance DNA repair activity. RNA expression of LINP1 is also downregulated
through interactions with miR-29 in a p53-dependent manner. Importantly, p53-mediated inhibition of
LINP1 increases the sensitivity of breast tumor cells to radiotherapy [111].
4.2.2. POU6F2-AS2
Recently, POU6F2-AS2 was identified as a novel lncRNA involved in the DNA damage response
that regulates the sensitivity of cancer cells to ionizing radiation in esophageal squamous cell carcinoma.
Further experiments demonstrated that POU6F2-AS2 interacts with YBX1 (Y-box binding protein)
protein and regulates chromatin localization [112]. YBX1 has been characterized as a DNA and
RNA binding protein involved in the regulation of DNA damage response, DNA repair regulation,
pre-mRNA splicing and mRNA packaging. Moreover, YBX1 is highly overexpressed in multiple cancer
types and may serve as a potential prognostic marker for poor outcomes and drug resistance in specific
cancer types [113]. Thus, POU6F2-AS2 may be a master regulator that participates in DNA or RNA
synthesis and other processes [112].
4.3. LncRNAs Associated with both EMT and Radioresistance
4.3.1. TUG1
Taurine-upregulated gene 1 (TUG1) was initially reported to be induced following treatment
with taurine in mouse retinal cells [114]. TUG1 has been identified as a tumor suppressor or
oncogene in various cancer types [115–119]. Recent studies also support an important role of TUG1
in cancer cell invasion and resistance to radiotherapy. For instance, an earlier study demonstrated a
significant increase in expression of TUG1 in high-grade bladder cancer tissues while its silencing led
to suppression of cell proliferation and metastasis. TUG1 expression was markedly elevated upon
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radiation treatment [120]. Notably, TUG1 expression promoted cancer cell invasion and radioresistance
via triggering EMT. Further experiments disclosed that reciprocal repression of miR-145 mediates
the effects of TUG1. Suppression of miR-145 by TUG1 resulted in re-expression of ZEB2 (zinc finger
E-box binding homeobox 2), a master inducer of EMT downregulated by miR-145, and consequently,
enhanced EMT and radioresistance [119]. Additionally, silencing of TUG1 was shown to enhance
sensitivity to radiotherapy via suppression of HMGB1 (high mobility group box 1) expression [120].
HMGB1 has been identified as a chromosome-binding protein that participates in DNA repair,
transcription and nucleosome packaging [121]. The data collectively indicate that TUG1 acts as
a potential regulator of radioresistance in cancer through EMT induction and DNA repair regulation.
4.3.2. HOTAIR
Homeobox (HOX) transcript antisense RNA (HOTAIR) initially identified as a spliced and
polyadenylated RNA participating in the promotion of carcinogenesis and cancer progression,
is considered a prognosis marker for various cancer types [122–124]. In general, HOTAIR is a
transacting lncRNA that interacts with Polycomb Repressive Complex 2 (PRC2) and lysine-specific
demethylase 1 to negatively influence the expression of cancer-related genes [124,125]. PRC2 is
a histone methyltransferase involved in epigenetic silencing during different processes, including
cancer development [126]. In addition to promoting cancer progression and initiation, recent evidence
indicates an important role of HOTAIR in radiotherapy for cancer. For instance, HOTAIR is upregulated
in breast cancer [127], cervical cancer cells [128], CRC [129], pancreatic ductal adenocarcinoma (PDAC)
and Lewis lung cancer [130,131]. Overexpression of HOTAIR in MDA-MB-231 causes radioresistance
by promoting HOXD10 expression and activation of the PI3K/AKT-BAD signaling pathway [127].
Additionally, increased HOTAIR expression in cervical cancer cells is reported to enhance aggressive
characteristics, such as invasion, proliferation, and radioresistance, via suppression of p21 [128].
Conversely, silencing of HOTAIR in CRC cells inhibits cell invasion and increases sensitivity to radiation
by regulating apoptosis-related genes, such as BCL-2 and BAX [129]. In PDAC and Lewis lung cancer
cells, radiation treatment was shown to repress cell viability and HOTAIR while enhancing WIF-1
(WNT inhibitory factor 1) expression. WIF-1 has been identified as an inhibitor of WNT/β-catenin
signaling [132]. Silencing of HOTAIR expression promotes WIF-1 expression and inhibits the nuclear
translocation of β-catenin. In contrast, upregulation of HOTAIR appears to enhance nuclear β-catenin
expression via inhibiting WIF-1 expression, leading to radioresistance in both PDAC and Lewis lung
cancer cells [130,131]. These findings collectively support the utility of HOTAIR as a valid therapeutic
target for reversal of radioresistance in several types of cancer.
4.4. LncRNAs Associated with Epigenetic Regulation
PARTICLE
PARTICLE (promoter of MAT2A-antisense radiation-induced circulating lncRNA) was recently
identified as a novel lncRNA participating in the regulation of cellular response to radiotherapy [133].
PARTICLE is located within the MAT2A gene and transcribed in an antisense orientation to
the forward plus strand from the MAT2A promoter. MAT2A encodes the catalytic subunit of
methionine adenosyltransferase (MAT), a crucial cellular enzyme contributing to production of
s-adenosylmethionine (SAM), the principal methyl donor of cells [134,135]. PARTICLE is upregulated
in both breast cancer cell lines and cells from head-and-neck cancer (HNC) patients after radiation
treatment. Radiation-induced nuclear PARTICLE forms a DNA-lncRNA triplex at a CpG island
upstream of the MAT2A promoter, which provides a recruitment platform for methyltransferase and
subunits of polycomb repressor complex, including G9a (euchromatic histone lysine methyltransferase
2) and SUZ12 (SUZ12 polycomb repressive complex 2 subunit), leading to transcriptional repression of
MAT2A. In addition, cytosolic PARTICLE serves as the scaffold for MAT2A. Colocalized PARTICLE
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and MAT2A cytosolic transcripts are exported via exosomes in response to radiation treatment in both
cancer cells and clinical samples.
MAT2A is the key enzyme catalyzing the formation of SAM, the methyl donor for
transmethylation, and plays an important role in DNA repair and protein methylation. Moreover, the
level of epigenetic DNA methylation is increased through radiation-induced activation of MAT2A [136].
Thus, dysregulation of PARTICLE may be an important factor influencing the outcome of radiotherapy.
4.5. Plasma LncRNAs Associated with Radiotherapy
GAS5
Recently, Fayda et al. [18] evaluated the plasma levels of three lncRNAs (GAS5, lincRNA-p21, and
HOTAIR) in the treatment response in 41 patients with HNC after chemoradiotherapy. The predictive
values of these lncRNAs were investigated in patients with complete response (CR) versus those with
partial response (PR)/progressive disease (PD). Data from the clinical analyses revealed significantly
higher levels of post-treatment GAS5 in patients with PR/PD, compared to patients with CR. Moreover,
the pretreatment GAS5 level was markedly increased in patients with PR/PD, compared to those with
CR, in an MRI-based response evaluation. However, the levels of pre- or post-treatment lincRNA-p21
and HOTAIR were not informative in terms of determining treatment response. Furthermore, GAS5
has been reported to be down-regulated in multiple cancers and serve as a prognosis marker [137].
Thus, lncRNA GAS5 may serve as an effective biomarker to predict treatment response in patients
with HNC [18].
4.6. Identification of Novel LncRNAs That Potentially Participate in Resistance to Radiotherapy
5-FU-based concurrent chemoradiation is recommended as the standard treatment for colorectal
cancer cells. A recent study established chemoradiation-resistant HCT116 cells to investigate the
potential lncRNAs involved in treatment resistance. Following microarray expression analysis and
further validation, three novel lncRNAs, TCONS_00026506, ENST00000468960, and NR_038990, were
identified, which may serve as potential therapeutic targets for radioresistant cancer cells [138].
A recent comparison between the parental nasopharyngeal cancer (NPC) cell line, CNE-2, and
radioresistant CNE-2 via next-generation deep sequencing led to the annotation of 2054 novel and
781 known lncRNAs [139]. Further validation via qRT-PCR in both established radioresistant CNE-2
and 6-10B cell lines showed that three novel lncRNAs (n373932, n409627 and n386034) exhibit significant
expression changes after radiation treatment. Further examination of the expression patterns of n373932
and its associated gene, SLITRK5, in clinical specimens revealed a negative correlation between
expression of n373932 and SLITRK5. In view of the results, it is proposed that n373932, n409627 and
n386034, and interactions between n373932 and SLITRK5 are involved in radioresistance of cancer
cells [139].
In another study, Zhou et al. [140] performed microarray analysis to identify changes in the
lncRNA expression profiles during the time-period of development of radioresistant cells from
parental hypopharyngeal squamous cell carcinoma (HSCC), FaDu, after radiation therapy. Among the
consistently dysregulated lncRNAs, TCONS_00018436 was identified as a potential lncRNA mediating
resistance of HSCC cells to radiation. Further experiments demonstrated that TCONS_00018436
exhibits anti-apoptotic activity following radiotherapy and its expression is dysregulated in recurrent
HSCC clinical tissue samples [140].
5. Cellular Functions of LncRNAs in CSCs
Targeting of CSCs is considered a promising approach for improving radiotherapeutic outcomes
and preventing tumor recurrence and metastasis. Several studies have demonstrated that the
dysregulation of lncRNAs in malignant tumors is closely related to the function of CSCs. Investigations
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linking lncRNAs with CSCs are an increasing focus of cancer therapy. Here, we have reviewed
documented studies in the literature regarding lncRNAs participating in CSC regulation.
5.1. LncRNAs Associated with Stemness and Self-Renew of CSCs
5.1.1. LincRNA-p21
Recent studies have demonstrated that lincRNA-p21 is a potent suppressor of the stem-like
traits of CSCs purified from both CRC and glioma cells. LincRNA-p21 displays anti-EMT activity
and is downregulated in CRC and glioma CSCs, compared to non-CSC cancer cells. The lncRNA
suppresses β-catenin signaling, leading to decreased cell viability, self-renewal, and glycolysis of CSCs.
Its overexpression is reported to dramatically decrease the self-renewal capacity and tumorigenicity
of CSCs in xenograft mice. Based on the findings to date, lincRNA-p21 is considered a promising
therapeutic agent against CSCs in CRC [79,141].
5.1.2. LncTCF7
LncTCF7 is located near the TCF7 gene that is overexpressed in HCC and NSCLC [142,143]. TCF7
plays an important role in EMT induction in both HCC and NSCLC cells. The lncRNA is strongly
induced in HCC cells via the IL-6/STAT3 signaling axis and appears important for promotion of EMT
by IL-6 [142,143]. LncTCF7 is overexpressed in HCC and NSCLC stem cells and shown to be critical
for self-renewal while its silencing leads to suppression of the CSC fraction and stem cell-related gene
expression. Notably, lncTCF7 regulates self-renewal of HCC stem cells, as confirmed by tumor sphere
formation in vitro and tumor initiating frequency in vivo. Studies to date have shown that the lncRNA
recruits the SWI/SNF complex to bind the TCF7 promoter and activate its expression, and TCF7 which
could activate the WNT signaling pathways to accelerate self-renewal of HCC stem cells. [142].
5.1.3. HIF2PUT
The lncRNA HIF2PUT (hypoxia-inducible factor-2α promoter upstream transcript) has been
identified as a promoter upstream transcript (PROMPT) of hypoxia-inducible factor-2α (HIF-2α) in
CRC and osteosarcoma stem cells [144,145]. The function of PROMPTs is often associated with adjacent
protein-coding transcripts [146] and HIF-2α is closely linked to stem cell properties [147]. HIF2PUT
expression is positively correlated with HIF-2α levels in patients with osteosarcoma and CRC. Notably,
combined higher expression of HIF2PUT and HIF-2α is predictive of poorer prognosis of patients with
osteosarcoma. Knockdown of HIF2PUT has been shown to inhibit HIF-2α expression and CSC-related
genes and properties as well as spheroid formation ability, colony formation and invasiveness in
CRC cells. These studies support the potential utility of HIF2PUT as a novel therapeutic target for
different cancers.
5.1.4. HOTAIR
HOTAIR has been investigated in relation to many cancer types [122–124]. In breast cancer,
HOTAIR enhances metastasis [125]. Additionally, HOTAIR regulates breast CSCs, and microarray
profiles and functional analyses have revealed that its overexpression induces genes related to stem cell
activity and EMT, including CD44, STAT3, ALDH2, ZEB1, Vimentin and SOX2, at least partially
through transcriptional suppression of miR-34a [148,149]. HOTAIR expression is necessary for
maintenance of the CSC phenotype in colon and breast cancer cell lines [149]. Furthermore, this
lncRNA suppresses miR-7 expression through inhibition of HoxD10 in breast CSCs. Conversely,
overexpression of miR-7 reverses EMT and decreases the CSC population in breast cancer cells via
suppressing the STAT3 signaling pathway [150].
HOTAIR has also been shown to participate in the maintenance of stemness in CRC. Its silencing
in CD133+ CRC cells leads to decreased cellular proliferation, metastasis and colony-forming properties
as well as decreased Vimentin with enhanced E-cadherin expression [151]. Additionally, CD133+ CRC
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cells with low HOTAIR expression show decreased capacities of tumor growth and lung metastasis
in xenograft mouse models [151]. Therefore, HOTAIR may present a potential therapeutic target
against cancers.
5.1.5. Lnc34a
The microRNA, miR-34a, is a downstream target of p53 involved in suppression of various
cancer types [152]. Among its many functions, miR-34a has been shown to limit self-renewal of
CSCs [153]. Recently, the lncRNA Lnc34a, which initiates asymmetric division of stem cells by directly
targeting miR-34a and causing disruption of spatial balance, was shown to be overexpressed in CSCs
of CRC [154]. Lnc34a recruits DNMT3A (DNA methyltransferase 3 α) via PHB2 (prohibitin 2) and
HDAC1 (histone deacetylase 1) to simultaneously methylate and deacetylate the promoter region of
miR-34a. The epigenetic regulation of miR-34a is independent of its upstream regulator, p53. Higher
Lnc34a levels promote CSC self-renewal capacity and tumor growth of CRC cells in xenograft models.
Moreover, Lnc34a is overexpressed in late-stage CRCs, leading to epigenetic silencing of miR-34a and
regulation of CRC malignancy [154].
5.1.6. TUG1
TUG1 is cancer-related, binds to PRC1 or PRC2, and suppresses gene expression. Expression of
TUG1 is closely associated with cancer progression and therapy [117,118,120,155]. Notch signaling
has been shown to promote CSC self-renewal and activity and suppress differentiation [156]. Recent
studies have reported that Notch-directed TUG1 acts as an epigenetic modulator that regulates the
glioma cancer stem cell population [155]. TUG1 is upregulated in CSCs of gliomas and downregulated
upon inhibition of Notch. Overexpressed TUG1 promotes self-renewal of glioma cells by functioning
as a molecular sponge for miR-145, an important CSC regulator [157], in the cytoplasm and recruiting
Polycomb via YY1 binding activity to repress differentiation genes in the nucleus, such as BDNF(brain
derived neurotrophic factor), NGF (nerve growth factor), and NTF3 (neurotrophin 3). TUG1 presents
another specific therapeutic target to eliminate the GSC population [155].
5.1.7. TALNEC2
TALNEC2 was identified as a novel E2F1-regulated lncRNA localizing to the cytosol [158].
TALNEC2 is overexpressed in GBM from patients with poor prognosis and glioma stem cells. E2Fs
serve as transcription factors involved in the regulation of cell cycle progression, in particular, G1/S
transition [159,160]. Expression of TALNEC2 is increased in synchronized cells progressing through
the late G1 and early S phases. Silencing of this lncRNA in various cancer cell lines causes cell cycle
arrest at the G1 phase and inhibits cellular proliferation. Further functional analyses have revealed
that inhibition of TALNEC2 triggers repression of miR-21 and miR-191, and consequently decreases
the self-renewal and mesenchymal transformation of CSCs, increases radiosensitivity and prolongs
the survival of xenograft mice bearing CSCs of glioma [158]. Therefore, TALNEC2 is considered an
attractive therapeutic target for GBM.
5.1.8. HOXA11-AS
Homeobox A11 antisense (HOXA11-AS) is an lncRNA located near the homeobox A11 (HOXA11)
gene that is highly expressed in several cancer types [161]. A recent study demonstrated that
HOXA11-AS expression is correlated with poor cervical cancer prognosis. Overexpression of
HOXA11-AS in cervical cancer cells promotes proliferation, metastasis and the CD133+/CD44+
CSC subpopulation. Conversely, its knockdown suppresses these aggressive biologic features,
accompanied by decreased EMT and CSC-related genes, including NANOG, OCT4, SOX2, and
β-catenin. Accordingly, HOXA11-AS is under investigation as a potential novel target for cervical
cancer treatment [162].
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5.1.9. LncRNA-Hh
LncRNA-Hh was recently identified as a Notch, Hedgehog (Hh) pathway-associated lncRNA [163].
Expression of lncRNA-Hh is upregulated in TWIST-positive mammosphere cells and involved in
modulation of the Hh pathway. Overexpression of lncRNA-Hh in breast cancer cells increases Hh
signaling accompanied by elevated levels of SOX2 and OCT4 via targeting to GAS1 (growth arrest
specific 1), and consequently contributes to activation of EMT, CSC maintenance and tumorigenesis of
breast cancer cells. Conversely, its silencing reverses these oncogenic effects. The data suggest that the
Twist-lncRNA-Hh pathway is an important link between EMT and the CSC phenotype of cancer [163].
5.1.10. Linc00617
The lncRNA TUNA is required for pluripotency of mouse embryonic stem cells (mESC) [164].
TUNA physically binds the promoters of NANOG, SOX2, and FGF4 (fibroblast growth factor 4),
and activates transcription by recruiting the protein complex including PTBP1 (polypyrimidine
tract binding protein 1), hnRNP-K, and NCL (nucleolin). Recently, the human ortholog of TUNA,
Linc00617, was identified on chromosome 14 [165]. Linc00617 is overexpressed in breast cancer cell
lines and cancer specimens, and closely associated with poor prognosis. Overexpression of Linc00617
promotes metastasis of breast cancer cells and enhances EMT, accompanied by the acquisition of
CSC properties. Furthermore, linc00617 has been shown to physically bind the SOX2 promoter and
activate its transcription by recruiting hnRNP-K. Conversely, silencing of linc00617 suppresses tumor
progression. Linc00617 has therefore emerged as a novel therapeutic target for aggressive breast cancer.
5.1.11. HULC
The lncRNA, highly upregulated in liver cancer (HULC), is involved in HCC development
and progression [166–168]. A recent report has shown that HULC affects the stemness of HCC
cells by cooperating with MALAT-1, contributing to the promotion of liver cancer stem generation
through binding and loading on the promoter region of telomere repeat-binding factor 2 (TRF2) to
enhance telomerase activity [168]. HULC also regulates lipid metabolism of hepatoma via regulating
miR-9-PPARA (peroxisome proliferator activated receptor α) axis [166]. The findings suggest that
HULC, in combination with MALAT1, may contribute significantly to malignant growth of liver cancer
stem cells through metabolism regulation.
5.1.12. UCA1 (CUDR)
Cancer-upregulated drug resistant (CUDR) or urothelial cancer-associated 1 (UCA1) is an
independent prognostic biomarker highly expressing in various human tumors and involved in
tumorigenesis [169,170]. Recent studies have shown that CUDR enhances the interactions of SET1A
and phosphorylated RB1 (pRB1) in HCC, producing an activated pRB1-SET1A complex. This complex
subsequently generates a high level of H3K4 trimethylation that loads on the TRF2 promoter region,
causing overexpression of TRF2, which participates in the malignant transformation of HCC stem cells
via inducing alterations in telomere length [169]. Concurrently, another report suggested that lncRNA
CUDR functions as an oncogene via the CUDR-HULC and CUDR-β-catenin signaling pathways [171].
Mechanistically, CUDR upregulates HULC and β-catenin by inhibiting methylation at the HULC
promoter and promoting the formation of a β-catenin promoter-enhancer chromatin loop through
interactions with CTCF [171]. Furthermore, CUDR inhibits methylation of the promoter of the
lncRNA H19 by combining with Cyclin D1 to form a complex. CUDR-cyclinD1 upregulates H19 and
subsequently, TERT and C-MYC, to promote self-renewal and proliferation of HCC stem cells [172].
The results collectively suggest that CUDR plays a significant role in the self-renewal and proliferation
of HCC stem cells through multiple signaling pathways.
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5.1.13. NEAT1
The lncRNA NEAT1 is required for maintenance of CSCs of glioma [173,174]. NEAT1 is
overexpressed in CD133+ human glioma primary and CD133+ U87 cells. In an earlier study,
its knockdown in CD133+ glioma cells resulted in decreased colony formation, cell proliferation,
metastasis and increased cell cycle arrest and apoptosis. These effects were accompanied by induction
of miR-107 and inhibition of CDK6 (cyclin dependent kinase 6) protein and the microRNA let-7e.
Further experiments revealed that restoration of let-7e suppresses proliferation and metastasis but
promotes apoptosis in NEAT1 knockdown CSCs of glioma, which may be attributable to repression
of NRAS, a direct target of let-7e known to induce tumorigenesis and stemness [174,175]. The data
support a critical role of NEAT1 in the maintenance of stemness of glioma cells via multiple pathways.
5.2. LncRNAs Associated with both EMT and CSCs Generation
5.2.1. LncRNA-ROR
LncRNA-ROR has been identified as a modulator of cell reprogramming and pluripotency.
For instance, in breast cancer, linc-ROR appears to function as a ceRNA of miR-205 to prevent
degradation of ZEB2, promoting EMT and generating cells with stem cell-like properties [94]. Moreover,
linc-ROR serves as a sponge for miR-145 to inhibit its suppressive effect on OCT4, SOX2 and NANOG
expression [176]. LncRNA-ROR is also considered a key inducer of stemness transcriptional factors
(OCT4, SOX2, and NANOG) and affects the CSC population in gastric cancer [177].
5.2.2. H19
H19 is an imprinted oncofetal lncRNA aberrantly expressed in various cancer types with
multifaceted roles throughout tumorigenesis [178]. H19 is induced by signals involving the EMT
process and stemness, such as TGF-β, hypoxia, and HGF, suggesting a pivotal role in enhancing
stemness of cancer cells via EMT [179]. Overexpression of lncRNA H19 promotes metastasis,
angiogenesis, and stemness in glioblastoma and cholangiocarcinoma cells through effects on EMT [180]
and is associated with poor prognosis [180,181]. Furthermore, knockdown of H19 has been shown to
downregulate the stem cell-related genes SOX2, OCT4, and NANOG, as well as other CSC markers in
glioblastoma and embryonic carcinoma cell lines [182,183]. These results support the utility of H19 as
a therapeutic target for cancers.
5.2.3. FOXF1-AS1
FOXF1-AS1 has been identified as a novel lncRNA regulating NSCLC progression [184].
Expression of FOXF1-AS1 is downregulated in tissues of lung cancer. Overexpression of this lncRNA
suppresses the migration and invasion of lung cancer cells through regulating EMT while its silencing
enhances the stem-like properties of lung cancer cells. Further experiments have revealed that
FOXF1-AS1 physically associates with the PRC2 component, EZH2 (enhancer of zeste 2 polycomb
repressive complex 2 subunit), and its knockdown mediates metastasis and stemness of cancer cells in
the EZH2-dependent manner. The collective data suggest that FOXF1-AS1 may serve as an effective
therapeutic target for treatment of NSCLC [184].
5.2.4. MALAT1
MALAT1 is reported to participate in the regulation of CSCs in various cancer types [185,186].
MALAT1 is overexpressed in CSCs of pancreatic cancer and its elimination leads to a decrease in
the pancreatic CSC fraction [186]. Knockdown of MALAT-1 has been shown to inhibit expression of
SOX2, suggesting that it contributes to the CSC phenotype via SOX2 regulation. MALAT1 has been
identified as a ceRNA for both miR-200c and miR-145, both of which target SOX2 [186–188]. Thus,
the protein appears to regulate pancreatic CSCs through the miR-200c/miR-145/SOX2 signaling axis.
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Additionally, loss of MALAT-1 in the glioma stem cell line, SHG139S, is associated with suppression of
stemness markers, such as SOX2 and Nestin [185].
6. Conclusions
Radiotherapy is one of the major treatment modes for patients with cancer and widely used for
various malignant tumors [1]. Radiation treatment induces DNA damage via ionization or generation
of reactive oxygen species (ROS), leading to elimination of tumor cells, but can concomitantly promote
cancer cell metastasis through activation of EMT [3,8,12,13,42,44–47]. Metastasis is a major problem in
cancer treatment and closely associated with the rates of morbidity and mortality [2,3,8,44]. Cancer
cells with higher EMT activity have been shown to acquire stem cell-like activity [2,48]. Radiotherapy
promotes the acquisition or activation of CSCs in cancer via inducing the expression of EMT-related
genes [61,63]. CSCs represent a small subpopulation of tumor cells exhibiting radioresistant property
within heterogeneous cancer masses. Notably, upon radiation treatment, a small number of non-stem
cancer cells have been found to exhibit CSC characteristics. Radiation-induced CSC-like cells with
intrinsic stem cell properties subsequently trigger relapse and metastasis of cancer (Figure 1A) [4,61,62].
Determination of CSC-related biomarkers for prediction of radiotherapy outcomes and the
molecular mechanisms mediating CSCs and radioresistance remain an urgent requirement for the
successful development of novel therapeutic strategies. LncRNAs have emerged as crucial players
in the complex signaling network controlling the activation of CSCs and radioresistance. LncRNAs
aberrantly expressed in CSCs are active participants in the major signaling pathways governing DNA
damage response, DNA repair, apoptosis, and EMT [72,189].
Previous studies have suggested the crucial role of lncRNAs deregulation in cancer recurrence
and prognosis [17,18]. Furthermore, advances in profiling of lncRNAs expressions in cancers have
highlighted the potential roles as biomarkers in diagnosis and prognosis of the patients. Compared with
protein-coding RNAs, lncRNAs are the functional molecules and which expressions are more closely
associated with the real tumor status and biological function. In addition, the sensitivity and specificity
of lncRNAs are higher than the conventional protein-based markers. Moreover, lncRNAs can be
utilized in clinics as non-invasion and convenient biomarkers due to their presence in body fluids [190].
In the current article, several dysregulated lncRNAs involved in the regulation of radioresistance,
metastasis and cancer stem cell properties, such as ANRIL, TUG1, LOC285194, LncRNA-ROR, MALAT1,
NEAT1, HOTAIR, POU6F2-AS2, GAS5, HIF2PUT, H19, TALNEC2, HOXA11-AS, Linc00617, HULC,
and UCA1, have been found to be associated with the outcomes of radiotherapy and act as valuable
prognostic biomarkers (Table 1 and Figure 1B,C). Additionally, HOTAIR, MALAT1, H9 and GAS5 have
been reported as prognostic markers in the plasma of cancer patients [190].
To date, two major mechanisms have emerged regarding lncRNA-mediated effects on CSC
activity and radioresistance via regulation of EMT, DNA repair, apoptosis and stemness: (1) epigenetic
regulation of genes, particularly via recruitment of the Polycomb repressor complex (PRC2); and
(2) post-transcriptionally by acting as competing endogenous RNAs (ceRNAs) for miRNAs that
target genes involved in stemness and radioresistance [100]. The potential lncRNAs influencing
radioresistance through CSC generation and the molecular mechanisms involved in radioresistance
and stemness are listed in Table 1. Moreover, radiotherapy has been shown to paradoxically induce
metastasis of resistant cancer cells, and CSCs are proposed to have utility in predicting tumor recurrence
and metastasis [2,48].
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Recently, several studies utilizing large-scale genetic and molecular analyses have
identified RNA-binding proteins (RBPs) as crucial regulators in genome stability after radiation
treatment [191,192]. Upon DNA damage (e.g., ultraviolet and ionizing radiation), RBPs are activated
to regulate DNA-damage response (DDR) involving DNA repair, cell cycle progression, and late
responses involving genes regulation that influence cell fate. In addition to mRNAs, RBPs also
bind lncRNAs, many of which are regulated in response to DNA damage and involved in the
radioresistance. For instance, hnRNP-K RBP physically associates with lincRNA-p21 and mediates in
trans the transcriptional repression of a large set of genes in a p53-dependent manner [74]. Another
study indicates that radiation-induced LINP1 acts as a scaffold to stabilize Ku80 and DNA-PKcs
interactions and coordinates the NHEJ pathway to enhance DNA repair activity [111]. Dysregulated
lincRNA-p21 and LINP1 are shown to influence the radiosensitivity of cancer cells. Further studies on
the lncRNAs and RBPs involved in CSCs and radioresistance should ultimately yield useful insights
into the molecular mechanisms underlying radiation-induced CSC generation and cancer metastasis
to facilitate the development of effective novel therapeutic strategies against cancer.
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Abstract: Although bone metastases represent a major challenge in the natural history of breast
cancer (BC), the complex interactions involved have hindered the development of robust in vitro
models. The aim of this work is the development of a preclinical model of cancer and bone stromal
cells to mimic the bone microenvironment. We studied the effects on osteoclastogenesis of BC
cells and Mesenchymal stem cells (MSC) cultured alone or in combination. We also analyzed:
(a) whether the blockade of the Epithelial Growth Factor Receptor (EGFR) pathway modified their
influence on monocytes towards differentiation, and (b) the efficacy of bone-targeted therapy on
osteoclasts. We evaluated the osteoclastogenesis modulation of human peripheral blood monocytes
(PBMC) indirectly induced by the conditioned medium (CM) of the human BC cell line SCP2,
cultured singly or with MSC. Osteoclastogenesis was evaluated by TRAP analysis. The effect
of the EGFR blockade was assessed by treating the cells with gefitinib, and analyzed with the
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay and Western Blot (WB).
We observed that SCP2 co-cultured with MSC increased the differentiation of PBMC. This effect was
underpinned upon pre-treatment of the co-culture with gefitinib. Co-culture of SCP2 with MSC
increased the expression of both the bone-related marker Receptor Activator of Nuclear Factor κB
(RANK) and EGFR in BC cells. These upregulations were not affected by the EGFR blockade. The
effects of the CM obtained by the cells treated with gefitinib in combination with the treatment
of the preosteoclasts with the bone-targeted agents and everolimus enhanced the inhibition of the
osteoclastogenesis. Finally, we developed a fully human co-culture system of BC cells and bone
progenitor cells. We observed that the interaction of MSC with cancer cells induced in the latter
molecular changes and a higher power of inducing osteoclastogenesis. We found that blocking EGFR
signaling could be an efficacious strategy for breaking the interactions between cancer and bone cells
in order to inhibit bone metastasis.
Keywords: breast cancer; co-culture; osteoclasts; mesenchymal stromal cells; non-canonical
osteoclastogenesis
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1. Introduction
Bone metastases are a common event in breast cancer (BC) patients [1], often leading to
severe symptoms such as pain, bone fractures, spinal cord compression and hypercalcemia [2].
The mechanisms underlying BC-derived bone metastases have been intensively investigated but
the complex interactions involved have hindered both the development of comprehensive in vitro
systems [3] and the generation of translational benefits [4,5].
Mesenchymal stromal cells (MSC) are multipotent stem cells precursors of tissue-specific cell
lineages in many adult tissues [6]. Within the bone marrow, MSC give rise to both bone stromal cells,
i.e., osteoblasts, osteocytes, adipocytes, and more specialized, niche-maintaining cells such as CAR
cells, leptin-receptor-positive cells, and sinusoid-associated pericytes [7]. Together with osteoblasts,
MSC express two essential factors for the maturation of osteoclasts, the giant, multinucleated,
monocyte-derived cells responsible for bone resorption: the Receptor Activator of Nuclear Factor
kappa-Bligand (RANKL) and the macrophage colony-stimulating factor (M-CSF) [8]. The inhibition
of either the maturation or the activity of osteoclasts has already proven effective in treating bone
metastases [1,9], and has led to the development of many osteoclast-targeted drugs [10,11]. These
pharmacological agents, which constitute the bone-targeted therapy, are mainly represented by
the anti-RANKL antibody denosumab (Den), and bisphosphonates, such as zoledronic acid (Zol).
Everolimus (Eve) has been recently considered suitable for targeting bone metastases as it inhibits
both cancer cells and osteoclasts. [12–14]. EGFR, also known as ErbB-1 or HER1, is one of the four
members of the ErbB tyrosine kinases receptors family. EGFR is frequently amplified or overexpressed
in many neoplastic lesions, including lung, breast, colorectal, head and neck, pancreatic and gastric
cancers [15]. A higher expression of EGFR in “triple-negative” BC has been shown to correlate with
a higher incidence of metastases [16]. This receptor is also expressed by MSC, and the activation
of the EGFR pathway is involved with MSC in the regulation of RANKL and OPG secretion [16].
Thus, a deregulated EGFR signaling in MSC may alter the homeostatic ratio of RANKL/OPG of the
bone microenvironment, initiating a “vicious cycle” that leads to the uncoupling of the physiological
balance between bone erosion and bone deposition, driving it towards cancer cell metabolism [8,16,17].
Gefitinib (Gef), a selective, reversible inhibitor of EGFR, effective in treating locally advanced or
metastatic non-small-cells lung cancer (NSCLC), has received FDA approval as a first-line treatment in
NSCLC patients [18]. In spite of the antitumor activity shown by Gef both in vitro and xenograft models
of breast and prostate cancers [19–22], phase-I/-II clinical trials on advanced BC patients treated with
Gef yielded conflicting results, with little assessed clinical benefits for patients [8,23–27]. However,
treatment of bone metastases with Gef has also been explored [28,29], based on the unexpected
observation that treatment with this type of tyrosine kinase inhibitor (TKI) could relieve bone pain in
BC patients [30,31]. Ultimately, the available data from both preclinical studies and clinical observations
may pave the way for the use of Gef and other TKIs for the treatment of bone metastases.
The aim of this study was to develop a preclinical model for studying the effects of the crosstalk
between stromal cells and cancer cells on osteoclastogenesis. Furthermore, we investigated if
the blockade of the EGFR pathway in cancer and bone cells could have an effect on the bone
microenvironment. We combined direct sharing medium and indirect co-cultures (COCOs) (Figure 1) in
order to understand the molecular relation between cancer cells and MSC and their effect on osteoclasts.
Firstly, we co-cultured cancer cells and MSC by direct sharing medium COCO. We then performed
osteoclastogenesis assays in presence of the CM obtained from the cells previously mono- and
co-cultured. These interactions were then challenged by treating the COCOs of stromal and cancer
cells with Gef.
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Study design:
Analyses to do:
- MSC: Evaluation of EGFR-P to
ascertain inhibition of EGFR
- SCP2: Gene expression analyses to
evaluate the effect of the interaction







+ Gef NO Gef
Day 0: monocytes Day 14 : OCsDownstream analysis:
RNA Osteoclastogenesis markers
TRAP osteoclast count
We conditioned monocytes with the CM collected
from all the treated/untreated conditions
Figure 1. Experimental design: the preclinical model optimized in this paper includes a 2-phase cell
culture; in the first phase cancer cells and Mesenchymal stem cells (MSC) were co-cultured sharing
medium using transwell inserts. The media obtained from SCP2, MSC and the COCO were collected
and used to condition the monocytes toward differentiation throughout the osteoclastogenic assay
(CM changed every 2–3 days; assay total duration, 14 days). The conditioning of the monocyte with
the CM derived from all the samples during the second phase of the experiment (indirect COCO).
2. Results
2.1. Mesenchymal stem cells (MSC) Induce the Expression of RANK and EGFR in Cancer Cells
We first investigated the effects of the COCO with MSC on the SCP2 gene expression in
order to understand if cancer cells behave differently when in contact with bone microenvironment
factors. We selected markers recapitulating different hallmarks of cancer progression, in particular
bone metastasis. We selected 3 markers of osteomimicry: connexin 43 (cx43), osteopontin (spp1),
and RANK. Osteomimicry is the capability of cancer cells to colonize the bone in order to form
metastasis, and express the genes, that are usually expressed by bone cells, by adapting to the new
microenvironment [32,33]. Marker cx43 is usually expressed on osteoblasts and osteocytes, and it is in
charge of mechanotransduction and the control of body mass. Marker spp1 is a matrix protein involved
in the attachment of osteoclasts to the bone matrix [34] RANK is a receptor of osteoclast precursors
that, when binding to the RANK ligand, mediates their differentiation into mature osteoclasts. It has
been shown that BC cells with high tropism to the bone often overexpress RANK [35,36]. We assayed
the expression of TFF1, a marker expressed at higher levels in primary BC patients with relapse
to the bone [37] and angiopoietin-1 (angpt1), which is involved in the angiogenic response of the
osteomimicry-related markers [38,39]. We added EGFR to the panel, as one of the aims of this study
was to understand the role of the EGFR pathway in the bone microenvironment. To this aim, the
expression of markers related to cell–cell communication, invasion and bone marrow colonization
was analyzed in SCP2 cells after co-culturing for 72 h with MSC. SCP2 cells were cultured with MSC,
using the inserts cultured with cancer cells that had been laid on well plates where MSC had been
previously seeded. This type of COCO allows for media sharing and interactions between cells seeded
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on different floors (Figure 1). Data on cancer cell gene expression were normalized using baseline
SCP2 culture as reference. As shown in Figure 2, we found that the COCO with MSC showed a trend
towards the upregulation of two genes involved in the bone vicious cycle: EGFR and RANK [36,40,41],
the latter showing an increase by over 1.5 times the basal level.
 
Figure 2. Co-culture with MSC upregulates EGFR and RANK expression in SCP2. Expression of angpt1,
cx43, spp1, egfr, rank and tff1 in SCP2 cells co-cultured with MSC. Fold change compared to SCP2
monoculture at baseline.
2.2. Cancer Cells and MSC Contribute to Osteoclastogenesis
In order to understand if cancer cells and MSC affect bone microenvironment contributing to
osteoclastogenesis, we dissected the contribution of either SCP2 or MSC on osteoclastogenesis, by
supplementing pre-osteoclasts with the CM of either the SCP2 or the MSC mono-cultures and the
SCP2-MSC COCO. To achieve the COCO CM, we harvested the CM both after 24 h (Early-CM) and
after 72 h (Late-CM) of COCO. In order to consider the osteoclastogenic power of CM with respect
to the positive and negative control, we measured the average number of TRAP-positive osteoclast
cell-like cells and their average surface area, given that a large surface area is one of the features of
mature osteoclasts.
Cancer cells and COCO promote Osteoclastogenesis
At a molecular level, both CM from SCP2 and MSC induced osteoclastogenesis upregulating
the osteoclast marker cathepsin k (ctsk), as shown in Figure 3A,B, with MSC-derived CM.
We observed no upregulation of the early osteoclast-specific transcription factor Jun dimerization
protein 2 (jdp2), probably because it had been already turned off on day 14 of differentiation [42].
Compared to undifferentiated pre-osteoclasts (negative control, i.e., monocytes cultured without GF
supplementation), SCP2-derived CM showed a trend towards the induction of osteoclastogenesis,
both as for the number of TRAP-positive osteoclasts (Figure 3C) and the surface area measurement
(Figure 3D).
The CM from COCO induced a significant increase of the expression of ctsk in pre-osteoclast
cultures, without affecting the expression of jdp2, and with no major differences between Early- and
Late-CM (Figure 3B). Based on this result, we performed the TRAP assay on the osteoclasts cultured
with Late-CM only (COCO), comparing data with both the positive and negative controls. The
average surface area of the osteoclasts generated by the CM derived from the SCP2-MSC COCO was
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comparable to that of the osteoclasts cultured in the positive control, and was significantly higher than

























































































Figure 3. SCP2 and MSC mono-culture and COCO induce osteoclastogenesis. Expression of jdp2
and ctsk in osteoclasts cultured either in DM or in pre-osteoclast medium supplemented with CM
from: (A) SCP2 or MSC monoculture; (B) SCP2-MSC COCO after 24 h (Early-CM) or 72 h (Late-CM)
of COCO. qPCR data refer to RNA from pre-osteoclasts. Data were normalized on pre-osteoclasts.
t-test was performed comparing the gene expression of the different conditions with the control.
* p < 0.05; *** p < 0.01. Average number (C) and average surface area (D) of TRAP-positive osteoclasts
induced by culture in DM, pre-osteoclast medium (CTRL) or pre-osteoclast medium supplemented
with SCP2-CM (SCP2), with MSC-CM (MSC) or with CM from SCP2-MSC COCO; t-test was performed
for all conditions taking the negative control as control (CTRL). * p < 0.05; *** p < 0.01; (E) pictures of
osteoclasts on day 14 obtained in the different experimental conditions performed at 10× magnification.
Osteoclasts are not the only TRAP-positive polinucleated cells of a monocytic origin. In a previous
work we confirmed that the osteoclast cell-like cells positive to TRAP are real osteoclasts, as we
observed the presence of two specific osteoclast markers, i.e., Actin ring and calcitonin receptor (CTR),
both in the negative control and in the differentiation medium (DM) condition [12].
2.3. Gef Induces RANK and EGFR mRNA Expression and Inhibits the EGFR Pathway at the Protein Level
To investigate the involvement of the EGFR pathway on the crosstalk of SCP2 cells and MSC, we
treated both SCP2 and MSC monocultures and COCOs with Gef. As the first step, we tested the effect
of different concentrations of Gef on SCP2 cells. As expected, the SCP2 cell line, like the parental cell
line MDA-MB-231 [19], was not very sensitive to the EGFR blockade induced by Gef (Figure 4A). We
then analyzed the expression of angpt1, cx43, spp1, egfr, rank and tff1 after treating the SCP2 culture or
the SCP2-MSC COCO with Gef at 1 μg/mL (plasmatic peak concentration) for 24 h (Figure 4B), after
normalizing the gene expression on the SCP2 culture at baseline, to evaluate any molecular changes.
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Gef-treated cells showed a modulation only of RANK and EGFR compared to the negative control
(monocytes cultured without GF and CM). RANK increased both in SCP2 cultured singly (Figure 3B)
and in COCO. We observed the same trend also for EGFR (Figure 3). The treatment with Gef induced
a significant upregulation of rank, compared to untreated baseline SCP2 cells, once again showing a
gene expression profile similar to untreated SCP2-MSC COCO.
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Figure 4. Gef inhibits the EGFR pathway and modulates cancer cell gene expression analyses.
(A) Survival rate of SCP2 treated with Gef. Data were normalized to untreated sample (CTRL);
(B) Expression of angpt1, cx43, spp1, egfr, rank and tff1 in SCP2 cells (SCP2 Gef) or in SCP2-MSC COCO
(TRW Gef) treated with Gef 1μg/mL. Fold change compared to SCP2 culture at baseline. * p < 0.05.
*** p < 0.01; (C) Synthesis of phosphorylated-EGFR (pEGFR) in SCP2 and MSC in absence (CTRL) and
treated with Gef. In each condition we added EGFR with an incubation step of 10 min (50 ng/mL).
To confirm that our observations depended on the blocking of EGFR, we tested the activation of
the EGFR pathway at the protein level, both in SCP2 and MSC cultures. After the addition of EGF
cytokine we detected the activation of the EGFR pathway, in terms of phospho-EGFR, in the cultures
of SCP2 and MSC Gef treatment inhibited EGFR signaling, as we observed lack of phospho-EGFR in
the treated cells (Figure 4C).
2.4. Gefitinib Impairs Osteoclastogenesis Induced by MSC-SCP2 COCO
We investigated the effect of Gef on the osteoclastogenic potential of CM from SCP2 and MSC
mono- and co-cultures. We observed a statistically significant downregulation of ctsk in the CM from
Gef-treated MSC and COCO (Figure 4A,B). The treatment did not inhibit the osteoclastogenic power
of the CM obtained from SCP2. This could mean that the osteoclastogenic induction by MSC depends
on the EGFR pathway; this trend was confirmed by the data obtained from counting the number of
osteoclasts and quantifying the surface area, with statistical significance reached by the decreased
mean surface area Figure 5C,D. No significant modulation of jdp2 could be detected. At the cytological
level, the CM of the Gef -treated cultures reduced the osteoclastogenic potential as shown in Figure 4B.
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We observed no statistically different level of osteoclastogenesis from the negative control, neither in





































































Figure 5. Gef impairs osteoclastogenesis induced by MSC-SCP2 COCO. Expression of jdp2 (A) and ctsk
(B) in osteoclasts cultured either in DM or with CM from SCP2, MSC or SCP2-MSC COCO previously
treated (grey bars) or not (black bars) with Gef 1 μg/ml. Significance is compared to undifferentiated
pre-osteoclasts (CTRL); Average number (C) and average surface area (D) of osteoclasts cultured in
pre-osteoclast medium (CTRL), in DM or with CM from SCP2, MSC or SCP2-MSC COCO previously
treated (grey bars) or not (black bars) with Gef 1μg/mL. * p < 0.05; *** p < 0.01. Gef was not added to
CTRL and DM conditions in this context (absence of grey bars).
2.5. Bone-Targeted Therapy Empower Gef Inhibition of Osteoclastogenesis
As in clinical practice bone metastasis patients are usually treated with bone target therapy as
Den and Zol, we treated the monocytes with these drugs to understand the impact of the inhibition of
EGFR on standard treatment. We also tested the effect of Eve, as we previously had observed its strong
effect on osteocolstogenesis inhibition. We employed CM from MSC, SCP2 and SCP2-MSC COCO
for each treatment. At the end of the assay, the number of osteoclasts was considerably decreased in
all the conditions. Compared to the control without treatment, all the drugs showed an important
inhibitory effect on the percentage of differentiated osteoclasts, both in DM and CM conditions. Zol
had the strongest effects on this reduction. We also evaluated the effects of the CM derived from
the cells treated with Gef. All the combinations underpinned the development of mature osteoclasts
(Figure 6B). The greatest effect on osteoclast development was performed by Zol, which showed a
complete inhibition of the CM from MSC and SCP2 conditions (Figure 6B).
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A
B
Figure 6. Eve and Zol on osteoclasts together with Gef treatment on MSC and SCP2 totally abrogated
osteoclastogenesis. (A) Osteoclastogenesis assay from PBMC treated with bone-targeted therapy drugs
(Den and Zol) and Eve. Osteoclastogenesis differentiation was evaluated in PBMC cultured with basal
media with the addition of growth factors MCSF and RANKL, or with CM from MSC-SCP2 in COCO
or mono-culture and treated with drugs; (B) Drug effects on osteoclastogenesis in combination with
Gef. During the osteoclastogenic assay bone-targeted therapy drugs and Eve were added. Significance
was compared to untreated osteoclasts; * p < 0.05.
3. Discussion
This study aimed to evaluate the crosstalk between BC cells and bone-derived stromal cells
through the development of a fully human preclinical model useful for studying drug activity on the
bone microenvironment. We used the SCP2 BC cell line, an MDA-MB-231-derived triple-negative
cell line with an intrinsic bone metastatic signature [43], which constitutes a good candidate for
investigating BC metastasis in vitro.
Several studies have investigated the interactions of BC cells with primary osteoblasts or with
osteogenically differentiated [19–22,44] and undifferentiated [45,46] MSC.Since undifferentiated MSC
represent a key mediator in the bone microenvironment crosstalk [44,47,48], we investigated their
interactions with cancer cells. First, we allowed the MSC to interact through medium sharing with the
SCP2 cells. Then, we assayed this dynamically generated CM to modulate osteoclastogenesis.
We challenged this optimized preclinical model with Gef and bone-targeted therapies and Eve to
evaluate the contribution of the EGFR pathway to the interaction between MSC and SCP2 cells, as well
as to the osteoclastogenic effect of the CM.
Lu et al. showed that Gef significantly reduced the development of metastasis after intracardic or
intratibial inoculation of mice with SCP20 cells, a highly bone-metastatic clone of the MDA-MB-231
cells [19]. Normanno et al. extensively investigated the contribution of the EGFR pathway to the
crosstalk of different stromal cell populations within the bone marrow, and of stromal cells with cancer
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cells. They showed relevant cytological effects of Gef in the setting assayed, including the direct
cytotoxic effect of the drug and the inhibition of osteoclastogenesis [17,46,49].
Our results indicated that MSC induced the upregulation of RANK in SCP2 and, to a lesser extent,
of the EGFR pathway, suggesting that the crosstalk with MSC promoted the stimulation of these two
signaling pathways. Considering that RANK, as previously discussed, is related to osteomimicry,
this remarkable observation supports that our experimental approach is informative of the molecular
interactions occurring in vivo. On the other hand, EGFR is the target of Gef: its increase after COCO
with bone cells endorses the biological rationale to use this drug for inhibiting cancer cells in the
bone microenvironment.
Treatment of MSC-SCP2 COCO with Gef only partially altered this upregulation. This finding
should undergo further investigation as recent studies have evidenced the interaction between these
two signaling pathways, for example in bone metastasis from soft tissue sarcomas [50]. Interestingly,
the CM from MSC-SCP2 COCO seemed to induce osteoclastogenesis more efficiently than the CM
from either MSC or SCP2 monocultures. The treatment of MSC-SCP2 COCO with Gef, although not
affecting the number of induced osteoclasts, significantly reduced their relative surface area, thus
highlighting an interfering effect of this drug on the osteoclastogenesis process.
When the osteoclasts were treated with BTT and Eve, we observed that all drugs showed
an inhibition effect on osteoclastogenesis. Zol and Eve performed the strongest inhibition on the
development of mature osteoclasts in the MSC-sample, cultured singly or co-cultured with SCP2.
4. Materials and Methods
4.1. Cell Cultures and Reagents
The SCP2 cell line was kindly provided by Yibin Kang laboratory, where these cells had been
initially isolated, as an osteotropic clone of the BC cell line MDA-MB-231 [38]. Human MSC where
purchased from Lonza (Lonza, Basel, Switzerland). Cells were cultured as a monolayer in 75 cm2
flasks at 37 ◦C in a 5% CO2 atmosphere in DMEM medium (Euroclone, Milan, Italy) supplemented
with 10% fetal bovine serum (Euroclone, Milan, Italy), 1% penicillin/streptomycin (PAA, Piscataway,
NJ, USA) and 1% glutamine (PAA), referred as “complete medium”.
4.2. Drug Sensitivity Assay
To assess SCP2 sensitivity to Gef, the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide (MTT) assay was performed (Sigma-Aldrich, Steinheim, Germany). Five thousand SCP2 cells
were plated in a 96-well plate and treated for 24 h with Gef at the following concentrations: 0.0625,
0.125, 0.25, 0.5 and 1 μg/mL. After treatment, medium was discarded and cells were cultured with
fresh DMEM for further 24 h, for washing out the drug. Then, a stock solution of MTT (5 mg/mL)
was diluted 1:10 in fresh DMEM and 100 μL were dispensed in each well. Cells were incubated for
2 h at 37 ◦C in the dark. After incubation, the MTT solution was discarded and cells were incubated
with 100 μL of an HCl isopropanol solution in order to solubilize formazan crystals. Absorbance was
determined by spectrophotometric measurement at 550 nm.
4.3. MSC-SCP2 COCO Assay and Generation of CM
For COCO assays, 2 × 105 MSC were plated in 6-well plates and, separately, 1 × 105 SCP2 cells
were plated in a 24 mm diameter transwell insert with 0.4 μm pores (Corning Ltd., Flintshire, UK).
Cells were then allowed to adhere to their supports and, after 24 h, SCP2-seeded inserts were placed
over the MSC cultures to start COCO. One SCP2-seeded insert was harvested for gene expression
analysis at baseline. Cells were co-cultured in 4 mL complete DMEM for 24 h, then medium from
COCOs was harvested to produce the Early-CM and replaced with 4 mL fresh complete DMEM, either
or not supplemented with 1 μg/mL Gef. After 24 h of refreshment, media were completely discarded
and cells were cultured in fresh complete DMEM, for washing out the drug. After further 24 h, COCOs
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were stopped to harvest the Late-CM from the cells not treated with Gef, and the Gef-CM from the
cells treated with Gef. CM were harvested also from MSC and SCP2 cultured separately. CM were
collected, centrifuged for 5 min at 1200 rpm and immediately stored at −20 ◦C. SCP2 and MSC were
harvested for RNA and protein extraction, respectively.
4.4. Generation of Pre-Osteoclasts
Human pre-osteoclasts were generated from PBMC, following a previously established
protocol with some modifications [12]. Briefly, PBMC of healthy donors who had given their
written informed consent were separated by Ficoll density centrifugation (Lymphosep, Biowest,
Nuaillé, France), counted and seeded in αMEM medium (Lonza) supplemented with 10% FBS, 1%
penicillin/streptomycin, 1% glutamine (referred to as complete αMEM), in 24-well plates at a density
of 750,000 cells/cm2. After 2–3 h the medium was replaced with pre-osteoclast medium (complete
αMEM supplemented with 20 ng/mL recombinant human M-CSF, Peprotech, Rocky Hill, NJ, USA).
Pre-osteoclasts were cultured in pre-osteoclast medium, with medium refreshment every 3 days until
cultures had reached about 80% confluency.
4.5. Osteoclastogenesis Assay with CM and Drugs
Pre-osteoclasts were cultured either in DM (complete αMEM supplemented with 20 ng/mL
M-CSF and 20 ng/mL RANKL), or in pre-osteoclast medium (as a negative control for
osteoclastogenesis) or in pre-osteoclast medium supplemented with 20% of CM collected in the
COCO assay. Culture conditions for osteoclastogenesis assay are summarized in Table 1.
















MSC culture MSC culture MSC culture
SCP2 culture SCP2 culture SCP2 culture
COCO COCO COCOC
After 14 days of the beginning of the experiment, cells were fixed by incubation in 3.7% PBS
buffered formaldehyde (Polyscience, Niles, IL, USA) for 10 min at room temperature and then stained
for tartrate-resistant acid phosphatase (TRAP kit, Sigma-Aldrich, Steinheim, Germany). Nuclei were
counterstained with hematoxylin (TRAP kit). Multinucleated (>4 nuclei), TRAP-positive cells with
at least 3 nuclei were marked as osteoclast cell-like cells. To measure the extent of osteoclastogenesis
in the different experimental conditions, we measured the osteoclast surface area. Three pictures per
well per culture condition were taken with AxioVision software (ZEISS, Oberkochen, Germany) and
the surface area of osteoclasts was measured with ImageJ software (http://imagej.nih.gov/ij, NIH,
Bethesda, MD, USA). The resulting total area was then divided by the number of measured osteoclasts,
to obtain the average value. Experiments were done in triplicate.
Osteoclastogenesis assay was performed also in presence of drugs. Eve 0.1 μg/mL was added
(Afinitor®, Novartis, East Hanover, NJ, USA) on day 3, and Zol 10 μmol (Zometa©, Novartis,
East Hanover, NJ, USA) and Den (5 μg/mL) (XGEVA®, Thousand Oaks, CA, USA) on day 7. Each
drug was added for 72 h. For each condition the CM of MSC, SCP2 and the COCO treated with and
without Gef were added.
4.6. Western Blot
For phosphorylated-EGFR (pEGFR) evaluation in MSC and SCP2, proteins were isolated by
direct cell lysis with a lysis buffer composed of 50 mM Tris-HCl (pH 8), 150 mM NaCl, 1% Triton
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X-100 and 0.1% SDS, supplemented with 1 mM phenylmethylsulfonyl fluoride and 1:100 protease
inhibitors (Sigma-Aldrich, Milan, Italy). For pEGFR positive controls, MSC and SCP2 cultures were
treated with 50 ng/mL human recombinant EGF (Merck Millipore, Billerica, MA, USA) 15 min before
cell lysis. The protein content was quantified using BCA protein assay kit (Thermo Fisher Scientific,
Waltman, MA, USA). An equal amount of protein was separated from each sample on Bolt 4–12%
Bis-Tris Plus 10 well (Novex, Life Technologies, Carlsbad, CA, USA) and transferred to Mini Format,
0.2 μm PVDF (Biorad, Hercules, CA, USA). The membranes were blocked for 2 h in 5% non-fat
dry milk PBS with 0.1% Tween 20 (Sigma-Aldrich, Milan, Italy) at room temperature and incubated
overnight at 4 ◦C with primary antibody. After washing, the membranes were incubated for 1 h at
room temperature with goat anti-mouse IgG-HRP (1:5000, Santa Cruz Biotechnology, Dallas, TX, USA)
and goat anti-rabbit IgG-HRP (1:5000, Santa Cruz Biotechnology) for anti-vinculin, and anti-pEGFR
pretreated membranes, respectively. The acquisition was performed after 5 min of treatment with
ClarityTM (Western ECL Substrate, Hercules, CA, USA). The following primary antibodies were used:
anti-pEGFR (Tyr1173) (1:500, Upstate Cell Signaling Solution, Lake Placid, NY, USA), anti-vinculin
(1:1000, Thermo Fisher Scientific).
4.7. RNA Extraction and Real-time Quantitative PCR (qPCR)
SCP2 and osteoclast cultures were directly lysed with 800 μL TRIzol® reagent (Life Technologies).
RNA was then extracted according to the manufacturer’s protocol, resuspended in molecular-grade
bidistilled water and quantified with Nanodrop-1000 (Thermo Scientific). Five hundred ng of RNA
for SCP2 and 250 ng of osteoclasts were then used for RT-PCR using iScript™ cDNA Synthesis Kit
(Biorad, Hercules, CA, USA) according to the manufacturer’s protocol. For qPCR, either SYBR® green
or TaqMan® chemistry was used, according to the specific target gene assay (Table 2).
Table 2. Primers and probes.
SYBR™ Green Assays















For SYBR® assays, SYBR® Select Master Mix (Life Technologies) was used with the following
cycling conditions: 5 min at 50 ◦C and 5 min at 95 ◦C (hold), followed by 15 s at 95 ◦C and 60 s at
60 ◦C for 40 cycles, followed by melting curve stage. For TaqMan® assays, TaqMan® Universal PCR
Master mix (Life Technologies) was used, with the same thermal profile as for intercalating dyes assays,
excluding the melting curve stage. Gene expression was quantified by the Δ–Δ Ct method, normalizing
samples first on the housekeeping genes actb and hprt, and then on the baseline reference samples.
97
Int. J. Mol. Sci. 2017, 18, 1655
4.8. Satistical Analysis
Each experiment was performed in triplicate. Data are presented as mean ± SD. Differences were
assessed by a two-tailed Student’s t-test and accepted as significant at p < 0.05.
5. Conclusions
We developed a fully human COCO system of BC cells and bone progenitor cells resembling
some of the molecular interactions observed in vivo. We observed that MSC interaction with cancer
cells induced molecular changes in the RANK pathway necessary for osteoclastogenesis and key to
the formation of bone metastasis and the EGFR pathway. Our model also confirmed that the crosstalk
between cancer and bone cells is crucial for bone metastasis.
The observation of the EGFR upregulation supports our idea of challenging the model with a
TKI drug, as the EGFR inhibition caused a fault in the osteoclastogenesis process. This effect was
enhanced by the osteoclast treatment with either Eve or Zol. These results open the way for further
investigation on the combination of conventional therapy with EGFR-targeting drugs in patients with
bone metastasis.
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EGFR epidermal growth factor receptor
Eve everolimus
MSC mesenchymal stromal cells
GF growth factors
M-CSF macrophage colony-stimulating factor
MTT (4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
NSCLC non-small cell lung cancer
PBMC human peripheral blood mononuclear cells
Den denosumab
RANKL receptor activator of nuclear factor kB ligand
TKI tyrosine kinase inhibitor
TRAP tartrate-resistant acid phosphatase
WB western blot
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Abstract: After oncogenic transformation, tumor cells rewire their metabolism to obtain sufficient
energy and biochemical building blocks for cell proliferation, even under hypoxic conditions.
Glucose and glutamine become their major limiting nutritional demands. Instead of being
autonomous, tumor cells change their immediate environment not only by their metabolites but also
by mediators, such as juxtacrine cell contacts, chemokines and other cytokines. Thus, the tumor cells
shape their microenvironment as well as induce resident cells, such as fibroblasts and endothelial
cells (ECs), to support them. Fibroblasts differentiate into cancer-associated fibroblasts (CAFs),
which produce a qualitatively and quantitatively different extracellular matrix (ECM). By their
contractile power, they exert tensile forces onto this ECM, leading to increased intratumoral pressure.
Moreover, along with enhanced cross-linkage of the ECM components, CAFs thus stiffen the ECM.
Attracted by tumor cell- and CAF-secreted vascular endothelial growth factor (VEGF), ECs sprout
from pre-existing blood vessels during tumor-induced angiogenesis. Tumor vessels are distinct from
EC-lined vessels, because tumor cells integrate into the endothelium or even mimic and replace
it in vasculogenic mimicry (VM) vessels. Not only the VM vessels but also the characteristically
malformed EC-lined tumor vessels are typical for tumor tissue and may represent promising targets
in cancer therapy.
Keywords: abnormal tumor vasculature; anti-angiogenesis; cancer-associated fibroblasts;
endothelial cell–tumor cell interaction; targeted tumor therapy; tumor neovascularization; tumor
metabolism; tumor stroma; tumor vessel disruption; vasculogenic mimicry
1. Introduction
In the last few decades, tumor therapy has made appreciable progress. In addition to surgical
intervention, radio- and chemotherapy have significantly increased survival of tumor patients.
Most recently, immunotherapy directed against immune checkpoint inhibitors has been improved and
advanced to first line therapy for different cancers [1,2].
While the oncogenically transformed tumor cell has been and will continue to be the focus of
cancer therapy, an increasing number of publications in recent years has also shed light on cells in
the vicinity of tumor cells and their role in tumor progression. Stromal fibroblasts, endothelial cells
(ECs) and immune cells belong to this cellular environment. They are not unaffected bystanders,
but their behavior changes in response to neighboring tumor cells. Thus, they may support growth
and progression of cancer cells which eventually subvert the resident cells. This review highlights
metabolic alterations and intercellular communication of tumor cells and their neighboring stromal
fibroblasts and ECs. In addition, immune cells, such as macrophages, granulocytes, and leukocytes,
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are affected in a solid tumor and in turn affect tumor growth. These immunological aspects have been
excellently reviewed elsewhere [3] and will not be covered here. This review focuses on fibrotic and
vascular phenomena within growing solid tumor tissue.
2. Setting the Stage: Cancer Cells Determine the Tumor Microenvironment via Metabolites and
Cytokines, via Cell–Matrix and Cell–Cell Contacts
2.1. Metabolic Reprogramming of Cancer Cells
Proliferating tumor cells lack oxygen due to a malfunction or even absence of a proper tumor
vasculature. Lack of oxygen strongly contributes to a reprogramming of cancer cell metabolism and is
typical of the tumor microenvironment (TME) [4]. Driven by the oxygen-dependent hypoxia-inducible
transcription factor-1α (HIF-1α) [4] and by the transcription factor cellular Myelocytomatose
(c-Myc) [5], expression of key enzymes which regulate fundamental metabolic pathways is controlled
in an orchestrated and cancer cell-specific way [6–8]. Glycolysis and glutaminolysis are the most
prominently activated pathways in cancer cells (Figure 1) which, together with hypoxia, belong to
the metabolic hallmarks of cancer [9]. The prime carbon and energy source of proliferating tumor
cells is glucose (Glc in Figure 1), which, after uptake by glucose transporter tye 2 (GLUT2), is utilized
via glycolysis. Glycolytic key enzymes, such as hexokinase 2 and the pyruvate kinase isoform M2
(PK-M2), are upregulated [10]. Moreover, PK-M2 forms a less active dimer instead of the highly
active tetramer found in normal cells [11,12]. Only high concentrations of fructose-1,6-bisphosphate
triggers the formation of the enzymatically active tetramer of PK-M2 [11,12]. Reduced pyruvate kinase
activity results in accumulation of upstream metabolites [7,8,13], such as phosphoenolpyruvate (PEP in
Figure 1), prompts the synthesis of the amino acids serine (Ser) and glycine (Gly) and stimulates the flow
of metabolites into the pentose phosphate pathway, which yields nicotinamide adenine dinucleotide
phosphate (NADPH + H+) and ribose-5-phosphate (R5P), the building block for nucleotides, RNA and
DNA. Folate-bound C1 bodies (methylene, hydroxymethyl, formyl groups) for purine and pyrimidine
synthesis are provided by the conversion of serine to glycine [6,12].
Instead of being transported into mitochondria, the end product of glycolysis, pyruvate,
is cytosolically reduced to lactic acid, which dissociates into lactate and protons, and both are
transported out of the cells. This explains the tumor-characteristic increase of extracellular lactate
and the acidification of the tumor environment. Almost a century ago, Otto Warburg discovered that
tumor cells prominently use glycolysis, even if sufficient oxygen is provided [14]. The lactic acid
produced by aerobic glycolysis fails to feed the mitochondrial tricarboxylic acid (TCA) cycle [15].
To fuel the TCA cycle, glutamine (Gln in Figure 1) becomes another carbon source of the cancer
cell metabolism. Glutamine utilization is mainly regulated by the glutaminase transporter and by
mitochondrial glutaminase-1 in a c-Myc-dependent manner [16]. Its product, glutamate, not only
replenishes the TCA cycle, but also serves as starting material for glutathione (GSH) synthesis in
the cytosol. As GSH is part of the predominant intracellular redox buffer, the increased glutamine
demand of tumor cells also affects redox homeostasis. The end product of glutaminolysis, α-KG,
not only fuels the TCA cycle but can be converted by mutated isocitrate dehydrogenase isoforms to
2-hydroxyglutarate, whose concentration is elevated in several brain tumors [17].
This characteristic reprogramming of the metabolism allows to identify and to target tumor
cells for diagnosis and therapy of cancer patients. Increased uptake and utilization of glucose
and glutamine by cancer cells is diagnostically exploited by using 2-deoxy-2-(18F)fluoro-D-glucose
(18FDG) in positron emission tomography-computed tomography (PET-CT) and labeled glutamine
derivatives [16]. Several transport proteins for glucose and glutamine, as well as key enzymes of
the aberrantly activated glycolysis and glutaminolysis, have been identified as therapeutic targets
in cancer therapy, such as GLUT2, hexokinase-2, pyruvate kinase type M2 [8,10], glutaminase-1 and
glutamate dehydrogenase [16,18].
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Figure 1. Metabolic reprogramming and an altered intercellular communication are hallmarks of
cancer cells. Enhanced demands of glucose (Glc) and glutamine (Gln) as well as low supply of
oxygen are characteristic features of cancer cell metabolism. They activate distinct transcription
factors, such as hypoxia-inducible factor 1α (HIF-1α), cellular Myelocytomatose (c-Myc) and nuclear
factor κ-light-chain-enhancer of activated B cells (NFκB), and upregulate expression of glycolytic and
glutaminolytic key enzymes. Aerobic glycolysis leads to a high lactate concentration and a low pH of the
tumor microenvironment (TME). Glycolytic metabolites stimulate the pentose phosphate pathway to
produce ribose-5-phosphate (R5P) and the production of the amino acids serine (Ser) and glycine (Gly),
thereby filling the tetrahydrofolate pool of C1-groups ([C1]-folate). The tricarboxylic acid (TCA) cycle is
fueled by glutamine (Gln) via glutamate (Glu) and α-ketoglutarate (αKG). Glutamate is also converted
to glutathione (GSH), an intracellular redox buffer. Metabolites, phosphoenolpyruvate and oxaloacetate
are abbreviated to PEP and OA, respectively. Membrane-bound cell adhesion molecules (e.g., integrins)
and cell–cell contact molecules (e.g., cadherin), as well as secreted and soluble growth factors and
chemokines are other key communicator molecules between cancer cells and their neighboring stromal
cells. Cell adhesion molecules bind to the extracellular matrix (ECM) and sense its rigidity and
mechanical forces.
The metabolic reprogramming of tumor cells and secretion of metabolites also contribute to
communication with stromal cells. In some cancer types, cancer-associated fibroblasts (CAFs) and
cancer cells seem to establish a symbiotic relationship regarding their energy metabolism [19–21].
Lactate, produced and secreted by cancer cells is taken up by CAFs and utilized as an energy source
for their pro-tumorigenic functions [22]. Conversely, cancer cells release reactive oxygen species (ROS)
that induce aerobic glycolysis in CAFs, which leads to secretion of additional lactate and pyruvate.
They may provide metabolic energy for cancer cells [22,23]. The direction in which the lactate/pyruvate
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flows depends on the conditions of the TME [19]. Caused by excess lactic acid production, the pH
drop likely contributes to the acquisition of drug resistance in tumor cells [24]. Likewise, ECs near
tumor cells adjust their metabolism and alter the glycolytic metabolism, a property that has recently
been highlighted to be a potential therapeutic approach [25,26].
2.2. Cohesion, Adhesion and Soluble Mediators in the Communication between Tumor Cells
Cell–cell contacts (cohesion) between layer-forming epithelial and ECs are mediated by cadherins
and other cell–cell contact molecules. Epithelial cell-derived carcinoma cells typically express
E-cadherin, while VE-cadherin is the principal cadherin of ECs. Cadherins are transmembrane
proteins consisting of five extracellular IgG-folds, a transmembrane part and a cytoplasmic tail,
the latter of which is anchored via α-, β-, and γ-catenins to the actin cytoskeleton [27]. Two cadherin
molecules of one cell form a homodimer which interacts with a cadherin homodimer of the same
type on a neighboring cell in a Ca2+-ion dependent manner, thus mediating cell-type specific cohesion
and ruling out interactions with cells of other tissues which bear other cadherin types (Figure 1).
While E-cadherin-expressing carcinoma cells cohere, loss of cadherin expression or function promotes
contact loss to neighboring tumor cells. Thus, a carcinoma cell can disseminate from a tumor cell cluster,
a hallmark of malignancy. A detached carcinoma cell changes its cellular morphology and increases
its migratory potential, a process called epithelial–mesenchymal transition (EMT). EMT correlates
with tumor cell scattering and metastasis [28]. E-Cadherin surface exposure is regulated at the
transcriptional level by the key transcription factors, Snail family transcriptional repressor 1 (SNAI1)
and TWIST1, and by epigenetic factors, such as DNA-hypermethylation, as well as by endocytosis
and subsequent degradation [28]. Moreover, growth factor receptors, such as Epidermal growth factor
receptor (EGFR) and hepatocyte growth factor receptor (HGFR, c-Met), may activate Src, which triggers
phosphorylation and endocytosis of E-cadherin, leading to dissemination of tumor cells from the
tumor mass. Even if not completely abolished, reduced E-cadherin levels have been observed in
subgroups of carcinoma cells, which migrate collectively. Downregulation of E-cadherin during
EMT may be accompanied by the upregulation of mesenchymal cadherins, such as N-cadherin and
cadherin-11, which allow new interactions of tumor cells with stromal fibroblasts. Moreover, by
expressing VE-cadherin, tumor cells may also mimic ECs and thus are able to establish unconventional
interactions with ECs. Such heterotypic cohesion events may enable tumor cells to contact with stromal
fibroblasts and ECs directly via cell–cell contacts [28].
Adhesion is the interaction of cells with their extracellular matrix (ECM). As a three-dimensional
interstitial fibrillar meshwork, the ECM scaffolds the stromal tissue and as a two-dimensional
basement membrane (BM), it supports epithelial or endothelial tissue layers. Integrins, heterodimeric
transmembrane proteins consisting of an α subunit and a subgroup-determining β-subunit, are the
corresponding adhesion receptors on adherent cells (Figure 1). Integrins with a β1, β3, and β4
subunit bind via their ectodomains to ECM proteins, which trigger integrin clustering and subsequent
signaling. Lacking a kinase domain, integrins interact with several adaptor, signaling, and cytoskeletal
proteins via their cytoplasmic domains, thereby transducing both environmental cues and mechanical
forces between the ECM and the cytoskeleton [29,30]. It is of special interest that tumor cells generate
mechanical forces via actin-associated motor proteins, such as myosin II. These intracellular forces
are transmitted to the ECM network via integrins and build up tension in it. This mechanical tension
is another key parameter which determines the TME and is sensed by resident cells, e.g., fibroblasts.
Diagnostically, the BM plays a pivotal role in tumor metastasis. It is a sheet-like matrix structure
containing characteristic proteins, such as type IV collagen, laminins, nidogens, and the principal BM
proteoglycan perlecan. In addition to its physiological functions as morphogen, the BM acts as a cell
barrier. Physiologically, it can only be penetrated by leukocytes during immune surveillance of tissues.
Pathologically, oncogenically transformed tumor cells are able to breach the BM due to their altered
integrin repertoire and expression of ECM degrading matrix metalloproteinases (MMPs), and thus
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they are considered malignant [31]. Breaching the BM defines malignancy and is another hallmark of
cancer [9].
Growth factors and chemokines are other means of communication between tumor cells and
within the TME (Figure 1). These soluble signaling molecules are produced by tumor cells or by resident
cells. As a consequence of the TME, tumor cells may produce growth factors, such as Hepatocyte
growth factor (HGF), Fibroblast growth factors (FGFs), Transforming growth factor β isoforms (TGFβs),
Vascular endothelial growth factors isoforms(VEGFs), and cytokines, such as Receptor activator of
nuclear factor kappa-B ligand (RANKL) and other members of the Tumor necrosis factor α (TNFα)
superfamily [32,33]. This cocktail of growth factors and cytokines also contributes to the specific TME.
The growth factors act in an autocrine and/or paracrine manner on tumor cells and/or resident cells,
and stimulate their proliferation. Tumor cells alter the expression and activity of secreted cytokines as
well as of various cytokine receptors. This alters their responsiveness to such factors. Several mutations
in growth factor receptors, such as EGFR, hepatocyte growth factor receptor (cMET), and Fibroblast
growth factor receptor isoforms (FGFRs), have been described to initiate uncontrolled cell proliferation
of transformed cells [34,35]. Secreted by cancer cells, transforming growth factor-β (TGFβ) is a key
driver in the differentiation of fibroblasts to Cancer-associated fibroblasts (CAFs). VEGF-A produced by
tumor cells, under hypoxic conditions, attracts ECs to the tumor cell mass resulting in tumor-induced
angiogenesis. Conversely, growth factors and cytokines produced by the resident cells may affect
the cancer cells and may induce them to change their repertoire of integrins and cadherins [36–38].
For example, after stimulation by HGF, cMet triggers the internalization and subsequent degradation
of E-cadherin in carcinoma cells, resulting in EMT and tumor cell dissemination [28].
In all body fluids, extracellular membrane vesicles (EVs) of different size, such as exosomes,
microparticles or microvesicles, and apoptotic bodies, contain numerous signaling molecules
dependent on their cellular origin. They are released from sender cells to be taken up by target
cells. In this way, they convey intercellular signals in autocrine, paracrine, and even endocrine
manners [39–41]. Thus, they crucially mediate intratumoral signaling, tumor progression, metastasis,
and chemotherapy resistance. Exosomes with a diameter of 30–100 nm generally contain membrane
fusion proteins (e.g., tetraspanins, lactadherin, and integrins), cytoskeletal proteins (e.g., actin
and tubulin), membrane trafficking proteins (e.g., Rab proteins, ADP ribosylation factor (ARF)
GTPases, and annexins), cytoplasmic enzymes (e.g., Glyceraldehyde 3-phosphate dehydrogenase
(GAPDH), peroxidases, pyruvate kinases, and lactate dehydrogenase) and, signal transduction proteins
(e.g., protein kinases and heterotrimeric G-proteins) [42,43].
Tumor cells communicate with neighboring resident cells via local metabolic parameters, such as
lactic acid-mediated acidosis, low oxygen supply and increased ROS levels. Furthermore, secreted
mediators, such as growth factors and chemokines, and the composition and mechanical tension of the
ECM and integrin-mediated cell–matrix contacts, as well as cadherin-mediated cell–cell contacts are
other means of communication in the TME (Figure 1). These factors determine the TME, in which the
resident cells change their metabolism and behavior in support of the tumor cell. This niche supports
cancer progression and can be compared to the “soil” in which, according to Stephen Paget’s “seed
and soil” theory (1889) [44], cancer cells thrive or metastasizing cells settle. The tumor cells prepare
this “soil” either directly or by making neighboring cells, such as fibroblasts and ECs, change the “soil”
in favor of the tumor.
3. Stromal Fibroblasts, the Immediate Neighbors of Tumor Cells
The TME constitutes a very complex niche, with extreme importance for the maintenance and
progression of the tumor cells [45]. It consists of two components: cells and the ECM. The tumor stroma,
or “reactive stroma” comprises three important cell groups [19,46]: CAFs (described in more detail in
this section), angiogenic vascular cells (discussed in the next section) and infiltrating immune cells [3].
The pro-tumorigenic TME is characterized by an increased deposition and an altered composition of
the ECM, by higher microvessel density, and by the activation of cancer-recruited stromal cells [46].
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However, the TME differs between tumors, with diverse tumor stroma composition and different
portions and activation states of stromal cells and it may alter during tumor progression, due to the
evolving environmental conditions and oncogenic signals from growing tumors [47]. Differences in
the TME are also observed within the same tumor, with disparities between the invasive edge and the
tumor core, in line with the metabolic alterations, such as the availability of oxygen and nutrients [47].
Additionally, the presence of different cell types producing specific growth factors influences the tumor
cells differently [48]. Finally, mechanical aspects of the tumor stroma, such as stiffness of the ECM
and interstitial fluid pressure, play a crucial role in the TME [46,49]. As complex and diverse as it is,
the TME dictates the fate of the tumor by providing survival and expansion signals, by setting the
selection criteria of mutant subclones and by creating tumor cell heterogeneity, thereby posing an
enormous challenge in cancer therapy [48].
3.1. CAFs Are Crucial for the Maintenance of a Pro-Tumorigenic TME
CAFs are the most prominent cell type in the tumor stromal compartment. They are crucial
in forming and maintaining a pro-tumorigenic niche. Their presence in the tumor tissue has been
associated with a poor prognosis in many cancer types as, e.g., gastric [50], colon [51], breast [52],
and pancreatic cancers [53]. CAFs have been described as myofibroblasts, resembling the activated
fibroblasts in wound healing. In some aspects, the tumor stroma is similar to granulation tissue, since
the main cellular components are fibroblasts, together with immune, inflammatory and ECs [54].
Furthermore, in both tumor progression and wound healing, more ECM is deposited and cross-linked.
As a consequence of this, the ECM scaffold is remarkably stiffened. In addition, more soluble cytokines,
such as TGFβ1, are tethered to the ECM scaffold [54,55]. Dvorak even defined a tumor as “a wound
that never heals” [54].
Normally, the ECM is sparsely populated by undifferentiated spindle-shaped fibroblasts [56].
When tissue injury takes place, these fibroblasts are activated. They start to express high levels of
α-smooth muscle actin (αSMA), gain a stellate shape and produce more ECM [56]. Differentiating into
myofibroblasts, they acquire contractile properties to close the wound. Moreover, they take on a
secretory, migratory, and proliferatory phenotype. This further enhances activation and recruitment
to the damaged tissue [56,57]. Once wound healing is accomplished, these cells revert to their normal
phenotype or undergo apoptosis [56,58]. In a neoplastic lesion, this reversion or apoptosis does not happen.
Instead, their proliferation, secretion of paracrine and autocrine cytokines [59], and ECM production and
remodeling are enhanced [60]. Among the cytokines, TGFβ1, monocyte chemotactic protein (MCP1),
platelet-derived growth factor (PDGF), and FGF, as well as secreted proteases have been implicated
in CAFs activation [61,62]. Cancer cell-derived exosomes containing TGFβ and betaglycan have been
reported to induce differentiation of fibroblasts to myofibroblasts by SMAD signaling and upregulation
of basic FGF (bFGF, FGF2) production and α-smooth muscle actin expression [63]. While normal
fibroblasts were reported to suppress tumor formation [64], CAFs emerge in the tumor as promoters of a
pro-tumorigenic TME and thus lay an indispensable foundation for cancer progression. What is the origin
of the CAFs present in the TME? There are several and controversial hypotheses about possible precursor
cells and about different stimuli which ultimately induce formerly tumor-suppressing fibroblasts to
express miscellaneous other marker proteins and change their phenotype into that of pro-tumorigenic
CAFs. In accordance to these hypotheses is a description of CAFs as a heterogeneous cell population with
numerous and different functions in the tumor. This heterogeneity complicates their investigation.
Specific markers for CAFs have not yet been identified, but diverse proteins are altered upon
differentiation of fibroblasts into CAFs. αSMA, a component of cytoskeletal stress fibers, was one
of the first proteins to be described as a marker for myofibroblasts in both fibrotic tissue and
cancer [65]. In addition, a filament-associated, calcium-binding protein called fibroblast-specific
protein 1 (FSP1) was typically expressed de novo in activated fibroblasts [66]. Platelet derived growth
factor receptor-β (PDGFRβ) and NG2 chondroitin sulfate proteoglycan (NG2) were found in some
populations of pancreatic CAFs, in co-localization with αSMA and FSP1, albeit in different percentages.
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This may indicate different subpopulations of CAFs [67]. Fibroblast activation protein (FAP) is another
marker, originally described as a cell surface glycoprotein of reactive stromal fibroblasts [68]. ECM
protein tenascin C was also described to be a typical secretion product and hence potential marker
of CAFs [69]. The lack of a universal CAFs marker is likely to be due to the diversity of CAFs.
Depending on the tumor type and organ in which they differentiate, diverse CAF populations exist
which possess different characteristics [51]. Herrera et al. showed that different subpopulations
of colon CAFs, obtained from different patients, had distinct promigratory effects on colon cancer
cells [51]. The diversity of tumor CAFs may be rooted in their origin [51]. CAFs can originate from
several cell types, such as normal fibroblasts, myofibroblasts, adipocytes, smooth muscle cells, or bone
marrow-derived progenitor cells [70,71]. Moreover, the differentiation pattern of CAFs may depend on
environmental cues provided by different components of the TME, such as the ECM and the cytokine
mixture. Local fibroblasts from the stroma where the neoplastic lesion develops can differentiate into
CAF, as a result of stimulation by cytokines of the PDGF or TGFβ family produced by the cancer cells,
macrophages and other stromal cells [72,73]. CAFs may also originate from ECs in a process called
endothelial to mesenchymal transition, which ECs undergo when submitted to fibrotic conditions,
e.g., under the influence of TGFβ1 [74]. By using two different tumor mouse models (pancreatic
neuroendocrine tumor and melanoma), Zeisberg et al. demonstrated, that ECs acquire a mesenchymal
phenotype and express markers such as FSP1, and to a smaller extent, αSMA [74]. This study showed
that ECs are a possible source for CAFs in the microenvironment of angiogenic tumors.
Various functions are attributed to CAFs. Due to their acquired secretory phenotype, they play
a central role in processes such as EMT, angiogenesis and immune cell recruitment. CAFs secrete
TGFβ1 and thus induce EMT in many carcinomas by TGFβ1-mediated loss of adherens junctions and
by increased motility of cancer cells which results in enhanced invasion and metastasis abilities [59,75].
Moreover, some of the first studies on the role of stromal cells in tumor angiogenesis used transgenic
mice expressing green fluorescent protein (GFP) under the control of the vascular endothelial
growth factor (VEGF) promoter. In spontaneous mammary tumors, as in wounds, the predominant
GFP-positive cells were fibroblasts [76]. CAFs also have been reported to promote angiogenesis by
different mechanisms: mouse cervical CAFs produce pro-angiogenic fibroblast growth factors FGF-2
and FGF-7 and, consequently interception of FGF impairs angiogenesis [77]. Another CAF-related
mechanism to stimulate angiogenesis is to recruit endothelial progenitor cells (EPCs) into the carcinoma
site by secretion of stromal cell-derived factor 1 (SDF-1), also known as C-X-C motif chemokine 12
(CXCL12) [78]. Moreover, Orimo et al. described that the interaction of CAF-secreted CXCL12
with its receptor C-X-C chemokine receptor type 4 (CXCR-4 (CXCR4), expressed by carcinoma cells,
results in enhanced tumor growth [78]. This chemokine is also associated with an inflammatory
response by recruiting leukocytes into the tumor stroma, where they contribute to angiogenesis by
producing angiogenic factors, by remodeling the ECM via stimulated secretion of MMP-9, and by
direct differentiation into ECs [79–81]. Moreover, immunosuppressive CAFs at the invasive front of a
tumor interfere with dendritic cell differentiation [47]. CAFs also modulate the immune response by
secreting cytokines and chemokines, such as interleukin-1 and MCP1, respectively [62]. In addition to
cytokines, CAFs secrete exosomes, containing soluble factors that promote breast cancer cell migration.
Such exosomes are yet another means of communication between cancer cells and stroma cells, but also
between primary and secondary sites of a tumor [82].
3.2. ECM Is a Means of Communication in the TME and Signals via Distinct Parameters: Qualitative and
Quantitative Composition, Cross-Linkage of Supramolecular Structures, Tensional Status and Degradation
The ECM forming the extracellular scaffold for fibroblasts is the characteristic component of
connective tissue. Its border, the BM, forms the foundation to which cells of all other tissues,
such as epithelial and ECs, muscle cells, neurons and adipocytes, are anchored. However, during
carcinogenesis, the ECM is remodeled. This is mainly done by stromal cells, such as CAFs [83].
Moreover, breaching of the BM by tumor cells is a hallmark of malignancy.
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The constitution of the ECM in different tumor types is highly heterogeneous. In addition, within
the same tumor, differences can be noted, as ECM deposition may change depending on tumor
staging [84]. Different types of collagens, laminins, proteoglycans, glycosaminoglycans, fibronectin,
and vitronectin are among the most abundantly expressed ECM proteins in cancer stroma. They are
deposited and remodeled by stromal cells, such as CAFs. The ECM in the TME is also functionally
diverse, and the multiple interactions between the different constituents increase this diversity.
As major components of the BM, laminins are crucial in tumor angiogenesis and metastasis [85,86].
Usually laminin α4 chain is overexpressed in breast cancer and promotes cell detachment in vitro,
and in vivo it stimulates tumor re-initiation in multiple organs, and disseminated metastatic cell
proliferation [87].
Expression of fibronectin is upregulated in CAFs at metastatic sites, e.g., in the lung, and serves as a
docking site for the hematopoietic progenitor cells and invading tumor cells [47]. Being part of the TME
scaffold of aggressive tumors, it comes in two different splice variants which differ in the presence of
the extra-domains (ED) A or B, called EDA and EDB [88–90]. Bordeleau et al. described the alternative
splicing as an adaptation of the cells to their microenvironment [91]. The increased production of the
EDB fibronectin isoform by ECs correlates with ECM stiffness [91]. Matrix stiffness-regulated splicing
depends on the activation of various splice factors, on intracellular Rho/Rho-associated protein
kinase (ROCK)-mediated contractility and on PI3K-AKT signaling [91]. Regulation of alternative
splicing by ECM stiffness is likely to occur in other cell types, too [91]. In contrast, the alternatively
spliced EDA fibronectin variant is deposited in regions of active fibrosis, e.g., in idiopathic pulmonary
fibrosis [92,93]. In this context, EDA fibronectin plays a role in TGFβ-dependent differentiation of
fibroblasts into myofibroblasts via autocrine/paracrine feedback loops and in metastasis, while EDB
fibronectin is likely involved in EC proliferation and vascular morphogenesis, tumorigenesis and
EMT [88,94].
Tenascin-C and periostin are matricellular proteins produced by CAFs. They collaboratively
contribute to lung metastasis, in a process involving Wingless-related integration site (Wnt) and
Notch signaling pathways [95]. Periostin recruits Wnt ligands and presents them to stem-like
metastasis-initiating cells [96]. On the other hand, tenascin-C, produced by both CAFs and tumor
cells, activates Wnt and Notch pathways, supporting the fitness of metastasis-initiating breast cancer
cells and their “seeding” at the metastatic site [97]. Moreover, periostin also contributes to proper
assembly and homeostasis of collagen. In addition, its deposition enables tenascin-C to bind to
other ECM molecules such as collagen-I and fibronectin [98,99]. Tenascin-W, the fourth and newest
member of the tenascin family, was discovered ten years ago. It is expressed in activated tumor
stroma, facilitating tumorigenesis by supporting the migratory behavior of breast cancer cells [100].
Both tenascin-C and -W can be expressed in tumor stroma usually at similar percentages, being most
likely produced by CAFs [101]. However, they do not necessarily coexist in a tumor, likely due to
independent modulation mechanisms [101]. For example, tenascin-W is enriched in low-grade cancers,
while tenascin-C expression is found irrespective of the tumor grade [100]. In addition, in colon
cancer, tenascin-W, in contrast to tenascin-C, is ectopically expressed in tumor tissue and is considered
as cancer biomarker of unfavorable disease progression, since it is not detectable in healthy colon
stroma [102]. Moreover, tenascin-W is present in the stroma of mouse mammary tumor models
developing metastasis, whereas tenascin-C is absent from both non-metastatic tumors and normal
mammary tissue [103].
A fibrotic overexpression of collagenous ECM components contributes to a desmoplastic TME [83].
The mechanical robustness and stiffness of the ECM is strongly increased through inter- and
intramolecular cross-linkages of fibrous collagen and elastin. They are catalyzed by members of
the lysyl oxidase (LOX) gene family, such as lysyl oxidase-like protein-1 (LOXL1). The expression
of this amine oxidase seems to correlate with increased tumor malignancy, since it is expressed in
metastatic but not in non-metastatic cell lines [104,105]. Other experimental observations point out
that LOXL1-expressing tumors are highly fibrotic and surrounded by many dense collagen fibers, [104].
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Inhibition of LOX-dependent collagen crosslinking decreases tissue desmoplasia, tumor incidence and
growth, and reduces mechanotransduction in the mammary epithelium [49].
The mechanical forces that increase ECM stiffening and intratumoral pressure are generated
intracellularly by cytoskeletal motor proteins and transmitted via transmembrane integrins to
ECM proteins such as collagens and laminins. The integrin repertoire of tumors alters during
cancerogenesis [106]. Integrins are both mechanotransducers of tensile force and also elicit intracellular
signaling pathways. Thereby, they regulate cell differentiation and fate [106]. Tumor cells express, e.g.,
β4 integrins which endow them with resistance to apoptosis [107]. In addition, β1-integrin expression
has been described as critical for tumorigenesis initiation and for maintaining the proliferative capacity
of late-stage tumor cells [108].
TGFβ stimulates CAFs by autocrine signaling to produce and deposit more collagens I and III
and fibronectin, which then promote cell adhesion and strengthen mechanical signaling between
CAFs and tumor cells [83]. Noteworthy, the ECM can also tether and store growth factors, e.g., latent
TGFβ1 [109]. Integrin-mediated ECM contraction by CAFs releases TGFβ1 from ECM fibers under
tension, especially in a fibrotic and stiffened matrix, and protease-independently activates TGFβ1 [109].
Excess production, remodeling, stiffening of the ECM and CAF differentiation mutually promote
each other, resulting in increased release of TGFβ1 into the TME. Such self-sustaining growth signals
promote cell activation, proliferation, and EMT, thereby reinforcing tumor progression [109].
Matrix stiffening and increased tensile forces modulate the cytoskeletal contractility in CAFs via
the signaling molecules Yes-associated protein (YAP) and ROCK in a self-reinforcing positive feedback
loop, by which CAFs maintain their differentiated phenotype [110]. Moreover, in vitro studies from our
lab have shown that the stiffness of the ECM substrate influences not only the cytoskeletal αSMA-rich
stress fibers but also the adhesion and proliferation of fibroblasts (Figure 2).
A stiff stroma and elevated Rho-dependent cytoskeletal tension promote focal adhesion formation,
disruption of adherens junctions, and disturb tissue polarity [106,111,112]. In a striking study, Paszek et al.
show that matrix stiffness is associated with integrin clustering, Extracellular signal–regulated kinase
(ERK)-enhanced activation, and increased ROCK-generated contractility and formation of focal adhesions,
in a mechanoregulatory circuit [106]. If this process becomes chronic, it promotes cell growth,
disturbs tissue organization, and thus supports malignant transformation [106]. The desmoplastic
response with enhanced matrix stiffening also influences the metastatic potential of epithelial cancer
cells. Transformed cells often exert abnormally high forces, and these forces consequently disrupt cell–cell
junctions, compromise tissue polarity, allow anchorage-independent survival, and ultimately increase
invasion [49]. The cell-generated forces can also account for increased invadopodia, focal adhesion
maturation and actomyosin contractility [49]. Tension-dependent matrix remodeling can also occur, as a
consequence of increased contractility of tumor cells and CAFs, as it is observed in a reorientation of
collagen fibrils surrounding the invasive front of the tumor [49]. Moreover, contraction of CAFs and
tumor cells, and matrix stiffening cause high interstitial pressure which is another characteristic feature
of the TME. Practically, the high tissue tension and high interstitial tension mechanically affects tumor
vasculature by obliterating and provoking the collapse of blood and lymphatic vessels in the tumor [46,83].
Degradation of collagen and of other ECM molecules also contributes to tumor-induced
ECM-remodeling and is another essential requirement for tumor invasion, where MMPs play a
crucial role [113]. In mesenchymal cell migration, invading cells present focalized cell–matrix
adhesions containing multi-molecular integrin clusters and increased proteolytic activity against
ECM substrates [113]. Overexpression of MMPs-3, -11, -12, and -13 was detected in tumor stroma,
along with MMP-2 in transformed mammary epithelial cells [49,114]. Furthermore, tumor cells recruit
MMP-2- and MMP-9-producing neutrophils and macrophages [114]. Notably, immune cells tend to
accumulate and migrate within dense collagen-enriched tumor stroma regions [115]. The activity of
MMPs can be countered by both endogenous and pharmacological inhibitors. High expression of
protease inhibitors (e.g., serpin family members) is associated with good prognosis, whilst tumors
with high expression of integrins and MMPs correlate with poor prognosis and risk of recurrence [116].
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Therapies employing pharmacological MMP inhibitors have been tested for various cancers with
limited success so far [48].
Figure 2. Mechanical stiffness of ECM is a crucial factor in CAF differentiation. Fibroblasts seeded
in collagen-I coated polyacrylamide gels of defined stiffness (elastic modulus is given in kPa)
exhibited increased adhesion and increased formation of α-Smooth muscle actin (αSMA)-rich stress
fibers (red fluorescence). αSMA immunostaining was quantified as total corrected fluorescence.
This experiment reflects in vivo conditions, where the stiff scaffold of desmoplastic ECM contributes
to CAF differentiation, together with soluble factors such as TGFβ that are stored bound to ECM
fibers and released when CAFs exert force on those fibers. Upon differentiation, CAFs change their
morphology and express different biomarkers, such as αSMA stress fibers (red fluorescence). CAFs
proliferate at higher rate, exhibit a secretory phenotype and enhanced contractibility; thus, they play
an essential role in forming the TME. Scale Bar = 50 μm.
Proteolytic fragmentation of ECM proteins not only leads to remodeling or degradation of
the ECM scaffold, but also release defined ECM protein fragments, so-called matrikines, which act
as soluble mediators such as cytokines and influence both cancer and resident cells of the tumor
tissue. Moreover, they have attracted special attention as potential new anti-cancer agents [117].
Matrikines can block pathways that are involved in proliferation and invasion of tumor cells, and they
affect angiogenic and lymphangiogenic processes [117]. Collagen XVIII-derived endostatin [118] and
perlecan-cleaved endorepellin [119], strongly inhibit tumor growth in many preclinical cancer models
and show angiogenesis-blocking effects on sprouting ECs [117].
4. Interactions of Cancer Cells with Endothelial Cells
4.1. Tumor Vascularization
In the prevascular phase of tumor dormancy, there is a dynamic equilibrium between proliferation
and hypoxia-induced apoptosis of cancer cells [120]. The oxygen diffusion limit in tissue is around
150 μm which restricts avascular tumor growth to just a few millimeters [121]. When a tumor grows
beyond this size, it flips an angiogenic switch and triggers an angiogenic cascade to recruit its own
vasculature and connect to the blood circuit [122,123]. The vasculature becomes permanently activated
to form new vessels by sprouting from pre-existing vessels in order to supply the tumor with blood and
sustain its growth [9]. This angiogenesis is driven by numerous pro-angiogenic cytokines, chemokines,
and matrix-degrading enzymes during tumor development [124–127]. In addition to tumor cells
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themselves, infiltrating bone marrow-derived monocytes that differentiate into tumor-associated
macrophages (TAMs) [128] are a further source of angiogenic factors [129–131] that recruit endothelial
and mural cells, such as pericytes [132,133]. From the microscopic premalignant phase onwards,
this neovascularization enables the tumor to grow exponentially [9,122,134,135].
Tumor blood vessels appear little differentiated, highly tortuous, disorganized, and chaotic. This is
why blood flow is disturbed and drug delivery hampered. Tumor vasculature is unexpectedly complex
and can be classified into at least six types [136]. Its specific organization and the underlying tumor
vascularization mechanisms have been reviewed in [127,137–139]. A lack of mural cells, a poorly
formed BM and a discontinuous endothelium, in which even tumor cells may be incorporated, render
the tumor vasculature leaky and also promote metastasis, The tumor vasculature-surrounding ECM is
anomalously rich in the oncofetal fibronectin ED-B splice variant, which is synthesized by neoplastic
cells [140,141], and in tenascin-C and -W, which are synthesized by melanoma and glioblastoma cells
and by CAFs of most carcinomas [101,142]. Tenascin-C promotes the survival of tumor stem cells,
inhibits immune surveillance, stimulates angiogenesis, proliferation, invasiveness, and metastasis of
tumor cells [101,142]. Furthermore, Tenascin-C expressing neuroblastoma cells can transdifferentiate
into tumor cell-derived ECs [143]. Tenascin-W is exclusively detectable in tumor stroma and can
be used as a tumor marker for breast and colon cancer [102,144]. In addition to preexisting vessels
that can be co-opted by tumor cells (Figure 3A), neovessel formation can originate from quiescent
vasculature in various ways, which are collectively called tumor angiogenesis. This general term
includes EC sprouting, intussusceptive and glomeruloid angiogenesis (Figure 3B–D). Vasculogenesis,
in contrast, is a process of tumor neovascularization in which bone marrow-derived cells are recruited
and differentiate into EPCs (Figure 3E). Thus, tumor ECs are heterogeneous and can originate from
multiple sources [145]. Furthermore, cancer stem-like cells can accomplish vasculogenesis [146],
and tumor cells themselves may differentiate to take over EC functions and line partly or even
completely plasma containing conduits [147]. Integration of tumor cells into an EC layer forms mosaic
vessels (Figure 3F), and the complete lining of blood-filled tubes with tumor cells is a process called
vasculogenic mimicry (VM) (Figure 3G–H) [148,149]. These heterogeneous formation mechanisms
together with the persistent tumor vessel growth lead to a constantly shape-changing, tortuous,
and highly irregular tumor vasculature of which about 30% comprise arteriovenous shunts that
bypass capillaries [120]. The consequential poor perfusion causes hypoxia of ECs, which hereupon
release more pro-angiogenic molecules and stimulate further tumor angiogenesis [120]. The highly
irregular architecture of the tumor vasculature together with irregular direction of flow, turbulences,
and pressure conditions renders the tumor vasculature intrinsically leaky [150–152]. This causes an
increased interstitial pressure, which makes it difficult for chemotherapeutics that are administered
via the bloodstream to reach their site of action [153].
The proliferation of tumor cells alongside of preexisting vessels is termed vessel co-option and
occurs predominantly early in tumor growth, although there is evidence that hijacking vessels by
co-option might persist during all stages of tumor growth [137,154,155]. With progressive tumor
growth, tumor cells proliferate around constantly formed neovessels which markedly differ from
normal vessels in morphology and molecular composition [156,157]. Angiogenic sprouting of
ECs, which are pivotal in blood vessel growth [158], is usually involved in the formation of these
vessels [159]. Triggered by an angiogenic stimulus, select ECs differentiate into tip cells that migrate
along a stimulatory gradient into the avascular ECM. Other ECs start to proliferate and form cord-like
structures behind the tip cells. These cords develop into endothelial tubes that finally anastomose;
pericytes and smooth muscle cells are recruited, and a new BM is formed [160–162]. New tumor vessels
can also arise via EC columns that move into the vessel lumen, and these transluminal pillars enlarge
and form new vessel walls that split the pre-existing vessel into two in a process called intussusceptive
angiogenesis [163–165]. Neovascularization by intussusceptive rather than sprouting angiogenesis
is energy-saving and faster, and occurs inter alia in gliosarcoma multiforme, melanoma, breast and
colon cancer [166]. Glomeruloid angiogenesis, found in many aggressive tumors, is another way
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of tumor angiogenesis in which several microvessels are ensheathed by a BM of varying thickness
containing few pericytes to form complex vascular structures termed glomeruloid bodies [137,167,168].
Additionally, there is evidence for vasculogenesis by recruitment of bone marrow-derived EPCs that
differentiate into ECs [120,169–171]. EPCs also promote the angiogenic switch and the transition
from micro- to macro-metastasis [172]. Furthermore, in many cancers highly invasive and genetically
dysregulated tumor cells have been reported to adopt an EC-like phenotype [173,174] and form
partially non-EC-lined mosaic vessels and even completely non-EC-lined vascular-like channels to
support their own blood supply by VM [148,149]. Such VM channels can arise either by tubular or
patterned matrix type VM [175,176]. While VM networks of the tubular type morphologically resemble
the pattern of embryonic vascular networks [137,177], the morphology and topology of the patterned
matrix type strongly differs from EC-lined vessels. It displays an intricate meshwork of extravascular
patterned depositions of matrix proteins such as laminins, collagens IV and VI, and heparan sulfate
proteoglycans that wrap around interdigitating and branching cylinders of tumor cells and, unlike
fibrovascular septa, form hollows that anastomose with blood vessels [175,178,179]. All these types of
vessel formation can occur in parallel, and also gradual transitions are possible. All of them comprise
numerous sequential steps which crucially depend on integrins [127] and MMPs [31,180–182] as well
as on soluble growth factors [183].
 
Figure 3. Different types of vascularization allow the blood supply of tumor tissue. Different types
of vascularization can occur simultaneously and even merge: (A) co-option of preexisting vessels;
(B) sprouting angiogenesis of endothelial cells; (C) intussusceptive angiogenesis; (D) glomeruloid
angiogenesis; (E) vasculogenesis by recruitment of bone marrow-derived endothelial progenitor
cells (EPCs); (F) in mosaic vessels, patches of tumor cells insert into the endothelium; (G) tubular
type vasculogenic mimicry (VM) of tumor cells; and (H) patterned type VM of tumor cells.
While angiogenesis (B–D), and vasculogenesis (E) depend on proliferation of ECs and bone
marrow-derived EPCs, vessel co-option and VM (F–H) are EC proliferation-independent ways to
support tumor growth. The recruitment of bone marrow-derived EPCs from distant parts of the body
impairs radiation therapy, while vessel co-option and VM are unassailable to anti-angiogenic therapy.
Vascularization mechanisms that are susceptible to anti-angiogenic therapy are highlighted in green,
those that are insusceptible in red.
Once the tumor is connected to the vasculature, ECs become part of the tumor tissue and
communicate with the other cells in the tumor tissue. Cancer progression is promoted when this
communication goes awry [184,185]. At a later progression stage of a primary tumor, both angiogenetic
and lymphangiogenic vessels allow tumor cells to disseminate and use the blood or lymph as a
direct route of transportation to colonize distant organs. In this way, a cancer cell that successfully
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transmigrates through the endothelium into another tissue can form a metastasis. Regarding cancer
invasion and metastasis, the endothelium acts rather as a launching site than as a barrier. ECs can
affect the invasiveness of cancer cells by controlling their vascular dissemination [186] or by increasing
their invasive capability [187].
Angiogenesis, vasculogenesis and vessel-based metastasis are controlled by cancer-endothelial
cell (CEC) interactions. Different molecular modes of action underlying CEC interactions can
be distinguished: (i) chemokine- and soluble factor-mediated interactions; (ii) tumor-endothelial
communication via extracellular vesicles; and (iii) biomechanical (physical) interactions by, e.g., gap
junctions and adheren junctions.
4.2. Soluble Factors Mediate CEC Interactions during Angiogenesis and Vasculogenesis
Tumor cell-secreted growth factors influence the TME and attract ECs. Such factors usually
activate receptor kinases or ion channels to trigger an intracellular response. The most important
endothelial growth and survival factors are the VEGFs. The VEGF family consists of five members
(VEGF-A, -B, -C, and -D, and placental growth factor) that can bind to three tyrosine kinase receptors
(VEGFR-1, -2, and -3) [188]. VEGF-A is the most significant inducer of local angiogenesis. Chronic
VEGF stimulation in tumors promotes excessive sprouting and branching by tip cells leading to
irregularities in the tumor endothelium and loss of its barrier function [189]. Almost all tumors express
VEGF-A as essential growth factor in pathological angiogenesis. Furthermore, it is the prime elicitor of
the angiogenic switch [190].
Originally identified as mediators of inflammatory diseases, chemokines link tumor and
stromal cell communication networks to induce a proper microenvironment for tumor growth and
metastasis [191]. Chemokines are a family of small cytokines secreted by cells. They bind to G
protein-coupled chemokine receptors on target cells. CXCL12 is the most important CXC chemokine
and is implicated in cancer cell extravasation and metastasis [192,193]. It is found in many tissues and
in serum. Expressed by stromal cells of distant organs, CXCL12 promotes metastasis by attracting
cancer cells and stimulating cancer cell extravasation, migration, and adhesion to ECM and to stromal
cells. On cancer cells, it binds to and signals via CXC chemokine receptors type 4 (CXCR4) and
7 (CXCR7). A simultaneous and enhanced expression of CXCL12 and CXCR4 has been found in
many cancers, such as breast [194], gastric [195], pancreatic [196,197], ovarian [198,199], cervical [200]
and oral squamous cell carcinoma [191]. CXCL12 promotes the attachment of prostate cancer and
breast cancer cells to ECs, and increases their transendothelial migration in vitro. Murakami et al.
also demonstrated that ectopic expression of CXCR4 has similar effects on melanoma cells in vitro,
and that it enhances lung metastasis in vivo [201].
Micro RNAs (miRNAs) are also significant regulators of angiogenesis and tumor metastasis.
They are short (20–24 nucleotides) non-coding endogenous RNAs that occur in multicellular organisms
and can influence the expression of many genes by post-transcriptional silencing or by causing
the degradation of their mRNAs. miRNAs, which are frequently deregulated in many types of
cancer, facilitate tumor growth, invasion, angiogenesis, and immune evasion through controlling
translation of their target mRNAs [202,203]. For instance, in ECs co-cultured with hepatocellular
carcinoma cells, three miRNAs, miR-146a, miR-181a*, and miR-140-5p, are upregulated, whereas
miR-302c is downregulated [204]. Upregulation of miR-146a promotes EC migration and proliferation,
as well as tumor growth and vascularization [204]. Furthermore, miRNAs can selectively be
exported from cells in membrane-bound vesicles (exosomes and MPs), lipoproteins, and other
ribonucleoprotein complexes. The content of these vesicles/particles varies with and corresponds to
the (patho)physiological state distinct signature of the secreting cell. After the uptake of exosomal
miRNAs by neighboring or distant cells, these miRNAs modulate the gene expression in the recipient
cell [205]. Zhuang et al. have demonstrated that, via microvesicles, miR-9 transfers information from
cancer to ECs. Thus, miR-9 supports angiogenesis and tumor growth [206].
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4.3. Direct Tumor Cell–Endothelial Cell Interaction and Integration of Tumor Cells in Mosaic Vessels
Fifteen percent of vessels in xenografted and spontaneous human colon carcinomas have been
reported to be of a mosaic type (Figure 3F) [207]. It is not yet clear whether these abnormal vessel
structures are formed by cancer cells which integrate into the EC layer of the vessel wall or whether they
arise by apoptosis of ECs and exposure of underlying cancer cells. Along with their incorporation into
tumor blood vessels, cancer cells undergo epithelial–mesenchymal transition and acquire endothelial
characteristics. The interaction between endothelial-like cancer cells (EndCC) and ECs, blood
components, and inflammatory signals procures the differentiation of cancer cells into EndCCs.
EndCCs interact with neighboring ECs, but they also possess migratory and invasive properties [208].
By biomechanical interaction of breast cancer cells with the endothelium, ECs stimulate proliferation,
survival, and stemness of breast cancer cells and thus metastatic dissemination [209].
Gap junctions are special channels through the plasma membrane that directly connect the
cytoplasms of neighboring cells and thus mediate short-range and direct intercellular communication
which is necessary for proper tissue development and homeostasis [210]. They consist of
transmembrane proteins of the connexin family [210] and allow free diffusion of small molecules and
ions, and also the transport of miRNAs and small interfering RNA (siRNA) silencing signals [211,212]
between cells. Altered expression of gap junction proteins is an important step in carcinogenesis [213].
Moreover, connexins play a crucial role in the direct cellular communication between cancer cells
and ECs [214–217]. Extravasating breast cancer cells induce in ECs tyrosine phosphorylation of
connexin 43 which facilitates further tumor cell extravasation [218]. The gap junction inhibitor,
oleamide, significantly decreases homotypic communication between cancer cells and also heterotypic
interaction between cancer cells and-ECs. Oleamide treatment in vitro attenuates the expression levels
of several angiogenic factors, such as VEGF, HIF-1α, CXCR4, Cx26, Cx43, and MMP-9, presumably via
an impaired connexin-mediated intercellular communication [219].
ECs are tightly connected via VE-cadherin-containing adherens junctions [220–222]. VE-cadherin’s
C-terminus is linked via β-catenin or plakoglobin to the actin cytoskeleton [223]. Blocking VE-cadherin
by monoclonal antibodies inhibits angiogenesis, tumor growth, and metastasis [224]. Endothelial barrier
integrity depends on differential phosphorylation of six out of nine tyrosine residues in the cytoplasmic tail
of VE-cadherin [225,226]. Especially phosphorylation of Y658 and Y731 decreases vessel tightness [227].
Different cancer types vary with respect to VE-cadherin phosphorylation in neighboring ECs,
which differentially affects cancer metastasis [228–230].
5. Tumor Cells Imitating Endothelial Cells in Vasculogenic Mimicry Vessels
Vasculogenic Mimicry and Its Molecular Phenotypes
Vasculogenic mimicry as one form of neovascularization was first described by Maniotis et al. [148].
Unlike angiogenesis and vasculogenesis, VM does not depend on ECs, but tumor cells themselves form
vascular channels to support at least the supply with oxygen and nutrients. Since the first report of
VM in 1999, its existence was controversially debated [231]. Notwithstanding, VM is clearly associated
with tumor aggressiveness, and poor prognosis [232,233]. VM channels are typically characterized as an
intricate meshwork of micro-channels of irregular diameter that anastomose with endothelium-lined blood
vessels, but in contrast to them they are devoid of endothelial markers such as CD31. Simultaneously,
they are covered by extravascular depositions of glycosylated matrix proteins, such as laminins, collagens
IV and VI, and heparan sulfate proteoglycans that are positive for periodic acid Schiff (PAS) staining
(Figure 4) [175,178,179,234]. Continuity and anastomosis with endothelium-lined normal vessels is a
prerequisite for the functional significance of such VM channels [231], together with red blood cells in
their lumen [148]. Moreover, it is conceivable that VM channels, which are too small to transport red
blood cells, could also supply tumor tissue with nutrients and oxygen by hemoglobin from ruptured
erythrocytes [147,235]. In a murine xenograft tumor model of inflammatory breast cancer, tumor cell
lines that either do or do not show VM were used. Thus, VM channels could be discriminated from
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other tumor vasculature by three-dimensional contrast-enhanced dynamic micro-Magnetic resonance
imaging (MRI) with G6-(1B4M-Gd)256 dendrimer as contrast agent [236,237]. Meanwhile, VM has been
observed in more than fifteen cancers, such as astrocytoma World Health Organization (WHO) grade
II–III [238], glioblastoma (astrocytoma WHO grade IV) [177], melanoma [239,240], cancers of breast [237],
gallbladder [241], pancreas [242], liver [243], esophageal [244], gastrointestinal [245], and colorectal
tract [246], lung [247,248], ovaries [249,250], prostate [251], and various sarcomas [252,253]. In multiple
myeloma, bone marrow macrophages and mast cells are additionally involved in VM of bone marrow
vascularization [254,255].
 
Figure 4. Vasculogenic mimicry of cancer cells lining tumor vessels. CD31-negative/PAS-positive VM
channels in a HT1080 xenograft mouse tumor model were visualized by consecutive immunostaining
and histochemical staining of the same cryosection: (A,C) normal CD31-positive blood vessels are
labeled in green; and (B,C) CD31-negative VM channels are detectable by PAS staining. Nuclei are
stained blue. (A) Cryosections were first immunostained and photographed; (B) subsequently,
histochemically PAS-stained and photographed again; and (C) then the images were overlaid to
demonstrate numerous CD31-negative/periodic acid Schiff (PAS)-positive VM channels (arrows).
Representative images are shown.
Unlike the prediction based on numerous preclinical models, tumors are very likely to acquire
an intrinsic resistance to angiostatic drugs [256,257]. Moreover, extrinsic mechanisms can contribute
to resistance, demonstrating the important role that stromal cells play in the context of tumor
neovascularization [258]. Tumor cells release many chemokines, inter alia the pro-angiogenic factors
CCL2, CCL5, and CXCL12 [259] and cytokines, among them redundant pro-angiogenic cytokines,
such as basic fibroblast growth factor (bFGF), interleukin-8 (IL-8), hepatocyte growth factor (HGF),
PDGF, and VEGF [260], which are difficult to inhibit simultaneously. Furthermore, a tumor’s blood
supply by non-angiogenically originated vessels (Figure 3) is also not impaired by anti–angiogenic
treatment [261]. The tumor stroma contains many different cells, among them ECs, mural cells,
platelets, CAFs, and TAMs, whose roles in resistance to angiostatic therapy have been reviewed
recently [258]. Similar to mesenchymal stem cells, which are capable of tubulogenesis in vitro [262],
it appears that some aggressively growing tumor cells can phenotypically mimic or transdifferentiate
into several of these cell types, e.g., they can adopt features of ECs [173,174], pericytes [263,264],
and even platelets [265–267]. In initiation of VM, both EMT and tumor-initiating cancer stem-like cells
(CSCs) play important roles [149,268,269]. In glioblastoma, a portion of the tumor vasculature arises
from CSCs which have been reported to differentiate to tumor vessel pericytes upon CXCL12/CXCR4
and TGFβ signaling [263]. Macrophage migration inhibitory factor (MIF) also triggers via CXCR4 and
AKT EMT in glioblastoma [270]. However, there are conflicting data whether CSCs transdifferentiate
into ECs and/or pericytes [271].
To produce a functional tumor vasculature, many signaling molecules and pathways interact
in a complex network, and the molecular regulation of tumor angiogenesis has been reviewed
earlier to indicate therapeutic possibilities [272–274]. VM exhibits multiple molecular phenotypes,
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because several signaling pathways are interconnected here which are involved in vascular and
embryonic/stem cell differentiation and in adaption to hypoxic conditions [174,275–277]. In adaption
to the hypoxic conditions prevailing in tumor tissue, HIFs are crucially responsible. The HIF-driven
pathways have been recently reviewed [278,279]. Hypoxia-response elements (HREs) are involved
in regulating cell proliferation, cell death, angiogenesis, blood vessel co-option, cell adhesion
molecules, secretion of MMPs, antigen presentation mechanisms and immunosuppressive factors,
and additionally in vasculogenic mimicry [280]. Under normoxic conditions the α-subunit (HIF-1α,
HIF-2α or HIF-3α) of the hypoxia-induced transcription factor HIF is rapidly degraded in the cytosol,
whereas under hypoxic conditions it binds to the constitutively present β-subunit, thus forming an
active heterodimer that translocates to the nucleus, where it controls gene expression by binding
to HREs ([279] and references therein). While the transcription factor HIF-1α plays an important
role in promoting sprouting angiogenesis [281], HIF-2α promotes EMT and thus VM in pancreatic
cancer [282]. This is in line with the observation that VM is especially found in a hypoxic tumor
core [283]. In a neuroblastoma model, an immunotherapy targeting tumor-derived ECs failed, because
the treatment increased hypoxia, causing further EMT and tumor-derived EC trans-differentiation,
and adaptation to the hypoxic microenvironment [284].
Hypoxia modulates the expression of many genes involved not only in angiogenesis, but also in
VM, inter alia VEGF-A, VEGFR-1, Erythropoietin-producing human hepatocellular (EPH) receptor
A2 (EphA2), TWIST, COX-2, and Nodal [285]. The transcription factor HIF-2α promotes EMT
in pancreatic cancer by upregulating the transcription factors TWIST1 and TWIST2 in carcinoma
cells which then upregulate VE-cadherin [282] and downregulate E-cadherin respectively [286].
Such VE-cadherin-expressing carcinoma cells may readily incorporate into the endothelium and
give rise to composite vessels and eventually VM. Furthermore, under the selection pressure imposed
by hypoxia, polyploid giant colorectal cancer cells have been reported to express EMT-related genes,
to become pluripotent, and to give rise to erythroid cells expressing embryonic and fetal hemoglobin,
and also to acquire EC-like features to form VM channels [287,288]. Furthermore, peroxiredoxin 2
(PRDX2), a major antioxidant enzyme, stimulates VM channel formation in colorectal cancer by keeping
VEGFR-2 in its activated state [289]. The VM phenotype is thus associated with transdifferentiation
of CSCs and cell plasticity [276,290], and VM channel-lining tumor cells phenotypically mimic ECs.
However, they differ from ECs regarding their expression of TIE-1, VEGF-C, neuropilin.1 (NRP1),
endoglin, Tissue factor pathway inhibitor (TFPI1), Laminin subunit γ2 (LAMC2), and EphA2, whereas
they do not express Tyrosine kinase with immunoglobulin-like and EGF-like domains 2 (TIE-2),
VEGFR-1, VEGFR-2, P-selectin, vascular adhesion protein-1 (VCAM-1), and CD31 [276].
Important transcription factors for the expression of VM-relevant genes are TWIST1 and
BMI1, which are also relevant for EMT [291,292]. The EMT marker TWIST1 is activated by B-cell
lymphoma 2 (Bcl-2) [293] and by metadherin (MTDH) [294], which drives CSC expansion and VM.
Furthermore, CCL21/CXCR7 signaling activates the transcription factor SNAI2/Slug via ERK and
Phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K)/AKT signaling in chondrosarcoma, and thus
promotes EMT [295]. Together with TWIST1 and the Snail family transcription factors SNAI1/Snail
and SNAI2/Slug, the Zinc finger E-box-binding homeobox 1 proteins ZEB1 and ZEB2 are pivotal
EMT regulators with significant overlap in their signaling networks [296]. ZEB2, triggered by TGFβ1,
promotes cell motility, invasiveness, expression of EC markers, and formation of VM vessels in
hepatocellular carcinoma [296]. The paired-related homeobox transcription factor 1 (Prrx1) is also
implicated in EMT, but although it is co-expressed and cooperates with TWIST1 in EMT, it suppresses
stemness properties of cancer cells, and thus uncouples EMT and stemness [297]. In VM channel
formation and differentiation, VE-cadherin [276], erythropoietin-producing hepatocellular receptor
A2 (EphA2) [298], phosphatidyl inositol 3-kinase (PI3K) [298], MMPs [299], VEGFR-1, and HIF-1α are
instrumental [174,300]. The migration inducting gene Mig-7 is expressed early in placenta development
during maximal cytotrophoblast invasion and vascular remodeling, and also by carcinoma cells,
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where it is linked to VM [301,302]. Focal adhesion kinase (FAK) and Mig-7 induce upregulation of
MMP-2 and MMP-9, which are involved in ECM degradation and VM [301,303–305].
The laminin binding lectin galectin-1 [306] is overexpressed on tumor-associated ECs and in
their surrounding ECM [307]. It is also involved in the interaction of regulatory T (Treg) cells
with dendritic or T cells, and it is upregulated in Treg cells upon T cell receptor activation [308].
In squamous cell carcinoma ECs, galectin-1 is overexpressed and binds directly to neuropilin-1 (NRP1),
thereby enhancing phosphorylation of VEGF-R2 and triggering signaling via Mitogen-activated protein
(MAP) kinases SAPK1/c-Jun N-terminal kinase (Jnk), which increases EC proliferation and adhesion,
and in combination with VEGF-A it enhances cell migration [307]. The likewise laminin-binding
galectin-3 [309] essentially promotes VM in melanoma by upregulating in melanoma cells the ectopic
expression of genes that are otherwise typical for ECs, such as VE-cadherin, IL-8, fibronectin-1,
endothelial differentiation sphingolipid G-protein receptor-1 (EDG-1), and MMP-2 [310]. While MMP-2
creates fragments from laminin-332 that increase EGFR and F-actin expression and promote VM in large
cell lung cancer, MMP-13 counteracts VM by releasing different laminin-332 fragments that decrease
expression of EGFR and F-actin [311]. Increased NRP1 expression upon upregulation of VEGFA,
secretion of MMP-2 and -9, and activation of αvβ5 integrin furthermore correlates with tumor cell
invasiveness and VM [312,313]. Elevated NRP-1 expression levels are also implicated in development
of resistance to anti–angiogenic therapy with VEGF-A blocking antibodies [314]. This may be due to
the fact that NRP1 is not only a coreceptor of VEGFR-2 for VEGF-A but also signals upon binding of
other growth factors such as class 3 semaphorins, TGFβ, HGF, FGF, and PDGF [315]. Upon PDGF-C
stimulation, NRP-1 triggers invasion and VM of VEGFR-and PDGFR-deficient melanoma cells [313].
Nodal plays an essential role in VM such as in embryonic/stem cell differentiation as demonstrated
by an impaired VM of aggressive melanoma cells upon downregulation of Nodal [174,316]. Notch 1
triggers EMT in hepatocellular carcinoma and promotes VM [317], while Notch4 is highly expressed in
melanoma CSCs, where it promotes metastasis via the TWIST/VE-cadherin/E-cadherin pathway [269].
In addition to transcription factors, miRNAs are involved in post-transcriptional regulation
of VM, thereby modulating tumor angiogenesis and cancer metastasis. TWIST1 upregulates 18
miRNAs in hepatocellular carcinoma cells, among them miR-27a-3p which targets VE-cadherin and
suppresses EMT and VM [318]. Pointing in the same direction, miR-27a negatively regulates the
expression of EphA2, SNAI1, and SNAi2 [319]. miR-27b binds to the 3′-untranslated region (3′-UTR) of
VE-cadherin mRNA and inhibits ovarian cancer cell-mediated VM through suppression of VE-cadherin
expression [320]. Loss of miR-26b promotes VM by increased EphA2 expression in glioma [321].
miR-124 regulates the expression of several EMT- and VM-relevant genes, such as CD151, ROCK1,
integrin β1, Rac1, SNAI2, and angiomotin-like protein 1 (AMOTL1) [322–326]. TWIST1 downregulates
miR-26b-5p in hepatocellular carcinoma by binding to its promotor region, thereby unchecking
Smad1 expression and deregulating BMP4/Smad1 signaling, which promotes EMT [327]. miR-26-5p
in hepatocellular carcinoma is a negative regulator of VE-cadherin, SNAI1, and MMP-2, and thus
VM [328]. miR-186 downregulates the expression of TWIST1 in prostate cancer and thereby among
other effects inhibits EMT and VM [329]. Loss of miR-4638-5p promotes VM in castration resistant
prostate cancer by activating PI3K/AKT signaling via the kinase D-interacting substrate of 220 kDa
(KIDINS220) scaffold protein [330]. KDKDM4b hypermethylates the miRNA-615-5p promotor in
hepatocellular carcinoma, thereby epigenetically silencing this miRNA and consecutively increasing
expression of the Ras-related protein RAB24, which activates the Rab-Ras-pathway and promotes
adhesion, EMT, and VM [331].
Long non-coding RNAs (lncRNAs) are a recently discovered class of gene regulators in many
physiological and pathological processes [332], and by their interaction with miRNAs [333] they
are involved in metabolic reprogramming and EMT [334,335]. lncRNAs and their interaction with
miRNAs in EMT have been reviewed recently [333]. The oncogenic lncRNA metastasis-associated
lung adenocarcinoma transcript 1 (MALAT1) is implicated in tumor angiogenesis and also in VM by
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upregulating the expression of VE-cadherin, β-catenin, MMP-2, MMP-9, MMP-14, p-ERK, p-FAK, and
p-paxillin [336], by upregulating N-cadherin and fibronectin, and by suppressing E-cadherin [113].
To maintain an anti-coagulatory milieu in VM vessels, channel lining tumor cells can upregulate
the expression of tissue factor (TF), TF pathway inhibitor-1 (TFPI-1), and TFPI-2 [337]. VM channels
not only supply the tumor with oxygen and nutrients but also might, to a limited extent, aid in some
of the draining function of lymphatics [179,337,338].
Tumor growth and metastasis are promoted by angiogenic and vasculogenic pathways as well as
by vessel co-option and VM. The latter two are notorious for conveying drug resistance. VM occurs
in many, albeit not all, tumor tissues, but not in the healthy body, although some authors believe
that hypoxic trophoblasts in placenta tissue are able to contribute to their own blood supply by
VM [279]. VM correlates with a poor prognosis [247,339], because it promotes cancer growth and
hematogenic dissemination of detaching tumor cells leading to metastasis [300,340–344]. In colorectal
cancer, VM is positively associated with invasion depth, lymph node metastasis, distant metastasis
and tumor-node-metastasis stages and negatively with patients’ overall survival [345]. Likewise in
ovarian carcinoma, VM is associated with tumor and lymph node metastasis grade, implantation,
and stage, and with reduced patients’ overall survival [346]. In ovarian carcinoma, VM correlates
with the immunohistochemical detection of ALDH1, Kisspeptin (KiSS-1), and Metastasis associated in
colon cancer-1 (MACC1), which are used to predict metastasis and prognosis, and VM proved to be
a prognostic marker, as well as a potential target to treat epithelial ovarian carcinoma [346]. Similar
data have been reported for colorectal carcinoma [345]. In addition, in non-small cell lung cancer, VM,
promoted by Dickkopf-related protein 1 (DKK1) is associated with poor differentiation, advanced
stage, and distant metastasis [347]. In hepatocellular carcinoma, both tubular and patterned type VM
have been reported, and the latter has been ranked as an unfavorable prognostic marker [348].
6. Perspective: New Cancer Therapies Targeting Tumor Vasculature and CAFs
6.1. Anti-Angiogenesis and Normalization of the Tumor Vasculature
Cancer therapy comprises surgery, radio- and chemotherapy, targeted therapy, immunotherapy,
hypothermia, hormone therapy, stem cell therapy and combinations of these methods [349].
Radiation therapy and chemotherapy target both cancer cells and tumor vasculature. Bone marrow-derived
cells can restore radiation-damaged blood vessels, and they can support surviving tumor cells [272].
In addition, EPCs between the smooth muscle and adventitial layer of vessel walls, may trigger tumor
neo-vascularization [156,272].
Endostatin and other anti–angiogenic inhibitors specifically target ECs rather than tumor cells
to inhibit tumor angiogenesis. Such an anti–angiogenic therapy has four advantages over the
usually applied cytotoxic chemotherapeutic drugs [272]: (i) angiogenesis is a homogeneous process,
and therefore its inhibition should be effective in any solid tumor; (ii) an anti–angiogenic therapy
approach is not impaired by tumor cells that become resistant to chemo- or radiation therapy; (iii) ECs
can be directly targeted with blood-borne drugs without the need to counteract the usually high tumor
interstitial pressure; and (iv) the tumor vasculature can be specifically targeted due to a differentially
upregulated expression of receptors on tumor ECs versus normal EC. Therefore, anti–angiogenic
therapies targeting VEGF family members, their receptors, or other pro-angiogenic factors raised high
expectations [350]. However, they have not yet produced the clinical benefits initially envisioned [351].
In contrast to anti–angiogenesis, “vascular normalization” returns malformed and dysfunctional
tumor vessels into vessels with a similar appearance and functionality as in normal tissues. It aims
to overcome the serious problems arising from: (i) the physical barrier of tumor vessel walls; (ii) the
high interstitial pressure in tumors; and (iii) the acquisition of drug resistance by genetic or epigenetic
mechanisms [153]. However, delivery of chemotherapeutics may be impeded by an impervious
endothelial layer [352]. Tumor-vascular disruptive agents induce a tumor-selective breakdown of the
vessel wall barrier, and a combined targeting of both tumor vasculature and tumor cells may increase
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the efficacy of chemotherapeutics [250,353]. Until now, strategies to normalize tumor vasculature did
not yet meet the initially high expectations [354], and other strategies are sought.
When anti-VEGF-induced vascular normalization ceases to be effective, the tumor becomes
resistant to additional anti–angiogenic therapy and grows even more aggressive, for not yet understood
mechanisms [355,356]. Various reasons may underlie this resistance to anti–angiogenic therapy
and may occur simultaneously: Anti–angiogenic treatment-induced hypoxia may increase the
production of other redundant angiogenic factors or the invasiveness of tumor cells. Tumor cells
may also acquire mutations that render them tolerant to hypoxia. Moreover, some anti–angiogenic
therapies lack specificity and have toxic side effects [273,274,357]. Such a development of drug
resistance after initial success and even more aggressive tumor growth was not anticipated [358,359],
and anti–angiogenic treatment turned out to have promised too much for various reasons [134,360–362].
Even if angiogenesis is curbed, neovascularization of tumor tissue may occur by other modes such
as intussusceptive or glomeruloid angiogenesis, by CSC-promoted vasculogenesis, or even by VM
of tumor cells [363]. In addition, vessel co-option confers resistance to anti–angiogenic therapy [155].
Moreover, many other tumor stromal cells, such as ECs, mural cells, platelets, CAFs, and TAMs,
can contribute to the development of resistance to angiostatic therapy [258]. The balance between
ECs on the one hand side and stromal fibroblasts and inflammatory cells, which release many
cytokines and angiogenic factors other than VEGF, on the other hand could be disturbed by anti-VEGF
therapy [123,261,364]. In this sense, CAFs even have been denounced Trojan horse-like mediators of
resistance to anti-VEGF therapy [365].
6.2. VM Channels Are a Promising New Therapeutic Target
The so far little considered concept of VM as a new therapeutic target structure attracts increasing
interest [276], because in VM channels tumor cells line the vasculature and hence are directly amenable
to therapeutics from the bloodstream [276,366,367]. They have been suggested as targets for vascular
disrupting agents, drug delivery, and antitumor therapy [136,353,368]. A combination of either VM
inhibitors or VM disruptive agents with anti–angiogenic therapies may be promising, even if targeting
VM channels, that show great diversity with respect to cellular phenotype in diverse tumors, is not as
universally applicable as EC-targeting therapies, that aim at largely uniform ECs [300].
By now, numerous VM-characteristic molecular determinants and signaling pathways have
already been delineated [276,278,366,369]. Tumor cells isolated from malignant pleural effusions,
which develop in various malignancies due to impaired fluid drainage by blood or lymphatic
vessels, inflammation and increased vascular permeability and are routinely drained for diagnosis,
have been employed to test VM tube formation in vitro. Such cells may help to pinpoint drugable
molecular targets (Figure 5) and to develop and optimize personalized therapy [370]. In addition,
a standardized assay, which in vitro recreates the formation of fluid conducting VM channels by cancer
cells surrounding a glycoprotein-rich inner layer, may be instrumental in finding and characterizing
VM targeting drugs [371]. Potential molecular targets of special interest may be EMT-inducing
transcription factors (EMT-TFs), such as TWIST1, SNAI1/2, and ZEB1/2 (Figure 5) [296], where ZEB2
is not only an EMT regulator but also involved in VM [372]. Expression of the transcription factor
high mobility group box-1 (HMGB-1), that also interacts with nucleosomes and histones [373], is
upregulated by anti–angiogenic treatment [284]. Hence, HMGB-1 has been proposed as a target for
tumor therapy [374].
In addition, migration-inducting gene 7 (Mig-7), which is involved in VM by carcinoma cells, but not
expressed in normal cells, may be a promising target in VM channels [302], and Mig-7-inhibitory agents
together with anti–angiogenic or other conventional anti-cancer drugs might act synergistically [301,302].
The extracellular matrix metalloproteinase inducer (EMMPRIN, CD147) may also be a potential
target for anti–angiogenic therapy in glioma [375]. The angiogenic factor YKL-40 (human cartilage
glycoprotein HC-gp39, CHI3L1) is produced by cancer cells, inflammatory cells, and stem cells [376].
By transdifferentiation of glioma stem-like cells into vascular pericytes/smooth muscle cell- and EC-like
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cells, YKL-40 promotes both angiogenesis and VM [377], which in a xenograft tumor model is susceptible
to treatment with a neutralizing monoclonal antibody against YKL-40 in combination with radiation
therapy [378].
Figure 5. Molecular phenotype-defining signaling pathways in vasculogenic mimicry (VM). Signaling
molecules that have been targeted to inhibit VM are highlighted in yellow and targeting compounds
are marked in blue. Regulatory miRNAs are labeled green. EMT (highlighted in orange), which is
pivotal for VM, and VM (highlighted in red) are the focal points in which all these signaling pathways
converge. For details and references, see text.
More than ECs, cancer cells may be responsible for drug resistance to anti–angiogenic
therapy [174]. Especially in VM developing tumors, VM channels lacking ECs are at least
partially responsible for resistance to VEGF inhibition [379] or to anti-angiogenic agents, inter
alia angiostatin and endostatin [367]. However, endostatin combined with radiotherapy
suppresses VM formation through inhibition of EMT in esophageal cancer [380]. HET0016
(N-Hydroxy-N′-(4-butyl-2-methylphenyl)-formamidine), which was initially characterized as
a selective inhibitor of 20-HETE (20-hydroxy-5,8,11,14-eicosatetraenoic acid) formation from
arachidonic acid [381], can be used to target VM channels, whose formation is triggered by
the small molecule proteinase kinase inhibitor vatalanib, which is used as anti–angiogenic
therapeutic, [283]. Norcantharidin (3,6-endoxohexahydrophthalic anhydride), a demethylated
derivative of cantharidin [382] downregulates MMP-9 via NFκB in hepatocellular carcinoma cells
in vitro [383,384]. In vivo it also downregulates MMP-2 in a human melanoma mouse model [385], and
MMPs-2 and -14 in gallbladder cancer, thereby enhancing the VM-inhibiting activity of TIMP-2 [386].
Mosaic vessel and VM channel formation in a B16F10 mouse melanoma model are reduced by
thalidomide which inhibits expression of VEGF, NFκB, PCNA, MMP-2 and MMP-9 [387]. In addition,
natural products with anti–angiogenic and anti-VM activity are very important for the development
of new drugs. Such natural compounds and their molecular modes of action have been reviewed
recently [388]. Genistein inhibits the expression of VEGF-A, PDGF, TF, urokinase-type plasminogen
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activator (uPA), and MMPs-2 and -9, whereas it stimulates expression of PAI-1, endostatin and
angiostatin, as well as thrombospondin-1 [389]. In vivo, compounds such as genistein, jatrorrhizine
hydrochloride, and curcumin inhibit VM in uveal and choroidal melanoma, respectively, via regulating
VE-cadherin and EphA2 expression [390–392], whereas the antioxidant resveratrol has been reported
to suppress VM in a murine melanoma model by decreasing the expression of VEGF and its
receptors 1 and 2 [393]. The latter observation is in line with the finding that luteolin, likewise an
antioxidant, inhibits Notch1-VEGF signaling and thus reduces VM formation in gastric cancer
cells [394]. In addition, in a human hepatocellular carcinoma mouse model using GFP-labeled
MHCC97-H cells, an ethnopharmacologically used Celastrus orbiculatus extract containing 11 terpenes,
of which the effective component is not yet known, reduces VM formation by targeting Notch1
signaling [395]. An also not yet fully characterized ethanolic extract from Paris polyphylla has been
reported to inhibit VM in a human osteosarcoma mouse model by downregulating the expression of
FAK, Mig-7, and MMPs-2 and -9 [396]. Furthermore, inhibition of MMP-14 and tumor angiogenesis
in two murine sarcoma and colon carcinoma models has been reported for the green tea ingredient
(−)-epigallocatechin gallate (EGCG) [397].
Tumor vasculature targeting drug delivery systems have been reviewed recently, inter alia VM
targeted approaches [398]. Targeting liposomes to endocytosis-prone surface receptors with ligand
derivatives or antibodies improves the cellular internalization of encapsulated drugs. In combination
therapy, liposomes and especially passive and active ligand-targeted liposomes have turned out
to be efficient co-delivery systems for hydrophilic and lipophilic chemotherapeutic agents, such as
drugs, anti-cancer metals, and gene agents [349]. Liposomes functionalized with a mannose-vitamin E
derivative conjugate and a dequalinium lipid derivative to cross the blood brain barrier (BBB) and
loaded with both the antimalarial drug artemether, as a regulator of apoptosis and VM channels, and
the anticancer drug paclitaxel have been demonstrated in brain glioma-bearing rats to eliminate CSCs
and tumor cells, and also to destroy VM channels [399]. In addition, aptamer-conjugated peptides allow
delivering chemical drugs and gene drugs, e.g., antagomirs, simultaneously, as was demonstrated by
co-delivery of the VM blocking ROCK inhibitor fasudil and VEGF inhibiting miR-195 [400].
6.3. Therapeutic Potential of Targeting CAFs
As CAFs are such central players in the tumor stroma, understanding the effect of CAFs on therapy
and the development of a CAF-directed remedial treatment are of utmost importance as well. Indeed,
CAFs affect irradiation therapy, as damaged or irradiated CAFs support tumor cell growth stronger
than non-treated CAFs, possibly through up-regulation of cMet expression or its phosphorylation and
MAP kinase activity in cancer cells [401]. Moreover, tumor stromal CAFs contribute to an increased
intratumoral interstitial pressure, due to their potential to contract and to exert force on the ECM, thus
compressing the interstitial space. This eventually results in attenuating therapeutic efficiency [46].
The interaction between cancer cells and CAFs can also reduce cytotoxic effects of chemotherapeutic
drugs such as cisplatin by cell–cell adhesion through N-cadherin that activates the survival-promoting
protein kinase B (PKB)/AKT and blocks pro-apoptotic Bad [402]. However, a clinical trial in which
the Hedgehog signaling pathway was targeted and the tumor-induced mesenchyme activation was
affected, did not show any therapeutic benefit [48].
7. Conclusions
As invasive cancer rates worldwide are continually increasing due to increased life expectancy, changes
in lifestyle and nutrition, and environmental factors, cancer treatment is of prime importance. VM, albeit
usually viewed as a negative prognostic marker, may constitute a potential new target for anti–angiogenic
therapy [261,363]. VM and CAFs are not only passive bystanders but also active players within the
tumor stroma, which contribute to tumor progression and dissemination. A better understanding of their
molecular phenotypes and of their supportive roles for cancer cells are indispensable for pharmacological
intervention, to resolve the burning issues of resistance to chemotherapeutic drugs and anti–angiogenic
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therapies, and to develop multimodal anti-angiogenic, anti-VM, and anti-proliferative strategies [138].
While tumors frequently develop resistance to anti–angiogenic drugs, new strategies that combine an
anti–angiogenic therapy with a VM- or CAF-targeting approach may improve treatment success.
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Akt Protein kinase B
AMOTL1 Angiomotin-like protein 1
ARF ADP ribosylation factor
αSMA α-Smooth muscle actin
Bcl-2 B-cell lymphoma 2
bFGF Basic fibroblast growth factor
BM Basement membrane
Bmi1 B lymphoma Mo-MLV insertion region 1 homolog
BMP Bone morphogenetic protein
CAF Cancer-associated fibroblast
CD Cluster of differentiation
CEC Cancer-endothelial cell interaction
CHI3L1 Chitinase-3-like protein 1
CSC Cancer stem-like cell
cMET Hepatocyte growth factor receptor
c-Myc Cellular Myelocytomatose (transcription factor)
COX-2 Cyclooxygenase-2
CXC Cysteine-any amino acid-cyteine motif
CXCL12 C-X-C motif chemokine 12 = stromal cell-derived factor 1 (SDF-1)
CXCR4 C-X-C chemokine receptor type 4
DKK1 Dickkopf-related protein 1
EC Endothelial cell
ECM Extracellular matrix
EDA Extra-domain A fibronectin splice variant
EDB Extra-domain B fibronectin splice variant
EDG-1 Endothelial differentiation sphingolipid G-protein receptor-1
EGCG (−)-Epigallocatechin gallate
EGF(R) Epidermal growth factor (receptor)
EMMPRIN Extracellular matrix metalloproteinase inducer
EMT Epithelial–mesenchymal transition
EndCC Endothelial like cancer cell
EPC Endothelial progenitor cell
EphA2 Erythropoietin-producing human hepatocellular (EPH) receptor A2
Erk Extracellular signal–regulated kinase
FAK Focal adhesion kinase
FGF(R) Fibroblast growth factor (receptor)
GAPDH Glyceraldehyde 3-phosphate dehydrogenase
Glc Glucose
Gln Glutamine
GLUT2 Glucose transporter type 2
GSH Glutathione
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Jnk c-Jun N-terminal kinase
KDM4b Lysine-specific demethylase 4B
KIDINS220 Kinase D-interacting substrate of 220 kDa
KiSS-1 Kisspeptin
LAMC2 Laminin subunit γ2
Lam5g2 Laminin-332 γ2chain
LOX lysyl oxidase
MACC1 Metastasis associated in colon cancer-1
MALAT1 Metastasis-associated lung adenocarcinoma transcript 1
MCP1 Monocyte chemotactic protein




MRI Magnetic resonance imaging
MTDH Metadherin
NADPH + H+ Nicotinamide adenine dinucleotide phosphate
NFκB Nuclear factor κ-light-chain-enhancer of activated B cells
NICD Notch intracellular domain
NRP1 Neuropilin-1
p130Cas Cellular apoptosis susceptibility protein of 130 kDa
PAS Periodic acid Schiff
PDGF Platelet-derived growth factor
PEP Phosphoenolpyruvate
PI3K Phosphatidylinositol-4,5-bisphosphate 3-kinase
PK-M2 pyruvate kinase isoform M2
PPEE Paris polyphylla ethanol extract
Prdx2 Peroxiredoxin-2
PRRX1 Paired-related homeobox transcription factor 1
ROCK Rho-associated protein kinase
Rab Ras superfamily of monomeric G protein
Rac1 Ras-related C3 botulinum toxin substrate
RANKL Receptor activator of nuclear factor κ-B ligand
Ras Rat sarcoma protein
ROCK Rho-associated protein kinase
ROS Reactive oxygen species
Smad Small body size/mothers against decapentaplegic protein




TFPI1 Tissue factor pathway inhibitor
TGFβ1 Transforming growth factor-β1
TIE Tyrosine kinase with immunoglobulin-like and EGF-like domains
TME Tumor microenvironment
TNFα Tumor necrosis factor α
VEGF(R) Vascular endothelial growth factor (receptor)
VM Vasculogenic mimicry
WHO World Health Organization
Wnt Wingless-related integration site
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YAP Yes-associated protein
YKL-40 Human cartilage glycoprotein HC-gp39, Chitinase-3-like protein 1, CHI3L1
ZEB Zinc finger E-box-binding homeobox
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Abstract: Tanshinone IIA (Tan-IIA) is an extract from the widely used traditional Chinese medicine
(TCM) Danshen (Salvia miltiorrhiza), and has been found to attenuate the proliferation of bladder
cancer (BCa) cells (The IC50 were: 5637, 2.6 μg/mL; BFTC, 2 μg/mL; T24, 2.7 μg/mL, respectively.).
However, the mechanism of the effect of Tan-IIA on migration inhibition of BCa cells remains unclear.
This study investigates the anti-metastatic effect of Tan-IIA in human BCa cells and clarifies its
molecular mechanism. Three human BCa cell lines, 5637, BFTC and T24, were used for subsequent
experiments. Cell migration and invasion were evaluated by transwell assays. Real-time RT-PCR
and western blotting were performed to detect epithelial-mesenchymal transition (EMT)-related
gene expression. The enzymatic activity of matrix metalloproteinases (MMP) was evaluated by
zymography assay. Tan-IIA inhibited the migration and invasion of human BCa cells. Tan-IIA
suppressed both the protein expression and enzymatic activity of MMP-9/-2 in human BCa cells.
Tan-IIA up-regulated the epithelial marker E-cadherin and down-regulated mesenchymal markers
such as N-cadherin and Vimentin, along with transcription regulators such as Snail and Slug in BCa
cells in a time- and dose-dependent manner. Mechanism dissection revealed that Tan-IIA-inhibited
BCa cell invasion could function via suppressed chemokine (C-C motif) ligand 2 (CCL2) expression,
which could be reversed by the addition of CCL2 recombinant protein. Furthermore, Tan-IIA could
inhibit the phosphorylation of the signal transducer and activator of transcription 3 (STAT3) (Tyr705),
which cannot be restored by the CCL2 recombinant protein addition. These data implicated that
Tan-IIA might suppress EMT on BCa cells through STAT3-CCL2 signaling inhibition. Tan-IIA inhibits
EMT of BCa cells via modulation of STAT3-CCL2 signaling. Our findings suggest that Tan-IIA can
serve as a potential anti-metastatic agent in BCa therapy.
Keywords: bladder cancer; chemokine (C-C motif) ligand 2; epithelial-mesenchymal transition;
signal transducer and activator of transcription 3; tanshinone IIA
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1. Introduction
Bladder cancer (BCa) is one of the most prevalent types of cancer and is the leading cause of death
among patients with urinary tract disease [1]. In 2016, the United States alone recorded more than
76,000 new cases of BCa and 16,000 deaths [2]. Most BCa cases are diagnosed as non-muscle invasive
tumors; however, 50–70% of these tumors recur frequently and approximately 15% eventually develop
into muscle-invasive or metastatic BCa [3,4]. Current treatment methods including radical cystectomy
and systemic chemotherapy are effective in some muscle-invasive BCa patients, but 95% of metastatic
BCa patients die within 5-years diagnosis, indicating the need for new therapeutic strategies [5].
Tan-IIA (C19H18O3) is one of the major lipophilic compounds extracted from the root of a
traditional Chinese medicine, Danshen (Salvia miltiorrhiza) [6,7], and has been used for the treatment of
cardiovascular disease via its anti-oxidant and anti-inflammatory activity [8,9]. In addition, Tan-IIA
has been found to exert antitumor activity in various types of cancer including osteosarcoma [10],
gastric [11], lung [12], esophageal [13], and prostate cancers [14]. The antitumor activity of Tan-IIA
mainly occurs through proliferation inhibition, apoptosis induction, and metastasis inhibition [15–18].
For instance, Tan-IIA increased CCAAT/enhancer-binding protein homologous protein (CHOP) and
caspase-4 expression, and induced apoptosis of human esophageal Ec-109 cells via the endoplasmic
reticulum (ER) stress pathway [19]. Tan-IIA induced cytochrome c-mediated caspase cascade apoptosis
in A549 human lung cancer cells via the JNK pathway [20]. Tan-IIA caused apoptosis in human
oral cancer KB cells through a mitochondria-dependent pathway [21]. However, Tan-IIA did not
show significant cytotoxicity on human normal prostate epithelial cells (PrEC) and normal mammary
epithelial cells (HMEC) at the concentrations high as 50 μM [22,23]. Also, the toxicity in normal tissues
was not observed in Tan-IIA treated mice [24]. In our previous study, Tan-IIA was found to induce
mitochondria-dependent apoptosis and suppress migration in BCa cells [25]. However, the mechanism
by which Tan-IIA inhibits the migration and invasion of BCa cells remains undetermined.
Previous reports found a correlation of urinary CCL2 levels with tumor stage, grade and
metastasis in patients with BCa [26,27], and patients with stages T2–T4 BCa were found to have
a higher mean CCL2 concentration in their urine as compared to those with T1 stage tumors [27].
Previous studies also showed that CCL2 can regulate tumor progression and metastasis by altering the
tumor microenvironment [28–30]. CCL2 induced epithelial mesenchymal transition (EMT) in order to
promote tumor metastasis in various cancer types [31–33]. Down-regulation of CCL2 expression by
inhibiting phosphorylation of STAT3 led to the suppression of metastasis in breast and lung cancer [34].
STAT3 signaling is an important pathway which is frequently activated in many tumors including
BCa [35,36]. The transcriptional activity of STAT3 is required for the phosphorylation at the tyrosine
residue 705 (Tyr705) and has been demonstrated to be critical for BCa cell growth and survival [36,37].
In addition, activation of STAT3 promoted migration and invasion of BCa cells [38]. Thus, we seek to
elucidate the role of STAT3-CCL2 signaling in Tan-IIA-induced EMT inhibition in BCa cells.
The results of the present study demonstrate that Tan-IIA inhibited the migration and invasion
of human BCa cells. Tan-IIA inhibited EMT in BCa cells via the suppression of CCL2 expression
which cannot be reversed by addition of CCL2 recombinant protein. In addition, Tan-IIA suppressed
the phosphorylation of STAT3 (Tyr705), which cannot be restored by addition of CCL2 recombinant
protein. Our data suggests that Tan-IIA might inhibit EMT in BCa cells through the STAT3-CCL2
signaling inhibition.
2. Results
2.1. Tan-IIA Inhibits the Migration and Invasion of Human BCa Cells
Human BCa cells were treated with 4 μg/mL Tan-IIA for 24 h and then subjected to migration
(24 h) and invasion (48 h) assay (Figure 1A). In the migration assay, Tan-IIA decreased the number
of migrating cells to 25.6 ± 4.7% (5637), 32 ± 2.9% (BFTC), and 70.5 ± 9.7% (T24) as compared to the
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control group. In the invasion assay, Tan-IIA decreased the number of migrating cells to 11 ± 2.9%
(5637), 51.8 ± 4.4% (BFTC), and 22.8 ± 9.8% (T24) as compared to the control group.
Figure 1. Tan-IIA inhibited migratory and invasive ability in human BCa cells. (A) Human BCa cells
were treated with 0.2% DMSO as a vehicle control or 4 μg/mL Tan-IIA for 24 h and then seeded onto
the transwell hanging insert for migration (24 h) and invasion (48 h) assays. Images were captured
using an inverted microscope with 200× magnification; Scale bar: 50 μm. The migration and invasion
of BCa cells were quantified by counting the stained cells that migrated into the underside of the
hanging insert membrane; (B) human BCa cells were treated with different concentrations of Tan-IIA
(1, 2 and 4 μg/mL) for 48 h. The protein of total cell lysates were then used to detect MMP-9/-2 protein
expression using western blot, and the (C) supernatant was used to detect the enzymatic activity using
zymography analysis. M: marker. Data are presented as means ± S.D. from three different experiments.
** p < 0.01 versus vehicle.
Western blot results indicated Tan-IIA down-regulated the protein expression of MMP-9/-2 in a
dose-dependent manner (Figure 1B). Zymography analysis also showed that Tan-IIA attenuated the
enzymatic activity of MMP-9/-2 in a dose-dependent manner (Figure 1C). Taken together, these results
suggested that Tan-IIA might be an effective inhibitor of cell migration and invasion of BCa cells.
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2.2. Tan-IIA Inhibits EMT in Human BCa Cells
EMT is a crucial step for the invasion and metastasis of BCa cells. We first show that Tan-IIA could
inhibit cellular migration and invasion in BCa cells, and this is accompanied by the up-regulation of
epithelial marker E-cadherin, the down-regulation of mesenchymal markers N-cadherin and Vimentin,
and the down-regulation of transcription factor Snail and Slug, at both the mRNA and protein level as
evidenced by quantitative RT-PCR (qRT-PCR) (Figure 2A) and western blot (Figure 2B,C).
 
Figure 2. Tan-IIA inhibited EMT on human BCa cells. (A) Human BCa cells were treated with 4 μg/mL
Tan-IIA for 24 h. The expression of EMT-related genes was detected by qRT-PCR analysis; (B) human
BCa cells were treated with 4 μg/mL Tan-IIA for 24 to 72 h. The expressions of EMT-related genes were
detected by western blot. (C) Human BCa cells were treated with increasing concentrations of Tan-IIA
(1, 2 and 4 μg/mL) for 48 h. The expressions of EMT-related genes were detected by western blot. Data
are presented as means ± S.D. from three different experiments. * p < 0.05 versus vehicle.
2.3. Tan-IIA Inhibits EMT via Down-Regulated CCL2 Expression in Human BCa Cells
Previous reports suggested that high levels of CCL2 expression play a key role in BCa progression
and metastasis in vitro and in vivo [27,32,39]. Thus, we analyzed the CCL2 expression in the culture
medium of human BCa cells treated with or without Tan-IIA. As shown in Figure 3A, Tan-IIA inhibited
the CCL2 expression in all BCa cell lines detected by PCR and qRT-PCR. Furthermore, ELISA tests
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confirmed that the protein level of CCL2 secreted by BCa cells was inhibited by Tan-IIA treatment
in a dose-dependent manner (Figure 3B). These results showed that Tan-IIA down-regulated CCL2
expression in BCa cells.
Figure 3. Tan-IIA inhibited the CCL2 expression and reversed the EMT in human BCa cells. (A) Human
BCa cells were treated with increasing concentrations of Tan-IIA for 24 h. The expression of CCL2 was
detected by PCR and qRT-PCR; (B) Human BCa cells were treated with increasing concentrations of
Tan-IIA for 48 h. The supernatant was collected for CCL2 protein detection using ELISA assay; (C) BFTC
cells were treated with or without 4 μg/mL Tan-IIA in the presence or absence of CCL2 recombinant
protein for 48 h. The EMT-related gene expression was detected by western blot; (D) BFTC cells were
treated with or without 4 μg/mL Tan-IIA in the presence or absence of 100 ng/mL human CCL2
recombinant protein for 24 h, followed by migration (24 h) or invasion (48 h) assays and analyzed as
previous described. Data are presented as means ± S.D. from three different experiments. *** p < 0.001
versus vehicle.
To investigate the mechanism by which Tan-IIA inhibits CCL2 resulting in metastatic inhibition,
BFTC cells were treated with or without human CCL2 recombinant protein (10 or 100 ng/mL) in the
presence or absence of 4 μg/mL Tan-IIA for 48 h to examine the EMT-related genes expression.
As shown in Figure 3C, treatment with CCL2 recombinant protein increased the expression of
mesenchymal marker N-cadherin and Vimentin, along with transcription factor Snail and Slug, which
were down-regulated by Tan-IIA treatment. In addition, treatment with CCL2 recombinant protein
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attenuated the inhibitory effect on migration and invasion induced by Tan-IIA treatment (Figure 3D).
Together, these findings indicate that Tan-IIA inhibited EMT in BCa cells via the down-regulation
of CCL2.
2.4. Tan-IIA Inhibits STAT3-CCL2 Signaling in Human BCa Cells
Recent studies indicated that CCL2 signaling plays a pivotal role in regulating STAT3 activation
and EMT [40], and the inhibition of STAT3 signaling may reduce the invasiveness of BCa [41]. We
further examined whether Tan-IIA could inhibit the activation of STAT3 on BCa cells. Human BCa
cells were treated with Tan-IIA for indicated time points and p-STAT3 (Tyr705) was analyzed by
western blot. As shown in Figure 4A,B, Tan-IIA inhibited the activation of STAT3 by decreasing
the phosphorylation of STAT3 at Tyr705 in all BCa cell lines in a time- and dose-dependent manner.
To elucidate the mechanism by which Tan-IIA inhibits CCL2 through regulating STAT3, BFTC cells
were transfected with the STAT3 siRNA and the expression of STAT3 and CCL2 were examined by
western blot. Silencing the expression of STAT3 leads to the inhibition of CCL2 expression (Figure 4C).
However, treatment with human CCL2 recombinant protein (10 or 100 ng/mL) cannot restore the
regulation of STAT3 via phosphorylation of Tyr705, and this was inhibited by Tan-IIA treatment.
These results suggested that Tan-IIA down-regulated the CCL2 expression via inhibition of the STAT3
pathway in human BCa cells.
Figure 4. Tan-IIA inhibited STAT3-CCL2 signaling in human BCa cells. (A) Human BCa cells were
treated with 4 μg/mL Tan-IIA for indicated time points, and the expression of phospho-STAT3 (T705)
was detected by western blot; (B) human BCa cells were treated with increasing concentrations of
Tan-IIA for 48 h, the expression of phospho-STAT3 (T705) were detected by western blot; (C) BFTC
cells were transfected with control or STAT3 siRNA for 24 h, and the expression of STAT3 and CCL2
was detected by western blot; (D) BFTC cells were treated with or without 4 μg/mL Tan-IIA in the
presence or absence of human CCL2 recombinant protein for 48 h. The expression of phospho-STAT3
(T705) and STAT3 was detected by western blot.
150
Int. J. Mol. Sci. 2017, 18, 1616
3. Discussion
Our previous study reported that Tan-IIA could inhibit the proliferation and migration of human
BCa cells [25], but the underlying mechanism of Tan-IIA attenuating the migration and invasion
of BCa cells remains unclear. EMT is a process by which epithelial cells gradually transform into
mesenchymal-like cells to promote the migration and invasiveness of cancer cells [42]. Our results
showed that Tan-IIA treatment could inhibit the process of EMT as evidenced by increased level of the
epithelial marker E-cadherin and decreased level of mesenchymal markers (N-cadherin and Vimentin).
Activation of MMP proteins leads to cell migration and penetration to the basement membrane, playing
an important role in EMT processes [43]. In previous studies, Tan-IIA decreased migration or invasion
through inhibiting MMP-9/-2 secretion in gastric cancer and osteosarcoma [11,18]. Similar results
observed in our study showed that Tan-IIA suppressed both the protein expression and enzymatic
activity of MMP-9/-2 on human BCa cells (Figure 1B). Together, these findings suggest that Tan-IIA
inhibits EMT in human BCa cells.
Several reports have demonstrated the importance of CCL2 and EMT signals in BCa progression.
Chiu et al. reported that blocking the CCL2/CCR2 pathway could decrease the migration and invasion
of BCa cells [39]. Additional reports show that CCL2 signals promote EMT in various tumors including
BCa [32,40,44,45]. The present study provides evidence that Tan-IIA decreased CCL2 expression
in a dose-dependent manner by qRT-PCR and ELISA analysis (Figure 3). The addition of CCL2
recombinant protein resulted in a partial reversal of EMT markers, and attenuated the Tan-IIA-induced
migration and invasion inhibition in BCa cells. Our results show that Tan-IIA inhibits the EMT in BCa
cells via the suppression of CCL2 expression.
Additional reported data suggested that CCL2 induced EMT through the activation of STAT3
signals [33,40] and inhibited STAT3 signaling to reduce the invasiveness of tumor cells [41,46]. Our
data showed that Tan-IIA could inhibit the p-STAT3 (Tyr705) in a time- and dose-dependent manner.
Besides, inhibition of STAT3 expression by STAT3 siRNA transfection attenuated the expression of
CCL2. The phosphorylation of STAT3, inhibited by Tan-IIA, cannot be restored by CCL2 recombinant
protein addition. These data suggested that Tan-IIA inhibits EMT of human BCa cells via modulation
of STAT3-CCL2 signaling (Figure 5). Several effects of Tan-IIA on human cancer were also integrated
to get a better view of possible anti-cancerogenic effects of Tan-IIA [47–50]. In addition, since the
results from this study were based on in vitro assays of human BCa cells, the in vivo experiments are
necessary for future study.
EMT is orchestrated by several signaling pathways, including JAK/STAT3 and TGF-β/Smad
signaling. Recent studies have demonstrated that TGF-β-mediated cancer metastasis was associated
with the activation of STAT3 pathway in colorectal and lung cancer [51,52]. STAT3 activation can
increase smad7 expression and form an inhibitory complex with smad3 which eventually suppress
EMT [53]. Recent study elucidated the mechanisms behind the tumoricidal activity of TCM clinical
prescription Jianpi Huayu Decoction (JHD) in Hepatocellular carcinoma (HCC) treatment. Their
results indicated that Tan-IIA might be the one of crucial components of the JHD that targets on
the TGF-β/Smad3 pathway and inhibits EMT [50]. Taken together, the targeted blockade of the
STAT3/smad3 axis in tumor cells may be an effective therapeutic strategy against tumor metastatic
progression and worth for further investigation.
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Figure 5. Schematic representation the anti-cancerogenic roles of Tan-IIA. CCL2: Chemokine (C-C
motif) ligand 2; EMT: Epithelial-Mesenchymal Transition; HIF-1α: Hypoxia-inducible factor-1α; MMP:
Matrix MetalloProteinases; mTOR: mammalian target of rapamycin; P: phosphorylation; p70S6K:
p70 ribosomal protein S6 kinase; STAT3: signal transducer and activator of transcription 3; Tan-IIA:
Tanshinone IIA; TGF-β: transforming growth factor β. ↓: stimulatory modification; ⊥: inhibitory
modification; Dashed arrow: putative stimulatory modification [47–50].
4. Materials and Methods
4.1. Chemicals and Antibodies
Tanshinone IIA (C19H18O3, >97% HPLC), Dimethyl sulfoxide (DMSO), [3-(4,5-dimethyl
thizol-2-yl)-2,5-diphenyl tetrazolium bromide] (MTT), Tween-20, methanol, and horseradish
peroxidase-conjugated secondary antibodies were purchased from Sigma Chemical Co. (St. Louis,
MO, USA). The antibodies against p-STAT3 (Tyr705), STAT3, E-cadherin, N-cadherin, Vimentin,
Slug, Snail, MMP-2, MMP-9 and β-actin were all purchased from Cell Signaling Technology, Inc.,
(Danvers, MA, USA). The human CCL2 recombinant protein was purchased from Santa Cruz
Biotechnology, Inc. (Dallas, TX, USA). Polyvinyldenefluoride (PVDF) membranes, BSA protein
assay kit and western blot chemiluminescence reagent were purchased from Amersham Biosciences
(Arlington Heights, IL, USA).
4.2. Cell Culture
The human BCa cell lines 5637 (grade II carcinoma), BFTC (BFTC 905, papillary transitional cell
carcinoma), and T24 (transitional cell carcinoma) were purchased from BCRC (Bioresource Collection
and Research Center, Hsinchu, Taiwan). Cells were cultured in appropriate medium supplemented
with 10% FBS, 100 U/mL penicillin and 100 U/mL streptomycin (all from Invitrogen, Carlsbad, CA,
USA) at 37 ◦C in a humidified atmosphere with 5% CO2.
4.3. Western Blot Analysis
Five hundred thousand cells per 6-cm plate were lysed with 200 μL M-PER mammalian protein
extraction reagent containing protease inhibitor cocktail (Thermo Scientific, Rockford, IL, USA) and
centrifuged at 13,000× g at 4 ◦C for 10 min. The protein concentration in the supernatants was
quantified using a BSA Protein Assay Kit. Electrophoresis was performed on a NuPAGE Bis-Tris
Electrophoresis System using 20 μg of reduced protein extract per lane. Resolved proteins were
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transferred to PVDF membranes, blocked with 5% skim milk for 1 h at room temperature, finally
probed with the specific primary antibodies at 4 ◦C overnight. After the PVDF membrane was
washed three times with TBS/0.2% Tween-20 at room temperature, it was incubated with appropriate
secondary antibody labeled with horseradish peroxidase (Sigma Chemical, St. Louis, MO, USA)
for 1 h at room temperature. All resolved proteins bands were detected using Western Lightning™
Chemiluminescence Reagent Plus (Amersham Biosciences, Arlington Heights, IL, USA).
4.4. Cell Migration and Invasion Assay
The trans-well assay was performed using Hanging inserts (Millipore Co., Billerica, MA, USA)
with 8 μm polycarbonate membrane in a 24-well plate. Cells were seeded in 6 well plates and treated
without or with 4 μg/mL Tan-IIA with or without CCL2 for 24 h. Cells were then detached and
seeded (5 × 104) to the upper chamber of the transwell plates. Upper chambers were filled with
serum free medium and lower chambers were filled with cultured medium containing 10% FBS as
a chemo-attractant. Incubation was carried out at 37 ◦C for the indicated 24 h. The hanging inserts
were washed with PBS, and cells on the upper filter surface were wiped away with a cotton swab.
The inserts were subsequently fixed with 10% formalin for 10 min at room temperature, stained with
0.2% w/v crystal violet, washed with PBS, the remaining cells were counted on the opposite site
of the filter under a light microscope operating at 200× magnification. The migration cell numbers
of control group were considered as 100%. For the invasion assay, a Matrigel basement membrane
matrix (BD Biosciences, San Jose, CA, USA) was coated to the upper side of the hanging inserts at
a concentration of 2 mg/mL. Cells were seeded onto the coated hanging inserts and followed by
migration assay protocol.
4.5. RNA Extraction and Real-Time RT-PCR
Total RNA was extracted from cell lines using RNeasy Mini Kit® (Qiagen, Valencia, CA, USA)
and reverse transcribed at 37 ◦C for 60 min with Omniscript RT Kit® (Qiagen) according to the
manufacturer’s instructions. Real-time RT-PCR analysis was performed in triplicate in a Step One Plus
Real-Time PCR system (Applied Biosystems, Foster City, CA, USA) with Power SYBR® Green PCR
Master Mix (Applied Biosystems) in a final volume of 20 μL/reaction. Threshold cycle (Ct) value of
each tested gene was normalized to the Ct value of the GAPDH control from the same RNA preparation.
The ratio of transcription of each gene was calculated as 2–(ΔCt), where ΔCt is the difference Ct(test
gene)−Ct(GAPDH). Real-time RT-PCR primer sequences used in this study are listed in Table 1.
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4.6. Enzyme-Linked Immunosorbent Assay (ELISA)
Human MCP-1/CCL2 ELISA kit was purchased from R&D Systems. BCa cells were cultured in
serum-free medium with or without Tan-IIA for 72 h. The medium were collected (400 μL/sample in
96-well) for ELISA assay according to manufacturer’s instructions.
4.7. Gelatin Zymography
The BCa cells were cultured in serum-free medium containing Tan-IIA (0, 1, 2, 4 μg/mL) for 48 h
and the supernatant was collected. The supernatant was mixed with non-reducing SDS gel sample
buffer. Electrophoresis was carried out using 10% native polyacrylamide gel containing 0.1% gelatin
(Sigma, St. Louis, MO, USA) on a NuPAGE Bis-Tris Electrophoresis System. After electrophoresis,
the gels were washed in wash buffer containing 2.5% Triton X-100 at room temperature, and then
incubated with the reaction buffer containing l M CaC12, 2% NaN3, 1 M Tris-HCl (pH 8.0) at 37 ◦C
overnight. Gels were stained by Coomassie Brilliant Blue R-250 solution and gelatinolytic activity was
shown as clear areas in the gel.
4.8. Small Interfering RNA (siRNA) Transfection
STAT3 siRNA (#6582) was purchased from Cell Signaling Technology, Inc., (Danvers, MA, USA).
Non-targeting siRNA (ON-TARGET plus non-targeting pool) were purchased from Dharmacon RNAi
Technologies (Lafayette, CO, USA). Non-targeting control sequences were not provided. BFTC cells at
50–60% confluence were transfected with siRNA (40 or 80 nM) using the DharmaFECT 4 transfection
reagents (GE Healthcare Dharmacon, Lafayette, CO, USA) according to the manufacturer’s protocol.
Cells were cultured for 24 h, and then treated with Tan-IIA or vehicle for an additional 48 h. Proteins
were then isolated for western blotting.
4.9. Statistical Analysis
All data were shown as mean ± S.D. Statistical differences were analyzed using the Student’s
t-test for normally distributed values.
5. Conclusions
In conclusion, our study demonstrated that Tan-IIA inhibits EMT in human BCa cells. The
anti-metastatic effects of Tan-IIA in human BCa cells were shown by migration and invasion assay.
Tan-IIA is shown to regulate EMT-related gene expression via the suppression of CCL2. The inhibition
of CCL2 might be linked to the phosphorylation inhibition at Tyr705 of STAT3 by Tan-IIA. Tan-IIA
has been shown to inhibit EMT in human BCa cells, and the mechanism involved was mediated
through the modulation of STAT3-CCL2 signaling. Thus, our findings suggest a novel role of Tan-IIA
in controlling BCa, suggesting that Tan-IIA might be a potential option for treating BCa metastasis.
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Abbreviations
CCL2 Chemokine (C-C motif) ligand 2
EMT Epithelial-mesenchymal transition
MMP Matrix metalloproteinases
STAT3 Signal transducer and activator of transcription 3
Tan-IIA Tanshinone IIA
References
1. Siegel, R.L.; Miller, K.D.; Jemal, A. Cancer statistics, 2016. CA Cancer J. Clin. 2016, 66, 7–30. [CrossRef]
[PubMed]
2. Antoni, S.; Ferlay, J.; Soerjomataram, I.; Znaor, A.; Jemal, A.; Bray, F. Bladder cancer incidence and mortality:
A global overview and recent trends. Eur. Urol. 2017, 71, 96–108. [CrossRef] [PubMed]
3. Jemal, A.; Siegel, R.; Ward, E.; Hao, Y.; Xu, J.; Murray, T.; Thun, M.J. Cancer statistics, 2008. CA Cancer J. Clin.
2008, 58, 71–96. [CrossRef] [PubMed]
4. Lutzeyer, W.; Rubben, H.; Dahm, H. Prognostic parameters in superficial bladder cancer: An analysis of
315 cases. J. Urol. 1982, 127, 250–252. [CrossRef]
5. Wu, X.R. Urothelial tumorigenesis: a tale of divergent pathways. Nat. Rev. Cancer 2005, 5, 713–725. [CrossRef]
[PubMed]
6. Che, A.J.; Zhang, J.Y.; Li, C.H.; Chen, X.F.; Hu, Z.D.; Chen, X.G. Separation and determination of
active components in Radix Salviae miltiorrhizae and its medicinal preparations by nonaqueous capillary
electrophoresis. J. Sep. Sci. 2004, 27, 569–575. [PubMed]
7. Zhou, L.; Zuo, Z.; Chow, M.S. Danshen: An overview of its chemistry, pharmacology, pharmacokinetics,
and clinical use. J. Clin. Pharmacol. 2005, 45, 1345–1359. [CrossRef] [PubMed]
8. Wei, B.; You, M.G.; Ling, J.J.; Wei, L.L.; Wang, K.; Li, W.W.; Chen, T.; Du, Q.M.; Ji, H. Regulation of antioxidant
system, lipids and fatty acid β-oxidation contributes to the cardioprotective effect of sodium tanshinone
IIA sulphonate in isoproterenol-induced myocardial infarction in rats. Atherosclerosis 2013, 230, 148–156.
[CrossRef] [PubMed]
9. Fan, G.; Jiang, X.; Wu, X.; Fordjour, P.A.; Miao, L.; Zhang, H.; Zhu, Y.; Gao, X. Anti-Inflammatory Activity
of Tanshinone IIA in LPS-Stimulated RAW264.7 Macrophages via miRNAs and TLR4-NF-κB Pathway.
Inflammation 2016, 39, 375–384. [CrossRef] [PubMed]
10. Huang, S.T.; Huang, C.C.; Huang, W.L.; Lin, T.K.; Liao, P.L.; Wang, P.W.; Liou, C.W.; Chuang, J.H. Tanshinone
IIA induces intrinsic apoptosis in osteosarcoma cells both in vivo and in vitro associated with mitochondrial
dysfunction. Sci. Rep. 2017, 7, 40382. [CrossRef] [PubMed]
11. Su, C.C. Tanshinone IIA decreases the migratory ability of AGS cells by decreasing the protein expression of
matrix metalloproteinases, nuclear factor κB-p65 and cyclooxygenase-2. Mol. Med. Rep. 2016, 13, 1263–1268.
[PubMed]
12. Xie, J.; Liu, J.; Liu, H.; Liang, S.; Lin, M.; Gu, Y.; Liu, T.; Wang, D.; Ge, H.; Mo, S.L. The antitumor effect of
tanshinone IIA on anti-proliferation and decreasing VEGF/VEGFR2 expression on the human non-small cell
lung cancer A549 cell line. Acta Pharm. Sin. B 2015, 5, 554–563. [CrossRef] [PubMed]
13. Wang, J.F.; Feng, J.G.; Han, J.; Zhang, B.B.; Mao, W.M. The molecular mechanisms of Tanshinone IIA on the
apoptosis and arrest of human esophageal carcinoma cells. BioMed Res. Int. 2014, 2014. [CrossRef] [PubMed]
14. Chiu, S.C.; Huang, S.Y.; Chen, S.P.; Su, C.C.; Chiu, T.L.; Pang, C.Y. Tanshinone IIA inhibits human prostate
cancer cells growth by induction of endoplasmic reticulum stress in vitro and in vivo. Prostate Cancer
Prostatic Dis. 2013, 16, 315–322. [CrossRef] [PubMed]
15. Tsai, M.Y.; Yang, R.C.; Wu, H.T.; Pang, J.H.; Huang, S.T. Anti-angiogenic effect of Tanshinone IIA involves
inhibition of matrix invasion and modification of MMP-2/TIMP-2 secretion in vascular endothelial cells.
Cancer Lett. 2011, 310, 198–206. [CrossRef] [PubMed]
16. Wu, W.Y.; Yan, H.; Wang, X.B.; Gui, Y.Z.; Gao, F.; Tang, X.L.; Qin, Y.L.; Su, M.; Chen, T.; Wang, Y.P. Sodium
tanshinone IIA silate inhibits high glucose-induced vascular smooth muscle cell proliferation and migration
through activation of AMP-activated protein kinase. PLoS ONE 2014, 9, e94957. [CrossRef] [PubMed]
155
Int. J. Mol. Sci. 2017, 18, 1616
17. Yun, S.M.; Jung, J.H.; Jeong, S.J.; Sohn, E.J.; Kim, B.; Kim, S.H. Tanshinone IIA induces autophagic cell
death via activation of AMPK and ERK and inhibition of mTOR and p70 S6K in KBM-5 leukemia cells.
Phytother. Res. 2014, 28, 458–464. [CrossRef] [PubMed]
18. Zhang, Y.; Wei, R.X.; Zhu, X.B.; Cai, L.; Jin, W.; Hu, H. Tanshinone IIA induces apoptosis and inhibits the
proliferation, migration, and invasion of the osteosarcoma MG-63 cell line in vitro. Anticancer Drugs 2012, 23,
212–219. [CrossRef] [PubMed]
19. Zhu, Y.Q.; Wang, B.Y.; Wu, F.; An, Y.K.; Zhou, X.Q. Influence of tanshinone IIA on the apoptosis of human
esophageal Ec-109 cells. Nat. Prod. Commun. 2016, 11, 17–19. [PubMed]
20. Zhang, J.; Wang, J.; Jiang, J.Y.; Liu, S.D.; Fu, K.; Liu, H.Y. Tanshinone IIA induces cytochrome c-mediated
caspase cascade apoptosis in A549 human lung cancer cells via the JNK pathway. Int. J. Oncol. 2014, 45,
683–690. [PubMed]
21. Tseng, P.Y.; Lu, W.C.; Hsieh, M.J.; Chien, S.Y.; Chen, M.K. Tanshinone IIA induces apoptosis in human oral
cancer KB cells through a mitochondria-dependent pathway. BioMed Res. Int. 2014, 2014, 540516. [CrossRef]
[PubMed]
22. Gong, Y.; Li, Y.; Lu, Y.; Li, L.; Abdolmaleky, H.; Blackburn, G.L.; Zhou, J.R. Bioactive tanshinones in Salvia
miltiorrhiza inhibit the growth of prostate cancer cells in vitro and in mice. Int. J. Cancer 2011, 129, 1042–1052.
[CrossRef] [PubMed]
23. Gong, Y.; Li, Y.; Abdolmaleky, H.M.; Li, L.; Zhou, J.R. Tanshinones inhibit the growth of breast cancer cells
through epigenetic modification of aurora a expression and function. PLoS ONE 2012, 7, e33656. [CrossRef]
[PubMed]
24. Liu, F.; Yu, G.; Wang, G.; Liu, H.; Wu, X.; Wang, Q.; Liu, M.; Liao, K.; Wu, M.; Cheng, X.; et al.
An NQO1-initiated and p53-independent apoptotic pathway determines the anti-tumor effect of tanshinone
IIA against non-small cell lung cancer. PLoS ONE 2012, 7, e42138. [CrossRef] [PubMed]
25. Chiu, S.C.; Huang, S.Y.; Chang, S.F.; Chen, S.P.; Chen, C.C.; Lin, T.H.; Liu, H.H.; Tsai, T.H.; Lee, S.S.; Pang, C.Y.;
et al. Potential therapeutic roles of tanshinone IIA in human bladder cancer cells. Int. J. Mol. Sci. 2014, 15,
15622–15637. [CrossRef] [PubMed]
26. Vazquez-Lavista, L.G.; Lima, G.; Gabilondo, F.; Llorente, L. Genetic association of monocyte chemoattractant
protein 1 (MCP-1)-2518 polymorphism in Mexican patients with transitional cell carcinoma of the bladder.
Urology 2009, 74, 414–418. [CrossRef] [PubMed]
27. Amann, B.; Perabo, F.G.; Wirger, A.; Hugenschmidt, H.; Schultze-Seemann, W. Urinary levels of monocyte
chemo-attractant protein-1 correlate with tumour stage and grade in patients with bladder cancer. Br. J. Urol.
1998, 82, 118–121. [CrossRef] [PubMed]
28. Brana, I.; Calles, A.; LoRusso, P.M.; Yee, L.K.; Puchalski, T.A.; Seetharam, S.; Zhong, B.; de Boer, C.J.;
Tabernero, J.; Calvo, E. Carlumab, an anti-C-C chemokine ligand 2 monoclonal antibody, in combination
with four chemotherapy regimens for the treatment of patients with solid tumors: An open-label, multicenter
phase 1b study. Target Oncol. 2015, 10, 111–123. [CrossRef] [PubMed]
29. Mitchem, J.B.; Brennan, D.J.; Knolhoff, B.L.; Belt, B.A.; Zhu, Y.; Sanford, D.E.; Belaygorod, L.; Carpenter, D.;
Collins, L.; Piwnica-Worms, D.; et al. Targeting tumor-infiltrating macrophages decreases tumor-initiating
cells, relieves immunosuppression, and improves chemotherapeutic responses. Cancer Res. 2013, 73,
1128–1141. [CrossRef] [PubMed]
30. Mitchem, J.B.; DeNardo, D.G. Battle over CCL2 for control of the metastatic niche: neutrophils versus
monocytes. Breast Cancer Res. 2012, 14, 315. [CrossRef] [PubMed]
31. Lee, C.C.; Ho, H.C.; Su, Y.C.; Lee, M.S.; Hung, S.K.; Lin, C.H. MCP1-Induced Epithelial-Mesenchymal
Transition in Head and Neck Cancer by AKT Activation. Anticancer Res. 2015, 35, 3299–3306. [PubMed]
32. Rao, Q.; Chen, Y.; Yeh, C.R.; Ding, J.; Li, L.; Chang, C.; Yeh, S. Recruited mast cells in the tumor
microenvironment enhance bladder cancer metastasis via modulation of ERβ/CCL2/CCR2 EMT/MMP9
signals. Oncotarget 2016, 7, 7842–7855. [CrossRef] [PubMed]
33. Chen, W.; Gao, Q.; Han, S.; Pan, F.; Fan, W. The CCL2/CCR2 axis enhances IL-6-induced
epithelial-mesenchymal transition by cooperatively activating STAT3-Twist signaling. Tumor Biol. 2015, 36,
973–981. [CrossRef] [PubMed]
156
Int. J. Mol. Sci. 2017, 18, 1616
34. Hsu, Y.L.; Hung, J.Y.; Tsai, Y.M.; Tsai, E.M.; Huang, M.S.; Hou, M.F.; Kuo, P.L. 6-shogaol, an active
constituent of dietary ginger, impairs cancer development and lung metastasis by inhibiting the secretion of
CC-chemokine ligand 2 (CCL2) in tumor-associated dendritic cells. J. Agric. Food Chem. 2015, 63, 1730–1738.
[CrossRef] [PubMed]
35. Kortylewski, M.; Yu, H. Stat3 as a potential target for cancer immunotherapy. J. Immunother. 2007, 30, 131–139.
[CrossRef] [PubMed]
36. Yu, H.; Pardoll, D.; Jove, R. STATs in cancer inflammation and immunity: A leading role for STAT3.
Nat. Rev. Cancer 2009, 9, 798–809. [CrossRef] [PubMed]
37. Chen, C.L.; Cen, L.; Kohout, J.; Hutzen, B.; Chan, C.; Hsieh, F.C.; Loy, A.; Huang, V.; Cheng, G.; Lin, J. Signal
transducer and activator of transcription 3 activation is associated with bladder cancer cell growth and
survival. Mol. Cancer 2008, 7, 78. [CrossRef] [PubMed]
38. Yang, C.; Zhang, W.; Wang, L.; Kazobinka, G.; Han, X.; Li, B.; Hou, T. Musashi-2 promotes migration and
invasion in bladder cancer via activation of the JAK2/STAT3 pathway. Lab. Investig. 2016, 96, 950–958.
[CrossRef] [PubMed]
39. Chiu, H.Y.; Sun, K.H.; Chen, S.Y.; Wang, H.H.; Lee, M.Y.; Tsou, Y.C.; Jwo, S.C.; Sun, G.H.; Tang, S.J.
Autocrine CCL2 promotes cell migration and invasion via PKC activation and tyrosine phosphorylation of
paxillin in bladder cancer cells. Cytokine 2012, 59, 423–432. [CrossRef] [PubMed]
40. Izumi, K.; Fang, L.Y.; Mizokami, A.; Namiki, M.; Li, L.; Lin, W.J.; Chang, C. Targeting the androgen
receptor with siRNA promotes prostate cancer metastasis through enhanced macrophage recruitment via
CCL2/CCR2-induced STAT3 activation. EMBO Mol. Med. 2013, 5, 1383–1401. [CrossRef] [PubMed]
41. Sun, Y.; Cheng, M.K.; Griffiths, T.R.; Mellon, J.K.; Kai, B.; Kriajevska, M.; Manson, M.M. Inhibition of STAT
signalling in bladder cancer by diindolylmethane: Relevance to cell adhesion, migration and proliferation.
Curr. Cancer Drug Targets 2013, 13, 57–68. [CrossRef] [PubMed]
42. Sung, W.J.; Kim, H.; Park, K.K. The biological role of epithelial-mesenchymal transition in lung cancer
(Review). Oncol. Rep. 2016, 36, 1199–1206. [CrossRef] [PubMed]
43. Horejs, C.M. Basement membrane fragments in the context of the epithelial-to-mesenchymal transition.
Eur. J. Cell Biol. 2016, 95, 427–440. [CrossRef] [PubMed]
44. Deshmane, S.L.; Kremlev, S.; Amini, S.; Sawaya, B.E. Monocyte chemoattractant protein-1 (MCP-1):
An overview. J. Interferon Cytokine Res. 2009, 29, 313–326. [CrossRef] [PubMed]
45. Raman, D.; Baugher, P.J.; Thu, Y.M.; Richmond, A. Role of chemokines in tumor growth. Cancer Lett. 2007,
256, 137–165. [CrossRef] [PubMed]
46. Arabzadeh, A.; Dupaul-Chicoine, J.; Breton, V.; Haftchenary, S.; Yumeen, S.; Turbide, C.; Saleh, M.;
McGregor, K.; Greenwood, C.M.; Akavia, U.D.; et al. Carcinoembryonic Antigen Cell Adhesion Molecule
1 long isoform modulates malignancy of poorly differentiated colon cancer cells. Gut 2016, 65, 821–829.
[CrossRef] [PubMed]
47. Ding, L.; Wang, S.; Wang, W.; Lv, P.; Zhao, D.; Chen, F.; Meng, T.; Dong, L.; Qi, L. Tanshinone IIA affects
autophagy and apoptosis of glioma cells by inhibiting phosphatidylinositol 3-Kinase/Akt/Mammalian
target of rapamycin signaling pathway. Pharmacology 2017, 99, 188–195. [CrossRef] [PubMed]
48. Li, X.; Li, Z.; Li, X.; Liu, B.; Liu, Z. Mechanisms of tanshinone II a inhibits malignant melanoma development
through blocking autophagy signal transduction in A375 cell. BMC Cancer 2017, 17, 357. [CrossRef] [PubMed]
49. Sui, H.; Zhao, J.; Zhou, L.; Wen, H.; Deng, W.; Li, C.; Ji, Q.; Liu, X.; Feng, Y.; Chai, N.; et al. Tanshinone IIA
inhibits β-catenin/VEGF-mediated angiogenesis by targeting TGF-β1 in normoxic and HIF-1α in hypoxic
microenvironments in human colorectal cancer. Cancer Lett. 2017, 403, 86–97. [CrossRef] [PubMed]
50. Zhong, C.; Zhang, Y.F.; Huang, J.H.; Wang, Z.Y.; Chen, Q.Y.; Su, L.T.; Liu, Z.T.; Xiong, C.M.; Tao, Z.; Guo, R.P.
The Chinese medicine, Jianpi Huayu Decoction, inhibits the epithelial mesenchymal transition via the
regulation of the Smad3/Smad7 cascade. Am. J. Transl. Res. 2017, 9, 2694–2711. [PubMed]
51. Calon, A.; Espinet, E.; Palomo-Ponce, S.; Tauriello, D.V.; Iglesias, M.; Cespedes, M.V.; Sevillano, M.; Nadal, C.;
Jung, P.; Zhang, X.H.; et al. Dependency of colorectal cancer on a TGF-β-driven program in stromal cells for
metastasis initiation. Cancer Cell 2012, 22, 571–584. [CrossRef] [PubMed]
157
Int. J. Mol. Sci. 2017, 18, 1616
52. Liu, R.Y.; Zeng, Y.; Lei, Z.; Wang, L.; Yang, H.; Liu, Z.; Zhao, J.; Zhang, H.T. JAK/STAT3 signaling is required
for TGF-β-induced epithelial-mesenchymal transition in lung cancer cells. Int. J. Oncol. 2014, 44, 1643–1651.
[CrossRef] [PubMed]
53. Luwor, R.B.; Baradaran, B.; Taylor, L.E.; Iaria, J.; Nheu, T.V.; Amiry, N.; Hovens, C.M.; Wang, B.; Kaye, A.H.;
Zhu, H.J. Targeting Stat3 and Smad7 to restore TGF-β cytostatic regulation of tumor cells in vitro and in vivo.
Oncogene 2013, 32, 2433–2441. [CrossRef] [PubMed]
© 2017 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
158




Epithelial-to-Mesenchymal Transition via PKM2
Relative-mTOR/p70s6k Signaling Pathway in
Cervical Carcinoma Cells
Keyan Cheng and Min Hao *
Department of Obstetrics and Gynecology, The Second Hospital of Shanxi Medical University, Taiyuan 030000,
China; chengkey@126.com
* Correspondence: eryuanhaomin@126.com; Tel./Fax: +86-35-1336-5114
Academic Editors: Gianni Sava and Alberta Bergamo
Received: 10 September 2016; Accepted: 22 November 2016; Published: 30 November 2016
Abstract: Background: Epithelial-to-mesenchymal transition (EMT) plays a prominent role in
tumorigenesis. Metformin exerts antitumorigenic effects in various cancers. This study investigated
the mechanisms of metformin in TGF-β1-induced Epithelial-to-mesenchymal transition (EMT) in
cervical carcinoma cells. Methods: cells were cultured with 10 ng/mL TGF-β1 to induce EMT
and treated with or without metformin. Cell viability was evaluated by CCK-8 (Cell Counting
Kit 8, CCK-8) assay; apoptosis were analyzed by flow cytometry; cell migration was evaluated
by wound-healing assay. Western blotting was performed to detect E-cadherin, vimentin, signal
transducer and activator of transcription 3 (STAT3), snail family transcriptional repressor 2 (SNAIL2),
phosphorylation of p70s6k (p-p70s6k) and -Pyruvate kinase M2 (PKM2) Results: TGF-β1 promoted
proliferation and migration, and it attenuated apoptosis compared with cells treated with metformin
with or without TGF-β1 in cervical carcinoma cells. Moreover, metformin partially abolished
TGF-β1-induced EMT cell proliferation and reversed TGF-β1-induced EMT. In addition, the anti-EMT
effects of metformin could be partially in accord with rapamycin, a specific mTOR inhibitor.
Metformin decreased the p-p70s6k expression and the blockade of mTOR/p70s6k signaling decreased
PKM2 expression. Conclusion: Metformin abolishes TGF-β1-induced EMT in cervical carcinoma
cells by inhibiting mTOR/p70s6k signaling to down-regulate PKM2 expression. Our study provides
a novel mechanistic insight into the anti-tumor effects of metformin.
Keywords: metformin; mammalian target of rapamycin; epithelial-mesenchymal transition; PKM2
1. Introduction
Cervical carcinoma is the second common gynecological carcinoma worldwide with more than
0.52 million new cases and 0.27 million deaths globally each year. Approximately 30% of cervical
carcinoma patients will ultimately fail after surgery, radiotherapy, or chemotherapy treatment [1].
There is increasing evidence that Epithelial-to-mesenchymal transition (EMT) plays a prominent role in
carcinoma tumorigenesis. The EMT enables carcinoma to invade and metastasize [2,3], induces cancer
chemoresistance [4], and radioresistance [5,6], and has an immunoprotective effect [7]. Therefore,
the EMT constitutes a major malignant propensity to cancer development and is a major obstacle to
cure cancer.
During the EMT, epithelial cells undergo extensive genetic alterations, resulting in the loss of
apical-basal polarity, the severing of cell-cell adhesion structures, and the degradation of basement
membrane components [8]. The loss of E-cadherin is generally accepted as a hallmark of the
EMT [9], which reduces cell-cell adhesion and destabilizes the epithelial architecture. This process is
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accompanied by increased expression of vimentin, which bestows a motile phenotype on cancer cells
through changes in cellular architecture and cell-matrix interactions [10,11]. Snail, a transcription factor,
acts as repressor of E-cadherin in response to TGF-β signaling [12], and has been linked to the induction
of the EMT under different cellular contexts. A signal transducer and activator of transcription 3
(STAT3) is also involved in EMT by regulating the transcriptional regulators of E-cadherin [13]. Large
studies indicated that alterations of EMT-related markers have been associated with metastatic disease
and reduced survival, including cervical carcinoma [14,15].
Recent studies showed overexpression of pyruvate kinase M2 (PKM2) induced the
epithelial-to-mesenchymal transition (EMT) and increased the metastatic potential of cancer cells [16].
PKM2 is an alternatively-spliced variant of the pyruvate kinase gene that is preferentially expressed
during embryonic development and in cancer cells [17,18]. PKM2 regulates in the cancer-specific
Warburg effect, which is responsible for the final rate-limiting step of glycolysis. Moreover, in cancer
cells, PKM2 expression is associated with attenuated pyruvate kinase activity to meet the biosynthetic
demands, which allows the diversion of glycolytic flux into the pentose phosphate pathway [18].
Metformin exerts its antitumorigenic effects through indirect mechanisms by increasing insulin
sensitivity, inhibiting liver gluconeogenesis [19], and direct mechanisms involving activating
AMP-activated protein kinase (AMPK), followed by inhibition of the mammalian target of the
rapamycin (mTOR) pathway [20,21]. Moreover, metformin also plays a crucial role in modulating cell
energy metabolism [22], and repressed the EMT through the mTOR signaling pathway [23]. Hosono
et al. report that the mechanisms underlying the suppression on aberrant crypt foci formation of
metformin are associated with the inhibition of the mTOR pathway [24]. Dann et al. reported that
mTOR Complex1-S6K1 signaling is at the crossroads of obesity, diabetes, and cancer [25].
These mechanisms of metformin indicated that there likely is an antitumorigenic effect relationship
between the mTOR pathway and PKM2 in various cancers. Moreover, the potential role of metformin
in treating gynecologic oncology has been explored in a number of studies. A study reported that
metformin inhibits βKlotho-related ERK1/2 signaling and AMPKα signaling to reverse the EMT in
endometrial adenocarcinoma [26]. However, none of research involves the relationship of mTOR
pathway and PKM2.
In this study, we investigate the role of metformin on inhibited TGF-β1-induced EMT in
cervical carcinoma cells and explore the mechanisms that might be involved in tumorigenesis.
Our data showed that the metformin reversed EMT. Metformin as the same anti-tumor effects as
rapamycin, which decreased p-p70s6k and PKM2 expression. We infer that metformin is involved in
mTOR/p70s6k/PKM2 signaling to promote cervical carcinoma resistance.
2. Results
2.1. Transforming Growth Factor Beta 1 (TGF-β1) Induces Epithelial-to-Mesenchymal Transition (EMT) in
Cerivical Cancer Cells
In order to determine whether TGF-β1 induced EMT, HeLa, and SiHa cells were incubated
with 10 ng/mL TGF-β1 for 48 h based on Hamabe’ study [16]. The results obtained indicate that
cells displayed an altered morphology, with flattened, stretched, and scattered fibroblast-like shapes.
As shown in Figure 1, almost all HeLa (A) and SiHa (B) cells acquired spindle and fibroblastoid shapes
with increased cell gaps. Moreover, protein levels of E-cadherin were abundantly expressed in the
absence of TGF-β1 (pre-EMT). After these cells were stimulated by 10 ng/mL TGF-β1, E-cadherin
expression was significantly decreased (post-EMT). In contrast, compared with the pre-EMT state,
vimentin was increased (post-EMT), stimulated by TGF-β1 (Figure 1). In view of the changes in cell
morphology and marker protein expression, these data indicated that EMT was induced when cervical
carcinoma cells were stimulated with 10 ng/mL TGF-β1.
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Figure 1. TGF-β1 induces EMT in cerivical cancer cells. (A,B) Photomicrographs of the morphological
change in HeLa (A) and SiHa (B) cells. The number of hours indicates the period since EMT induction
was initiated (scale bar, 50 μm). Western blot assays of E-cadherion, vimentin, and β-actin are shown
in comparison with those in the pre-EMT condition; and (C) schematic representation of the procedure
for EMT induction. The cells incubated for 48 h after seeding are defined as pre-EMT, and the cells
cultured with 10 ng/mL TGF-β1 are defined as post-EMT. ** p < 0.01.
2.2. Metformin Inhibits the TGF-β1-Induced Proliferation, Migration, and Induces Apoptosis
To evaluate the potential anti-proliferative effect of metformin in cervical carcinoma cells,
Cells were treated with 0, 1, 2.5, 5, 10, and 15 mM metformin, or 10 mM metformin with or without
10 ng/mL TGF-β1. The Cell Counting Kit-8 (CCK-8, Dojindo, Tokyo, Japan) assays were performed to
determine the proliferation of cells. As shown in Figures 2A and 3A, metformin led to a significant
decrease in proliferation compared with untreated (control) cells, which inhibited the proliferation of
HeLa (Figure 2A) and SiHa (Figure 3A) cell lines in a dose-dependent manner. In addition, treatment
with TGF-β1 significantly increased the proliferation of both cell lines in comparison with treated
metformin with or without TGF-β1 at 72 h, which was abolished by the addition of metformin.
When comparing the metformin plus TGF group with the metformin group, cells treated with
metformin plus TGF significantly proliferated faster than the metformin cells in SiHa cells, but not HeLa.
It appears from the data in Figures 2 and 3 that metformin only partially reversed the changes seen
with TGF-β1.
The migration of cells were evaluated using wound-healing assays. Cells were treated with 10 mM
metformin and with or without 10 ng/mL TGF-β1. Metformin significantly decreased the migration
of cells compared with untreated (control) cells, and TGF-β1 significantly increased cell migration
compared with untreated (control) cells in HeLa (Figure 2B) and SiHa (Figure 3B) cell lines at 24 h,
which was abolished by the addition of metformin It was found that there is a statistical significance
between the metformin group and the metformin with TGF-β1 group in HeLa cells (Figure 2B),
but not in SiHa cells (Figure 3B). These data indicated that metformin could inhibit the migration
ability of cells and reverse TGF-β1-induced EMT’s migration ability of cells.
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Figure 2. Metformin inhibits TGF-β1-induced proliferation, migration, and induces apoptosis in
HeLa cells. (A) HeLa cells were treated with metformin (0, 1, 2.5, 5, 10 and 15 mM) or TGF-β1 with
or without 10 mM metformin. Cell numbers were measured by CCK-8 assays at indicated times;
(B) wound-healing assays. Representative images were obtained at 40× magnification. Graphs show
the relative migration distance after 24 h incubation; (C) annexin V-FITC apoptosis assay. Cells were
harvested and stained with Annexin V-FITC/PI (propidium iodide, PI), and cell apoptosis was analyzed
using flow cytometry. Representative images are shown. TGF-β1: transforming growth factor β1;
Met: metformin. * p < 0.05, ** p < 0.01.
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Figure 3. Metformin inhibits TGF-β1-induced proliferation, migration, and induces apoptosis in
SiHa cells. (A) SiHa cells were treated with metformin (0, 1, 2.5, 5, 10, and 15 mM) or TGF-β1 with
or without 10 mM metformin. Cell numbers were measured by CCK-8 assays at indicated times;
(B) wound-healing assays. Representative images were obtained at 40× magnification. Graphs show
the relative migration distance after 24 h incubation; (C) annexin V-FITC apoptosis assay. Cells were
harvested and stained with Annexin V-FITC/PI (propidium iodide, PI), and cell apoptosis was analyzed
using flow cytometry. Representative images are shown. TGF-β1: transforming growth factor β1;
Met: metformin. ** p < 0.01.
To explore the potential effect of metformin for antagonzing the anti-apoptosis effect of TGF-β1 on
cervical carcinoma cells by Annexin V-FITC and propidium iodide (PI) staining, we detected the effect
of metformin with and without TGF-β1 on the apoptosis of HeLa (Figure 2C) and SiHa (Figure 3C)
cells. The results obtained indicated that TGF-β1 induced a slight increase apoptosis compared with
untreated cells in Hela cells (Figure 2C), but there was no statistical significance. Meanwhile, In SiHa
(Figure 3C) cells treated with TGF-β1, the total apoptotic cells (early apoptotic + apoptotic) showed
no effect compared to untreated cells. However, the apoptosis rate was increased by the addition
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of metformin in both cell lines. In addition, metformin with or without TGF-β1 exhibited a marked
increase in apoptosis levels in both cell lines (Figures 2C and 3C). These data indicated that the addition
of metformin significantly abolished the TGF-β1-induced anti-apoptosis effects in both cell lines.
2.3. PKM2 Expression Is Required to Induce EMT
Hamabe et al. reported that they used TGF-β1 to induce EMT in colorectal cancer cells. Then,
siRNAs targeting PKM2 were designed to knockdown PKM2 in EMT conditions. They found that
PKM2 knockdown failed to induce spindle-shaped morphological changes, and Western blot showed
that PKM2 knockdown hindered E-cadherin loss and vimentin gain compared with the control [16].
To determine whether the EMT condition stimulates an increase in PKM2 compared with levels in
the pre-EMT state. HeLa and SiHa cells were grown in a medium with 10 ng/mL TGF-β1. Consistent
with this report, our results obtained showed that HeLa (Figure 1A) and SiHa (Figure 1B) cells
changed morphology from epithelial to fibroblastic-like and spindle-shaped. E-cadherin expression
was suppressed, whereas vimentin, and snail family zinc finger 2 (SNAIL2) expression were increased
in the post-EMT condition (Figure 4). Moreover, PKM2 gene expression was induced in the EMT
condition (Figure 4). The data indicated that the induction of EMT resulted in decreased E-cadherin
expression, increased vimentin expression, and up-regulated PKM2 (Figure 4). These results confirmed
that PKM2 expression was induced in the EMT condition.
Figure 4. EMT condition stimulates an increase in PKM2. (A) HeLa and (B) SiHa cells were detected
E-cadherin, vimentin, SNAIL2, and PKM2 expression by Western blot between pre-EMT and post-EMT
state. Columns represent the average of at least three independent experiments; error bars represent
the SD of the mean from triplicate results. ** p < 0.01.
2.4. mTOR/p70s6k Signaling Involved in Regulating PKM2 Expression in the EMT Condition
To investigate whether the mTOR pathway affects PKM2 expression in the EMT condition,
the mTOR pathway was inhibited by rapamycin (an mTOR inhibtior) to evaluate PKM2 (a critical
glycolytic enzyme), and p70s6k (S6K1, a downstream effector of mTOR) expression. HeLa and SiHa
cells were induced by TGF-β1 for 48 h, then were treated with or without 50 nM rapamycin for
24 h, respectively. Rapamycin was dissolved in dimethylsulfoxide (DMSO) and the same dose of
DMSO was used as a control. As shown in Figure 5, TGF-β1 significantly increased the expression
of PKM2 and phosphorylation of p70s6k. While, rapamycin, a specific mTOR inhibitor, inhibited the
phosphorylation of p70s6k expression, ribosomal p70S6 kinase (S6K1) is one of main downstream
mTOR effectors. Moreover, to investigate whether inhibition of mTOR/p70s6k signaling decreased
PKM2 expression, which is one of the main downstream S6K1 effectors, rapamycin was added to
cell cultures to inhibit the mTOR pathway. The results obtained indicate that inhibition of the mTOR
pathway significantly decreased the expression of PKM2 and phosphorylation of p70s6k in HeLa
(Figure 5A) and SiHa cells (Figure 5B). In addition, at a concentration of 50 nM rapamycin reversed
TGF-β1-induced EMT expression by repressing PKM2 and p-p70s6k expressions in HeLa (Figure 5A)
and SiHa cells (Figure 5B). These data indicated that the inhibition of EMT was through the PKM2
relative-mTOR/p70s6k signaling pathway in cervical carcinoma cells.
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Figure 5. mTOR/p70s6k signaling involved in regulating PKM2 in the EMT condition. HeLa (A) and
SiHa (B) cells were treated with TGF-β1, with or without rapamycin. Rapamycin was dissolved in
DMSO and the same dose of DMSO was used as a control, and the p-p70s6k and PKM2 expressions
were detected by Western blot. DMSO: dimethylsulfoxide; Rapa:rapamycin. ** p < 0.01.
2.5. Metformin Reverses TGF-β1-Induced EMT Involved in mTOR/p70s6k/PKM2 Signaling Pathways in
Cervical Carcinoma Cells
To determine the mechanism of metformin involved the regulation of EMT in cervical carcinoma,
the expression of EMT-related markers were examined by Western blot. The results obtained revealed
that 10 mM metformin caused an accumulation of E-cadherin, and decreased vimentin, STAT3, and
SNAIL2 expression in HeLa (Figure 6A) and SiHa cells (Figure 7A). Moreover, TGF-β1 significantly
decreased the expression of E-cadherin and increased the expressions of vimentin, STAT3, and SNAIL2
in HeLa (Figure 6A) and SiHa cells (Figure 7A). In addition, concentration of metformin reversed
TGF-β1-induced EMT marker expression by repressing vimentin, STAT3, and SNAIL2 expressions
and restoring E-cadherin expression in HeLa (Figure 6A) and SiHa cells (Figure 7A).
Next, we explored the possible signaling pathways that may be involved. As shown in
Figures 6 and 7, Western blots showed that metformin decreased the phosphorylation of p70s6k
and down-regulated PKM2 levels in Hela (Figure 6A) and SiHa (Figure 7A) cells. TGF-β1 significantly
increased the phosphorylation of p70s6k, which is the main downstream signaling intermediate of
mTOR signaling. Simultaneously, TGF-β1 significantly up-regulated the expression of PKM2 in HeLa
(Figure 6A) and SiHa cells (Figure 7A). While metformin reversed TGF-β1-induced EMT by repressing
phosphorylation of p70s6k and PKM2 in HeLa (Figure 6A) and SiHa cells (Figure 7A). These results
suggested that metformin reverses TGF-β1-induced EMT via the mTOR/p70s6k/PKM2 pathway.
Next, we examined the effect of metformin with or without TGF-β1 on the morphology of HeLa
and SiHa cell lines. Metformin led to a significant decrease in proliferation in the both cells. Moreover,
after stimulation with 10 ng/mL TGF-β1 for 48 h, both HeLa (Figure 6B) and SiHa cells (Figure 7B)
cells became scattered, acquired a spindle-shaped morphology, and lost cell-cell contacts, which
are characteristics of a mesenchymal-like morphology. Treatment with 10 mM metformin for 48 h
abolished the TGF-β1-induced EMT morphological changes in HeLa and SiHa cells.The cells tended
to aggregate and lose the spindle-shaped morphology.
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Figure 6. Metformin reverses TGF-β1-induced EMT in HeLa cells involving mTOR/p70s6k/PKM2
signaling pathways. (A) Cells were treated with TGF-β1, metformin, or both agents for 48 h.
The protein expression levels of E-cadherin, vimentin, SNAIL2, STAT3, PKM2, p-p70s6k, and β-actin
were detected by Western blot. β-actin was used as a loading control; and (B) the morphology of HeLa
cells were treated with TGF-β1 and with or without metformin for 48 h. The cells were observed using
phase contrast microscopy at 200× magnification. Scale bar: 50 μm. The data are presented as the
mean ± SD of three replicates per group. TGF-β1: transforming growth factor β1; Met: metformin.
** p < 0.01.
Figure 7. Metformin reverses TGF-β1-induced EMT in SiHa cells involving mTOR/p70s6k/PKM2
signaling pathways. (A) Cells were treated with TGF-β1, metformin, or both agents for 48 h.
The protein expression levels of E-cadherin, vimentin, SNAIL2, STAT3, PKM2, p-p70s6k, and β-actin
were presented by Western blot. β-actin was used as a loading control; and (B) the morphology of SiHa
cells were treated with TGF-β1 with or without metformin for 48 h. The cells were observed using
phase contrast microscopy at 200× magnification. Scale bar: 50 μm. The data are presented as the mean
± SD of three replicates per group. TGF-β1: transforming growth factor β1; Met: metformin. ** p < 0.01,
* p < 0.05.
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3. Discussion
In this study, we demonstrated that metformin inhibited TGF-β1-induced EMT in proliferation,
migration, and induced apoptosis. Our result suggested that metformin inhibits TGF-β1-induced EMT
via the mTOR/p70s6k/PKM2 signaling pathway in cervical carcinoma cells.
Metformin is an anti-diabetic drug with potential anti-neoplastic action, which decreases the
incidence and progression of multiple human cancers [27,28], and improves patients’ overall survival
rate [29]. For example, in one study, ovarian or endometrial cancer patients with diabetes mellitus,
who were being treated with metformin at the time of diagnosis, exhibited half the risk of mortality
than that of the non-metformin-treated patients [29]. Moreover, metformin decreases hepatocellular
carcinoma risk in a dose-dependent manner [30]. Several studies have also shown that metformin
decreases cancer cell viability by inducing apoptosis in various cancer. Griss et al. reported that
metformin inhibited cancer cell proliferation by suppressing mitochondrial-dependent biosynthetic
activity [31], and metformin could induce breast cancer cell apoptosis [32]. In our study, we observed
that metformin not only induced apoptosis and decreases cancer cell viability, but also reversed the
anti-apoptosis effect of TGF-β1-induced EMT in cervical carcinoma cells. These data suggested the
potential therapeutic implication of metformin for cervical carcinomas.
Recent studies indicated that metformin was a novel TGF-β suppressor with therapeutic potential
for numerous diseases [33]. In our study, we used TGF-β1 to induce EMT and explore the possible
mechanism of metformin that inhibited TGF-β1-induced EMT in cervical cancer. Moreover, metformin
has been reported to inhibit EMT in lung adenocarcinoma [34], hepatocellular carcinoma [35],
and inhibit mTOR signaling. PKM2 involved in tumorigenesis and affected the EMT situation.
Silvestri et al. [36] reported that metformin induced apoptosis and down-regulated PKM2 in breast
cancer cells. These studies showed that the mechanism of metformin may be associated with the
following observations: (1) metformin inhibits mTOR activation by AMPK-dependence in different
cancers [37–39]; (2) mTOR signaling regulates P70S6K signaling in cervical carcinoma cells [40];
(3) metformin induce intrinsic apoptosis via the inhibition of the HIF1α/PKM2 signaling pathway [41];
and (4) metformin is also a poisoner of mitochondria by impairing the function of complex I [42],
leading to the increased aerobic glycolysis as compensation.
The mTOR pathway is a central regulator of glucose metabolism and glycolysis, and is
important in the transcriptional program of glucose transporters and multiple rate-limiting glycolytic
enzymes [43,44]. Meanwhile, the phosphorylation of p70 ribosomal S6 kinase 1 (S6K1), a downstream
effector of mTOR, is modulated by the mTOR pathway [45]. Nobukini et al. reported that the activities
of dS6k and S6K1 are regulated by the mammalian target of rapamycin (mTOR). They found the
mechanisms regulating the mTOR/S6K1 signaling pathway will be fundamental in determining the
mechanisms which control cell growth [46]. Montagne et al. reported that the deactivation of dS6K,
the orthologue of mammalian S6K, is involved in slow overall growth rate and decreased cell size [47].
Consistent with these reports, in our study, we observed that metformin not only induced apoptosis
and decreased cancer cell viability, but also abolished the TGF-β1 induced morphological changes
through the mTOR/p70sk signaling pathway in cervical carcinoma cells.
Next, Hamabe et al. found that PKM2 plays a crucial role in the EMT development of cancer [16].
Recent studies also showed that PKM2 was an important glycolytic enzyme in the oncogenic
mTOR-induced Warburg effect, in which hypoxia inducible factor-1α (HIF-1α) and c-Myc-hnRNP
cascades are the transducers of mTOR regulation of PKM2 [48]. Sun et al. reported that mTOR
up-regulation of pyruvate kinase isoenzyme type M2 plays a crucial role in aerobic glycolysis
and tumor growth. PKM2 expression was augmented in mouse kidney tumors and consequent
mTOR activation, and was reduced by mTOR suppression [48]. These studies illustrated that
there was a correlation between mTOR/p70s6k/PKM2 signaling and EMT. Our data showed that
TGF-β1 significantly increased the expression of PKM2 and phosphorylation of p70s6k, which means
PKM2 and p70s6k are involved in EMT. Rapamycin, a mTOR inhibitor, inhibits the mTOR pathway,
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while p-p70sk6 and PKM2 were decreased. We prove that mTOR/p70s6k/PKM2 signaling is involved
in EMT development.
Based on these studies, we propose that metformin exerts its antitumorigenic effects and
abolished TGF-β1-induced EMT through mTOR/p70s6k/PKM2 signaling in cervical carcinoma
cells. In the present study, we showed that metformin significantly decreased cell proliferation
and migration and reverses EMT in cervical carcinoma cells. More importantly, we demonstrated
that mTOR/p70s6k/PKM2 signaling is the target of metformin. This claim is supported by the
observation that mTOR activity is inhibited by addition of metformin in vitro. Moreover, we found
that the role of metformin inhibit phosphorylation of p70s6k when cervical carcinoma was treated
with metformin. In addition, our results indicated that metformin attenuates the phosphorylation of
p70s6k and PKM2. Metformin reversed TGF-β1-induced epithelial-to-mesenchymal transition via the
mTOR/p70s6k/PKM2 signaling pathway (Figure 8).
Figure 8. Schematic representation of metformin roles in TGF-β1-induced epithelial-to-mesenchymal
transition in cervical carcinoma cells. EMT: Epithelial-to-Mesenchymal Transition; PKM2: Pyruvate
kinase M2; P: STAT3: signal transducer and activator of transcription 3; SNAIL2: snail family
transcriptional repressor 2; P: phosphorylation.
4. Materials and Methods
4.1. Cell Cultures and Treatments
The human cervical carcinoma cell lines HeLa (ATCC® CRM-CCL-2™) and SiHa (ATCC®
HTB-35™) (ATCC, Rockville, MD, USA) were maintained in dulbecco’s modified eagle medium
(DMEM)medium, supplemented with 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin
at 37 ◦C in a humidified environment with 95% air and 5% CO2. Rapamycin (PeproTech, Rocky
Hill, NJ, USA), a specific mTOR inhibitor, was dissolved in dimethylsulfoxide (DMSO) at a stock
concentration of 6.25 mM, and metformin (PeproTech, Rocky Hill, NJ, USA) was dissolved in
phosphate-buffered saline (PBS) at a stock concentration of 50 mM. Both were stored at 4 ◦C.
The cells were treated with 10 ng/mL TGF-β1 (PeproTech, Rocky Hill, NJ, USA) and with or without
10 mM metformin. The cells were collected for migration assay, CCK8 (CCK-8, Dojindo, Tokyo, Japan),
and Western blot. The morphological changes of cells were observed under an inverted microscope.
4.2. Cell Viability Assay
Cell viability was detected by cell counting kit-8 (CCK-8, Dojindo, Tokyo, Japan) assay. Cells were
seeded into 96-well plates at 1 × 104 cells/well and cultured overnight at 37 ◦C. At 24 h after seeding,
the indicated concentrations of metformin, with or without TGF-β1, were added to each well and the
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cells were cultured for an additional 24, 48, and 72 h, respectively. At harvest time 10 μL of CCK-8 was
added into each well and after one hour’s incubation, cell viability was determined by measuring the
absorbance of the converted dye at 450 nm. The experiments were performed in triplicate.
4.3. Wound Healing Assay
A wound healing assay was performed to test cell migration. The cells were plated in six-well
culture plates in complete culture medium and allowed to grow to 90% confluence. An injury line
was made using a 2-mm-wide plastic pipette tip. After washing three times with PBS, the cells were
cultured with fresh serum-free medium containing 10 ng/mL TGF-β1 with or without the indicated
concentration of metformin for 24 h. Subsequently, the ability of the cells to migrate into the cleared
section was observed using a microscope. The migration rate was quantified by (scratch distance
at 0 h—scratch distance at 24 h)/scratch distance at 0 h. Representative images were obtained at
40× magnification. All experiments were repeated at least three times.
4.4. Annexin V-FITC Apoptosis Assay
Cells were seeded in six-well plates at 4 × 105 cells/well and then treated with different
concentrations of metformin, with or without 10 ng/mL TGF-β1 for 24 h. Apoptotic cells were
detected by flow cytometry using an Annexin V-FITC kit according to the instructions.
4.5. Western Blot Analysis
The cells were harvested by centrifugation and washed with PBS. The cells were lysed in RIPA
buffer containing protease inhibitors. Equal amounts of protein were separated by 10% sodium
dodecyl sulfate-polyacrylamide gel electrophoresis and then transferred to Polyvinylidene Fluoride
(PVDF) membranes by electroblotting. The membranes were blocked with 5% nonfat milk in
Tris-buffered saline/0.1% Tween 20 for 1 h at room temperature and then incubated overnight at
4 ◦C with the primary antibodies. The anti-human E-cadherin, anti-human vimentin, anti-human
SNAILl2, anti-human STAT3, and anti-human phospho-p70s6k primary antibodies were purchased
from Cell Signaling Technology (Danvers, MA, USA). The anti-human β-actin primary antibodies
and Horseradish Peroxidase (HRP)-conjugated goat anti-rabbit and HRP-conjugated goat anti-mouse
secondary antibodies were purchased from ZSGB-BIO (Beijing, China). After incubation with the
secondary antibody for 1 h at room temperature, the protein bands were detected using the ECL
detection system (BD Biosciences, New York, NY, USA).
4.6. Statistical Analysis
The statistical analyses were performed using SPSS 19.0 (SPSS Inc., Chicago, IL, USA). The values
are expressed as the means ± SD. Significant differences among groups were analyzed by one-way
analysis of variance (ANOVA). An appropriate post-test has been applied for internal comparisons.
5. Conclusions
To our knowledge, this is the first study showing that metformin could reverse TGF-β1-induced
EMT in tumor cells through mTOR/p70s6k/PKM2 pathways. Collectively, our data showed that
TGF-β1induced proliferation and EMT, and metformin inhibited cell proliferation and reverseed
EMT. The mechanism involved in the suppression of PKM2 activation was mediated by inhibiting
mTOR/p70s6k signaling. Our data provides novel mechanistic insights into the antitumor effects
of metformin.
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Abstract: Cyprodinil (CYP) is a pyrimidine amine fungicide that has been extensively used
in agricultural areas. 3,3′-Diindolylmethane (DIM) is a derivative of the dietary phytoestrogen,
indole-3-carbinol (I3C), which is derived from cruciferous vegetables and considered to be a
cancer-preventive phytonutrient agent. In this study, the effects of CYP and DIM were examined on
the cell viability, invasion, and metastasis of human endometrial cancer cells, Ishikawa, via epithelial
mesenchymal transition (EMT). CYP increased the level of cell viability of Ishikawa cells compared
to DMSO as a control, as did E2. Ishikawa cells lost cell-to-cell contact and obtained a spindle-shaped
or fibroblast-like morphology in response to the application of E2 or CYP by the cell morphology
assay. In the cell migration and invasion assay, CYP enhanced the ability of migration and invasion
of Ishikawa cells, as did E2. E2 and CYP increased the expressions of N-cadherin and Snail proteins,
while decreasing the expression of E-cadherin protein as EMT-related markers. In addition, E2
and CYP increased the protein expressions of cathepsin D and MMP-9, metastasis-related markers.
Conversely, CYP-induced EMT, cell migration, and invasion were reversed by fulvestrant (ICI 182,780)
as an estrogen receptor (ER) antagonist, indicating that CYP exerts estrogenic activity by mediating
these processes via an ER-dependent pathway. Similar to ICI 182,780, DIM significantly suppressed
E2 and CYP-induced proliferation, EMT, migration, and invasion of Ishikawa cancer cells. Overall,
the present study revealed that DIM has an antiestrogenic chemopreventive effect to withdraw the
cancer-enhancing effect of E2 and CYP, while CYP has the capacity to enhance the metastatic potential
of estrogen-responsive endometrial cancer.
Keywords: cyprodinil (CYP); 3,3′-diindolylmethane (DIM); epithelial-mesenchymal transition
(EMT); metastasis
1. Introduction
Phytoestrogens of plant origin, such as plant polyphenols, are xenoestrogens that show
structural similarity to 17β-estradiol (E2), the mammalian steroid hormone [1]. Phytoestrogens
are generally categorized according to four main classes. The first group is isoflavones, such as
daidzein, kaempherol, and genistein, while the second group consists of lignans, such as lariciresinol,
Int. J. Mol. Sci. 2018, 19, 189 173 www.mdpi.com/journal/ijms
Int. J. Mol. Sci. 2018, 19, 189
matairesinol, pinoresinol, and secoisolariciresinol. The third group consists of coumestans, such
as coumestrol, and the last comprises stilbenes, such as resveratrol [2]. Among plant-derived
xenoestrogens, phytoestrogens are primarily found in fruits, soy, and vegetables. Phytoestrogens
are also regarded as sources of cancer-preventive phytonutrient complex because they inhibit the
growth and advance of many types of cancer [3–5]. For example, genistein, a major soy isoflavone, and
3,3′-diindolylmethane (DIM), a derivative of the dietary phytochemical complex, indole-3-carbinol
(I3C), which is derived from cruciferous vegetables, are phytoestrogens known for reducing the risk of
prostate and breast cancer [6,7]. 3,3′-diindolylmethane has been reported to influence the prevention of
estrogen-dependent cancers similar to fulvestrant (ICI 182,780), an estrogen receptor (ER) antagonist [8].
Moreover, the in vitro effects of DIM were shown to inhibit epithelial-mesenchymal transition (EMT)
and metastasis via the estrogen receptor (ER)-dependent pathway [9]. Previous studies have shown
that anti-estrogenic effects of phytoestrogens are implicated in their chemoprevention activity against
estrogen-dependent cancers via the ER-dependent pathway [10–12].
The EMT is an adjusted process that drives epithelial cells to lose their cell-cell and
cell-extracellular matrix (ECM) interactions and to become mesenchymal cells through genetic
reprogramming and cytoskeletal restructuration [13]. The EMT has potential driving forces in the
initiation and development of cancer cells [14]. Moreover, the EMT phenotype has advanced migratory
capacity, invasiveness, and increasing resistance to apoptosis [15]. Cancer cells that undergo EMT
augment the extent of expression of cell motility-related proteins and present improved invasion and
migration to other parts of the whole body, resulting in cancer metastasis [16].
It is generally agreed that estrogen plays a significant role in cancer metastasis. For example,
estrogens and endocrine disrupting chemicals (EDCs) such as benzophenon-1 and nonylphenol spur
metastasis through overexpression of cathepsin D in MCF-7 breast cancer cells via the ER-dependent
signaling pathway [17,18]. As a lysosomal aspartyl protease, cathepsin D is related to the metastasis of
estrogen-dependent cancer cells [19]. In other examples, BP-1 and octylphenol have been found to
induce EMT of BG-1 ovarian cancer cells expressing ERs [20]. In addition, bisphenol compounds can
give rise to EMT of BG1Luc4E2 ovarian cancer cells expressing ERs [21].
Cyprodinil (CYP) is an extensive pyrimidine amine fungicide that is utilized worldwide to protect
fruit plants and vegetables from many types of pathogens [22]. In fungi, this reagent prevents the
biosynthesis of methionine and amino acids of thionic types [23]. CYP gives rise to phosphorylation
of the extracellular signal-regulated kinase (ERK) by which growth factors and transcription factors
are phosphorylated. In mammalian cells, ERK regulates differentiation, migration, proliferation,
and survival [24], and activates ER signaling [25]. A previous study found that CYP as an activator
of aryl hydrocarbon receptor (AhR) and induces AhR-targeted genes, such as cytochrome P450 (CYP)
1A1 in ovarian granulosa cells, HO23, and potentially affects reproductive function through activating
both the AhR and ERK signaling [26]. Additionally, CYP was found to have the potential to affect ER
signaling in our previous study in which it promoted ovarian cancer proliferation via the ER-dependent
pathway [24]. Therefore, it can be estimated that CYP may act as a cellular physiological disrupter in
the human body.
The present study was conducted to investigate the CYP’s action as an endocrine disrupter
by examining its xenoestrogenic effects on cancer cell proliferation, EMT, and metastasis by
using an ER-dependent and estrogen-responsive Ishikawa endometrial cancer cell line, which is
a well-differentiated adenocarcinoma cell line derived from the human endometrial epithelium
that expresses functional ER [27]. In addition, anti-estrogenic and anti-cancer effects of DIM were
investigated using this cancer model.
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2. Results
2.1. Effects of CYP Exposure on Cell Viability of Ishikawa Endometrial Cancer Cells
This experiment was conducted to identify the effects of E2, CYP, and DIM on cell viability
of Ishikawa cells and determine the optimal concentrations of E2, CYP, and DIM for subsequent
experiments. As shown in Figure 1A, E2 (10−9 M) and CYP (10−11–10−6 M) augmented cell
viability when compared with 0.1% DMSO as a control. Moreover, CYP increased cell viability in a
concentration-dependent manner in the concentration range of 10−10–10−6 M, implying that CYP has
an estrogenic effect at these concentrations. Although DIM did not change the cell viability at 10−8,
10−7, or 10−6 M, it inhibited E2- or CYP-induced cell viability when combined with E2 or CYP at
these concentrations (Figure 1B,C). Based on these results, DIM was considered to have anti-estrogenic
activity, contrary to CYP. Among the concentrations of CYP and DIM tested in this experiment, 10−8
and 10−7 M of CYP and DIM, respectively, were selected to evaluate the in vitro effects of each
compound on the processes of EMT and metastasis of Ishikawa cells. Treatment with 10−8 M CYP
increased the cell viability of Ishikawa cells to the same level as E2, a positive control (Figure 1A). DIM
at 10−7 M was selected from 10−8, 10−7, and 10−6 M of DIM tested because there was no change in
E2-induced cell viability at these concentrations (Figure 1C).
Figure 1. Effects of Cyprodinil (CYP) exposure on cell viability of Ishikawa endometrial cancer cells.
Ishikawa cancer cells were treated with 0.1% DMSO as a control, E2 (10−9 M), CYP (10−11–10−5 M),
or 3,3′-Diindolylmethane (DIM) (10−8–10−6 M) for six days, after which the cell viability was measured
by MTT assay. The experiment was repeated three times, and data were reported as the means ± SD.
(A) Effects of E2 and CYP on cell viability. * indicates a significant difference in cell viability by E2 or
CYP compared to the control (p < 0.05 according to Dunnett’s multiple comparison test); (B) Effects of
the mixture of E2 and DIM on cell viability. * shows a significant difference in cell viability by E2 or
DIM compared to the control (p < 0.05 according to Dunnett’s multiple comparison test). # shows a
significant reduction in cell viability in response to E2 + DIM compared to E2 alone (p < 0.05 according
to Dunnett’s multiple comparison test); (C) Effects of the mixture of CYP and DIM. * shows a significant
difference in cell viability in response to E2, DIM, CYP, E2 + DIM, or CYP + DIM compared to the
control (p < 0.05 according to Dunnett’s multiple comparison test). # shows a significant reduction in
cell viability in response to E2 + DIM compared to E2 alone or CYP + DIM compared to CYP alone
(p < 0.05 according to Dunnett’s multiple comparison test).
2.2. Morphological Changes in Ishikawa Cells in Response to Treatment with E2 and CYP in the Presence or
Absence of ICI or DIM
To investigate the induction of EMT, morphological changes in Ishikawa cells in response to
treatment with E2 (10−9 M) and CYP (10−8 M) in the presence or absence of DIM (10−7 M) or ICI 182,780
(10−8 M) were observed. After treatment for 24 h, microscopic analysis showed that Ishikawa cells lost
cell-to-cell contact and developed a spindle- or a fibroblast-like morphology, which is a phenotype
of mesenchymal cells, in response to treatment with E2 and CYP. Conversely, when treatment was
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applied in conjunction with ICI 182,780, or DIM, most Ishikawa cells maintained a cobblestone-like
appearance, which is a typical morphology of epithelial cells (Figure 2). These results indicate that
CYP mediated the induction of the EMT process of Ishikawa cells, similar to E2 via ER; however, DIM
suppressed E2 or CYP-induced EMT process similar to ICI 182,780, an ER antagonist.
Figure 2. Morphological changes in Ishikawa cells in response to treatment with E2 and CYP in the
presence or absence of ICI 182,780 or DIM. Ishikawa cells were cultivated in six-well plates and treated
with E2 (10−9 M), CYP (10−8 M), DIM (10−7 M), or ICI 182,780 (10−8 M) for 24 h. Ishikawa cells were
photographed using a microscope at a magnification of 400×.
2.3. Effects of CYP and DIM on the Expression of EMT Related Genes
The effects of each agent on the protein expressions of EMT-related genes including epithelial
and mesenchymal cell markers were identified through Western blot assay. As shown in Figure 3,
CYP (10−8 M) decreased the protein expression of E-cadherin, a key epithelial marker, by about
50%, which was similar to E2 (10−9 M), and by approximately 80% when compared to DMSO as a
control (Figure 3A,B). Conversely, when ICI 182,780 (10−8 M) or DIM (10−7 M) was administered
in conjunction with E2 (10−9 M) or CYP (10−8 M), the expression of E-cadherin was restored to the
control level. Moreover, CYP (10−8 M) increased the protein expression of N-cadherin and Snail, which
are mesenchymal markers, by about 45%, similar to E2 (10−9 M), which increased N-cadherin and
Snail expression by 53% and 24%, respectively, compared to DMSO (Figure 3A,B). However, when
applied in conjunction with ICI 182,780 (10−8 M) or DIM (10−7 M), the expression of N-cadherin and
Snail returned to the control level. These results indicate that E2 and CYP induced the EMT process
of Ishikawa cells by regulating the protein expression of EMT-related genes, such as E-cadherin,
N-cadherin, and Snail, via the ER-dependent signaling pathway and that DIM inhibited the induction
of the EMT process by neutralizing the effects of E2 and CYP on the protein expression of these genes.
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Figure 3. Effects of E2, CYP, ICI 182,780, and DIM on the expression of EMT related genes. Ishikawa
cells were treated with 0.1% DMSO, E2 (10−9 M), CYP (10−8 M), a mixture of E2 (10−9 M) or CYP
(10−8 M) and ICI (10−8 M), or a mixture of E2 (10−9 M) or CYP (10−8 M) and DIM (10−7 M), respectively,
for 72 h. Total proteins were extracted and analyzed by Western blot. (A) Band images correspond to
E-cadherin, N-cadherin, and Snail proteins. Quantification of bands corresponding to (B) E-cadherin,
(C) N-cadherin, and (D) Snail proteins was conducted using Luminograph II. The experiment was
repeated three times, and data are presented as the means ± SD. a: A significant augmentation or
reduction in expression of each protein by E2 and CYP compared to the control (p < 0.05 according
to Dunnett’s multiple comparison test); b: a significant reduction in the expression of each protein by
the mixture with DIM or ICI and E2 compared to E2 alone (p < 0.05 according to Dunnett’s multiple
comparison test); and c: a significant reduction in expression of each protein by the mixture with DIM
or ICI and CYP compared to CYP alone (p < 0.05 according to Dunnett’s multiple comparison test).
2.4. Suppression of DIM on CYP-Induced Ishikawa Endometrial Cancer Cell Migration
Changes in migration activity of Ishikawa cells treated with E2, CYP, DIM, and ICI 182,780 were
identified by cell scratch assay. After the cells were treated with 0.1% DMSO as a control, E2 (10−9 M),
CYP (10−8 M), DIM (10−7 M), or ICI 182,780 (10−8 M) and scratched using a 1 mL micropipette tip,
wounded areas were photographed at 0, 24, and 48 h. Application of E2 or CYP reduced unrecovered
wound areas in a time-dependent manner when compared to those of the control (Figure 4A), implying
that CYP promoted the migration of Ishikawa cells as did E2.
After Ishikawa cells were treated with a combination of ICI 182,780 (10−8 M) or DIM (10−7 M) and
E2 (10−9 M) or CYP (10−8 M), unrecovered areas were unchanged at 48 h (Figure 4B,C). According to
these results, CYP may induce the migration of Ishikawa cells via the ER-dependent signaling pathway
and DIM can inhibit the E2 or CYP-induced cell migration.
2.5. Suppression of DIM on CYP-Induced Ishikawa Endometrial Cancer Cell Invasion
To check the altered invasion capacity of Ishikawa cells in response to treatment with E2, CYP,
DIM, and ICI 182,780, a transwell assay was conducted. After cells in the upper chamber of a transwell
were treated with E2 (10−9 M) or CYP (10−8 M) for 24 h, the number of Ishikawa cells that moved from
the top chamber to the bottom chamber was significantly augmented (Figure 5). Conversely, when
treated with a mixture of ICI 182,780 (10−8 M) or DIM (10−7 M) and E2 (10−9 M) or CYP (10−8 M),
the number of intruded cells was reduced to the control level (Figure 5A,B). These results indicate that
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CYP enhanced the invasion capacity of Ishikawa cells through an ER-dependent signaling pathway,
as did E2, and that DIM has the capacity to restrain E2 or CYP-induced invasion of Ishikawa cells.
Figure 4. Effects of ICI 182,780 or DIM on E2- or CYP-induced Ishikawa endometrial cancer cell
migration. Cells were treated with (A) 0.1% DMSO, E2 (10−9 M), CYP (10−8 M), (B) a mixture of E2
(10−9 M) or CYP (10−8 M) and ICI (10−8 M), or (C) a mixture of E2 (10−9 M) or CYP (10−8 M) and
DIM (10−7 M), respectively, then scratched with a 1 mL micropipette tip. The images presenting the
recovery of wounded area were captured at 0, 24, and 48 h using a microscope at a magnification of
40×. The percentage of the wound recovery area at each time point was calculated. The experiment
was repeated three times, and data are presented as the means ± SD. *: Mean values were significantly
differentiated from 0 h of each treatment, p < 0.05 (Dunnett’s multiple comparison test).
Figure 5. Effects of ICI 182,780 or DIM on E2- or CYP-induced Ishikawa endometrial cancer cell
invasion. Ishikawa cells (1 × 105 cells) were cultured in transwells with the bottom surface covered
with fibronectin in each well of a 24-well plate for 24 h. Cells were treated with 0.1% DMSO, E2
(10−9 M), CYP (10−8 M), a mixture of E2 (10−9 M) or CYP (10−8 M) and ICI (10−8 M) or a mixture
of E2 (10−9 M) or CYP (10−8 M) and DIM (10−7 M), respectively, for 24 h. The cells attached to the
bottom surface of the transwell were fixed with 10% formalin solution and stained with crystal violet.
(A) The stained cells were detected under a microscope, and (B) the number of invading cells was
counted. The experiment was repeated three times, and data were presented as the means ± SD.
*: Mean values were significantly different from 0.1% DMSO (control), p < 0.05 (Dunnett’s multiple
comparison test). #: Mean values of the mixture of ICI 182,780 or DIM and E2 and the mixture of
ICI 182,780 or DIM and CYP were significantly reduced from E2 or CYP alone (p < 0.05 according to
Dunnett’s multiple comparison test).
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2.6. Effects of CYP and DIM on the Expression of Metastasis Related Genes
To clarify the effects of E2 and CYP on protein expression of metastasis-related genes, such as
Cathepsin D and MMP-9, a Western blot assay was conducted. In cells treated with CYP (10−8 M),
the protein expression of Cathepsin D and MMP-9 increased by 67% (Cathepsin D) and by 79%
(MMP-9), similar to E2 (10−9 M; 47% for Cathepsin D and 55% for MMP-9) compared to a control
(Figure 6). Conversely, when cells were co-treated with ICI 182,780 (10−8 M) or DIM (10−7 M),
the expression of Cathepsin D and MMP-9 was restored to the control level (Figure 6A–C). These results
indicate that the metastasis of Ishikawa cancer cells may be induced by E2 or CYP through increased
expression of Cathepsin D and MMP-9 protein in Ishikawa cells via the ER-dependent signaling
pathway, and that DIM can suppress the metastatic potential of Ishikawa cells.
Figure 6. Effects of E2, CYP, ICI 182,780, and DIM on the expression of metastasis related genes.
Ishikawa cells were treated with 0.1% DMSO, E2 (10−9 M), CYP (10−8 M), a mixture of E2 (10−9 M)
or CYP (10−8 M) and ICI (10−8 M), or a mixture of E2 (10−9 M) or CYP (10−8 M) and DIM (10−7 M),
respectively, for 72 h. Total proteins were extracted and analyzed by Western blot. (A) Band images
correspond to Cathepsin D and MMP-9 proteins. Quantification of bands corresponding to (B)
Cathepsin D and (C) MMP-9 proteins was conducted using Luminograph II. The experiment was
repeated three times, and data are presented as the means ± SD. a: significant augmentation or
reduction in expression of each protein by E2 and CYP compared to the control (p < 0.05 according
to Dunnett’s multiple comparison test); b: significant reduction in expression of each protein by the
mixture with DIM or ICI and E2 compared to E2 alone (p < 0.05 according to Dunnett’s multiple
comparison test); and c: significant reduction in expression of each protein by the mixture with DIM or
ICI and CYP compared to CYP alone (p < 0.05 according to Dunnett’s multiple comparison test).
3. Discussion
Cancer metastasis, which is the spread of cancer cells by a cancerous tumor within the body,
is the primary cause of cancer mortality [28]. In the initiation step of the metastatic process, EMT
enables tumor cells to acquire migratory and invasive capabilities through the formation of motile
characteristics [28,29]. In estrogen-dependent cancers, E2 was found to increase the metastatic potential
by inducing EMT, migration, and invasion of cancer cells via the ER-dependent pathway [21,30,31].
In this regard, EDCs having estrogenic activity are also implicated with cancer progression and
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metastasis of estrogen-dependent cancers [30,32]. As typical EDCs, bisphenol A, and nonylphenol
were reported to enhance the EMT process and migration of ovarian cancer cells via the ER-dependent
pathway [12]. Conversely, phytoestrogens exerted anti-metastatic effects by inhibiting EMT, migration
and the invasion of estrogen-responsive cancer cells, which is associated with their anti-estrogenic
activity. For instance, genistein suppressed E2-induced EMT and the migration of ER-positive
BG-1 ovarian cancer cells [33]. Moreover, kaempferol restrained E2-induced EMT and the metastatic
behaviors of ER-positive MCF-7 breast cancer cells [10].
In the present study, we investigated the concurrent effects of CYP as an EDC and DIM as a
phytoestrogen on the cell viability, migration, and invasion capacities of Ishikawa endometrial cancer
cells that are estrogen responsive. A cell viability assay showed that treatment with E2 (10−9 M) or
CYP (10−10–10−6 M) increased the level of cell viability of Ishikawa cells. In addition, E2 (10−9 M)
and CYP (10−8 M) changed the cell morphology of Ishikawa cells from a cobblestone appearance,
which is a typical morphology of epithelial cells, to a spindle-shaped morphology or a fibroblast-like
morphology, which is typical of mesenchymal cells in the ER-dependent pathway. In the present study,
ER dependency of E2 and CYP was identified by co-treatment with ICI 182,780, an ER antagonist, which
counteracted the effects of E2, as well as CYP. In addition, E2 and CYP decreased the protein expression
of E-cadherin, but increased the expression of N-cadherin and Snail. E-cadherin as a typical epithelial
cell marker is a transmembrane protein that is responsible for the adherens junction [34]. During the
progression of invasive carcinoma, E-cadherin loss is permitted for a crucial stage causing the EMT
event [35]. However, N-cadherin and Snail as mesenchymal cell markers assign an invasive capacity
for metastasis to the cancer cells [36–38]. Over-expression of N-cadherin is associated with an invasive
capacity of breast tumor by increasing the interactions between tumor cells and stromal cells [39].
Based on the ability to induce the EMT process, E2 and CYP were found to promote the migration and
invasion of Ishikawa cancer cells and to increase the protein expression of metastasis-related genes,
such as Cathepsin D and MMP-9 [40,41], in the ER-dependent pathway. Therefore, these results indicate
that CYP may induce metastatic processes of endometrial cancer cells including EMT, migration, and
invasion, similar to E2. In our previous study, CYP was found to enhance cell cycle progression and cell
migration in an estrogen-responsive ovarian cancer model in an ER signaling-dependent manner [24].
On the contrary, when DIM was co-treated with E2 or CYP, DIM withdrew E2 and CYP-induced
cell viability, EMT, migration, and invasion of Ishikawa endometrial cancer cells, even at the low
concentration of 10−7 M. This effect of co-treatment of DIM was similar to that of co-treatment of
ICI 182,780 with E2 or CYP, indicating that DIM, as a phytoestrogen, has an anti-estrogenic activity
that is associated with its anti-metastatic potential to suppress E2 or CYP-induced metastasis of
estrogen-dependent endometrial cancer. A previous study reported that dietary I3C, a precursor
substance of DIM, prevents the development of estrogen-enhanced cancers as a negative regulator
of estrogen [42]. As anti-estrogens, I3C and DIM are known to have anti-tumorigenic properties by
targeting ER-alpha (ER-α), and DIM was more effective than I3C at depressing mRNA expression of
ER-α in MCF-7 breast cancer cells [43]. Additionally, in a study using thyroid cancer model, DIM was
found to inhibit E2-induced proliferation and clone formation of cancer cells in a similar fashion to ICI
182,780 and act as an anti-estrogen by possibly targeting E2-ER signaling pathways [44]. Although the
more detailed mechanism for anti-estrogenic properties of DIM in connection with its anti-EMT and
anti-metastatic potential in endometrial cancer was not identified in the present study, DIM was found
to suppress endometrial cancer metastasis by abrocating the effects of E2 and CYP in a similar way
to anti-estrogen.
In summary, as shown in Figure 7, CYP was shown to work as a xenoestrogen by stimulating
an increase in cell viability of Ishikawa cells. Moreover, CYP promoted the ability of metastasis of
Ishikawa cells by causing the EMT process, cell migration, and invasion through the regulation of
E-cadherin, N-cadherin, and Snail as EMT-related markers and Cathepsin D, as well as MMP-9,
as metastasis-related markers through the pathway of the ER-dependent signaling. Therefore,
the present study indicated that CYP is a risk factor for endometrial cancer progression through
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activating ER signaling. Conversely, DIM was shown to act as an anti-cancer agent by mimicking
the function of ICI 182,780 as an ER-antagonist by reducing the cancer progression effect of
endogenous estrogen and exogenous EDCs. However, more studies are needed to elucidate the
molecular mechanisms underlying the two conflicting effects of CYP and DIM revealed in endometrial
cancer progression.
 
Figure 7. Suppressive behaviors of DIM on E2- or CYP-induced EMT and metastasis of Ishikawa
cells. CYP was presented by acting as xenoestrogens via acceleration of the proliferation of
estrogen-responsive Ishikawa endometrial cancer cells. CYP also enhanced EMT, migration,
and invasion of Ishikawa cells by regulating EMT-related genes, such as E-cadherin, N-cadherin, and Snail,
as well as metastasis-related genes, including Cathepsin D and MMP-9 in an ER-dependent manner,
as did E2. Conversely, DIM was found to significantly suppress E2 and CYP-induced proliferation,
EMT, migration, and invasion of Ishikawa cancer cells, implying that while CYP has the capacity to
enhance the metastatic potential of estrogen-responsive endometrial cancer, DIM has an anti-estrogenic
chemopreventive effect that withdraws the cancer-enhancing effect of E2 and CYP (⊥; decrease or
inhibit, arrows; increase or promote).
4. Materials and Methods
4.1. Reagents and Chemicals
17β-estradiol (E2), CYP, and DIM were purchased from Sigma-Aldrich Corp. (St. Louis, MO, USA),
while fulvestrant (ICI 182,780) was purchased from Tocris Bioscience (Avon, Bristol, UK). All chemicals
were dissolved in 100% dimethyl sulfoxide (DMSO; Junsei Chemical Co., Tokyo, Japan) and stored at
room temperature.
4.2. Cell Culture and Media
The Ishikawa cell line was obtained from E.B. Jeung (College of Veterinary Medicine, Chungbuk
National University, Cheongju, Chungbuk, Korea). Ishikawa cells were cultivated in Dulbecco’s
modified Eagle’s medium (DMEM; HyClone Laboratories Inc., Logan, UT, USA) replenished with 10%
heat-inactivated fetal bovine serum (FBS; RMBIO, Missoula, MT, USA), 2% penicillin, streptomycin
(Capricorn Scientific, Ebsdorfergrund, Germany), and 1% HEPES (Thermofisher Scientific, Waltham,
MA, USA) at 37 ◦C in a humidified atmosphere of 95% air-5% CO2. To exclude estrogenic components
from DMEM and FBS, phenol red-free DMEM with 5% charcoal-dextran processed FBS (CD-FBS) was
utilized to cultivate Ishikawa cells and to estimate the estrogenicity of EDCs. The CD-FBS was made in
the laboratory as follows. Approximately 40 mL of distilled water (DW) was added to 2.2 g of charcoal
in a 50 mL conical tube (SPL Life Science, Seoul, Korea), mixed strongly, and centrifuged at 300 rpm for
5 min. After dropping DW into the tube, 40 mL of the new DW was added. This process was repeated
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20 times, after which the DW was discarded and 0.22 g of dextran was added to the tube. Next, 40 mL
of DW was added and centrifuged for 5 min at 300 rpm with strong inverting. After discarding all DW
in the tube, 40 mL of new DW was added. This process was repeated 20 times. Once clear, all DW
was discarded. Next, 42 mL of inactivated FBS was added and the samples were inverted strongly.
Samples were then filtered twice with a 0.22 μm bottle filter (Millipore, Billerica, MA, USA), after
which they were stored at −20 ◦C until use. Ishikawa cells were cultured in phenol red-free DMEM
with 5% CD-FBS for conducting the diverse assays tested in the present study. The cells were detached
with 0.05% Trypsin-EDTA (Life Technologies, Carlsbad, CA, USA).
4.3. Cell Viability Assay
A cell viability assay was conducted to estimate the influence of E2, CYP, and DIM on Ishikawa
cell proliferation. Ishikawa cells were implanted in 96-well plates (SPL Life Science) at a density of
3 × 103 cells per well at 37 ◦C in a humidified atmosphere supplemented with 5% CO2. For 48 h,
the cells were cultivated in phenol red-free DMEM with 5% CD-FBS. Samples were then treated with
diverse concentrations of E2, CYP, or DIM (E2: 10−9 M, CYP: 10−11–10−5 M, or DIM: 10−8–10−6 M)
in phenol red-free DMEM with 5% CD-FBS for six days. The media were switched, replaced with
identical new media every two days during this period. When adding chemicals to the media, 0.1%
DMSO was utilized as a vehicle. Cell viability was detected by the addition of EZ-cytox (DOGEN,
Cheongju, Chungbuk, Korea). Briefly, EZ-cytox solution diluted 1:10 was added to each well of a
96-well plate, after which samples were incubated for 90 min at 37 ◦C in a humidified atmosphere
supplemented with 5% CO2. The optical density (OD) per well was monitored at 450 nm using an
Epoch (BioTek, Winooski, VT, USA) to determine the number of viable cells.
4.4. Protein Extraction and Western Blot Assay
Ishikawa cells were cultivated in 100 mm dishes to a density of 1.0 × 106 cells, then treated
with 0.1% DMSO (control), E2 (10−9 M), CYP (10−8 M), DIM (10−7 M), or ICI 182,780 (10−8 M) or
combinations of ICI 182,780 (10−8 M) and E2, CYP or DIM. After treatment with chemicals, the proteins
from Ishikawa cells were yielded with RIPA lysis buffer (pH 8.0, 50 mM Tris-HCl; 0.1% SDS, 0.5%
deoxycholic acid, 1% NP-40, and 150 mM NaCl). Total protein concentrations were measured through
utilization of bicinchoninic acid (BCA; Sigma-Aldrich Corp.). Briefly, proteins on 10% SDS-PAGE gel
were transferred to a polyvinylidene fluoride (PVDF) membrane (BioRad Laboratories, Hercules, CA,
USA). The membrane was then cultivated with primary antibody (Table 1) at 4 ◦C overnight. Primary
antibody binding was identified using horseradish peroxidase (HRP) conjugated with secondary
antibody (anti-rabbit lgG (H + L) or goat anti-mouse lgG (H + L); 1:5000 dilution, BioRad Laboratories).
Aimed proteins were detected using WSE-7120 EzWestLumi plus (ATTO, Motoasakusa, Taito-ku,
Tokyo, Japan). Individual proteins were quantified by scanning the band density on a transfer
membrane using Lumino Graph II (ATTO).
Table 1. Antibodies utilized in this study.
Protein Company Cat No. Description Dilution Ratio
E-cadherin Abcam Ab15148 Rabbit pAb 1:500
Occludin Santa Cruz Sc-5562 Rabbit pAb 1:1000
N-cadherin Abcom Ab98952 Mouse mAb 1:2000
Snail Cell signaling 3895S Mouse mAb 1:1000
Cathepsin D Abcam Ab75852 Rabbit mAb 1:2000
MMP-9 Abcam Ab76003 Rabbit mAb 1:1000
GAPDH Abcam Ab8245 Mouse mAb 1:2000
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4.5. Effects of E2, CYP, or DIM on Ishikawa Cells Morphology
Ishikawa cells were seeded into 6-well plates, then treated with E2 (10−9 M), CYP (10−8 M),
or combinations of ICI 182,780 (10−8 M) or DIM (10−7 M) and E2 or CYP for 24 h. Before and after
treatment, samples were viewed under a microscope (Olympus IX-73 Inverted Microscopy, Olympus,
Tokyo, Japan) at 400× magnification.
4.6. Scratch-Wound Healing Assay
Ishikawa cells were cultivated in six-well plates at 37 ◦C in a humidified atmosphere
supplemented with 5% CO2 until over 70% confluent (approximately 1.0 × 10−6 cells). Monolayers
of Ishikawa cells implanted in wells were scratched to the same width and length using a 1 mL
micropipette tip, then treated with media including 5% CD-FBS with 0.1% DMSO as a control, E2
(10−9 M), CYP (10−8 M), DIM (10−7 M), or ICI 182,780 (10−8 M), or a combination of E2 (10−9 M),
CYP (10−8 M), DIM (10−7 M), or ICI 182,780 (10−8 M), respectively, then incubated for 48 h. In each
treatment group, the images were viewed under 40× magnification using an Olympus IX-73 Inverted
Microscope (Olympus).
4.7. Data Analysis
All experiments were repeated at least three times, and the data were analyzed using the
Graph-pad Prism software (San Diego, CA, USA). Data were presented as the means ± SD and
statistically analyzed as one-way analysis of variance (ANOVA) followed by Dunnett’s multiple
comparison test. p-Values < 0.05 were regarded as statistically significant.
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Abstract: With the growing interest in the use of nanoparticles (NPs) in nanomedicine, there is
a crucial need for imaging and targeted therapies to determine NP distribution in the body after
systemic administration, and to achieve strong accumulation in tumors with low background in other
tissues. Accumulation of NPs in tumors results from different mechanisms, and appears extremely
heterogeneous in mice models and rather limited in humans. Developing new tumor models in
mice, with their low spontaneous NP accumulation, is thus necessary for screening imaging probes
and for testing new targeting strategies. In the present work, accumulation of LipImageTM 815,
a non-specific nanosized fluorescent imaging agent, was compared in subcutaneous, orthotopic and
metastatic tumors of RM1 cells (murine prostate cancer cell line) by in vivo and ex vivo fluorescence
imaging techniques. LipImageTM 815 mainly accumulated in liver at 24 h but also in orthotopic
tumors. Limited accumulation occurred in subcutaneous tumors, and very low fluorescence was
detected in metastasis. Altogether, these different tumor models in mice offered a wide range of
NP accumulation levels, and a panel of in vivo models that may be useful to further challenge NP
targeting properties.
Keywords: prostate cancer; fluorescence imaging; bioluminescence imaging; fluorescence
tomography; enhanced permeability and retention (EPR) effect; LipImageTM
1. Introduction
New probes for tumor imaging and local therapies are an important clinical need. Currently,
clinical developments are mainly based on new radionuclides for positron emission tomography
(PET). However, there is growing interest in nanoparticles (NPs), because they offer various specific
properties, including high surface-to-volume ratio, high surface energy, and a wide range of additional
mechanical, thermal, electrical, magnetic, and optical properties [1–3]. NPs further offer possibilities to
combine several contrast agents for multimodal imaging, to be decorated with various biological and
chemical moieties and to cargo therapeutic agents.
Determining the distribution of nanocarriers within the body following systemic administration
in order to achieve high accumulation of NPs in tumors with low background in other tissues is the
major challenge for nanomedicine. NP characteristics have an impact on their pharmacokinetics [4,5],
and longer plasmatic half-life favors higher accumulation within the tumor. Such accumulation of NPs
in tumors results from different mechanisms, either specific or nonspecific, and involves different cell
populations, including cancer and stroma cells [6,7].
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The enhanced permeability and retention (EPR) effect [8,9] has been suggested to be the major
underlying mechanism of passive NP accumulation in tumors. The EPR effect, although efficient
in mice, appears to be extremely heterogeneous—or possibly totally ineffective—in humans [10,11],
resulting in low or no accumulation of NPs in human tumors. Since the EPR effect fails in the clinic,
new tumor models with low spontaneous NP accumulation are required to screen imaging probes and
to test new targeting strategies.
Fluorescent imaging on mice models is a convenient way to initiate the screening process of
NP-based imaging probes and to provide key information about NP properties. Although in vivo
fluorescence imaging does not discriminate between the different mechanisms involved in NP
accumulation in tumors, it allows for rapid evaluation of the overall targeting efficiency [12]. In order
to develop new tumor models in mice, the aim of the present work is to study NP accumulation
for a single tumor cell line according to different tumor locations. For this purpose, RM1, a murine
prostate cancer cell line, was used at different implantation sites to generate subcutaneous, orthotopic
and metastatic tumors. LipImageTM 815, a non-specific nanosized (80-nm diameter) fluorescent
imaging agent, was injected intravenously to compare NP accumulation in the various tumor locations
and types.
2. Results
2.1. In Vivo Imaging of LipImageTM 815 in Mice Bearing RM1-Subcutaneous Tumors
RM1-CMV/Fluc cells were injected subcutaneously (2 × 106 cells/100 μL) into the posterior right
leg of the mice (n = 3). One week after injection of cells, tumors were monitored by bioluminescence
imaging (BLI) (Figure 1A). LipImageTM 815 was then injected into the mice (14 × 1012 particles) via
the tail vein and could be monitored by live fluorescence imaging (Figure 1B and Video S1).
 
Figure 1. In vivo detection of LipImageTM 815 accumulation in subcutaneous tumors. (A) Bioluminescence
image (BLI) of a representative mouse; (B) Fluorescence reflectance imaging (FRI) of a representative mouse
at different time after LipImageTM 815 injection; (C) FRI of a representative mouse 6 h and 24 h after
LipImageTM 815 injection, respectively; (D) Ex vivo BLI and FRI of mouse organs 24 h after LipImageTM
815 injection.
The fluorescent signal was immediately detectable in vasculature, and within a few seconds in
the kidney. Hyper-vascularization revealed by instant fluorescence reflectance imaging (FRI) was
the first indication of the presence of a tumor on the right leg (Video S1). After 1 h, (Figure 1B), the
fluorescent signal had accumulated in the liver and in the tumor. At 6 h and 24 h, both instant FRI
(Figure 1B) and dark box FRI (Figure 1C) revealed a high fluorescent signal resulting from LipImageTM
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815 accumulation in the subcutaneous tumors and in the liver, with limited background fluorescence
in other tissues. As shown in Figure S1, LipImageTM 815 accumulation did not interfere with the
BLI signal, which increased as the tumor grew. Mice were euthanized 24 h after LipImageTM 815
injection, and organs were imaged by BLI and FRI (Figure 1D). BLI revealed the presence of tumor
cells exclusively in the tumor sample. Quantification of FRI signal for ex vivo samples is expressed
as photons·s−1·cm−2·sr−1. The highest fluorescent signal from LipImageTM 815 was found in the
liver (1.47 × 1010 ± 3.14 × 109 ph·s−1·cm−2·sr−1; n = 3). Lower levels were detected in the tumor
(4.55 × 109 ± 4.22 × 108 ph·s−1·cm−2·sr−1; n = 3), but also in the intestines, kidneys, lungs and spleen.
2.2. In Vivo Imaging of LipImageTM 815 in Mice Bearing RM1-Prostate Tumors
RM1-CMV/Fluc cells (5 × 105/10 μL per lobe) were injected into prostate lobes during open
surgery (n = 5). Tumor growth was monitored by BLI (Figure 2A). Four days after surgery, LipImageTM
815 was injected into the mice (14 × 1012 particles) via the tail vein, and the fluorescence signal
was followed by FRI and Fluorescence molecular tomography (FMT) 6 and 24 h after injection.
As shown in Figure 2B, FRI revealed a fluorescence signal on the ventral face in regions corresponding
to the location of the liver and prostate. FMT provided 3D images of the fluorescent signals in
the prostate (Figure 2C) and allowed quantification (Figure 2D). Mice were sacrificed 24 h after
LipImageTM 815 injection, and the excised prostates were immediately imaged by BLI (Figure 3A)
and FRI (Figure 3B). The fluorescent signal from LipImageTM 815 corresponded to the BLI signal
from RM1 cells. The fluorescence signal from LipImageTM 815 in the RM1 tumors was quantified
(1.65 × 1010 ± 4.22 × 108 ph·s−1·cm−2·sr−1; n = 5). Prostates were further processed for histology.
Hematoxylin-eosin-safran (HES) staining (Figure 3C) revealed cancer cells and NIR microscopy
(Figure 3D) revealed the presence of the NIR fluorophore.
Figure 2. In vivo detection of LipImageTM 815 accumulation in orthotopic prostate tumors.
(A) Bioluminescence image of a representative mouse; (B) FRI and (C) FMT of a representative
mouse 6 h and 24 h after LipImageTM 815 injection; (D) FMT-based quantification of LipImageTM 815
accumulation in the prostate tumor. Mean ± standard deviation.
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Figure 3. Ex vivo imaging and histology of LipImageTM 815 accumulation in prostate tumors. Prostates
were excised and imaged (A) by BLI and (B) by FRI; (C) HES coloration revealed tumor cells and (D)
epifluorescence revealed fluorescent signals from LipImageTM 815 in prostate cancer cryosection.
2.3. In Vivo Imaging of Metastasis with LipImageTM 815
Intra-cardiac echography-guided injection of RM1-CMV/Fluc cells (105/100 μL) in the left ventricle
(Video S2) resulted in metastatic dissemination. First metastasis was able to be detected by BLI as
soon as 7 days after cells injection (Figure S3; but in the present work, mice were assayed 13 days after
injection (Figure 4A,B) (n = 11). Six (Figure 4A; n = 6) and 24 h (Figure 4B; n = 5) after LipImageTM 815
intravenous injection, the main fluorescence location detected was in the liver, but other locations were
also detected without a consistent fit with BLI metastasis location (Figure 4A,B, 1st column).
 
Figure 4. In vivo detection of metastasis. BLI and FRI after LipImageTM 815 injection of 2 representative
mice bearing metastatic tumors. Images were taken (A) 6 h or (B) 24 h after LipImageTM 815 injection
first in vivo (column 1), then in euthanized and open mice (column 2). Individual organs were removed
and observed by BLI and FRI (columns 3–5). 1: kidneys, 2: prostate, 3: testicles, 4: splenic tumor,
5: heart, 6: intestines, 7: lungs, 8: stomach, 9: liver, 10: posterior legs, 11: anterior legs.
189
Int. J. Mol. Sci. 2017, 18, 2584
Mice were sacrificed 6 or 24 h after LipImageTM 815 injection. The peritoneal cavity was opened
and the skin was removed before BLI and FRI. Again, the liver remained the most fluorescent organ
detected (Figure 4A,B, 2nd column). Organs and regions exhibiting a BLI signal were dissected
and imaged for BLI and FRI (Figure 4A,B, columns 3–5). Apart from the legs (bone metastasis),
the fluorescent signal of NPs did not match the metastatic locations as revealed by BLI. As shown
on Figure 5, organs such as the liver and kidneys exhibited high background fluorescence signals
throughout the entire organ, and did not exhibit enhancement related to the location of cancer cells.
For other organs, such as the stomach or testicles, the fluorescence background was low, and hot
spots of fluorescent signal perfectly fitted with metastatic locations revealed by BLI. Nevertheless,
the fluorescence level in metastasis remained low, irrespective of location, nearing the background
level at 2.31 × 109 ± 1.44 × 109 ph·s−1·cm−2·sr−1 (n = 11).
Figure 5. Ex vivo imaging of LipImageTM 815 accumulation in organs containing metastasis. BLI
revealed the tumor location and FRI revealed LipImageTM 815 accumulation 6 h or 24 h after
intravenous injection. In the kidneys and liver, LipImageTM 815 resulted in a disperse fluorescence
signal without detectable accumulation in the metastasis; while in the stomach and testicles,
fluorescence coincided with metastasis location. The FRI display scale is identical for all images.
2.4. Ex Vivo Quantification of LipImageTM 815 Accumulation in Tumors and Organs
Quantification of fluorescence signals in tumors and organs from mice bearing subcutaneous
tumors, orthotopic tumors, or metastasis was assessed by FRI ex vivo and the data plotted (Figure 6).
The highest fluorescence level from LipImageTM 815 at 24 h was found in healthy livers and orthotopic
tumors. The fluorescence level in orthotopic tumors was very high compared with subcutaneous
tumors, which was, in turn, higher than metastasis. The fluorescence level in metastasis was very low;
lower than the fluorescence level in healthy organs.
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Figure 6. Quantification of fluorescent signal in organs ex vivo, 24 h after intravenous LipImageTM 815
injection. Mean ± standard deviation, (n) = number of mice.
3. Discussion
Using a single murine prostate cancer cell line (RM1), via different routes, to generate various types
of tumors (orthotopic, subcutaneous and metastatic), a constant dose of NPs and a wide panel of in vivo
and ex vivo fluorescence imaging techniques, we demonstrated here that the non-specific labeling
pattern varied according to tumor type. LipImageTM 815 accumulation was highly predominant in
orthotopic tumors when compared with subcutaneous tumors and disseminated metastasis.
RM1 is a mouse prostate cancer cell line syngenic in C57BL/6 mice [13]. It was genetically
modified to produce a constitutive Fluc reporter gene and to make in vivo detection by BLI possible,
even for small or deep tumors in mice. The BLI signal was not only used to follow tumor growth, but
also to compare BLI and fluorescence imaging patterns. As luciferase activity requires oxygen and
intraperitoneal injected luciferin (MW = 280 D) as a substrate, the BLI signal further confirms that the
tumors are not hypoxic, and are properly vascularized. RM1 tumors are very fast-growing, providing
significant orthotopic prostate tumors in 4 days, subcutaneous tumors in 7 days, and metastasis in
13 days. Thus, the present RM1 models provided a complete panel of different tumor types exhibiting
different levels of NP accumulation, making wide screening of NPs possible in a short period of time.
On the other hand, the rapid growth of RM1 tumors is not favorable for long term studies, as tumors
rapidly reached ethical endpoints. Finally, as RM1 is syngenic in C57BL/6 mice, the tumors grew in a
microenvironment more representative of the clinical physio-pathological context. The rapid growth
of RM1 tumors is a convenient feature for experimental purposes, but clearly diverges from a human
tumor growth rate that may influence tumor properties. In the current work, however, the level of NP
accumulation in RM1 tumors is not correlated with growing time.
Present data showed that the level of NP accumulation in a tumor was not a characteristic of the
tumor cells, but involved other parameters, including tumor location. As a limitation of the present
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study, the different tumor locations required different implantation methods, which may influence NP
accumulation. For metastasis, however, the fluorescence level is low, irrespective of location.
The fluorescent signal in tumors may result from several mechanisms, including retention
in extracellular space, binding to or internalization in tumor cells, and tumor microenvironment
components [6,7]. Variations in NP accumulation in tumors are often attributed to variations in EPR
effect. The EPR effect results from hyper-permeability of the tumor blood vessels and dysfunction
of intra-tumoral lymphatics drainage; the first mechanism enables nanoparticles to enter the tumor
interstitial space, while the second one allows particles to stay in the tumor for a longer time [14].
In the present work, solid evidence that accumulation results from a true EPR effect is lacking.
Vascularization is a key parameter for NP accumulation in different tumors types; but in the present
work, no information—such as pericytes coverage or fenestration sizes—is available. Regardless
of the mechanism involved, our results confirmed that the resulting non-specific accumulation of
NPs in tumors is highly variable. Conversely, accumulation found in some other normal tissues
demonstrates that these mechanisms are no more efficient within metastasis or subcutaneous tumors
than in healthy tissues.
LipImageTM 815 NPs (50 nm) have previously been characterized for their optical and
pharmacokinetic characteristics [15], and have been shown to display a long shelf life, as well as
colloidal and optical stabilities, with high brightness and strong and long accumulation in subcutaneous
tumors in mice [15]. Injection of these NPs in immunodeficient Swiss nude mice with implanted human
prostate cancer PC3 resulted in strong and long-term fluorescent labeling of the tumor [15], but data are
lacking concerning NP stability. LipImageTM 815 NPs (80 nm) also accumulated in RM1 subcutaneous
tumors at 24 h, but their long-term residence could not be confirmed, as tumors grew very quickly,
requiring rapid euthanasia of the mice. The post-mortem analysis of individual organs excised 24 h
post NP injection showed high accumulation in the liver, but the fluorescent signal in the tumor was
about 4 times less, and was not clearly different from those in organs such as the kidneys, intestines or
spleen. As subcutaneous tumors grew on the surface, fluorescence from NP accumulation was easily
detected, and changes in the fluorescence signal could be quantified. That makes this model quite
attractive, as small chemical modifications in NPs induced changes in NP accumulation in the tumor
that could be easily monitored by FRI [12].
RM1 orthotopic tumors are deep in the body and thus detection of the fluorescence signal was
impaired by photon absorption by the tissues. However, a deep tumor location is more favorable
for fluorescence tomography, and FMT allowed for fluorescence detection and absolute in-depth
quantification. Both in vivo and ex vivo imaging methods confirmed high levels of accumulation
of LipImageTM 815 in RM1 orthotopic tumors. Because they grow in an original microenvironment,
orthotopic tumors are relevant from a physio-pathological point of view; but, as they exhibit a high
level of passive NP accumulation, they behave quite differently from the clinical context.
LipImageTM 815 accumulation in disseminated metastasis is low at 24 h. Combined with
in-depth localization, the fluorescence signal is not detectable by in vivo fluorescence imaging. Tumor
localization is made possible by BLI, and a fluorescence signal is detectable by ex vivo FRI only in
organs with low background. The low level of LipImageTM 815 accumulation in RM1 metastasis may
be relevant for screening new strategies dedicated to circumventing EPR failures currently reported in
a clinical context [16].
The choice of animal model necessary for rapid and extensive evaluation of NPs requires
improvement towards a more clinically-relevant model for imaging probe evaluation. As illustrated
by this study using LipImageTM 815, even when using a single NP and a single cell line, non-specific
accumulation clearly depends on a lot of factors, including tumor type and location. Other factors, such
as tumor size, injection routes, doses and injection scheme, may further influence NP accumulation.
Although it is not wholly representative of the clinical context, each tumor type may be useful for
challenging NP properties.
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4. Materials and Methods
4.1. Animal Handling and Tumor Generation
Animal manipulations, approved by the local ethical committee (CEEA 50) under agreement
A50120196, were performed in agreement with French and European directives on the care and use of
animals. B6 Albino (B6N-Tyrc−Brd/BrdCrCrl) mice (6- to 8-weeks-old) were maintained in standard
conditions under a 12-h light/dark cycle with water and food provided ad libitum at the University
of Bordeaux animal facilities. Manipulations were performed on anesthetized animals using 2%
isoflurane (Belamont, Nicholas Piramal Limited, London, UK) in air.
Orthotopic tumors were induced by cell injection within the prostate on anesthetized mice.
The skin and the abdominal muscles were incised by a short section and the seminal glands were
pulled back outside the body. Cells (5 × 105/10 μL per lobe) were injected in the two dorsal prostate
lobes and the seminal glands returned to the abdomen. The incision was then closed with sutures.
Metastasis was induced by intra-cardiac cell injection (1 × 105/100 μL) in the left ventricle with
ultrasound guidance on anesthetized mice. Subcutaneous tumors were generated by cell injection
(2 × 106/100 μL) in the posterior right leg. Before the imaging session, regions to be imaged were
shaved with clippers and depilatory cream. LipImageTM 815 (31.5 μM of NIR fluorophore) were
injected via the tail vein. After in vivo imaging, organs were removed from euthanized mice and
placed in cold phosphate-buffered saline (PBS) in a petri dish and imaged ex vivo.
4.2. LipImageTM 815 Synthesis and Characterization
The IR780-lipid dye was first synthetized [15]. An oil premix with, respectively, 85, 255, and 65 mg
of oil, Suppocire NB™ (Gattefosse S.A., Saint-Priest, France) and lecithin was prepared. IR780-lipid dye
solution (10 mg/mL; 200 μL) in ethanol was poured into a 5-mL vial and mixed with the oil premix
melted at 50 ◦C. The mixture was homogenized and the solvent was then evaporated under argon flux.
After homogenization at 50 ◦C, the continuous aqueous phase, composed of 345 mg of MyrjTM S40
(Croda Uniquema; Chocques, France) and the appropriate amount of aqueous solution (154 mM NaCl
qs 2 mL), was introduced. The mixture was placed in a water bath at 50 ◦C and was then sonicated
for 5 min using a VCX750 Ultrasonic processor (power output 190 W, 3-mm probe diameter, Sonics).
LipImageTM 815 solution was dialyzed against 1000 times their volume in the appropriate aqueous
buffer overnight at room temperature (12 to 14,000 Da MW cut off membranes, ZelluTrans, Carl Roth,
France). The nanoparticle dispersion was finally sterilized by filtration through a 0.22 μm Millipore
membrane. Size distribution of LipImage™ 815 was measured with a Zetasizer (Nano ZS, Malvern
instrument, Worcestershire, UK) (Figure S2). The number of particles was calculated by dividing the total
volume of lipids (total mass of oil, wax, lecithin and PEG assuming an overall density of 1.05 g·cm−3)
divided by the individual volume of LipImageTM 815 nanoparticles (size = 74.4 nm; Figure S2).
4.3. Cell Line Generation and Culture
Murine prostate cancer cell line RM1, initially obtained from Dr. T.C. Thompson (Baylor
College of Medicine, Houston, TX, USA), was genetically engineered for constitutive expression
of firefly luciferase (RM1-CMV/Fluc) as previously described [12], and was maintained in Dulbecco’s
modified Eagle’s medium (Invitrogen, Carlsbad, CA, USA) supplemented with 10% fetal bovine serum
(Invitrogen), 1% antimycotic-antibiotic mix (PSA, Invitrogen) and blasticidin (10 μg/mL, Euromedex,
Souffelweyersheim, France). Cell line was maintained in a humidified 5% CO2 incubator at 37 ◦C.
4.4. Bioluminescence Imaging (BLI)
BLI was performed at Vivoptic (UMS 3767—Univ. Bordeaux) using Lumina LT (Perkin Elmer Inc.,
Boston, MA, USA). Mice received an intra-peritoneal injection of D-luciferin (2.9 mg in 100 μL PBS,
Promega, Madison, WI, USA), and were anesthetized 5 min later. Bioluminescence images (1 min,
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4 × 4 binning) and photographs (100 ms) were acquired successively 8 min after D-luciferin injection.
Images acquisition and analysis were performed using Living Image software.
4.5. Fluorescence Reflectance Imaging (FRI)
FRI was performed using the Lumina LT apparatus (Perkin Elmer, Boston, MA, USA) with the
745 nm excitation filter and the 810–875 nm emission filter. Fluorescence images (1 s, 4 × 4 binning)
and photographs (100 ms) were acquired successively, and analyzed using Living Image software. FRI
signal is expressed as photons·s−1·cm−2·sr−1.
FRI was also performed using the per-operatory camera system Fluobeam® (Fluoptics, Grenoble,
France) at a spectral window of excitation of 780 nm and with an emission of 820 nm. The image was
analyzed using Image J software.
4.6. Fluorescence Molecular Tomography (FMT)
Mice were imaged in a Fluorescence Molecular Tomograph (FMT®) 4000 (Perkin Elmer, Boston,
MA, USA). Scanning was performed using the 745 channel, and the fluorescence signal was filtered
with the 770–800 nm filter emission. The images were reconstructed and analyzed using the
TrueQuant software.
4.7. Histology and Microscopic Imaging
Tumors were frozen and stored at −80 ◦C. Tumor slices (10 μm) were obtained, fixed with 4%
paraformaldehyde (10 min, room temperature), and hematoxylin-eosin-safran staining was performed.
LipImageTM 815 fluorescence detection was performed using Leica DM 5500 microscope fitted with
pE-100 (Ex 770 nm) Cool LED and a indocyanine (775/845 nm) filter (Leica Microsystems, Wetzlar,
Germany).
Supplementary Materials: Supplementary materials can be found at www.mdpi.com/1422-0067/18/12/2584/s1.
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Abstract: The downregulation of tight junction protein CLDN6 promotes breast cancer cell migration
and invasion; however, the exact mechanism underlying CLDN6 downregulation remains unclear.
CLDN6 silence is associated with DNA methyltransferase 1 (DNMT1) mediated DNA methylation,
and DNMT1 is regulated by the transforming growth factor beta (TGFβ)/SMAD pathway. Therefore,
we hypothesized that TGFβ/SMAD pathway, specifically SMAD2, may play a critical role for CLDN6
downregulation through DNA methyltransferase 1 (DNMT1) mediated DNA methylation. To test
this hypothesis, we blocked the SMAD2 pathway with SB431542 in two human breast cancer cell
lines (MCF-7 and SKBR-3). Our results showed that treatment with SB431542 led to a decrease of
DNMT1 expression and the binding activity for CLDN6 promoter. The methylation level of CLDN6
promoter was decreased, and simultaneously CLDN6 protein expression increased. Upregulation
of CLDN6 inhibited epithelial to mesenchymal transition (EMT) and reduced the migration and
invasion ability of both MCF-7 and SKBR-3 cells. Furthermore, knocked down of CLDN6 abolished
SB431542 effects on suppression of EMT associated gene expression and inhibition of migration
and invasion. Thus, we demonstrated that the downregulation of CLDN6 is regulated through
promoter methylation by DNMT1, which depends on the SMAD2 pathway, and that CLDN6 is a key
regulator in the SMAD2/DNMT1/CLDN6 pathway to inhibit EMT, migration and invasion of breast
cancer cells.
Keywords: CLDN6; DNMT1; methylation; SMAD2; breast cancer
1. Introduction
Claudins (CLDNs) are small transmembrane proteins, and 27 members have been identified for
this protein family [1–3]. Claudin 6 (CLDN6) is a component of tight junctions (TJs), which maintain
cell–cell junctions in epithelial cell sheets. In previous studies, we demonstrated that CLDN6 mitigated
the malignant phenotype of MCF-7 breast cancer cells, and the expression of CLDN6 was undetectable
or at low levels in human breast cancer cells [4]. Similarly, silencing of CLDN6 enhanced migration
ability of the human breast epithelium cell line HBL-100 [5]. Epithelial to mesenchymal transition
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(EMT) is one of the mechanisms of tumor migration and invasion [6–8]. During the initial stage of
EMT, the expression of epithelial genes is suppressed, whereas mesenchymal marker expression is
increased [9]. We believe that CLDN6 may inhibit migration and invasion of cancer cells via EMT
suppression. However, the exact mechanism underlying CLDN6 downregulation remains unclear.
DNA methyltransferases (DNMTs) lead to ectopic methylation and gene silencing. De novo
methylation is established by DNA methyltransferase 3 alpha (DNMT3A) and DNA methyltransferase
3 beta (DNMT3B) in early development. Once established, the methylation patterns are faithfully
maintained by DNA methyltransferase 1 (DNMT1) [10,11]. Our previous study showed that CLDN6
silencing in breast cancer cells was associated with DNMT1 mediated DNA methylation [12].
Furthermore, DNMT1 is regulated by transforming growth factor (TGF)β/SMADs pathway. In this
pathway, TGFβ regulates the transcription of downstream genes via the translocation of SMAD2/3
into the nucleus and then the formation of transcriptional complexes [13]. Therefore, we hypothesize
that SMAD2 plays a critical role in regulating the expression and activity of DNMT1, the upregulation
of which leads to CLND6 promoter hypermethylation and downregulation of CLDN6 expression,
which promote EMT and enhancesmigration and invasion ability of breast cancer cells. Our results
presented in current study provided evidence in support of the above hypothesis.
2. Results
2.1. SMAD2 Signaling Suppresses CLDN6 in MCF-7 and SKBR-3 Cells
To understand the mechanisms by which CLDN6 is regulated, we used SB431542, which
efficiently inhibits the activity of activated activin receptor-like kinase 4 (ALK4), ALK5, and ALK7
to phosphorylate SMAD2, to inhibit the activity of SMAD2 [14,15]. As shown in Figure 1, dose
dependent and time dependent effects of SB431542 on the reduction of P-SMAD2 were observed.
In both MCF-7 and SKBR-3 cells, the optimal concentration of SB431542 was 10 μM (Figure 1A,C), and
the optimal time was 24 h (Figure 1B,D). In all of the following experiments, 10 μM SB431542 was used
for 24 h. Simultaneously, substantial increases of CLDN6 protein was observed in a dose and time
dependent manner, which is very well correlated with the decrease of SMAD2 phosphorylation levels
(Figure 1A–D). We also examined the phosphorylated SMAD3 proteins in the two cell lines by Western
blot analysis (Figure 1E). Similarly, P-SMAD3 was also considerably downregulated by SB431542.
These results suggest that SMAD pathways regulate the expression of CLDN6, and inactivation of
SMAD2/3 proteins restore CLDN6 expression in breast cancer cells.
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Figure 1. SB431542 inactivated SMAD2 signaling, and suppressed CLDN6 in MCF-7 and SKBR-3
cells. (A–D) SB431542 downregulated P-SMAD2 expression in a time- and dose-dependent manner.
SB431542 treatment increased CLDN6 and decreased P-SMAD2. (A,C) MCF-7 and SKBR-3 cells were
incubated with SB431542 for 24 h at the indicated concentrations. (B,D) MCF-7 and SKBR-3 cells were
incubated with SB431542 at 10 μM for the indicated time (E) P-SMAD3 expression was decreased
by SB431542 treatment. Immunoblot analysis was used to determine the expression of P-SMAD2,
CLDN6, and P-SMAD3. Results of densitometry analysis of relative expression levels of P-SMAD2 and
P-SMAD3 after normalization to SMAD2 and SMAD3 and CLDN6 expression levels after normalization
to loading control β-actin are presented (* p < 0.05 and ** p < 0.01 are considered statistically significant
and highly statistically significant, respectively). Bars represent mean ± SE (n = 3).
2.2. SMAD2 Downregulated CLDN6 through DNA Methyltransferase 1 (DNMT1) Mediated Methylation
In order to determine whether SMAD2 suppresses CLDN6 expression through DNMT1 mediated
methylation, we measured the changes in DNMT1 levels and activity and CLDN6 expression in
MCF-7 and SKBR-3 cells after SB431542 treatment. As expected, addition of SB431542 to these
cells decreased the expression of DNMT1 and increased the expression of CLDN6 at both mRNA
and protein levels (Figure 2A,B), and the activity of DNMT1 was also decreased by 63.76 and
57.14% in MCF-7 and SKBR-3 cells, respectively (Figure 2C). To determine whether SB431542 altered
the methylation status of the CLDN6 promoter, we performed methylation-specific PCR (MSP) analysis
and demonstrated a decrease in methylation specific regions of CLDN6 promoter in MCF-7 and
SKBR-3 cells treated with SB431542 (Figure 2D). We also measured CpG island methylation within
the CLDN6 promoter region −300 bp~+200 bp by bisulfite sequencing PCR and found that DNA
demethylation occurred at the CLDN6 promoter following SB431542 treatment (Figure 2E). To validate
the impact of SB431542 on CLDN6 promoter demethylation by targeting DNMT1, we performed
the chromatin immunoprecipitation (ChIP) assay to detect changes in the binding of DNMT1 to
the CLDN6 promoter after treatment with SB431542. Consistent with our previous observation [12],
DNMT1 bound to the CLDN6 promoter and enhanced its methylation. More importantly, SB431542
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treatment substantially reduced the binding ability of DNMT1 to the CLDN6 promoter (Figure 2F).
Thus, our results suggest that SMAD2 may regulate CLDN6 through DNMT1 mediated methylation.
Figure 2. DNA methyltransferase 1 (DNMT1)-mediated upregulation of CLDN6 expression by
SB431542. (A,B) Real-time polymerase chain reaction (RT-PCR) and immunoblot analysis of DNMT1
and CLDN6, and densitometric analysis of relative gene expression levels after normalization to loading
controls GAPDH and β-actin are presented. (C) DNMT1 activity assays. (D) Methylation-specific
PCR (MSP) analysis of CpG island of CLDN6 promoter using bisulfite-treated genomic DNA isolated
from MCF-7 and SKBR-3 cells. (E) CpG island methylation within the CLDN6 promoter region was
measured by bisulfite sequencing in SKBR-3 cells. “Me” stands for methylated, and “U” stands for
unmethylated. (F) Chromatin immunoprecipitation-polymerase chain reaction (ChIP-PCR) assay to
detect the binding of DNMT1 to the promoter of CLDN6 (** p < 0.01). The lane “M” stands for marker;
bars represent mean ± SE (n = 3).
2.3. Inactivation of SMAD2 Suppressed Epithelial to Mesenchymal Transition (EMT) and Inhibited Migration
and Invasion of Breast Cancer Cells
To explore the outcome of SMAD2 inactivation on CLDN6 regulation, we first detected cellular
morphological alterations after treatment with SB431542. It is known that CLDN6 participates in
cellular TJ formation and TJ stability [16]. Thus, downregulation of CLDN6 could lead to a more
invasive phenotype in cancer cells. Indeed, after SB431542 treatment, cell migration and invasion were
examined and significant inhibition of both migration and invasion were found in SB431542 treated
breast cancer cells; 38.54 and 35.92% migration reduction and 72.84 and 77.01% cells invasion inhibition
were observed for MCF-7 and SKBR-3 cells, respectively (Figure 3A,B). To investigate the mechanism
by which migration and invasion were inhibited, we examined the changes in EMT associated genes
in MCF-7 and SKBR-3 cells after treatment with SB431542. SNAIL, vimentin, and N-cadherin were
found to be downregulated, while E-cadherin was upregulated at both mRNA (Figure 3C) and protein
(Figure 3D,E) levels following SB431542 treatment. Therefore, inactivation of SMAD2 upregulated
CLDN6 suppressed EMT, and subsequently inhibited the migration and invasion of breast cancer cells.
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Figure 3. DNMT1-regulated CLDN6 expression inhibited tumor cell migration and invasion by
blocking epithelial to mesenchymal transition (EMT). (A) Representative light microscope images
of wound-healing assays for MCF-7 and SKBR-3 cells after treatment with or without SB431542
to evaluate their migration rate into the cell-free area (bar, 200 μm). (B) Matrigel invasion assay.
Cells that invaded through the Matrigel were stained with Giemsa and counted. All results are
presented as the average of cells counted in 10 fields per condition (bar, 50 μm). (C) RT-PCR; and
(D) Western blotting analysis was used to determine the expression of EMT-related genes (SNAIL,
E-cadherin, N-cadherin, and vimentin) in MCF-7 and SKBR-3 cells. Results of densitometric analysis
of relative expression levels after normalization to loading control GAPDH or β-actin are presented.
(E) Immunofluorescence analysis of the expression levels of EMT markers in MCF-7 and SKBR-3 cells.
Representative immunofluorescence images (200×) generated using anti-E-cadherin, anti-N-cadherin,
and CLDN6 primary and FITC-conjugated secondary antibodies in the breast cancer cells. Blue, cell
nuclei were stained with 4,6-diamidino-2-phenylindole. Localization of E-cadherin, N-cadherin, and
CLDN6 (red) at the cell–cell junctions is indicated by white arrows (bar, 20 μm). ** p < 0.01. Bars
represent mean ± SE (n = 3).
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2.4. Deregulation of CLND6 Is Necessary for SMAD2 Induced EMT and Tumor Cell Migration and Invasion
The observations that SB431542 upregulated CLDN6, inhibited EMT, and suppressed migration
and invasion led us to ask whether SB431542 induced cellular phenotype changes were mediated by
CLDN6. Knocking down CLDN6 by shRNA (Figure 4A) leads to morphological change of MCF-7 cells
into a spindle-shaped cells, but morphological change is not obvious in SKBR-3 cell line (Figure 4B).
Furthermore, knocking down CLDN6 abrogated SB431542 mediated inhibition of migration and
invasion, as measured by wound healing and transwell migration assays (Figure 4C,D), as well as
suppressed the expression of EMT associated genes (Figure 4E–G). Thus, CLDN6 is the key regulator
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(b)
Figure 4. CLDN6 was required to inhibit EMT and tumor migration and invasion. Cells were
stimulated with 10 μM SB431542 for 24 h. (A) RT-PCR and immunoblot expression analyses
of CLDN6 in MCF-7-shGFP, MCF-7-shCLDN6, SKBR-3-shGFP, and SKBR-3-shCLDN6 cells, and
densitometric analysis of relative expression levels after normalization to loading control GAPDH or
β-actin are presented. (B) The effect of knocking down CLDN6 on cell morphology of SB431542
treated MCF-7 and SKBR-3 cells (bar, 100 μm). (C) Representative light microscope images of
wound-healing assays for MCF-7 and SKBR-3 cells treated with SB431542 to evaluate the impact
of CLDN6 on their migration rate into the cell-free area (bar, 200 μm). (D) Matrigel invasion assay.
Cells that invaded the Matrigel were stained with Giemsa and counted. All results are presented
as the average of cells counted in 10 fields per condition (bar, 50 μm). Results of: (E) RT-PCR; and
(F) Western blotting analyses to determine the impact of CLDN6 on the expression of EMT-related
genes (SNAIL, E-cadherin, N-cadherin, and vimentin) in MCF-7and SKBR-3 cells treated with SB431542,
and densitometric analysis of relative gene expression levels after normalization to the loading
control GAPDH or β-actin are presented. (G) Immunofluorescence analysis to evaluate the impact of
CLDN6 on the expression levels of EMT markers in MCF-7 and SKBR-3 cells treated with SB431542.
Representative immunofluorescence images (200×) generated using anti-E-cadherin, anti-N-cadherin,
and CLDN6 primary and FITC-conjugated secondary antibodies in the breast cancer cells. Blue, cell
nuclei were stained with 4,6-diamidino-2-phenylindole. Localization of E-cadherin, N-cadherin, and
CLDN6 (red) at the cell–cell junctions is indicated by white arrows (bar, 20 μm). ** p < 0.01. Bars
represent mean ± SE (n = 3).
3. Discussion
In earlier studies, we found that CLDN6 overexpression inhibited the migration and invasion of
MCF-7 cells in vitro [4], while the expression of CLDN6 was undetectable or low in several human
cancer cells [17,18]. The exact mechanism leading to CLDN6 downregulation, however, remains
unclear. We and others also demonstrated that the silencing of CLDN6 was linked to DNMT1 mediated
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DNA methylation [12], and that DNMT1was regulated by TGFβ/SMADs pathways [19,20]. DNMT1
possesses a unique capability of identifying the hemimethylated portion of newly replicated DNA.
This feature might explain why DNMT1 mediated methylation could be an epigenetic mechanism
maintaining the status quo [21,22]. It has been shown that DNMT1 maintains DNA methylation and
results in the silencing of tumor suppressor genes [23,24]. Biniszkiewicz and colleagues reported
that increased DNMT1 activity led to hypermethylation of CpG islands both in vivo and in vitro [25].
Hypermethylation of CpG islands is also frequently observed in cancer and has been shown to be
involved in the silencing of tumor suppressor genes [26]. A recent report showed that DNMT1 plays
a key role in the regulation of CLDN4 and CLDN7 by means of the SMAD signaling pathway [19].
Expression of CLDNs epithelial cells is a dynamic equilibrium pattern, high expression of some CLDN
member proteins leads to a low expression of other members of the CLDN family [27]. We also found
that, compared to immortalized breast epithelial cell line HBL-100, SMAD2 showed a higher expression
in breast cancer cells, whereas CLDN6 had a lower expression level in these cells.
In the current study, we aimed to explore the mechanism by which upstream signaling
downregulates CLDN6 during mammary cancer progression. The two different breast cancer cell
lines used, MCF-7 and SKBR-3, are luminal subtypes of metastatic adenocarcinoma. The MCF-7 cell
line is estrogen receptor (ER)+, progesterone receptor (PR)+, and ERBB2/HER2−, while the SKBR-3
cell line is ER−, PR−, and ERBB2/HER2+ [28]. After treating the two breast cancer cell lines
with SB431542, a TGFβ type I receptor inhibitor that specifically inhibits SMAD2 and SMAD3
phosphorylation [14,29,30], which leads to down regulation of DNMT1 and upregulation of CLDN6.
Furthermore, both DNMT1 enzyme activity and capacity to CLNDN6 promoter were reduced,
and simultaneously, the CLDN6 promoter methylation status also decreased significantly. We also
measured CpG island methylation within the CLDN6 promoter region by bisulfite sequencing and
found that DNA demethylation occurred at the CLDN6 promoter following SB431542 treatment.
Our data demonstrated that, in breast cancer cells, the low expression of CLDN6 was regulated by
DNMT1 mediated methylation, which was in turn regulated by the SMAD2 pathway.
Similar to our current results, CLDN6 has been found to be silenced by methylation in esophageal
squamous cell carcinoma [31]. Besides DNA methylation, CLDN6 also can be regulated by histone
modification [32]. Furthermore, in our previous study, we demonstrated that DNA methylation
of CLDN6 enhanced breast cancer cell migration and invasion by recruiting methyl CpG binding
protein 2 (MeCP2) and deacetylating histone 3 acetylation (H3Ac) and histone 4 acetylation (H4Ac) [12].
Our current study, we showed that DNMT1 could directly regulate CLDN6 through binding to its
promoter region. Papageorgis and colleagues showed that DNMT1 played a key role in the regulation
of CLDN4 and CLDN7 via the SMAD2 signaling pathway and that the depletion of SMAD2 led
to a significant decrease in the amount of DNMT1 bound to the promoter of the target genes, but
it did not decrease the expression level of DNMT1 [19], which is different with our current results.
Furthermore, SMAD pathways and many major signaling pathways, including those involving Wnt
and extracellular signal–regulated kinase (ERK)/Mitogen-activated protein kinase (MAPK), have been
reported to be involved in DNA methylation [20,33–36].
CLDNs are the main components of TJs, which have barrier and fence functions and maintain
cell polarity, cell adhesion, and cell signal transduction [37,38], and dysfunction of TJs was found
to be closely related to tumor development, e.g., CLDN6 overexpression inhibited the migration
and invasion of MCF-7 cells in vitro [4]. One of the mechanisms of migration and invasion in
epithelium-derived carcinoma was EMT [39] which led to the loss of epithelial cell adhesion and
the induction of a mesenchymal phenotype [40,41]. Recent reports have shown that EMT, which is
characterized by the loss of epithelial markers such as E-cadherin and the induction of mesenchymal
markers, including vimentin, N-cadherin, and fibronectin [42], plays a pivotal role in breast cancer
progression [43–45]. In the present study, CLDN6 expression in breast cancer cells was upregulated
by SB431542 treatment, and, subsequently, the invasion and migration were suppressed, along with
the upregulation of epithelial marker E-cadherin and the downregulation of mesenchymal markers
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SNAIL, N-cadherin, and vimentin. Thus, we demonstrated that CLDN6 inhibited invasion and
migration by reversing EMT.
Consistent with our data, CLDN3, CLDN4 [46], and CLDN7 [47] have been shown to suppress
EMT in ovarian carcinoma cells and lung cancer cells. However, CLDN1 suppressed E-cadherin and
subsequently induced EMT in hepatocellular carcinoma cells [48]. The levels of CLDN3 and CLDN4
were frequently elevated in pancreatic adenocarcinoma, ovarian cancer, endometrioid adenocarcinoma,
and prostate cancer [49–52], while CLDN7 has been found to be decreased in invasive ductal
carcinomas of the breast [53]. This can be attributed to tissue and cell specificity of expression
and distribution of CLDNs, which is the main reason for different TJ functions in different types of
epithelial tissues [54]. Similarly, the distribution of CLDNs differs greatly in different structures within
the same organization [55,56].
TGFβ was first described as an EMT inducer in normal mammary epithelial cells [57] and
has been recognized as an EMT master regulator in different cell types [40]. In the current study,
we demonstrated that SB431542 inhibited EMT and suppressed migration and invasion of MCF-7
and SKBR-3 cells by upregulating CLDN6 but not the direct effect of inactivation of TGFβ/SMAD
pathway. To verify this assumption, we knocked down CLDN6 in SB431542-treated MCF-7 and
SKBR-3 cells and found knocking down CLDN6 abrogated the inhibitory effects of SB431542 on EMT,
migration and invasion of breast cancer cells, indicating CLDN6 is the key regulator downstream of
the SMAD2/DNMT1/CLDN6 pathway. CLDN6 is also an epithelial marker, which was upregulated
when EMT was inhibited. It may be confused whether EMT was suppressed before the upregulation
of CLDN6. The results in Figure 4 demonstrated that CLDN6 was upregulated and then suppressed
EMT in SB431542-treated MCF-7 and SKBR-3 cells.
In conclusion, SMAD2 downregulated CLDN6 via DNMT1 mediated DNA methylation to
promote EMT, thereby accelerating the migration and invasion of breast cancer cells.
4. Materials and Methods
4.1. Cell Culture and Reagents
The human breast cancer cell lines MCF-7 and SKBR-3 were obtained from the Cell Bank of
the Chinese Academy of Sciences (Shanghai, China) and maintained in DMEM (Gibco, Carlsbad, CA,
USA) supplemented with 10% fetal bovine serum (Hyclone, Logan, UT, USA) and 100 units/mL
penicillin and streptomycin (Invitrogen, Carlsbad, CA, USA). All the cell lines were grown in
a humidified incubator at 37 ◦C and 5% CO2. SB431542 was purchased from Sigma (St. Louis,
MO, USA).
4.2. Reverse Transcription Polymerase Chain Reaction
Total RNA was extracted from cells using TRIzol (Invitrogen) following the manufacturer’s
instructions. One microgram of total RNA was subjected to reverse transcription to synthesize cDNA
using Moloney murine leukemia virus reverse transcriptase (TaKaRa, Osaka, Japan) at 42 ◦C for 1 h,
and 0.5 μg cDNA was used for PCR. SMAD2, CLDN6, DNMT1, SNAIL, E-cadherin, and N-cadherin
were amplified along with glyceraldehyde-3-phosphate dehydrogenase (GAPDH) as an endogenous
control following the instructions of the Premix LA Taq Kit (TaKaRa). The PCR conditions and primer
sequences are shown in Table 1. After electrophoresis, the gel was imaged and analyzed by an imaging
system (Syngene, Cambridge, UK).
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Table 1. Details of primers used for real-time polymerase chain reaction (RT-PCR), methylation-specific
PCR (MSP), and chromatin immunoprecipitation (ChIP) analyses.











































4.3. Western Blotting Analysis
Western blotting analyses were performed as described previously [12]. Anti-P-SMAD2, SMAD2,
P-SMAD3, SMAD3, and vimentin antibodies were purchased from Cell Signaling Technology (Beverly,
MA, USA); E-cadherin and SNAIL antibodies were from Bioworld Technology (Dublin, OH, USA);
and N-cadherin, DNMT1, and CLDN6 antibodies were from Abcam (Cambridge, UK). The anti-β actin
antibody was obtained from Santa Cruz (Santa Cruz, CA, USA). Primary and secondary antibodies
were diluted to 1:1000. The blots were stained using an ECL Western blotting system (GE, Fairfield,
CT, USA).
4.4. Immunofluorescence
An immunofluorescence assay was performed to evaluate expression as previously described [58].
Cells were incubated with primary antibodies against CLDN6 (1:400), E-cadherin (1:400), and
N-cadherin (1:250) at 4 ◦C overnight. The secondary antibody was Alexa Fluor 647 anti-mouse IgG
(1:200 dilution; Cell Signaling Technology, Beverly, MA, USA). Cells were visualized with a fluorescence
microscope (Olympus, Tokyo, Japan).
4.5. DNA Methylation Analysis
MSP based on bisulfite conversion was performed. Genomic DNA from cells was isolated using
the DNA extraction kit (Qiagen, Valencia, CA, USA), and the methylSEQr™ Bisulfite Conversion Kit
(Applied Biosystems, Grand Island, NY, USA) was used for sodium bisulfite treatment of the genomic
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DNA according to the manufacturer’s protocol. MSP primers were designed with the aid of the Methyl
Primer Express v1.0 software (Applied Biosystems, Lincoln, CA, USA) (Table 1). PCR products were
purified from 1.5% agarose gels using a Gel Extraction Kit (Qiagen) and cloned into the pGEM-T Easy
vector (Promega, Madison, WI, USA). Five randomly selected clones from each sample were chosen
for sequencing.
4.6. DNA Methyltransferase 1 (DNMT1) Activity Assays
Nuclear protein was isolated using the Nuclear Protein Extraction Kit (BSP009;
GeneChem Co. Ltd., Shanghai, China). The DNMT1 Activity Assay Kit (GMS50080; GenMed,
Plymouth, MN, USA) was used for detection of DNMT1 activity according to the manufacturer’s
protocol. Replicates of each sample (20 μg nucleoprotein, including blank and positive control) were
analyzed to validate the signal generated. The DNMT activity data were presented as OD/h/mg.
4.7. Wound Healing Assays
Cells (1 × 106) were grown overnight in 60 mm dishes to reach confluency, and a wound was
introduced using a Q tip. Images were obtained using a microscope (Olympus) at 0 and 24 h after
wounding to determine the width of the wounded area. The relative migration distance (percent of
recovery) was calculated as (W0 − W24)/W0 × 100% (W0 indicates wound width at 0 h, and W24
indicates wound with at 24 h).
4.8. Matrigel Invasion Assays
Matrigel invasion assays were performed using Transwells containing 8.0 μm pore membranes
(Corning, Lowell, MA, USA). MCF-7 and SKBR-3 cells were placed in the upper chamber of
the Transwell, and 48 h later, the chambers were washed twice with phosphate buffer solution (PBS).
The filter side of the upper chamber was cleaned with a cotton swab. Next, the membrane was cut out
of the insert. Cells were fixed in methanol and stained with 5% Giemsa for 30 min at room temperature.
4.9. Chromatin Immunoprecipitation Assay
Chromatin immunoprecipitation (ChIP) assay was performed using the EZ Magna ChIP
G Chromatin Immunoprecipitation kit (Millipore, Billerica, MA, USA) using chromatin isolated
from 1 × 106 cells per condition, according to the manufacturer’s protocol. Antibodies included
anti-DNMT1 (1:500, Cell Signaling Technology), anti-IgG (Millipore), and anti-DNA polymerase II
(Millipore); anti-IgG was the negative control and anti-DNA polymerase II was the positive control.
4.10. Transfection With Short Hairpin RNA
Cells were transfected with short hairpin RNA (shRNA) by using Lipofectamine 2000
(Invitrogen), following the procedure recommended by the manufacturer. shRNA targeting of
CLDN6 (5’-GTGCAAGGTGTACGACTCA-3’) and a negative control shRNA were purchased from
GeneChem Co. Ltd.
4.11. Statistical Analysis
All computations were carried out using the SPSS version 19.0 for Windows (SPSS Inc., Chicago,
IL, USA). Unpaired t-tests were performed to evaluate data for target mRNA and protein. The data
are presented as means ± standard error from at least three independent experiments. p < 0.05 was
considered statistically significant.
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Abstract: Metastatic breast cancer (BC) (also referred to as stage IV) spreads beyond the breast to the
bones, lungs, liver, or brain and is a major contributor to the deaths of cancer patients. Interestingly,
metastasis is a result of stroma-coordinated hallmarks such as invasion and migration of the tumor
cells from the primary niche, regrowth of the invading tumor cells in the distant organs, proliferation,
vascularization, and immune suppression. Targeted therapies, when used as monotherapies or
combination therapies, have shown limited success in decreasing the established metastatic growth
and improving survival. Thus, novel therapeutic targets are warranted to improve the metastasis
outcomes. We have been actively investigating the cytochrome P450 4 (CYP4) family of enzymes that
can biosynthesize 20-hydroxyeicosatetraenoic acid (20-HETE), an important signaling eicosanoid
involved in the regulation of vascular tone and angiogenesis. We have shown that 20-HETE can
activate several intracellular protein kinases, pro-inflammatory mediators, and chemokines in cancer.
This review article is focused on understanding the role of the arachidonic acid metabolic pathway in
BC metastasis with an emphasis on 20-HETE as a novel therapeutic target to decrease BC metastasis.
We have discussed all the significant investigational mechanisms and put forward studies showing
how 20-HETE can promote angiogenesis and metastasis, and how its inhibition could affect the
metastatic niches. Potential adjuvant therapies targeting the tumor microenvironment showing
anti-tumor properties against BC and its lung metastasis are discussed at the end. This review will
highlight the importance of exploring tumor-inherent and stromal-inherent metabolic pathways in
the development of novel therapeutics for treating BC metastasis.
Keywords: breast cancer metastasis; cytochrome P450; 20-HETE
1. Introduction
Breast cancer (BC) is composed of multiple subtypes with distinct morphologies and clinical
implications. Histologically, BC can be classified according to tissue morphology into ductal and
tubular types, which are further divided into benign or invasive subtypes [1]. Additionally, four major
molecular categories are used to classify BC according to their steroid hormone receptor status and
the presence or absence of the human epidermal growth factor receptor 2 (HER2). The luminal A
subtype is characterized by the presence of an estrogen receptor (ER) and/or progesterone receptor
(PR); luminal B is ER+ and/or PR+ and HER2+. The HER2-enriched tumors are positive for HER2+
expression and negative for both steroid hormone receptors. The basal-like or triple-negative breast
cancer (TNBC) subtype is negative for all three receptors. Other molecular classifications can be used to
complement distinctive gene and protein expression signatures such as claudin (low or high), Ki67 rates,
or mesenchymal and epithelial marker status to predict personalized treatment and prognosis for BC
patients. The percentage of each subtype presenting clinically, as well as their associated prognosis,
is summarized in Table 1.
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Remarkably, these molecular subtypes are strongly associated with survival: luminal A tumors
have the most favorable prognosis; luminal B, HER2-positive, and basal-like tumors are associated
with the shortest relapse-free and overall survival rates [13]. Molecular subtypes also predict
treatment response, with HER2-positive and TNBC tumors being more sensitive to preoperative
chemotherapy than the luminal tumors [14]. BC has a propensity for distant metastasis to the bones,
lungs, brain, and liver [15–18]. Bone metastasis is the first most common site of distant spread,
having the longest median survival duration of about two to five years. However, patients with
brain metastasis (BM) have the shortest survival of around four to seven months [16,19,20]. It has
been reported that up to 15–30% of metastatic BC patients will eventually develop BM during
the course of the disease [21,22]. Luminal A and B subtypes have a low risk of BM, of 2–9%
and 4–10%, respectively [20,23,24], while HER2-enriched and TNBCs exhibited high rates of brain,
lung, bone, and distant nodal metastases of 15–30%, 20–30%, 10–25%, and 17.2%, respectively [7,10,11].
Not all BC cells in primary tumors possess metastatic potential, and only a small subpopulation of cells
can home to distant tissues or organs [25]. Metastasis remains one of the major causes of mortality in
BC; however, no standardized therapy is available. Since the outcomes of tumor cell-targeted therapies
are poor, tumor-associated stroma could be targeted to inhibit BC metastasis.
Interestingly, BC has been shown to thrive in the tumor microenvironment (TME), which consists
of a pro-tumorigenic pathological immunosuppressive niche not only for BC cells themselves, but also
for a significant amount of surrounding stroma and tumor-associated cells. Diverse components of the
BC microenvironment, such as suppressive immune cells, re-programmed fibroblast cells, pathological
neovascular structures, altered extracellular matrix, and certain soluble factors, synergistically
impede an effective anti-tumor response and promote BC progression and metastasis [26]. BC cells
recruit tumor infiltrated lymphocytes such as T-regulatory cells, myeloid-derived suppressor cells
(MDSCs), and M2-macrophages to induce a pro-tumorigenic environment that attenuates anti-tumor
immunity [27,28]. Aberrant expansion and accumulation of MDSCs have been extensively reported in
BC. MDSCs are a heterogeneous population of immature granulocytes, macrophages, and dendritic
cells [29] that are recruited to the primary tumor as well as the metastatic site and play a crucial
role in inhibiting innate and adaptive immune responses by suppressing CD4+ T-cells, CD8+ T-cells,
and natural killer (NK) cells [30–32]. In clinical scenarios, circulating MDSCs have been shown to have
a positive correlation with BC stage and metastatic tumor burden [33]. In addition, increased numbers
of MDSCs are correlated with the rate of recurrence and metastasis of BC [28,34–37].
Another important pro-tumorigenic myeloid subset in the TME are the macrophages, which are
either residents or derived from the spleen or bone marrow [38,39]. Tumor-associated macrophages
(TAMs) can be present as an M1 subtype that produces type 1 pro-inflammatory cytokines promoting
the anti-tumorigenic role and an M2 subtype that produces type 2 anti-inflammatory cytokines that
facilitate a pro-tumorigenic environment [40]. In the hypoxic tumor core, M1 macrophages polarize
and switch phenotypes to M2 macrophages to promote pathological angiogenesis, thereby making
the tumor more aggressive and invasive [41]. Furthermore, a metastatic subpopulation of TAMs was
observed in a mouse model to promote the extravasation, invasion, and colonization of BC cells in the
metastatic site [38,42]. Current therapies, including chemotherapy and targeted therapies, are failing
due to the immunosuppression caused largely by MDSCs and TAMs in the primary tumor or the
metastatic sites [43]. It is therefore important to understand the mechanisms causing this therapy
resistance, tumor relapse, and refractoriness.
Recently, we observed that targeting the arachidonic acid (AA) pathway by inhibiting the synthesis
of 20-hydroxy-eicosatetraenoic acid (20-HETE) resulted in the decreased migration and invasion of
metastatic BC cells. In addition, in the same study, we found a synergistic reduction of the granulocytic
MDSC (g-MDSCs: CD11b+Ly6G+) populations in the metastatic niches [44]. In our previous studies,
we have been able to demonstrate a decrease in the levels of pro-angiogenic factors that are responsible
for the communication between tumor cells and the microenvironment with a selective 20-HETE
inhibitor, N-hydroxy-N′-(4-butyl-2 methyl phenyl) formamidine (HET0016), alone or in combination
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with anti-angiogenic therapies. Anti-20-HETE therapy was able to decrease breast and glioma tumor
sizes [45,46]. Interestingly, the anti-AA pathway therapy was more effective at reducing tumor volume,
the level of pro-angiogenic factors, and extent of metastasis than the antiangiogenic therapies used.
It is therefore important for researchers to focus on and understand the role of metabolic pathways in
tumors and their interplay with the stroma. In the current review, we have focused exclusively on the
AA-20-HETE pathway and its implications in modeling the TME.
2. Arachidonic Acid Metabolism
AA is a polyunsaturated ω-6 fatty acid present in the phospholipids of cell membranes,
which is abundant in the brain, muscles, and liver [47–49]. The main precursors (fatty acids) of
AA are obtained through the diet and its synthesis involves the expression of enzymes regulated in
situ [50] after the activation of phospholipase A2 (PLA2) by neuroeffectors such as norepinephrine,
angiotensin II, and bradykinin [51]. AA produces different biologically active metabolites through
three different enzymatic pathways (Figure 1): the cyclooxygenase (COX), lipoxygenase (LOX),
and cytochrome P450 (CYP) pathways [52]. These metabolic products can modulate renal, pulmonary,
and cardiovascular functions, vascular tone, and inflammatory responses as paracrine factors
and second messengers [53–55]. The COX pathway has two main enzymes, COX-1 and COX-2,
which are critical in the regulation of inflammation and tissue homeostasis. Both COX-1 and COX-2
enzymes act on the AA synthesized from the cell membrane phospholipid by PLA2, and then
metabolize AA into an intermediate prostaglandin (PG) H2 through PGG2 (Figure 1) [56,57].
PGH2 is an unstable endoperoxide that is catalyzed by specific synthases and generates five major
prostanoids such as PGD2, PGE2, PGF2α, PGI2 (prostacyclin), and thromboxane A2 that have an
important role in cancer-associated inflammation, tumor progression, and metastasis [57,58]. COX-1 is
constitutively expressed in almost all tissues and inflammatory cells, and generates PGs that control
homeostasis [56,57]. COX-2 is transiently and highly expressed in response to growth factors and
endotoxins and is often involved in inflammation, cell proliferation, and differentiation [56]. The COX-2
pathway has also been targeted in many cancer studies, including colon cancer, colorectal cancer, breast
cancer, gliomas, prostate cancer, esophageal carcinoma, pancreatic cancer, and lung carcinoma, due to
its increased expression and correlation with the reduction of survival rates in cancer patients [56–58].
It is already known that most cancerous tissues show signs of inflammation in the pre-cancer stages,
and chronic stimulation by innate immune cells, cytokines, and chemokines lead to malignant
transformation and tumor progression [58]. COX-2 inhibitors have been extensively studied through
their properties to inhibit tumor growth by suppressing inflammation and angiogenesis. However,
patients treated with celecoxib, a COX-2 inhibitor, in clinical trials demonstrated gastrointestinal
complications, a higher risk of cardiovascular toxicity, and death [58]. Even then, the toxicities of
COX-2 inhibitors do not exclude the importance of this treatment as an adjuvant in cancer therapy.
A third isoform of COX enzymes has been identified primarily in canine samples and
then confirmed in human tissue. COX-3 contains all of the COX-1 protein information, except
for the retained intron sequence that alters its enzymatic properties, significantly generating
PGE2 [59]. The functional COX-3 biosynthesis is an important concept that can help to explain
the prostaglandin-independent, anti-inflammatory actions previously attributed to the reactivation of
COX-2 activity at a later stage in enhancing inflammatory resolution [60,61]. However, further studies
showing whether there is a unique human COX-3 that acts independently of COX-1 and COX-2 and to
determine the role of COX-3 in tumor growth and development are still lacking.
The LOX pathway produces different leukotrienes (LTs), lipoxins (LXs), hepoxillins
(HOs), and hydroxy-eicosatetraenoic acids (HETEs), causing inflammation, allergic reactions,
bronchoconstriction, and vasoconstriction (Figure 1). The principal lipoxygenases expressed in humans
are 5-lipoxygenase (5-LOX), 8-lipoxygenase (8-LOX), 12-lipoxygenase (12-LOX), and 15-lipoxygenase
(15-LOX) type 1 and 2. In general, the LOX pathway catalyzes the oxygenation of AA into
hydroperoxy-eicosatetraenoic acid (HPETE) and converts HPETEs to LTs, LXs, Hos, and HETEs
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through the reduction of HPETE to HETE [62]. The four distinct enzymes insert oxygen at the specific
carbons 5, 8, 12, or 15 of AA, generating 5-, 8-, 12-, or 15-HPETE, which can be further reduced by
glutathione peroxidase (GPx) to the hydroxy forms (5-, 8-, 12-, 15-HETE), respectively [63]. The 5-LOX
pathway synthesizes the key pro-inflammatory LT mediators such as leukotriene A4 (LTA4) and
leukotriene B4 (LTB4) [58]. LTA4 is an unstable LT that can be converted into LTB4 or cysteinyl LTs
(LTC4, LTD4, and LTE4) [57]. High levels of LTB4, the main product of the 5-LOX pathway, were found
in prostate cancer samples [64], and its receptors were found to be overexpressed in gastric cancer
compared to normal tissue [65]. Interestingly, an LTB4 receptor antagonist in combination with
chemotherapy was able to decrease tumor growth and metastasis in vitro and in vivo in colon cancer
and pancreatic cancer models [66]. However, this combination did not change the survival rates
in pancreatic or lung cancer clinical trials [67]. 8-LOX and its products 8-HPETE and 8-HETE are
expressed in skin, mainly after irritation, but their importance in tumorigenesis remains unclear and
poorly reported [63].
Figure 1. Schematic representation of phospholipid-arachidonic acid metabolites produced via
the major enzymes cyclooxygenase (COX), lipoxygenase (LOX), and cytochrome P450 (CYP4A).
CYP4A produced 20-hydroxy-eicosatetraenoic acids (20-HETE) metabolite, which is known to promote
tumor growth. Legend: phospholipase A2 (PLA2); epoxy-eicosatrienoic acids—(EETs); epoxide
hydrolase (sEH); dihydroxy-eicosatrienoic acids (DHETs); hydroperoxy-eicosatetraenoic acid (HPETE);
glutathione peroxidase (GPx).
12-LOX also has a critical role in tumor angiogenesis, motility, invasion, and metastasis [68].
12-LOX is the main human 12-HETE-generating enzyme and can synthesize 12S-HPETE through AA
or either 12S- or 15S-HPETE through linoleic acid metabolism [57,63]. Three isoforms of the 12-LOX
enzyme have been identified, including the leukocyte and platelet type (named as S) and epidermal
type (named as R), expressed in various types of cells such as leukocytes, platelets, smooth muscle cells,
endothelial cells, and keratinocytes [57]. Evidence shows that both the leukocyte- and platelet-types
of 12-LOXs have been found in cancer tissues such as melanoma, prostate, and epidermal cancers
and promote cell proliferation and survival [69]. 12-LOX inhibition can decrease the proliferation and
induce apoptosis in human gastric cancer cells, prostate cancer cells, and carcinosarcoma cells [56,70,71].
12S-LOX also converts AA to HOs by reducing 12S-HETE into 8-hydroxy-11,12-epoxy-eicosatetraenoic
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acid (HxA3) and 10-hydroxy-11,12-epoxy-eicosatrienoic acid (HxB3) or by its isomerization [72].
HOs exhibit vast biological activities including the stimulation of insulin secretion by glucose
induction, an increase of intracellular calcium levels in pancreatic islets cells, and the induction
of hyperpolarization of the membrane potential in neurons [72].
15-LOX is subdivided into two isoforms, 15-LOX-1 and 15-LOX-2. They are widely distributed
in the tissues and mainly expressed in reticulocytes, eosinophils, pulmonary epithelial cells,
and macrophages [57]. 15-LOX has an ambiguous activity, being pro- or anti-tumorigenic depending
on its subtype. 15-LOX-1 metabolizes linoleic acid to 3-hydroxy-octadecadienoic acid (13S-HODE) and
metabolizes AA to 15S-HETE. However, 15-LOX-2 mainly converts AA to 15S-HETE [57,63].
Lipoxins are trihydroxy-eicosatetraenoic acids derived from three different pathways of AA
metabolism. They can be synthesized by the platelet–leukocyte interaction that involves the production
of LTA4 by 5-LOX in neutrophils and its conversion to lipoxin A4 (LXA4) and lipoxin B4 (LXB4) by
12-LOX in platelets upon their adherence to leukocytes. Without this interaction the production of
LXs does not happen [73]. The generation of LXs can also be achieved through the oxygenation
of AA in the presence of 15-LOX, generating 15S-HPETE, which serves as a substrate for 5-LOX,
or through COX-2 acetylation, which generates COX-2-derived HETE and is converted by 5-LOX
to 15-epi-lipoxin A4, also known as aspirin-triggered lipoxin (ATL) and 15 epi-lipoxin B4 [73,74].
Lipoxins and epi-lipoxins show anti-inflammatory effects through signals engendered by binding to
G protein-coupled lipoxin A4 receptor (ALX)/formyl peptide receptor (FPR2) [74]. Lipoxins have
been shown to downregulate NFκB expression and could be used as a potential treatment for several
cancer types [74]. LXA4 can decrease cell proliferation, inhibits cell invasion, and suppresses tumor
growth, exhibiting anti-inflammatory properties in cancer cells [58]. Since LXs can target a variety of
inflammatory and angiogenic molecules, inhibitors of LTA4 hydrolase could be potentially used in
a combination therapy along with standard chemotherapeutic drugs to treat cancer [58,74]. Further
in vivo studies are required to corroborate the idea of whether LXs could be used as an adjuvant in
preventing cancer progression.
The COX and LOX pathways represent two major routes of AA metabolism that controls
the biosynthesis and activity of LTs, LXs, HOs, and HETEs or intermediary products such as
HPETEs. These products can act as effectors in inflammatory responses or activate the production
of second messengers such as reactive oxygen species (ROS) through interaction with cognate G
protein-coupled cell-surface receptors or nuclear receptors such as peroxisome proliferator activated
receptors (PPARs) [75]. CYP enzymes require nicotinamide adenine dinucleotide phosphate (NADPH)
reductase and CYPb5 as cofactors and are a major source of superoxide ions, releasing a significant
amount of oxygen radicals in the vasculature, which makes the metabolism of AA by CYP enzymes an
important contributor to oxidative stress [53]. Oxidative stress activates a host of pro-inflammatory
cytokines and chemokines such as TNF-α and IL-8 and adhesion molecules such as ICAM-1, E-selectin,
or P-selectin. The metabolic end products generated as a result of the peroxidation of lipids also
serve as potent chemoattractants for inflammatory cells [76]. Two key inducible cytochrome P450
enzymes, CYP2E1 and CYP4A, involved in lipid peroxidation function complementarily, and this
may lead to interactions in the regulation of these enzymes [77,78]. CYP2E1 and CYP4A have been
demonstrated to function as leaky enzymes that are capable of undergoing “futile cycling”. During
this process, even in the absence of a substrate, these enzymes are capable of producing ROS such as
superoxide anions, hydroxyl radicals, and hydrogen peroxides [79–81]. Reduction in the levels of a key
antioxidant such as glutathione (GSH) by inhibiting GSH synthesis with buthionine sulfoximine (BSO)
dramatically upregulated the AA levels, causing toxicity. Overexpression of the antioxidant enzyme
catalase countered the pro-oxidant activity of CY2E1 [82]. In response to cell mediated injury by AA
metabolism, especially in CYP2E1-overexpressing cells, antioxidant molecules such as GSH were high
due to the upregulation of γ-glutamylcysteine synthetase [83], GSH S-transferases, and catalase [84].
The contributions of these pathways in cancer development and their interaction and deregulation
are still open for discussion. More extensive investigation is needed to delineate how COX and LOX
216
Int. J. Mol. Sci. 2017, 18, 2661
inhibitors could be more effective in decreasing tumor growth and metastasis. In this review, our main
focus is the CYP pathway and its metabolites in relation to various aspects of inflammation and cancer.
The cytochrome P450 (CYP) gene family consists of a complex 18 gene families that encode
more than 103 functional genes in mice and 57 genes in humans [85,86]. The CYP2, CYP3, and
CYP4 families encode more genes than the remaining 15 families in human as well as in rodent
genomes [86]. The majority of the genes found in the CYP1, CYP2, CYP3, and CYP4 families
encode enzymes involved in eicosanoid metabolism and are inducible by diet, chemical inducers,
drugs, pheromones, and other factors [86]. Their function is predominantly in the detoxification
of drugs, toxic compounds, chemotherapies, xenobiotics, and products of endogenous metabolism
such as bilirubin in the liver [85,86]. The CYP2 and CYP3 families are the most redundant, mutated,
or defective in one or more genes compared to the other 16 gene families that might be responsible for
the CYP-related diseases that will be directly involved in their critical life functions [86].
The CYP pathway is an enzymatic pathway divided into ω-hydroxylase and epoxygenase
pathways that use AA as a substrate to produce eicosanoids. Derivatives of the ω-hydroxylase
pathway (HETEs) cause inflammation, vasoconstriction, vascular remodeling, and cellular proliferation.
Metabolites of the epoxygenase pathways (epoxy-eicosatrienoic acids—EETs) resolve inflammation and
cause vasodilation, the protection of cardiac function, and cell proliferation [85,87,88]. In mammalian
cells, the most studied and effective subfamily to produce 20-HETE is CYP4A [53]. In rats, there are
four isoforms identified: CYP4A1, CYP4A2, CYP4A3, and CYP4A8 [89]. These isoforms share 66–98%
homology and common catalytic activity and are expressed in the liver, kidney, and brain [90].
CYP4A1 has the highest catalytic efficiency to convert AA into 20-HETE, followed by CYP4A2
and CYP4A3; however, CYP4A8 did not catalyze AA or linoleic acid [91]. In mice, CYP4A10,
CYP4A12a, CYP4A12b, and CYP4A14 are the principal isoforms that catalyze AA ω-hydroxylation
to 20-HETE [92]. CYP4A10 has a lower catalytic activity for 20-HETE production than the CYP4A12
isoforms. CYP4A12a and CYP4A12b have similar hydroxylase activity, constituting the major source
of 20-HETE synthesis [92]. Particularly, in addition to the CYP4A enzymes, the CYP4F isoforms are
also significant for 20-HETE production [90]. In humans, the isoforms CYP4A11, CYP4A22, CYP4F2,
and CYP4F3 are the most important in the production of 20-HETE, predominantly CYP4F2, followed
by CYP4A11 [93]. The isoforms and their species-specific expression are summarized in Table 2.
Table 2. CYP ω-hydroxylases that produce 20-HETE in mice, rats, rabbits, and humans. Data have
been obtained from Roman [48].
Species 20-HETE Production
Mouse CYP4A10; CYP4A12a; CYP4A12b; CYP4A14
Rat CYP4A1; CYP4A2; CYP4A3
Rabbit CYP4A4; CYP4A6; CYP4A7
Human CYP4A11; CYP4A22; CYP4F2; CYP4F3
The ω-hydroxylases from the CYP family 4, subfamily A (CYP4A), and F (CYP4F) genes convert
AA into 7-, 10-, 12-, 13-, 15-, 16-, 17-, 18-, 19-, and 20-HETEs, and the epoxygenases mainly encoded
by the CYP family 2 subfamilies C and J genes generate 5,6-EET, 8,9-EET, 11,12-EET, and 14,15-EET,
which will be further metabolized into the less active dihydroxy-eicosatrienoic acids (DHETs) through
epoxide hydrolase (sEH) [58,85]. All four EETs and their metabolite DHET can act as a long-chain of
fatty acids and stimulate the peroxisome proliferator response element to bind to PPAR [85]. 20-HETE
is the principal pro-inflammatory metabolite produced by the ω-hydroxylase enzymes and regulates
vascular remodeling and neovascularization under ischemic or hypoxic conditions [94–96]. 20-HETE
synthesis can be controlled through the activation of calcium/calmodulin-dependent kinase II and
mitogen-activated protein kinase (MAPK) in smooth muscle cells [97]. 20-HETE can be incorporated
into endothelial lipids through a coenzyme A-dependent process and is further metabolized by
ω-oxidation or β-oxidation to 20-carboxy-arachidonic acid (20-COOH-AA) [98]. The metabolism of
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20-HETE can also be regulated through COX-mediated pathways into 20-hydroxy-prostaglandin G2
and H2 [99]. 20-HETE stimulates the activation of the nuclear factor κB (NFκB) and MAPK/ERK
pathways, mediating pro-inflammatory effects, and also has an important role in epidermal growth
factor (EGF), hypoxia-inducible factor (HIF), and vascular endothelial growth factor (VEGF) activation,
showing pro-angiogenic effects and the stimulation of endothelial cell proliferation, migration, and cell
survival [94,100]. Recently, molecular studies highlighting the relationship between aberrant AA
metabolism through 20-HETE downstream signaling pathway activation and carcinogenesis have
provided novel molecular targets for cancer chemoprevention and treatments.
3. Cytochrome P450 Mechanisms in Obesity and Breast Cancer
Dysregulated energy metabolism is already known to be a hallmark of cancer [101]. One of the
main examples of dysregulated energy metabolism is obesity, which has been associated with high
levels of aromatase in breast tumors and undifferentiated adipose tissue [102]. Aromatase is a CYP19
enzyme responsible for the critical steps in the synthesis of estrogens [103] that are most related to
breast cancer risks. Several drugs, in particular anti-diabetic drugs, have shown effects in decreasing
tumor growth, breast cancer recurrence, and metastasis [102,104]. Metformin, for example, can inhibit
aromatase expression via 5′ AMP-activated protein kinase (AMPK) in breast adipose stromal cells [105].
In breast cancer, adipose tissue provides structural and paracrine support for tumor development and
growth. In addition to adipose tissue in the breast, other stromal cells can provide crucial metabolites
through the CYP-mediated lipid peroxidation pathway to favor tumor growth and the production of
pro-tumorigenic eicosanoids.
AA and its metabolites have been strongly implicated in the pathogenesis of obesity and related
complications in peripheral tissues and organs owing to their ability to provide fatty acids for the
production of pro-inflammatory cytokines [106]. The constituent expression of all the molecular
players crucial for the 5-LOX pathway to generate leukotrienes and the receptors (two LTB4 [BLT1 and
BLT2] receptors and two cysteinyl LT [CysLT-R1 and CysLT-R2]) receptors in the adipocyte and the
stromal vascular fraction highlight the importance of this pathway in obesity. LTB4 signaling plays a
crucial role in mediating the differentiation of preadipocytes to mature adipocytes, and 5-LOX-derived
leukotrienes are elevated in the obese adipose tissue [107–112]. 5-LOX has also been indicated in
the modulation of lipid metabolism to provide free fatty acids as substrates for the production of
pro-inflammatory eicosanoids [110]. In our studies, we have demonstrated that HET0016 is a selective
CYP4A and CYP4F ω-hydroxylase inhibitor that does not have any possible effects on the 5-LOX
signaling pathway to control obesity. However, a recent study by Park et al. [113] showed the effects of
the inhibition of CYP4A enzyme activity in type 2 diabetes mellitus (T2DM) in obese mice. The authors
reported that obesity is one of the important causes of elevated endoplasmic reticulum stress in obese
mice and identified 54 novel CYP4A enzyme isoforms that were upregulated in obesity-induced T2DM
in the db/db mice model, of which CYP4A10 and CYP4A14 levels were significantly upregulated [113].
Since HET0016 has specificity for the inhibition of CYP4A enzymes, it can be strongly hypothesized
that the effects of HET0016 can be observed in animals. Animals fed with a high-fat diet and treated
with HET0016 for 12 weeks presented a significantly decreased body weight and total fat-pad mass,
and improved glucose tolerance and insulin sensitivity compared with animals that were not fed
the high-fat diet [113]. The fasting blood glucose concentration in obese animals was comparable
to the levels observed in normal-diet-fed animals [113]. We did not find any evidence of studies in
humans. The specificity of CYP4A for ω-oxidation facilitates the degradation of long-chain fatty
acids, therefore providing a secondary metabolic pathway for the metabolism of fatty acids when
levels of these substrates increase during the physiological processes of lipolysis and hepatic fatty
acid uptake. It would be fascinating to investigate the other mechanisms involved in the inhibition
of the CYP4A-mediated control of obesity in these animals. However, the current review is focused
on presenting evidence as to how the inhibition of 20-HETE, an AA metabolite, might be a novel
therapeutic target in BC metastasis.
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4. Arachidonic Acid Pathway and 20-HETE in Primary Tumors and Metastasis
In tumors, the CYP4A/20-HETE axis promotes inflammation, endothelial cell migration,
and neovascularization [114–119]. When N-hydroxy-N′-(4-butyl-2 methyl phenyl) formamidine
(HET0016), a highly selective inhibitor of 20-HETE synthesis, was used alone in tumor-bearing animals,
a decrease in tumor growth was observed via impaired tumor neovascularization [44–46,120]. HET0016
is also shown to decrease MAPK signaling, pSTAT1, EGFR, and HIF-1α in glioblastoma (GBM) tumor
lysates [121]. When the expression of different pro- and anti-angiogenic factors and inflammatory
cytokines in the tumor lysates were analyzed, there were significant changes following HET0016
treatments compared to that of vehicle-treated tumors [46,121]. When the extravascular extracellular
space (EES), different vascular parameters, and neovascularization were examined, HET0016 treatment
significantly decreased EES, tumor blood volume, permeability, and neovascularization [46,121].
We also reported that HET0016 decreased vascular mimicry, a phenomenon where tumor cells
make blood vessel-like structures [120,122]. We found that the CYP4A/20-HETE axis plays a critical
role in metastasis in a syngeneic model of BC-mediated pulmonary metastasis. Targeting 20-HETE
production also decreased pulmonary metastasis in an aggressive BC model [44]. When applied
at the pre-metastatic stage, HET0016 significantly decreased pulmonary metastatic growth through
decreasing a survival pathway (p-AKT), inflammation pathway (canonical NFκB signaling), migration
pathway (matrix metalloproteinase-2 and -9, MMP2 and 9), and mesenchymal cancer stem cell markers
(CD44 and N-cadherin) in the metastatic lung niche [44]. In cancer studies, 20-HETE mediated
effects have been studied in the context of tumor cells and endothelial progenitor cells (EPCs).
Investigations regarding the contribution of tumor-associated stromal cells such as myeloid cells
are rare. The following sections will discuss the role of stromal and myeloid cell-mediated 20-HETE
production and its effects on tumor growth and metastasis.
5. Role of 20-HETE in Stromal Cells and Tumor Cells
Initially, the entirety of cancer research was focused on the idea that tumor growth and metastasis
were tumor-cell inherent/autonomously driven by mutations arising in these tumor cells to meet
with their metabolic and nutritional needs. This dogma has been refuted to incorporate the idea
of a “tumor microenvironment” comprised of stromal cells such as endothelial cells, fibroblasts,
and pericytes and also infiltrating myeloid cells such as monocytes, macrophages, and MDSCs to
favor tumor growth and metastasis [123–127]. The non-tumor cell-dependent contribution to tumor
growth and progression has gained immense popularity, thanks to the landmark hypothesis of tumor
angiogenesis proposed by Folkman in 1971 [128]. Tumor neovascularization has now been extended
to include vasculogenesis, intussusception, tumor cell transdifferentiation to endothelial phenotypes,
and vascular mimicry [129,130].
The ω-hydroxylation of therapeutic drugs, as well as endogenous compounds, e.g., fatty acids, by
the CYP4 family members functions to metabolically activate and further eliminate these compounds.
Eicosanoids, derived from AA, are key substrates of this cytochrome P450-dependent oxidation
reaction. Human CYP4 enzymes such as CYP4A11, CYP4F2, and CYP4F3B, hydroxylate AA at
the omega position to form 20-HETE. 20-HETE has already been shown to have hallmark effects
in tumor progression, angiogenesis, and inflammatory processes associated with tumor growth
and metastasis. The processes of tumor-associated angiogenesis and inflammation driving the
immunosuppression go hand-in-hand and thus exert significant influence on tumor growth and
metastasis. The pro-inflammatory cytokines and pro-growth factors work to promote tumor
growth; the tumor thereby releases various chemokines/cytokines that promote the recruitment
of MDSCs, neutrophils, macrophages, and other myeloid cells to facilitate the development of an
immunosuppressive niche conducive to tumor growth [131–133].
The first evidence pointing towards the role of the CYP4A/20-HETE axis in angiogenesis was
pointed out by Sa et al. in their study, where they reported that FGF-2-mediated activation of
cytosolic phospholipase A2 is responsible for AA production and CYP4A stimulation in endothelial
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cells [134]. Recent studies have shown that the CYP4A/F-20-HETE and VEGF pathways have a positive
feedback regulation in circulating EPCs. Both hypoxia and VEGF induced expression of the CY4A11
gene and protein in EPCs, and 20-HETE and VEGF had a synergistic effect on EPC proliferation.
Moreover, 20-HETE induced the expression of Very Late Antigen-4 (VLA-4) and CXCR4 in EPCs,
thereby promoting their role in neovascularization, and targeting the 20-HETE pathway attenuated
EPC-induced angiogenesis in a Matrigel plug angiogenesis assay [114]. 20-HETE offers a survival
advantage to bovine pulmonary artery endothelial cells by activating the pro-survival PI3-kinase and
Akt pathways, NADPH oxidase activation, and NADPH oxidase-derived superoxide, and thereby
protects these cells from undergoing apoptosis [135]. There is a dynamic interplay between the tumor
cells and the tumor stroma in regulating tumor growth, invasion, and metastasis, as shown in Figure 2.
A bi-directional synergism comes into play to meet the metabolic and nutrient demands of the tumors
and also to counter therapeutic resistance in the face of insult by chemotherapy and antiangiogenic
therapy (AAT).
Figure 2. Schematic representation of the involvement of the CYP4A/20-HETE pathway in
the primary tumor microenvironment and its potential metastatic site. (1) The CYP4A/20-HETE
pathway is overexpressed in myeloid-derived suppressor cells (MDSCs) recruited to the primary
tumor and in the tumor-associated stroma cells, promoting polarization to a g-MDSC phenotype;
(2) The CYP4A/20-HETE pathway increases pathological neovascularization in the tumor
microenvironment (TME); (3) The CYP4A/20-HETE pathway induces the expression of HIF1a,
VEGF, MMP2, MMP9, and other factors to increase migration, invasion, and metastasis. HET0016,
a selective inhibitor of 20-HETE in the CYP4A pathway, decreases the metastatic potential of tumor
cells, normalizes the blood flow, and controls abnormal neovascularization. The red boundary defines
the tumor-associated vascular structure.
Our laboratory has shown that using HET0016, a 20-HETE inhibitor, decreased the level of
several pro-angiogenic factors in a mouse model of TNBC, thereby affecting tumor growth [45].
T47D and BT-474 human BC cells overexpressing CYP4Z1 enhanced proliferation, migration, and tube
formation of human umbilical vein endothelial cells (HUVECs), and promoted angiogenesis in the
zebrafish embryo and chorioallantoic membrane of the chick embryo [136]. CYP4A1 expression
in U251 glioma cells induced hyperproliferation both in vitro and in vivo, possibly due to the
production of 20-HETE [117]. The CYP4A/20-HETE axis significantly increased tumor weight,
microvessel density (MVD), and lung metastasis by upregulating VEGF and MMP in non-small cell
lung cancer [137]. Many studies designed to understand tumor growth, the development of resistance
to therapies, and metastasis have focused on tumor neovascularization as a primary target. A novel
neovascularization mechanism that has gained widespread popularity amidst controversy is vascular
mimicry [130,138,139]. Studies from our laboratory have demonstrated the efficacy of targeting the
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CYP4A/20-HETE axis in controlling vascular mimicry-dependent AAT resistance [120,122]. In light
of the aforementioned evidence, studies of the CYP4A/20-HETE axis in mediating tumor growth,
invasion, and metastasis serve to be an exciting domain of investigation.
Reports on the emerging role of the CYP4A/20-HETE axis in immune regulatory myeloid cells
are building up. For the very first time, our laboratory has recently shown that pharmacological
targeting of the CYP4A/20-HETE axis through HET0016 decreased g-MDSCs in the metastatic
niche [44]. The growth factors and cytokines released by g-MDSCs can inhibit an effective T-cell
response and promote the growth of disseminated tumor cells [37,140,141]. Chen et al. in a similar
context, have shown that TAMs overexpressing a CYP4A10 variant can increase pre-metastatic
niche formation and pulmonary metastasis [142]. Similarly, a novel flavonoid FLA-16, through
inhibiting CYP4A pathways, normalized the tumor vasculature and improved survival. This was
accompanied by the decreased secretion of 20-HETE, VEGF, and transforming growth factor beta
(TGF-β) in TAMs and EPCs [143]. Altogether, CYP4A in TAMs is crucial for the tumor-dependent
macrophage phenotype shift, and its inhibition by HET0016 or FLA-16 decreased tumor-associated
phenotypes [142,143]. Moreover, these reports strongly suggest a critical role of the myeloid
cell-produced 20-HETE metabolite in tumor growth and metastasis. In the future, more experimental
investigations are needed to explore its role in other stromal cell types such as heterogeneous myeloid
subsets, e.g., MDSCs and T cell subsets, which display a profound role in tumor and metastatic
microenvironments (shown schematically in Figure 2). Since the TME is modeled around the
availability of neovascular structures to meet the nutrient and metabolic demands of the tumor,
the following section will highlight the role of the 20-HETE pathway in tumor and tumor-associated
stromal cells with a special emphasis on endothelial cells.
6. HET0016 as a Novel Therapeutic Agent in Treatment of Metastasis
Currently, there is a dearth of studies investigating the CYP4A/20-HETE axis and its involvement
in tumor growth and metastasis in patients. Increased levels of 12-HETE and 20-HETE were found in
patients with prostate cancer and with myeloid leukemia [52,144]. In fact, various human cancer cells
show the upregulation of 20-HETE-producing enzymes of CYP4A/F families including BC, colon and
ovary cancer, and melanoma [142,145]. Our laboratory has extensively employed HET0016, a selective
20-HETE synthesis inhibitor, as a treatment to reduce the hyperproliferation of glioma [121,146,147]
and BC cells [44,45].
Recently, we have shown that the growth of human glioblastoma was dwindled by an intravenous
(IV) formulation of HET0016. We optimized the route of administration of the drug by making a novel
IV formulation of HET0016 with 2-hydroxypropyl β cyclodextrin (HPβCD) to enhance bioavailability
(resulting in a seven-fold higher level in plasma and 3.6-fold higher level in the tumor in the first hour
compared to treatment via an intraperitoneal route) and to deliver an effective dose of the drug to the
tumor site with reduced off-target effects and rapid clearance. We saw significantly reduced tumor
growth with the IV HET0016 treatment in athymic nude rats that were orthotopically implanted with
U251 cells. Similar growth inhibition was observed in the syngeneic GL261 GBM immunocompetent
mouse model. Using magnetic resonance imaging (MRI), we evaluated the vascular kinetics in the TME,
which showed that the delayed IV HET0016-treated animals have significantly lower vp (blood plasma
pool), ve (extracellular space or interstitial volume), and Ktrans (forward permeability transfer constant),
and increased and normalized blood flow compared to that of the corresponding vehicle-treated groups.
We observed a reduced expression of markers of cell proliferation (Ki67) and neovascularization
(laminin, MVD, and αSMA), downregulation of pro-angiogenic proteins such as VE-cadherin (vascular
endothelial cadherin-vasculogenesis), bFGF (basic fibroblast growth factor), IL-8 (chemokine CXCL8),
SDF-1α (stromal cell-derived factor-1), and MCP-1 (a CCL2 ligand), and increased expression of
anti-angiogenic proteins such as Tie-2, angiostatin, and angiopoietin-2/Tie-1 in the IV HET0016
treatment group. We determined the expression of different proteins by western blot and confirmed that
HET0016 treatment decreases the level of markers of cellular proliferation (pERK), survival, migration,
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invasion (pAKT), inflammation (COX-1/2, p-NFκB), and angiogenesis (HIF-1α, EGFR, VEGF, and
MMP2). Furthermore, we observed significantly improved survival in patient-derived xenograft
(PDX) tumor models of GBM811 and HF2303 with HET0016 treatment alone or in combination with
temozolomide (TMZ) in irradiated animals. Overall survival was prolonged to 26 weeks after combined
treatment with HET0016 plus TMZ and radiation, while control animals survived for only 10 weeks in
the GBM811 model while survival was prolonged to 26 weeks vs. 17 weeks for the irradiated control
in the PDX model of HF2303 [121].
In one of our studies to understand the role of HET0016 in controlling metastasis, we have
shown that HET0016 decreases migration and invasion in the metastatic TNBC cell line from both
human (MDA-MB-231) and mouse (4T1) models in vitro. We also showed that IV HET0016 treatment
reduces primary tumor growth and lung metastasis in 4T1 bearing immunocompetent Balb/c mice.
Other studies have similarly observed a diminished expression of pro-inflammatory cytokines such as
EGF, Fas, SDF-1α, IL-1β, IL-4, IL-17A, MMP-2, and MMP-9, which led us to investigate the downstream
signaling mechanisms that could be affected by HET0016 [137,142,148–150]. The PI3K/Akt and MAPK
signaling pathways are thought to be climacteric to regulate proliferation, invasion, angiogenesis,
and metastasis ability [151–153]. Previously, it was found that 20-HETE is involved in activation of
ERK1/2 and PI3K/Akt in endothelial cells [116] and also alters cell growth in U251 human gliomas by a
mechanism that initially involves activation of the ERK1/2 pathway [117]. A schematic of the signaling
pathway presented by Shankar et al. [46] from our research group summarizes the possible therapeutic
actions of HET0016 in Figure 3. Yu et al. also showed that CYP ω-hydroxylase overexpression
enhanced the lung metastasis of A549 cells in the nude mouse by upregulating VEGF and MMP-9
expression via the PI3K and ERK1/2 signaling pathway [137]. Our results showed reduced protein
levels of pAKT, total AKT, pERK1/2, and pNFκB in lungs of animals treated with HET0016 compared
to 4T1-bearing control mice. In recent years, many studies have shown the pivotal role of MDSCs
in downregulating anti-tumor immunity and promoting tumor growth and metastasis [154–156].
We reported a novel role of HET0016 in impeding metastasis by decreasing the g-MDSCs polarization
in the metastatic site [44].
Figure 3. A possible mode of action of HET0016 in relation to growth factor pathways. (a) Treatment
with vatalanib causes a decrease in expression of vascular endothelial growth factor receptor
2 (VEGFR2), but increases the expression of hypoxia-inducible factor 1 α (HIF-1α) and VEGF,
which will cause increased neovascularization and tumor growth; (b) When HET0016 alone is used,
VEGF expression is decreased through different signaling pathways, which will cause decreased
neovascularization and tumor growth; (c) When HET0016 and vatalanib are used together some of
the effects of vatalanib (increased VEGF, increased neovascularization and tumor growth) can be
attenuated. Data obtained from Shankar et al. [46].
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7. Conclusions
Considering the evidence provided by studies from our and other research groups, the CYP4A/20-
HETE axis has a multi-faceted role in promoting tumor growth and metastasis. This axis has also
been highly activated in myeloid cells mediating immunosuppression in the TME. The tumor stroma
consisting of tumor-associated endothelial cells proliferate and lay down neovascular structures
induced by 20-HETE production. However, the CYP4A/20-HETE axis has been a neglected pathway in
the development of novel therapeutics. We have successfully employed HET0016 in controlling glioma
and breast tumor growth and metastasis. Therefore, novel therapeutics targeting the CYP4A/20-HETE
axis should gain considerable importance in translational medicine, either as monotherapy or in
combination with established chemotherapeutic and radiotherapeutic approaches.
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Abbreviations
20-HETE 20-Hydroxy-eicosatetraenoic acid
4T1 Triple negative metastatic murine breast cancer cell line
ALX/FPR2 Lipoxin A4 receptor/formyl peptide receptor
AA Arachidonic acid
AAT Antiangiogenic therapy
AKT Protein kinase B




BT-474 Breast cancer luminal B subtype cell line
COX Cyclooxygenase enzyme
CXCR4 C-X-C chemokine receptor type 4 also known as fusion or CD184;
CYP Cytochrome P450
CYP4A Cytochrome P450, family 4, subfamily A
CYP4F Cytochrome P450, family 4, subfamily F
DHETs Dihydroxy-eicosatrienoic acids
EES Extravascular extracellular space
EETs Epoxy-eicosatrienoic acids
EGF Epidermal growth factor
EGFR Epidermal growth factor receptor
sEH Epoxide hydrolase
EPCs Endothelial progenitor cells
ER Estrogen receptor
ERK Extracellular signal-regulated kinases
Fas Fas ligand or CD95 ligand
FGF-2 Basic fibroblast growth factor 2
FLA-16 Novel flavonoid
GBM Glioblastoma
GBM811 Glioblastoma-derived from patient
GL261 Murine glioblastoma cell line
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GM-CSF Granulocyte-macrophage colony-stimulating factor
GSH Glutathione
GPx Glutathione peroxidase
HER2 Human epidermal growth factor receptor2
HET0016 N-hydroxy-N′-(4-butyl-2 methyl phenyl) formamidine
HF2303 Glioblastoma-derived from patient












MAPK Mitogen-Activated Protein Kinase
MCP-1 Monocyte Chemoattractant Protein-1
MDA-MB-231 Triple negative metastatic human breast cancer cell line
MDSCs Myeloid-derived suppressor cells
MMPs Matrix metalloproteinases
MRI Magnetic resonance imaging
MVD Microvessel density
NADPH Nicotinamide adenine dinucleotide phosphate
NFκB Nuclear factor kappa-light-chain-enhancer of activated B cells






PPARs Peroxisome proliferator-activated receptors
PR Progesterone receptor
ROS Reactive oxygen species
SCF Stem cell factor
SDF-1α Stromal cell-derived factor 1 α
STAT1 Signal transducer and activator of transcription 1
T2DM Type 2 diabetes mellitus
T47D Breast cancer luminal A subtype cell line
TAMs Tumor-associated macrophages
TGF-β Transforming growth factor β 1
Tie-2 Transmembrane tyrosine-protein kinase receptor
TME Tumor microenvironment
TMZ Temozolomide
TNBC Triple-negative breast cancer
TNFα Tumor necrosis factor α
U251 Human glioblastoma cell line
ve extracellular space or interstitial volume
VE-cadherin Vascular endothelial cadherin
VEGF Vascular endothelial growth factor
VLA-4 Very late antigen-4
vp Blood plasma pool
α-SMA α-smooth muscle actin
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Abstract: Nanoscale secondary ion mass spectrometry (NanoSIMS) combined with transmission
electron microscopy (TEM) can be a powerful approach to visualize the exact distribution of
drugs at the sub-cellular level. In this work, we exploit this approach to identify the distribution
and localisation of the organometallic ruthenium(II)-arene drug Ru(η6-C6H5Me)(pta)Cl2, termed
RAPTA-T, in MDA-MB-231 and MCF-7 human breast cancer cells. These cell lines have been chosen
because the former cell lines are highly invasive and resistant to most chemotherapeutic agents and
the latter ones are very sensitive to hormonal-based therapies. In the MDA-MB-231 cells, RAPTA-T
was found to predominantly localise on the cell membrane and to a lesser extent in the nucleolus.
These findings are consistent with the previously reported anti-metastatic properties of RAPTA-T
and the observation that once internalized RAPTA-T is associated with chromatin. RAPTA-T shows
a lack of membrane accumulation on the non-invasive MCF-7 cells, which correlates well with its
selective anti-metastatic properties on invasive cell lines.
Keywords: breast cancer; invasion; metastasis; ruthenium
1. Introduction
Platinum-based drugs are widely used in the clinic [1,2]. However, in recent years, an increasing
number of ruthenium complexes, with profoundly different properties compared with the currently
used platinum drugs, e.g., higher cancer cell selectivity leading to reduced side-effects in vivo [3],
have been (pre-)clinically evaluated [4–7]. All these drugs possess the classical coordination
complexes structure, but there is now considerable interest in the anticancer properties of
organometallic complexes, i.e., those containing direct metal-to-carbon bonds [8,9]. Of these
organometallic compounds, the ruthenium(II)-arene drugs (Scheme 1), Ru(η6-arene)(pta)Cl2 where pta
= 1,3,5-triaza-7-phosphaadamantane, termed RAPTA compounds, are the most advanced in pre-clinical
studies, and many derivatives have been prepared and tested [10]. Specifically, Ru(η6-C6H5Me)(pta)Cl2
(RAPTA-T) possesses anti-metastatic properties in an in vitro model mimicking the detachment,
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invasion, migration, and re-attachment steps of metastasis formation [11]. This effect is much more
evident on the invasive MDA-MB-231 breast cancer cells than on non-invasive MCF-7 breast cancer
cells [11]. The in vitro studies were validated in an in vivo syngeneic, spontaneously metastasizing
mammary carcinoma murine model, which showed RAPTA-T treatment to be effective, resulting in a
reduction of lung metastasis formation of these tumours [12].
 
Scheme 1. Generic RAPTA (Ru(η6-arene)(pta)Cl2) structure (left) and the structures of RAPTA-T
(centre) and RAPTA-C (where the arene = p-cymene) (right).
RAPTA-T is not the only compound of this family that has the capacity to reduce metastasis
formation in experimental models [12]. However, RAPTA-T has other favourable physico-chemical and
biological characteristics, i.e., particularly good water solubility and an intrinsic cancer cell selectivity
demonstrated by a cytotoxicity difference between tumorigenic (74 μM) and non-tumorigenic
(>1000 μM) cells [12], making it suitable for pharmacological development. Nevertheless,
the development of RAPTA-T is also dependent on knowledge about its biological and pharmacological
mode of action. Although RAPTA-T was not derived from a targeted approach, but essentially from the
upgrading of clinically used platinum drugs [13], its mode of action is profoundly different, binding
preferentially to proteins rather than DNA [14]. It is therefore necessary to acquire as much data as
possible on the behaviour of RAPTA-T in cells as a function of cellular characteristics and of their
response to treatment.
An approach that produces visual distribution maps of metal-based drugs in cells, nanoscale
secondary ion mass spectrometry (NanoSIMS) [15] is attracting increasing attention [16] and has
been used to image RAPTA-T in cisplatin-resistant human ovarian cancer (A2780CR) cells [17].
Consequently, the aim of the present study is to determine the distribution of RAPTA-T in MDA-MB-231
and MCF-7 cells and to probe whether any difference in distribution exists between these cells
possessing different metastatic phenotypes. Both MCF-7 and MDA-MB-231 are breast cancer
adenocarcinomas isolated from pleural effusions [18]. MDA-MB-231 are a triple-negative cell
line lacking oestrogen and progesterone receptors in which the human epidermal growth factor
receptor 2 (HER2/Neu) is not amplified, making it resistant to most chemotherapeutic agents. These
characteristics differ to MCF-7 cells, which are positive for both oestrogen and progesterone receptors,
and are therefore sensitive to hormonal-based therapies [19].
2. Results
Secondary ion maps of 13C12C−/12C2−, 14N12C−/12C2−, 15N12C−/14N12C−, 31P−/12C2−,
34S−/12C2−, and 102Ru−/12C2−, as well as transmission electron microscopy (TEM) images of
MDA-MB-231 cells treated with 15N/13C-labelled RAPTA-T (500 μM, 24 h), are shown in Figure 1.
As observed previously in A2780CR cells treated with 15N+13C-labelled RAPTA-T [17], 13C enrichment
was not observed in RAPTA-T treated MDA-MB-231 and MCF-7 cells indicating that the sample
preparation dilutes the 13C-isotopic enrichment from the 13C-enriched toluene ligand to below the
detection limit [20]. In the MDA-MB-231 cells, all Ru hotspots found were co-enriched with 15N
(Figure 1, green boxes), suggesting that the phosphine (PTA) ligand remains coordinated to the Ru
centre. However, there were several 15N-enriched hotspots that did exhibit Ru enrichment, most likely
due to detachment of PTA from Ru.
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Figure 1. NanoSIMS secondary ion maps of 31P−/12C2−, 34S−/12C2−, 14N12C−/12C2−,
15N12C−/14N12C−, 102Ru−/12C2−, and 13C12C−/12C2− and TEM images of MDA-MB-231 cells
treated with 15N/13C-labelled RAPTA-T (500 μM, 24 h). Blue boxes indicate Ru-enriched hotspots,
yellow boxes indicate 15N-enriched hotspots, and green boxes indicate hotspots co-enriched with 15N
and Ru. Cellular organelles are labeled in the TEM image.
RAPTA-T was found to accumulate in the nucleolus of MDA-MB-231 cells (Figure 1).
This observation is consistent with other studies in which RAPTA-T has been shown to interact
with the histone proteins that package and order DNA into nucleosomes [21]. Accumulation of
RAPTA-T was also observed on the cell membrane of MDA-MB-231 cells where it could interact with
extracellular cell adhesion proteins implicated in its anti-metastatic activity [11]. Overlaying the 102Ru−
and 12C15N− maps with TEM images reveals that RAPTA-T also accumulate partially in cytoplasmic
vacuoles, which are potential drug targets [22,23], and in mitochondria. The distribution and action
of RAPTA-T in mitochondria has been reported previously, where treatment with the drug resulted
in an appreciable accumulation in mitochondrial fractions from A2780CR cells [24] and results in
perturbation of the expression of several mitochondrial proteins [25]. RAPTA-T accumulation tends to
correlate with the sulphur-rich regions of the MDA-MB-231 cells, which is not surprising considering
that most organelles in which RAPTA-T is distributed contain sulphur-rich biomolecules.
In MCF-7 cells, the accumulation profile of RAPTA-T is in part similar to that in MDA-MB-231
cells, i.e., with accumulation in the nucleolus and a general co-accumulation of the drug at sulphur-rich
hotspots (Figure 2). However, in contrast to MDA-MB-231 cells, accumulation of RAPTA-T was not
observed in the nucleus or on the cell membrane of MCF-7 cells. From the overlaid TEM images,
RAPTA-T was also found to accumulate partially in mitochondria and cytoplasmic vacuoles. The lack
of distribution in the nucleus and membrane of MCF-7 cells could partially explain the weaker
activity of RAPTA-T in preventing migration, detachment, and reattachment of these cells compared
to MDA-MB-231 cells.
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Figure 2. NanoSIMS secondary ion maps of 31P−/12C2−, 34S−/12C2−, 14N12C−/12C2−,
15N12C−/14N12C−, 102Ru−/12C2−, and 13C12C−/12C2− and TEM of MCF-7 cells treated with 15N and
13C-labelled RAPTA-T (500 μM, 24 h). Blue boxes indicate Ru enriched hotspots, yellow boxes indicate
15N enriched hotspots and green boxes indicate hotspots co-enriched with 15N and Ru. Cellular
organelles are labeled in the TEM image.
3. Discussion
Accumulation of RAPTA-T in the membrane of human breast cancer cell lines is significantly
higher in the invasive MDA-MB-231 cell line compared to MCF-7 cells. Such differences in RAPTA-T
accumulation must be due to differences in the cell type and phenotype. It has been shown
previously that A2780CR cells, unlike their cisplatin-sensitive (A2780) counterparts, undergo metastasis
and shorten survival rates of mice xenografted with these cells [26]. Hence, both A2780CR and
MDA-MB-231 cells are highly invasive, and the selective membrane association of RAPTA-T with these
cell lines might be correlated with the anti-metastatic properties of the compound. This selectivity
is exemplified by the lack of membrane accumulation of RAPTA-T on the less invasive MCF-7 cells.
Notably, in the A2780CR and MDA-MB-231 cell lines, the amount of RAPTA-T associated with the
membrane exceeds that inside the cells.
The distribution of RAPTA-T inside both cell lines is largely associated with accumulation in the
nucleolus. Interestingly, RAPTA-C, a closely related compound to RAPTA-T, has been shown to reduce
proliferation, migration, and tube formation in endothelial cells and also stimulate apoptosis [27].
These effects may be attributed to interactions of RAPTA-C with the endothelial cell membrane and to
epigenetic factors.
Overall, the differences observed in the NanoSIMS studies provide new insights into how
RAPTA-T distribution correlates with the phenotypic changes induced by its activity on cancer cells.
These data emphasise the role of targeting molecules to the cell membrane for the control of metastasis
of solid tumours. This aspect has already been stressed for the ruthenium(III) drug, NAMI-A, another
potent anti-metastatic drug, which has been shown to bind to integrins [28]. If it is found that RAPTA-T
is also able to target integrins, integrin modulation could become a highly attractive approach for
tumour control with metal-based drugs. Such a mechanism, which is profoundly different to the
development of DNA-damaging metal-based drugs [29], would stimulate the search for novel, selective
drugs to control tumour malignancy.
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4. Materials and Methods
4.1. Synthesis and Characterisation of 13C/15N Labelled RAPTA-T
15N enriched 1,3,5,7-tetraazatricyclo[3.3.1.1 (3,7)]decane (PTA) was synthesized according to a
literature method [30], with minor modifications consisting in the replacement of 14NH4OH with
15NH4OH in the described procedure [31]. 13C labelled metyl-cyclohexadiene was prepared from
a birch reduction of toluene-(phenyl-13C6) and used to prepare 15N/13C-RAPTA-T (Scheme 2) as
described previously [17].
Scheme 2. Structure of 15N/13C labelled RAPTA-T. Characterisation: 1H NMR (400 MHz, Methanol-d4)
= δ 5.95–5.22 (m, 5H), 4.60 (s, 6H), 4.35 (s, 6H), 2.17 (s, 3H). 13C NMR (101 MHz, Methanol-d4) only
enriched 13C = δ 108.33, 88.64–85.31 (m), 77.87–75.73 (m). 31P NMR (162 MHz, Methanol-d4) = δ 33.43.
HRMS (ESI+) m/z calculated for C713C6H20Cl15N3PRu [M-Cl+H]+: 395.0239; found: 395.0242.
4.2. Cell Culture
MDA-MB-231 and MCF-7 (human breast adenocarcinoma) cells were cultured in DMEM medium
supplemented with 10% foetal calf serum, penicillin 100 units/mL, and streptomycin 100 μg/mL
(Invitrogen, Carlsbad, CA, USA). Cells were incubated at 37 ◦C in a humid environment containing
5% CO2.
4.3. Cell Preparation
Cells were seeded 50,000 cells/well in 24-well or 500,000 cells/well in 6-well clear bottom plates
fitted with sapphire disks. After 24 h, cell media was aspirated and fresh media containing 15N
and 13C-RAPTA-T (500 μM) was added (a high concentration of compound was used due to the
reduced incubation time). Upon incubation, the sapphire disks were removed from the media and
then high pressure frozen (Leica HPM100, Leica Microsystems, Wetzlar, Germany) with excess 20%
BSA solution in 0.01 M PBS (phosphate buffer solution) to avoid any air bubbles becoming trapped
and the formation of ice crystals. The frozen cells were then embedded in resin at low temperature [32].
The sapphire discs were placed on a frozen solution of 1% osmium, 0.5% uranyl acetate, 5% water in
acetone. The samples where then warmed to room temperature in an ice bucket containing solid carbon
dioxide blocks that were allowed to sublime over a period of 2 h until they reached room temperature.
At this point the solution was removed and replaced with dry acetone. After washing twice with
acetone, the samples were embedded in increasing concentrations of epon resin in acetone. At 100%
concentration of resin, the samples were then left overnight to fully infiltrate and then polymerised in
a 60 ◦C oven for at least 12 h. Samples where then glued to empty resin blocks, trimmed, and sections
of alternating thickness of 500 nm and 50 nm cut sequentially from the face. The thicker sections
were collected onto a glass coverslip stained with 1% touldine blue and imaged with light microscopy
and NanoSIMS. The 50 nm thick sections were collected on to an electron microscopy slot grid ready
for imaging with transmission electron microscopy at a final magnification of around 1400 times
(Tecnai Spirit, FEI Company, Eindhoven, The Netherlands).
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4.4. NanoSIMS Analysis
NanoSIMS measurements were performed at the Laboratory of Biological Geochemistry, EPFL
and the University of Lausanne. Prior to NanoSIMS imaging the samples were gold-coated in order
to avoid charging effects. Before acquiring an image, Cs+ ions were implanted into the surface of the
sample in order to enhance the ionization of the element of interest. The electron multiplier detectors
were set up to measure 12C2−, 13C12C−, 12C14N−, 12C15N−, 31P−, 34S−, and 102Ru− secondary ions,
generated by bombarding the sample with a ~4 pA Cs+ primary beam focused to a spot size of
approximately 160 nm. In order to resolve possible isobaric interferences, the instrument was operated
at a mass-resolving power (MRP) of about 10,000. Due to the low signal of 102Ru− obtained from
cells, peak-shape and mass resolving power was checked using a Ru standard. Data acquisition was
performed by scanning the Cs+ primary beam over areas of 34 × 34 μm with a 256 × 256 pixel image
resolution. The per pixel dwell time of the primary ion beam was 10 ms. The final images are the
accumulation of 120 layers obtained by sequential scanning and correspond to a cumulated acquisition
time per pixel of 1.2 s. Between every layer, the transmission of the secondary ion beam was optimized
and automatic peak centring was performed for 12C2−, 13C12C−, 12C14N−, 12C15N−. The Ru peak
could not be centred due to the low count rates. However, post-analysis checks revealed that there was
no significant change in the peaks position during the entire acquisition time. The total acquisition
time including the centring procedure was 22 h per image.
4.5. Data Extraction and Image Processing
NanoSIMS image processing was performed with L’image (L. Nittler, Carnegie Institution of
Washington, Washington, DC, USA). Over the ~20 h of image acquisition, the image drift of a
34 × 34 μm image was less than 7 pixels (i.e., less than 1 μm). The data reduction software can
easily correct for such a drift by aligning the positions of identified structures. Regions of interest (ROI)
were defined manually based on identifiable cell features on the 31P− elemental map. Images were
accumulated from planes where accumulated counts per ROI were stable with 12C14N− used as the
alignment mass. All other elements were normalized against 12C2, the images of which are essentially
flat, to normalize out small ionization variations across the sample surface.
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Abstract: Pelvic Melanoma relapse occurs in 15% of patients with loco regional metastases, and 25%
of cases do not respond to new target-therapy and/or immunotherapy. Melphalan hypoxic pelvic
perfusion may, therefore, be an option for these non-responsive patients. Overall median survival time
(MST), stratified for variables, including BRAF V600E mutation and eligibility for treatments with
new immunotherapy drugs, was retrospectively assessed in 41 patients with pelvic melanoma loco
regional metastases. They had received a total of 175 treatments with Melphalan hypoxic perfusion
and cytoreductive excision. Among the 41 patients, 22 (53.7%) patients exhibited a wild-type BRAF
genotype, 11 of which were not eligible for immunotherapy. The first treatment resulted in a 97.5%
response-rate in the full cohort and a 100% response-rate in the 22 wild-type BRAF patients. MST was
18 months in the full sample, 20 months for the 22 wild-type BRAF patients and 21 months for
the 11 wild-type BRAF patients not eligible for immunotherapy. Melphalan hypoxic perfusion is
a potentially effective treatment for patients with pelvic melanoma loco regional metastases that
requires confirmation in a larger multicenter study.
Keywords: melanoma; BRAF; Melphalan; pelvic perfusion; hypoxia; stopflow
1. Introduction
Cutaneous melanoma is one of the most aggressive treatment-resistant cancers [1].
Proto-oncogenes and tumor suppressor genes involved in the Mitogen-Activated Protein Kinase
(MAPK) pathway have been implicated in the molecular pathogenesis of cutaneous melanoma,
with activating mutations in BRAF (v-Raf murine sarcoma viral oncogene homolog B) and NRAS
(neuroblastoma RAS viral oncogene homolog) encountered in approximately 70% of all melanomas [1].
Somatic BRAF mutation in codon 600 of exon 15 occurs in 40–50% of cutaneous melanomas, with V600E
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the most common mutation. BRAFV600E is now recognized as a validated therapeutic target, although
acquired resistance is almost universal [2].
Recently, novel immunotherapies that target negative immune checkpoint molecules have gained
a major interest in the treatment of melanoma [2]. Therefore, in the last six years, options for
treatment of advanced melanoma patients have significantly changed, thanks to new target therapy
and immunotherapy. The new era of effective systemic therapy, also involves patients with pelvic
locoregional metastases without lesions in the legs, which are approximately less than 2% of all
malignant melanoma patients [3,4].
Unfortunately, target therapy provides a significant overall median survival improvement in
only 50% of patients who carry the BRAFV600E mutation, with salvage immunotherapy, following
discontinuation of targeted therapy, frequently unsatisfactory [5,6]. Furthermore, these new
immunotherapies are effective in only 45% of wild-type BRAF melanoma patients, associated with
overall median survival times ranging from 11 to 20 months, with adverse events observed in 4–25%
of patients [7–9].
An effective treatment for melanoma patients with loco-regional pelvic metastases, who do not
respond to target therapy and/or new immunotherapy, remains an important area for clinical research.
A recent review has examined the role of surgery and loco-regional chemotherapy in the management
of in-transit disease, in the era of effective systemic therapy [10]. A decade ago, standard treatment for
patients with loco-regional melanoma metastases resulted in a median survival time of approximately
eight months [11,12] and high complex regional chemotherapy procedures containing Melphalan
were considered to have potential to improve clinical outcome [4,13–16]. However, techniques were
not standardised and results varied according to the experience of each institution. Since then,
more feasible procedures associated with lower morbidity and fewer adverse effects have been
developed, with particular emphasis on the use of interventional radiology [14]. An important question
however, remains to be answered, and that is whether loco-regional chemotherapy, performed by the
surgical or percutaneous approach, still has a place in the treatment of advanced stage melanoma?
In this report, we present a retrospective study of the efficacy of Melphalan hypoxic perfusion in
patients with pelvic metastatic melanoma stratified for prognostic factors, including BRAF.
2. Results
2.1. Patients Characteristics
A total of 41 melanoma patients with metastatic lesions were included in this study (13 males
and 28 females). Mean patient age (±SD, standard deviation) was 63.9 years (±13.6), mean male
age was 58.2 years (±14.7) and mean female age was 66.3 years (±12.5). Seven lymph node negative
patients with loco-regional metastases were classified as stage IIIB and 24 lymph node positive patients
were classified as stage IIIC. The ten stage IV patients were classified by the presence of concurrent
metastases to the lungs (four patients), bones (four patients) or abdomen (two patients).
2.2. Treatments
A total of 175 perfusions were performed, including 52 surgical procedures and 123 percutaneous
procedures. The mean (±SD) number of treatments received by each patient was 4.3 (±3.1) and the
median number of treatments received was four (range 2–5). Contemporary palliative cytoreduction
was performed in 35 patients (85.4%). With respect to hospitalization, the median length of
post-surgical perfusion recovery was 8.8 days, which was significantly longer (p < 0.01) than following
percutaneous perfusion (4.7 days).
Patients did not experience any technical (i.e., balloon rupture), hemodynamic, or vascular
complications, and no deaths occurred during the 175 procedures or during the post-operative period.
Hematological toxicity, resulting in the termination of treatment, occurred in three patients following
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the 4th procedure (9.7%) and in a single patient following the 14th procedure. Procedure-related
complications and toxicities are listed in Table 1.
Table 1. Procedure related complications and toxicity after 175 treatments in 41 metastatic
melanoma patients.
Complications Grade n (%)
Seroma 1 4 (2.3)
Persistent leakage of fluid from the incision 2 14 (8.0)
Wound infection 1 3 (1.7)
Inguinal hematoma 1 7 (4.0)
Wound dehiscence 2 7 (4.0)
Lymphangitis 2 3 (1.7)
Scrotum edema 1 6 (3.4)
Pelvic pain 1 6 (3.4)





Alopecia 1 7 (4.0)
Nausea and vomiting 1 26 (14.9)
n = numbers of cases.
2.3. BRAF Mutational Status
BRAF gene mutational analysis in the 41 metastatic melanoma tissues, identified the V600E BRAF
mutation in 19 metastases (19/41, 46.3%), with 22 samples (22/41, 53.7%) characterized as wild-type
BRAF. Eleven (11/41, 26.8%) wild-type BRAF patients were not suitable for immune check-point
therapy, three of which (3/41, 7.3%) were in disease progression after Ipilimumab immunotherapy
and 8 of which (19.5%) were ineligible due to hepatitis C (4 patients; 9.7%), human immunodeficiency
virus-HIV (one patient; 2.4%) and active inflammatory bowel disease (three patients; 7.3%).
2.4. Tumor Responses
Tumor response was related primarily to perfusion, with minimal contribution made by additional
surgical excision. In the full sample cohort, the overall response rate after the first treatment was 97.5%,
with a complete response observed in four patients (9.7%), a partial response observed in 36 patients
(87.8%) and stable disease observed in one patient (2.4%). No evidence of disease progression was
detected within 30 days, following initial treatment. In patients who underwent more than three
treatments the overall response rate was 27.3%.
In the 22 wild-type BRAF patients, the overall response rate following the initial treatment was
100%, with two complete responses (9.1%) and 20 partial responses (90.9%), recorded. In wild-type
BRAF patients who underwent more than three treatments, the overall response rate was 33.3%.
With respect to the 11 wild-type BRAF patients that were not eligible or non-responsive to
immunotherapy, two patients exhibited a complete response (18.2%) and nine patients exhibited a
partial response (81.8%), following the initial treatment. Partial responses were recorded for 10% of
patients following the second treatment, 11.1% of patients following the 3rd treatment and 16.7% of
patients following the fourth treatment.
2.5. Survival
The overall MST for this patient cohort was 18 months (range 9–22) (Figure 1A), with a mean
survival time of 27.6 (±35.7) months. The one-year, three-year and five-year survival rates were 63.4%,
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17.1% and 9.7%, respectively and the overall median progression free survival (PFS) was 15.5 months
(range 6–21), with a mean of 25.7 (±36.3) months.
Figure 1. Kaplan-Meyer survival. (A) overall; (B) 11 wild-type BRAF patients not eligible for
check-point therapy or non-responsive for progression or adverse events.
Table 2 shows factors associated with survival, including gender, age, stage of disease, number
and dimension of nodules, melanin cellular pigmentation, mitosis, associated excision, number of
treatments and BRAF status.
Table 2. Survival according to age, gender, stage, BRAF V600E status, burden, mitosis, associated
excision, cellular melanin pigmentation, number of treatments.
Variables (Number of Patients) MST (Months) Log-Rank χ2 p Value Cox HR
Age
<65 (n = 18) 17
≥65 (n = 23) 20 0.80 0.371
Gender
Female (n = 28) 19.5
Male (n = 13) 10 2.31 0.132
Stage
IIIB (n = 7) 37
IIIC (n = 24) 19
IV (n = 10) 8 21.44 0.001 4.03 [1.91–6.59]
BRAF status
Wild-type (n = 22) 20
V600E Mutated (n = 19) 13 0.36 0.551
Burden
Low (n = 23) 21
High (n = 18) 16.5 7.61 0.005 2.58 [1.26–5.58]
Mitosis
<1 (n = 17) 20
≥1 (n = 24) 14.5 3.66 0.064
Associate Excision
Yes (n = 35) 18
Not (n = 6) 17.5 2.41 0.128
Melanin cellular pigmentation
Yes (n = 15) 20
Not (n = 26) 14.5 0.15 0.691
Number of treatments
≤2 (n = 7) 5
>2 (n = 34) 19 1.58 0.203
MST = median survival time; HR = hazard ratio.
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Disease stage (p = 0.001) (Figure 2A), and “burden” (p = 0.005) (Figure 2B) significantly affected
survival, whereas gender, age, mitosis, melanin pigmentation, associate excision, number of treatments,
and BRAF V600E status did not.
Figure 2. Kaplan-Meyer survival. (A) Stratified by Stage; (B) stratified by Burden.
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In 22 wild-type BRAF patients, the MST was 20 months (range 11–21), with a mean survival
time of 31.3 (±41.9) months. Gender, the number of treatments and nodule number and dimension
(burden) all had an impact on survival that could not be evaluated statistically due to the small number
of patients in these sub-groups. The median PFS was 17.7 months (range 9.5–20), with a mean of
29.4 (±42.5) months.
In the 11 wild-type BRAF patients that were not eligible or non-responsive to checkpoint therapy,
the MST (Figure 1B) was 21 months (range 18–47), with a mean of 46.4 (±55.7) months. The median
PFS for this group was 20 months (range 16.5–45), with a mean of 44.4 (±56.8) months.
2.6. Follow-Up
Median follow-up was 18 months (range 9–22), with a mean of 27.6 (±35.7) months. Among the
41 patients studied, four (9.8%) are still alive without evidence of disease after 76, 109, 132 and
178 months, whereas the remaining 37 (90.2%) have deceased as a consequence of melanoma. Therapy
was interrupted in one patient due to Melphalan allergy, following the 10th treatment and another
patient developed a brain metastasis six-years after the last perfusion. This patient was referred for
surgical excision and remains disease-free after nine years.
With respect to the 20 patients who interrupted treatment due to disease progression, the median
MST was 10 months, with a mean of 12.1 (±8.6) months, which was significantly shorter
(p < 0.01) than the MST of the 10 patients who interrupted treatment due to worsening condition
(median 20; mean 27.5 ± 11.6 months) or the seven patients who retired the consent (median 20;
mean 17.0 ± 5.6 months; p < 0.04).
Disease progression in the pelvis was detected in 17 stage IIIC patients (one of which also developed
distant site relapse) and in two stage IIIB patients. Distant site relapse was observed in two stage IIIB
patients, seven stage IIIC patients and in 10 stage IV patients (one also with pelvic recurrence).
3. Discussion
In this retrospective study, we present evidence that demonstrates the potential efficacy
of Melphalan hypoxic pelvic perfusion in patients with pelvic and/or inguinal loco regional
melanoma metastases.
Prior to 2013, pelvic perfusion was an option for patients with loco regional melanoma metastases
who were non-responsive to standard treatments. Within the last four years, immunotherapy
with checkpoint inhibition and MAPK pathway targeted inhibitory therapy have led to important
improvements in patient outcomes and has become the first line of therapy. Reports suggest, however,
that up to 25% of melanoma patients may not respond to new target and immunotherapeutic drugs [17].
In our retrospective study, melanoma patients received repeated Melphalan hypoxic pelvic perfusions
associated with cytoreductive excision between 2002 and 2013. This cohort had several interesting
characteristics: (1) patients with loco regional pelvic melanoma metastases with or without leg
lesions below mid-thigh level, represent a very rare category (enrollment of three/four patients
per year) and the small sample size was a deliberate choice from a single institute in order to minimize
procedural and technical bias, consistent with similar sample sizes in previous reports [13–16]; (2) in all
41 patients, lymphocyte invasion into metastatic melanoma tissues was not detected. This condition
has been reported recently to associate with melanoma resistance to anti-PD1 antibody therapy [17].
Furthermore, melanomas did not exhibit desmoplasia with malignant spindle cells (DM). The prognosis
for melanoma with DM is controversial with a recent report indicating a similar survival rate for
case-matched patients with or without DM [18].
Molecular analysis of metastatic melanomas identified a BRAFV600E mutation-rate of 46.3%.
This frequency is similar to that commonly found for primary tumours in large series of cases [19]
and in other Italian cohorts [20]. It remains unclear, however, whether the primary tumour BRAF
mutation status is retained in metastases and we are unable to add anything more to this debate,
in this study.
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Among the 22 wild-type BRAF patients, 11 were not eligible for new immunotherapeutic drugs or
had therapy interrupted due to disease progression or adverse events. A recent review discusses the
reasons for which many patients seen in routine clinical practice do not qualify for immune checkpoint
inhibitor clinical trials and have been seriously underrepresented in new immunotherapy trials [21].
In this study, Melphalan mono-therapy was chosen for this patient cohort based upon the
rationale that Melphalan cytotoxicity is enhanced 3-fold in conditions of hypoxia-induced acidosis [22]
and a previous study reporting grade 3 post-perfusion neutropenia in 18% of patients treated with
Melphalan-based poly-chemotherapy [4]. In our study, pelvic perfusion was immediately followed by
hemofiltration to protect against toxicity, rather than the use of a pneumatic anti-shock garment [16],
which modifies hemodynamic and respiratory parameters but does not prevent leakage.
Long-term MST for Melphalan mono-therapy was 37 months for IIIB patients and 19 months
for IIIC patients, who previously progressed following standard therapy and surgery. MST was
decreased to eight months in stage IV patients and significantly lower survival characterized the
remaining 48.8% of patients who had interrupted perfusion due to disease progression, compared to
patients who interrupted treatments by refusing consent or due to general worsening of conditions.
One patient developed a skin reaction and mild dyspnea during the 10th Melphalan perfusion, which
were resolved by corticosteroid and antihistamine treatment. Allergy to Melphalan is not common but
has been reported in approximately 2% of patients [23].
MST in the wild-type BRAF cohort was 20 months with a median PFS of 17.7 months, and the
MST of the 11 patients not eligible for target therapy or new immunotherapy was 21 months. No other
therapy has demonstrated significant clinical efficacy in this wild-type BRAF subgroup and the only
alternative therapy suggested is systemic chemotherapy. A survival benefit of >10% is required for a
new therapeutic regimen or modality to be recommended. Very recently, overall survival of patients
with metastatic melanoma treated with new target and immunotherapies in a real-life setting has
been compared to an overall survival of 7.4 months in a 95-patients-cohort treated with systemic
chemotherapy [24]. In this retrospective study, a survival benefit of >10% was recorded for our
procedure in wild type BRAF melanoma patients, suggesting a potentially important survival benefit.
However, greater numbers will be required to confirm this.
It would be interesting to determine whether Melphalan pelvic perfusion under conditions of
hypoxia may generate an immune response that could be augmented by systemic immunotherapy
with anti-programmed cell death-ligand protein 1 (PD-L1) antibodies [25]. In this regard, two trials
are currently underway to explore the efficacy of Melphalan combined with Ipilimumab, as either
adjuvant (NCT01323517) or neo-adjuvant (NCT02115243) systemic immunotherapy.
A major limitation of our study is, however, the small sample size that cannot definitively establish
the true benefit of this approach in patients with wild-type BRAF metastatic melanoma who are not
eligible or non-responsive to new immunotherapeutic drugs. However, we defend our approach
as necessary in order to minimize surgical procedure variability. Finally, although hypoxic pelvic
perfusion is an expensive procedure, costs are similar to those incurred by isolated limb perfusion or
infusion procedures for metastatic melanoma [26].
4. Patients and Methods
4.1. Patients
This project has been performed in accordance with the Declaration of Helsinki and has been
approved by the ethics committee of University of L′Aquila, L′Aquila, Italy. Written informed consent
was obtained from each patient.
In this retrospective study, in order to respect performance homogeneity, a subset of patients
was selected from a larger database, which included melanoma patients from different sites who
underwent hypoxic perfusion. Forty-one melanoma patients with pelvic and/or inguinal loco-regional
metastases, treated with a total of 175 hypoxic perfusions between September 2002 and January 2013,
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were included in this study. Table 3 reports patient and tumor characteristics. Patients with associated
lesions below mid-thigh level, requiring a larger compartment for perfusion, were excluded from
this study. Prior to treatment initiation, all patients were characterised by disease progression after
previous therapies, including palliative surgery (39 patients; 95.1%), Dacarbazine-based systemic
chemotherapy (19 patients; 46.3%), immunotherapy with Interferon α and/or Interleukin-2 (15 patients;
36.6%), isolated limb perfusion with tumour necrosis factor (4 patients; 9.7%), electro-chemotherapy
(two patients; 4.8%), Ipilimumab (3 patients; 7.3%). Patients who had received any kind of
chemotherapy, immunotherapy and/or target therapy after the last perfusion treatment were also
excluded from this study. Patients with stage IV melanoma were included in this study, as loco-regional
therapy was performed in these patients to avoid severe local complications. Informed consent was
obtained from all patients who received complete information concerning their disease and the
implications of the proposed palliative treatment, as required by the ethical standards committee on
human experimentation of our institution.
Table 3. Characteristics of patients and tumors.









Low Burden * 23 (56.1)
High Burden ** 18 (43.9)
Patients with exclusion criteria for immune check-point therapy Yes 8 (19.5)
No 33 (80.5)




Anterior trunk 2 (4.9)
Back 3 (9.7)
Lower extremity 31 (75.6)
Melanin presence Yes 15 (36.6)
No 26 (63.4)
Mitotic rate
<1 mitosis per mm2 17 (41.5)
>1 mitosis per mm2 24 (58.5)
BRAF status
wild-type 22 (53.7)
V600E mutated 19 (46.3)
n = numbers of patients; * <10 nodules; or no lesion >3 cm; ** ≥10 nodules; or one lesion >3 cm.
4.2. Histopathological and Molecular Evaluation
Pathological examination revealed that all surgical specimens had an epithelioid cell pattern.
Lesions were classified as “pigmented” or “non-pigmented”, based on the presence or absence of
melanin-producing cells and lesions were also classified according to mitotic rate (<1 or ≥1 mitosis
per mm2). Tumor-infiltrating lymphocytes were not detected in any of the 41 tumor specimens.
DNA was isolated from five, 10 μm formalin fixed paraffin embedded (FFPE) tissue
sections from each excised lesion, using the DNA Mini Kit, as directed by the manufacturer
(Qiagen, Hilden, Germany), and DNA concentration and quality determined in a Qubit fluorometer
(Thermo-Fisher, Foster City, CA, USA). BRAF V600E mutation status was assessed using Competitive
Allele Specific hydrolysis probes (TaqMan) and PCR technology (CAST) (Thermo-Fischer Scientific,
Waltham, MA, USA) [29].
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4.3. Treatment Protocol
The eligibility criteria for hypoxic pelvic perfusion have been previously reported [4]. In particular,
all patients were free from renal and/or liver failure, deep venous thrombosis, severe atherosclerosis,
or coagulopathy. The clinical protocol provision was for repetitive cycles of perfusion and palliative
cytoreductive surgery at 6 to 7-week intervals, with purpose and timing of repetition based on previous
pilot studies [4,30]. Criteria for surgical excision and other treatment details have been recently
reported [25]. In the case of complete response to treatment, a prolonged treatment repetition interval
of 12 weeks was performed in order to gain the clinical result of one-year progression-free survival.
4.4. Hypoxic Pelvic Perfusion Technique and Melphalan Regimen
All 175 perfusions were performed under general anesthesia, as previously reported [4,31].
In 123 procedures (70.3%), a percutaneous technique was adopted; in 52 treatments (29.7%) the method
was surgical with 39 femoral-access, 13 iliac-access, and 49 lymphadenectomies. Details of the surgical
and percutaneous techniques plus hemofiltration characteristics have been recently reported [25].
Briefly, hypoxic perfusion with hemofiltration included three phases: isolation, perfusion and
hemofiltration. In the isolation phase, the blood flow to the aorta and inferior cava vein was blocked
by endovascular balloon catheters and at thigh-level by pneumatic cuffs. During the perfusion phase,
pelvic perfusion was performed via extracorporeal blood circulation at approximately 100 mL/min.
According to previous pilot studies [4,30], 30 mg/m2 of Melphalan in 250 mL of isotonic sodium
chloride solution was administered via the circuit over a 3-min period. The extracorporeal circuit
connected to the circulation device contained a heating element and a hemofiltration module controlled
by the device during perfusion and subsequent hemofiltration phases [32]. Following perfusion,
balloon catheters and pneumatic cuffs were deflated to restore normal circulation and hemofiltration
was then administered for 60 min (hemofiltration phase).
4.5. Criteria for Responses and Adverse Events
Tumor response was assessed using Response Evaluation Criteria in Solid Tumors, version 1.1 [33]
at 30 days after each loco-regional chemotherapy treatment. Patient responses prior to 2009 were
retrospectively re-classified. Computerized tomography (CT), Magnetic Resonance Imaging (MRI),
and Position-emission Tomography (PET) were used to evaluate responses for deep masses and
inspection with photo comparison employed for the monitoring of superficial lesions. Adverse events
were assessed using Common Terminology Criteria for Adverse Events of the National Cancer Institute
(CTCAE v4.03).
4.6. Statistical Analysis
Descriptive statistics estimated with 95% confidence are presented as mean ± SD Survival
estimates were calculated using the Kaplan-Meier product limit estimator. No patients were lost
to follow-up and no patients died of causes other than melanoma. Survival times were stratified
according to clinical variables that potentially influence survival. Log-rank tests were used to assess
the significant differences between the groups and hazard ratios were estimated using a proportional
hazard Cox regression model. Progression free survival time (PFS) was calculated from the first day
of loco-regional treatment. Statistical analyses were performed using STATA software, version 14
(Stata Corp., College Station, TX, USA).
5. Conclusions
In conclusion, we propose that Melphalan hypoxic perfusion is a potentially effective treatment
for pelvic metastatic melanoma, but this should be confirmed in a larger multicenter prospective
controlled trial.
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